DE69133326D1 - Verbesserte humanähnlich gemachte immunglobuline - Google Patents

Verbesserte humanähnlich gemachte immunglobuline

Info

Publication number
DE69133326D1
DE69133326D1 DE69133326T DE69133326T DE69133326D1 DE 69133326 D1 DE69133326 D1 DE 69133326D1 DE 69133326 T DE69133326 T DE 69133326T DE 69133326 T DE69133326 T DE 69133326T DE 69133326 D1 DE69133326 D1 DE 69133326D1
Authority
DE
Germany
Prior art keywords
immunoglobuline
improved human
variable region
chain variable
cdrs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69133326T
Other languages
English (en)
Other versions
DE69133326T2 (de
Inventor
L Queen
Sung Co
P Schneider
F Landolfi
L Coelingh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Biotherapeutics Inc
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24543134&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69133326(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Publication of DE69133326D1 publication Critical patent/DE69133326D1/de
Application granted granted Critical
Publication of DE69133326T2 publication Critical patent/DE69133326T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/088—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
DE69133326T 1990-12-19 1991-12-19 Verbesserte humanähnlich gemachte immunglobuline Expired - Lifetime DE69133326T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/634,278 US5530101A (en) 1988-12-28 1990-12-19 Humanized immunoglobulins
US634278 1990-12-19
PCT/US1991/009711 WO1992011018A1 (en) 1990-12-19 1991-12-19 Improved humanized immunoglobulins

Publications (2)

Publication Number Publication Date
DE69133326D1 true DE69133326D1 (de) 2003-11-13
DE69133326T2 DE69133326T2 (de) 2004-08-05

Family

ID=24543134

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69133326T Expired - Lifetime DE69133326T2 (de) 1990-12-19 1991-12-19 Verbesserte humanähnlich gemachte immunglobuline

Country Status (9)

Country Link
US (6) US5530101A (de)
EP (2) EP1386932A1 (de)
JP (1) JP3276369B2 (de)
KR (1) KR100231090B1 (de)
AT (1) ATE251639T1 (de)
AU (2) AU671949B2 (de)
CA (1) CA2098404C (de)
DE (1) DE69133326T2 (de)
WO (1) WO1992011018A1 (de)

Families Citing this family (5288)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
WO1989001340A1 (en) * 1987-08-17 1989-02-23 The United States Of America, As Represented By Th Method for treating malignancy and autoimmune disorders in humans
US20040049014A1 (en) * 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7247453B1 (en) * 1988-12-30 2007-07-24 Oklahoma Medical Research Foundation Calcium binding recombinant antibody against protein C
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
EP0486526B2 (de) 1989-08-07 2001-03-07 Peptech Limited Bindeligande für tumornekrosisfaktor
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
HUT60768A (en) 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7084260B1 (en) * 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6631842B1 (en) * 2000-06-07 2003-10-14 Metrologic Instruments, Inc. Method of and system for producing images of objects using planar laser illumination beams and image detection arrays
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
US20040143100A1 (en) * 1991-03-04 2004-07-22 Tan Kim Sze High affinity humanized monoclonal antibodies
US20020032313A1 (en) * 1991-03-29 2002-03-14 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US5367057A (en) * 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
US6797492B2 (en) * 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
US6800738B1 (en) * 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US6699472B2 (en) 1991-08-14 2004-03-02 Genentech, Inc. Method of treating allergic disorders
US6329509B1 (en) * 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
US7018809B1 (en) * 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
US5621083A (en) 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US6146850A (en) * 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
DK1024191T3 (da) * 1991-12-02 2008-12-08 Medical Res Council Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US20030229207A1 (en) * 1991-12-13 2003-12-11 Xoma Technology Ltd. Modified antibody variable domains
ES2202310T3 (es) * 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US20020102257A1 (en) * 1998-09-21 2002-08-01 Leslie Sid Johnson Human-murine chimeric antibodies against respiratory syncytial virus
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
IL104620A (en) 1992-02-06 2000-02-29 Schering Plough Corp Humanized monoclonal antibodies against human interleukin-5
ATE171472T1 (de) * 1992-02-19 1998-10-15 Schering Corp Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US5646253A (en) * 1994-03-08 1997-07-08 Memorial Sloan-Kettering Cancer Center Recombinant human anti-LK26 antibodies
US6042828A (en) * 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
US6824777B1 (en) * 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
GB9221654D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
PT676965E (pt) * 1992-11-16 2007-10-29 Centocor Inc Método para reduzir a imunogenicidade da região variável de anticorpos
US6210671B1 (en) * 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
WO1994012215A1 (en) * 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with l-selectin
US6307026B1 (en) * 1992-12-10 2001-10-23 Celltech Limited Humanized antibodies directed against A33 antigen
ATE173630T1 (de) 1992-12-29 1998-12-15 Genentech Inc Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
CA2153692C (en) * 1993-01-12 2011-11-08 Roy R. Lobb Recombinant anti-vla4 antibody molecules
US20030059428A1 (en) * 1993-02-26 2003-03-27 Boris Skurkovich Treatment of autoimmune diseases
US7592006B1 (en) * 1993-03-05 2009-09-22 Université Catholique de Louvain Composition comprising the LO-CD2a antibody
US5951983A (en) * 1993-03-05 1999-09-14 Universite Catholique De Louvain Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
US6080407A (en) * 1993-05-17 2000-06-27 The Picower Institute For Medical Research Diagnostic assays for MIF
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US20030108548A1 (en) * 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
WO1995000649A1 (en) * 1993-06-25 1995-01-05 Smithkline Beecham Plc Lipoprotein associated phospholipase a2, inhibitors thereof and use of the same in diagnosis and therapy
US6046012A (en) * 1993-07-19 2000-04-04 Hoffmann-La Roche Inc. Antibody to IL-12 receptor
US5847088A (en) * 1993-10-06 1998-12-08 Icos Corporation Antibodies specific for platelet-activating factor acetylhydrolase
US5821332A (en) * 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
AU697142B2 (en) * 1993-11-23 1998-10-01 Genentech Inc. Protein tyrosine kinases named Rse
GB9325182D0 (en) * 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US5877016A (en) * 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5506133A (en) * 1994-04-11 1996-04-09 Human Genome Sciences, Inc. Superoxide dismutase-4
US7473423B2 (en) 1994-04-29 2009-01-06 Mayo Foundation For Medical Education And Research Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5622701A (en) * 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
USRE39548E1 (en) * 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US5629193A (en) 1994-07-05 1997-05-13 Human Genome Sciences, Inc. Paraoxonase
US7354587B1 (en) * 1994-07-06 2008-04-08 Immunomedics, Inc. Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
US6048972A (en) * 1994-07-13 2000-04-11 Chugai Pharmaceutical Co., Ltd. Recombinant materials for producing humanized anti-IL-8 antibodies
AU701342B2 (en) 1994-07-13 1999-01-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
DE4425115A1 (de) * 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
US8771694B2 (en) * 1994-08-12 2014-07-08 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
ATE306930T1 (de) * 1994-08-12 2005-11-15 Immunomedics Inc Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
PT788513E (pt) * 1994-10-25 2001-06-29 Glaxo Group Ltd Utilizacao de agentes de ligacao a cd23 no tratamento de doencas autoimunes
US6538121B1 (en) * 1994-11-01 2003-03-25 Human Genome Sciences, Inc. Interleukin-1 β converting enzyme like apoptosis protease-3 and 4
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7820798B2 (en) * 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7399837B2 (en) * 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5693323A (en) * 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
WO1996021000A2 (en) * 1994-12-23 1996-07-11 Smithkline Beecham Corporation Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders
ES2197217T3 (es) * 1994-12-28 2004-01-01 University Of Kentucky Research Foundation Anticuerpo 3h1 monoclonal anti-id-murino.
US6537764B1 (en) * 1995-01-19 2003-03-25 Children's Medical Center Corporation Method of identifying inhibitors of C—C chemokine receptor 3
EP0813423B1 (de) * 1995-01-23 2002-07-03 Xenotech Incorporated Zusammensetzung zur verhinderung von osteolyse und metastasen
US5853721A (en) * 1995-01-31 1998-12-29 Hoffmann-La Roche Inc. Antibody to interleukin-12 receptor
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7803904B2 (en) * 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US5674748A (en) * 1995-03-14 1997-10-07 Thomas Jefferson University Human cyclin-dependent kinase-like proteins and methods of using the same
DK0766745T3 (da) * 1995-04-08 2002-11-25 Lg Chemical Ltd Monoklonalt antistof, som er specifikt for humant 4-1BB samt cellelinje, som producerer dette
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US5986054A (en) * 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
US5641751A (en) * 1995-05-01 1997-06-24 Centocor, Inc. Tumor necrosis factor inhibitors
IL118069A (en) * 1995-05-02 2000-06-01 Japan Tobacco Inc Monoclonal antibody reactive to human CETP and assay method for human CETP
US20030144483A1 (en) * 1995-05-04 2003-07-31 Medarex, Inc. Humanized antibodies to Fc receptors for immunoglobulin G on human mononuclear phagocytes
PT833911E (pt) * 1995-06-07 2004-09-30 Ortho Mcneil Pharm Inc Anticorpos anti-factor tecidular enxertados com cdr e metodos para a sua utilizacao
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US7264963B1 (en) * 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
EP0859841B1 (de) * 1995-08-18 2002-06-19 MorphoSys AG Protein-/(poly)peptidbibliotheken
AU710696C (en) * 1995-09-08 2002-10-24 Genentech Inc. VEGF-related protein
US6048734A (en) 1995-09-15 2000-04-11 The Regents Of The University Of Michigan Thermal microvalves in a fluid flow method
US7368111B2 (en) * 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
RU2270030C2 (ru) 1996-02-09 2006-02-20 Абботт Байотекнолоджи эЛтиди. СПОСОБ ИНГИБИРОВАНИЯ АКТИВНОСТИ ЧЕЛОВЕЧЕСКОГО TNFα (ВАРИАНТЫ), ПРИМЕНЕНИЕ ВЫДЕЛЕННОГО АНТИТЕЛА ЧЕЛОВЕКА ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩЕГО ФРАГМЕНТА В КАЧЕСТВЕ КОМПОНЕНТА ДЛЯ ПРОИЗВОДСТВА ЛЕКАРСТВЕННОГО СРЕДСТВА (ВАРИАНТЫ) И ВЫДЕЛЕННОЕ ЧЕЛОВЕЧЕСКОЕ АНТИТЕЛО ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ
EP0881299A4 (de) * 1996-02-15 2004-12-15 Chugai Seiyakukabushiki Kaisha Monoklonaler antikörper, der antigene auf der oberfläche von endothelzellen von tumorversorgenden blutgefässen erkennt.
AU2232597A (en) * 1996-03-06 1997-09-22 Chugai Seiyaku Kabushiki Kaisha Method of screening apoptosis inducing substances
US20040047864A1 (en) * 1996-03-14 2004-03-11 Human Genome Sciences, Inc. Apoptosis inducing molecule I
US6730300B2 (en) * 1996-03-20 2004-05-04 Immunomedics, Inc. Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) * 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US20020165157A1 (en) * 1996-04-01 2002-11-07 Genentech, Inc. Apo-2LI and Apo-3 polypeptides
US7241568B2 (en) * 1996-04-03 2007-07-10 Kyowa Hakko Kogyo Co., Ltd. Anti-fibroblast growth factor-8 monoclonal antibody
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US20060159688A1 (en) * 1996-05-15 2006-07-20 Ragupathy Madiyalakan Method for diagnosing efficacy of xenotypic antibody therapy
ATE233102T1 (de) * 1996-05-15 2003-03-15 Altarex Inc Verfahren und zusammensetzung zur umgestaltung multi-epitopischer antigene um die immunantwort einzuleiten
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
ATE403001T1 (de) 1996-05-22 2008-08-15 Viventia Biotech Inc Antigenbindungsfragmente die spezifisch krebszellen nachweisen, nukleotide die für diese fragmente kodieren, und deren verwendung zur vorbeugung und zum nachweis von krebs
JP4503706B2 (ja) * 1996-06-07 2010-07-14 ポニアード ファーマシューティカルズ，インコーポレイティド グリコシル化が改質されたヒト化抗体
US20050136066A1 (en) * 1996-06-12 2005-06-23 Yajun Guo Cellular vaccines and immunotherapeutics and methods for their preparation
US6805869B2 (en) 1996-06-12 2004-10-19 Shanghai Cp Guojian Pharmaceutical Co., Ltd. Cellular vaccines and immunotherapeutics and methods for their preparation
US5908925A (en) * 1996-06-27 1999-06-01 Exocell, Inc. Genetically engineered immunoglobulins with specificity for glycated albumin
DE69731836T2 (de) * 1996-07-23 2005-12-01 Pangenetics B.V. Induzierung von t zell toleranz unter verwendung eines löslichen moleküls, dass gleichzeitig zwei kostimulierungswege blockieren kann
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
US7147851B1 (en) † 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
WO1998010070A1 (fr) * 1996-09-02 1998-03-12 Sumitomo Electric Industries, Ltd. IMMUNOGLOBULINE HUMANISEE REAGISSANT SPECIFIQUEMENT AVEC UN LIGAND Fas OU L'UN DE SES FRAGMENTS ACTIFS ET REGION D'INDUCTION D'APOPTOSE PRENANT NAISSANCE DANS UN LIGAND Fas
US6114506A (en) * 1996-09-20 2000-09-05 General Hospital Corporation Composition and method for enhancing fibrinolysis
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
IL129164A (en) 1996-09-26 2007-05-15 Chugai Pharmaceutical Co Ltd An antibody against peptides associated with human parathyroid hormone
KR20000048820A (ko) 1996-10-01 2000-07-25 게론 코포레이션 텔로머라제 역전사 효소
US5908778A (en) * 1996-10-03 1999-06-01 Ludwig Institute For Cancer Research Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof
UA76934C2 (en) * 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
AU7180398A (en) 1996-11-13 1998-06-03 Morphogenesis, Inc. Antibody MG1 recognizing a small subset of human hematopoietic cells
US6743604B1 (en) * 1996-12-13 2004-06-01 Smithkline Beecham Corporation Substances and their uses
US20030223995A1 (en) * 1996-12-23 2003-12-04 Advanced Biotherapy, Inc. Treatment of pemphigus vulgaris
US20030086925A1 (en) * 1996-12-23 2003-05-08 Advanced Biotherapy, Inc. Treatment of autoimmune diseases
US20030228310A1 (en) * 1996-12-23 2003-12-11 Advanced Biotherapy, Inc. Treatment of skin diseases
US20030103967A1 (en) * 1997-01-07 2003-06-05 Habib Zaghouani Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US6455040B1 (en) 1997-01-14 2002-09-24 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
US8329179B2 (en) * 1997-01-28 2012-12-11 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US6342363B1 (en) * 1997-01-28 2002-01-29 Human Genome Sciences, Inc. Death domain containing receptor 4 nucleic acids and methods
US6433147B1 (en) * 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
US7452538B2 (en) 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US6590079B2 (en) 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US20010011125A1 (en) * 1997-01-30 2001-08-02 William D. Huse Anti-alpha v beta 3 recombinant human antibodies, nucleic acids encoding same and methods of use
US6596850B1 (en) * 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
US20030068316A1 (en) * 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
US6187536B1 (en) 1997-02-18 2001-02-13 Thomas Jefferson University Methods of identifying and detecting pancreatic cancer
US6893636B2 (en) * 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US7033589B1 (en) * 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US6011138A (en) * 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies
US7122636B1 (en) * 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US20040229282A1 (en) * 1997-03-10 2004-11-18 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US6541212B2 (en) * 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
US20030109680A1 (en) * 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) * 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US7749498B2 (en) * 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20080248046A1 (en) * 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
NZ508381A (en) * 1997-03-17 2002-09-27 Human Genome Sciences Inc Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
US20050233958A1 (en) * 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
US20040136951A1 (en) * 1997-03-17 2004-07-15 Human Genome Sciences, Inc. Death domain containing receptor 5
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US5935813A (en) * 1997-03-20 1999-08-10 Incyte Pharmaceuticals, Inc. Human pancreatitis-associated protein
US5914394A (en) * 1997-03-27 1999-06-22 Millenium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
US5955355A (en) * 1997-03-27 1999-09-21 Millennium Pharmaceuticals, Inc. Chromosome 18 marker
US5866412A (en) * 1997-03-27 1999-02-02 Millennium Pharmaceuticals, Inc. Chromosome 18 marker
US5939316A (en) * 1997-03-27 1999-08-17 Millennium Pharmaceuticals, Inc. Chromosome 18 marker
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7083786B2 (en) * 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US20070059302A1 (en) * 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
EP0973804B1 (de) * 1997-04-07 2006-12-27 Genentech, Inc. Anti-vefg antibodies
ATE402717T1 (de) * 1997-04-09 2008-08-15 Intellect Neurosciences Inc Für die termini des beta-amyloids spezifische, rekombinante antikörper, dafür kodierende dna und verfahren zu ihrer verwendung
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
ES2187954T3 (es) 1997-04-11 2003-06-16 Searle & Co Anticuerpos anti-integrina avb3 antagonistas.
AU6954498A (en) 1997-04-11 1998-11-11 G.D. Searle & Co. Methods for using antagonistic anti-avb3 integrin antibodies
US20030207346A1 (en) * 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
US7115722B1 (en) 1997-05-22 2006-10-03 Viventia Biotech, Inc. Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US20020098190A1 (en) * 1997-06-13 2002-07-25 Malaya Chatterjee Compositions and methods for treating tumors bearing HMFG and CEA antigens
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US20030059780A1 (en) * 1997-06-16 2003-03-27 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
KR100220645B1 (ko) * 1997-07-04 1999-09-15 구광시 벤젠유도체의 제조방법
US6998108B1 (en) * 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
US7087420B1 (en) 1997-07-17 2006-08-08 Cambia Microbial β-glucuronidase genes, gene products and uses thereof
US6391547B1 (en) * 1997-09-09 2002-05-21 Center For The Application Of Molecular Biology To International Agriculture Microbial β-glucuronidase genes, gene products and uses thereof
US6849258B1 (en) 1997-07-18 2005-02-01 Universite Catholique De Louvain LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
EP1015480A2 (de) * 1997-08-18 2000-07-05 Innogenetics N.V. Interferon gamma bindende moleküle zur behandlung von septischem schock, cachexia, immunkrankheiten und hautkrankheiten
US6737249B1 (en) * 1997-08-22 2004-05-18 Genentech, Inc. Agonist antibodies
US7361336B1 (en) * 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US20030170794A1 (en) * 1997-09-18 2003-09-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
RU2221809C2 (ru) * 1997-10-03 2004-01-20 Тугаи Сейяку Кабусики Кайся Способ получения природного гуманизированного антитела
KR100362974B1 (ko) * 1997-10-14 2002-11-30 츄가이 세이야꾸 가부시키가이샤 림프구계 종양에 대한 항체의 증진제
US20030207375A1 (en) * 1997-10-24 2003-11-06 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2307846A1 (en) 1997-11-21 1999-06-03 Genset S.A. Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
BR9814912A (pt) 1997-11-28 2000-10-03 Genset Sa Sequência genÈmica e polipeptìdeos de chlamydia trachomatis, fragmentos dos mesmos e usos dos mesmos, em particular para o diagnóstico, a prevenção e o tratamento de infecção
DK1039931T3 (da) * 1997-12-01 2005-08-08 Fang Fang Multivalente rekombinante antistoffer til at behandle HRV infektioner
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
DE69824039T2 (de) 1997-12-08 2005-08-18 Lexigen Pharmaceuticals Corp., Lexington Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
US6610497B1 (en) * 1997-12-11 2003-08-26 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
CA2316975C (en) 1997-12-23 2009-03-24 North American Vaccine, Inc. Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugate vaccines
CA2316769A1 (en) * 1997-12-23 1999-07-01 Lawrence E. Samelson The protein tyrosine kinase substrate lat and its use in the identification of (ant)agonists of the kinase
US6673914B1 (en) 1998-01-22 2004-01-06 John Wayne Cancer Institute Human tumor-associated gene
US7026456B1 (en) 1998-01-23 2006-04-11 Hoffman-La Roche, Inc. Antibodies against human IL-12
AU2469299A (en) * 1998-01-23 1999-08-09 Cornell Research Foundation Inc. Purified populations of stem cells
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
EP3056516A1 (de) 1998-02-20 2016-08-17 Genentech, Inc. Hemmer der komplementär aktivierung
CA2321161C (en) 1998-02-24 2011-12-20 Andrew D. Weinberg Compositions containing an ox-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response
JP2002505097A (ja) * 1998-03-03 2002-02-19 アブジェニックス インク． 治療薬としてのｃｄ１４７結合分子
CA2323787A1 (en) * 1998-03-13 1999-09-16 Wayne Marasco Humanized antibody and uses thereof
CA2323830A1 (en) 1998-03-16 1999-09-23 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating chromosome-18p related disorders
US20040176572A1 (en) * 1998-03-16 2004-09-09 Freimer Nelson B. Methods of compositions for diagnosing and treating chromosome-18p related disorders
CA2324115C (en) * 1998-03-17 2008-12-23 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for inflammatory bowel disease comprising il-6 antagonist as an active ingredient
EP1982990A1 (de) 1998-03-19 2008-10-22 Human Genome Sciences, Inc. Zytokinrezeptor wie eine gemeinsame Gammakette
US6077508A (en) * 1998-03-23 2000-06-20 American Diagnostica Inc. Urokinase plasminogen activator receptor as a target for diagnosis of metastases
SK14812000A3 (sk) * 1998-04-03 2001-08-06 Chugai Seiyaku Kabushiki Kaisha Chimérny reťazec protilátky, chimérna protilátka, v oblasť, humanizovaný reťazec protilátky, humanizovaná protilátka, dna, expresný vektor, hostiteľ, spôsob prípravy a liečivo
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US6864227B1 (en) * 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US20020029391A1 (en) * 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
JP2002512776A (ja) * 1998-04-28 2002-05-08 スミスクライン・ビーチャム・コーポレイション 免疫原性の低下したモノクローナル抗体
EP0953639A1 (de) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-spezifischer Antikörper mit verbesserter Produzierbarkeit
US6455677B1 (en) 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
US20030186368A1 (en) * 1998-05-13 2003-10-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2237915A1 (en) * 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
US20040022788A1 (en) * 1998-05-19 2004-02-05 Moser Tammy L. Compositions and methods for promoting or inhibiting angiogenesis
JP4044733B2 (ja) * 1998-05-20 2008-02-06 帝人株式会社 ベロ毒素ｉｉを認識するヒト型化抗体、および該抗体を産生する細胞株
AU765822B2 (en) 1998-05-23 2003-10-02 Leiden University Medical Center CD40 binding molecules and CTL peptides for treating tumors
US20040141975A1 (en) * 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US5973119A (en) * 1998-06-05 1999-10-26 Amgen Inc. Cyclin E genes and proteins
US20030109681A1 (en) * 1998-06-10 2003-06-12 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7387772B1 (en) 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US7833528B2 (en) * 1998-06-22 2010-11-16 Immunomedics, Inc. Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
US7405320B2 (en) 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
US20030167483A1 (en) * 1998-06-24 2003-09-04 Farese Robert V. Diacylglycerol O-acyltransferase
US7339033B2 (en) * 1998-06-26 2008-03-04 Genentech, Inc. Pro1481
CA2331386A1 (en) 1998-06-26 2000-01-06 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins
WO2000003016A1 (en) * 1998-07-10 2000-01-20 Connex Gmbh Immunological reagent specifically interacting with the extracellular domain of the human zeta chain
CA2331789C (en) 1998-07-13 2013-09-10 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6406693B1 (en) * 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
EP1096955B9 (de) * 1998-07-13 2006-07-05 Board of Regents, The University of Texas System Verwendung von antikörper gegen aminophospholipide zur krebsbehandlung
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
GB9815909D0 (en) * 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US6312689B1 (en) * 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
US6727349B1 (en) * 1998-07-23 2004-04-27 Millennium Pharmaceuticals, Inc. Recombinant anti-CCR2 antibodies and methods of use therefor
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
EP1112084B2 (de) 1998-08-11 2012-04-25 Biogen Idec Inc. Kombinationstherapien gegen b-zell-lymphome beinhaltend die verabreichung von anti-cd20-antikörpern
US20020172678A1 (en) * 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US7264801B2 (en) * 1998-08-11 2007-09-04 Genentech, Inc. EG-VEGF nucleic acids and polypeptides and method of use
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
AU757873B2 (en) 1998-09-14 2003-03-06 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
DE69931377T2 (de) * 1998-09-18 2007-05-10 Dynavax Technologies Corp., Berkeley Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
US6878528B1 (en) * 1998-09-25 2005-04-12 Schering Corporation Polynucleotides encoding a mammalian Langerhans cell antigen
WO2000021560A1 (en) * 1998-10-09 2000-04-20 Ludwig Institute For Cancer Research Flt4 (VEGFR-3) AS A TARGET FOR TUMOR IMAGING AND ANTI-TUMOR THERAPY
US6406695B1 (en) 1998-10-30 2002-06-18 University Of Miami Treatment of hepatitis C by administration of anti-IL-2 receptor monoclonal antibody
DE69938435D1 (de) * 1998-10-30 2008-05-08 Novozymes As Niedrigallergene Proteinvarianten
US6818749B1 (en) * 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
MY155913A (en) * 1998-11-09 2015-12-15 Biogen Inc Chimeric anti-cd20 antibody treatment of patients receiving bmt or pbsc transpants
WO2000027428A1 (en) 1998-11-09 2000-05-18 Idec Pharmaceuticals Corporation Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody
KR20000034847A (ko) * 1998-11-17 2000-06-26 성재갑 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
WO2000029431A1 (en) * 1998-11-17 2000-05-25 Tanox, Inc. Bispecific molecules cross-linking itim and itam for therapy
US7118743B2 (en) * 1998-11-17 2006-10-10 Tanox, Inc. Bispecific molecules cross-linking ITIM and ITAM for therapy
US20030096976A1 (en) * 1998-11-17 2003-05-22 Hong Hyo Jeong Humanized antibodies LB-00503 and LB-00506 specific for human 4-1BB and pharmaceutical compositions comprising said humanized antibodies
US6395511B1 (en) * 1998-11-27 2002-05-28 Darwin Discovery, Ltd. Nucleic acids encoding a novel family of TGF-β binding proteins from humans
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US20030035798A1 (en) * 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
US7666609B1 (en) * 1998-12-01 2010-02-23 Shanghai Cp Guojian Pharmaceutical Co. Ltd. Method and composition for diagnosis of melanocytic lesions
MXPA01005515A (es) * 1998-12-01 2003-07-14 Protein Design Labs Inc Anticuerpos humanizados para gamma-interferon.
DE69927520T2 (de) 1998-12-09 2006-06-22 Protein Design Labs, Inc., Fremont Verwendung von il-12 antikörpern zur behandlung von psoriasis
US7553487B2 (en) * 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
MXPA01006006A (es) 1998-12-14 2004-08-12 Genetics Inst Cadena receptora de citocina.
KR100856446B1 (ko) 1998-12-23 2008-09-04 화이자 인크. Ｃｔｌａ－４에 대한 인간 단일클론 항체
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US20030190669A1 (en) * 1998-12-30 2003-10-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
PT1149111E (pt) * 1999-01-06 2009-11-19 Univ Southern California Processo e composição para a inibição da angiogénese
US20050281821A1 (en) * 1999-01-06 2005-12-22 Flavia Pernasetti Method and composition for angiogenesis inhibition
TR200101998T2 (tr) 1999-01-07 2002-06-21 Zymogenetics, Inc. Çözünür reseptör BR 43x2 ve kullanım metodları
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
KR20010102978A (ko) 1999-01-15 2001-11-17 아스트루 마이클 제이 면역 질환 치료를 위한 트위크 길항약 및 트위크 수용체길항약 및 이들의 용도
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US6972125B2 (en) * 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
EP1159300A2 (de) * 1999-02-12 2001-12-05 Genetics Institute, Inc. Humanisierte immunoglobuline gerichtet gegen b7 moleküle und behandlungsmethoden damit
CA2363779A1 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US6403309B1 (en) 1999-03-19 2002-06-11 Valigen (Us), Inc. Methods for detection of nucleic acid polymorphisms using peptide-labeled oligonucleotides and antibody arrays
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6911429B2 (en) * 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6943235B1 (en) * 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
US7244827B2 (en) 2000-04-12 2007-07-17 Agensys, Inc. Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
ES2274781T3 (es) * 1999-04-13 2007-06-01 Wilex Ag Empleo diagnostico y terapeutico de anticuerpos contra el receptor de la urocinasa.
WO2000064946A2 (en) 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
WO2000066160A1 (fr) * 1999-04-28 2000-11-09 Yamanouchi Pharmaceutical Co., Ltd. Composition medicamenteuse parenterale a fragment d'anticorps monoclonal humanise et procede de stabilisation
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
NZ515678A (en) 1999-04-28 2004-01-30 Genetics Inst Human GIL-19/AE289 proteins and polynucleotides encoding same
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6900052B1 (en) * 1999-05-10 2005-05-31 Chugai Seiyaku Kabushiki Kaisha Method of culturing cells
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US7829064B2 (en) * 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US8119101B2 (en) * 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US20080286821A1 (en) * 1999-05-14 2008-11-20 Eaton Dan L Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7261881B1 (en) 1999-05-20 2007-08-28 Yale University Modulation of angiogenesis and wound healing
ATE401348T1 (de) * 1999-05-27 2008-08-15 Us Gov Health & Human Serv Immunokonjugate mit hoher bindungsaffinität
US7166573B1 (en) * 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
EA011384B1 (ru) 1999-06-01 2009-02-27 Байоджен Айдек Ма Инк. Способ лечения воспалительного заболевания
US20040219149A1 (en) * 2001-06-08 2004-11-04 Yuhong Zhou Methods for the modulation of il-13
US20030103948A1 (en) * 1999-06-07 2003-06-05 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US20030143233A1 (en) * 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
FR2794865B1 (fr) * 1999-06-09 2003-04-18 Pasteur Institut Methode de detection precoce des flavivirus et ses applications
WO2000076538A1 (en) 1999-06-10 2000-12-21 Michigan State University Feline calicivirus isolated from cat urine and vaccines thereof
US6531580B1 (en) 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
EP1218538A2 (de) 1999-06-30 2002-07-03 Ludwig Institute For Cancer Research Mit krebs in verbindung stehende antigene und deren verwendung
US20040001826A1 (en) * 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
TWI255718B (en) * 1999-07-02 2006-06-01 Chugai Pharmaceutical Co Ltd Ameliorative agent for low vasopressin concentration
IL147336A0 (en) 1999-07-07 2002-08-14 Zymogenetics Inc Human cytokine receptor
AU783019B2 (en) * 1999-07-13 2005-09-15 University Of Southern California Novel method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and beta1 integrins
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US6693176B1 (en) * 1999-07-23 2004-02-17 University Of Massachusetts Antitumor antibodies, proteins, and uses thereof
US7674466B2 (en) * 1999-08-05 2010-03-09 The Trustees Of The University Of Pennsylvania Targeting and prolonging association of drugs to the luminal surface of the pulmonary vascular endothelial cells using antibodies that bind to ICAM-1
BR0013231A (pt) 1999-08-09 2002-07-23 Lexigen Pharm Corp Complexos citocina-anticorpo múltiplos
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US7192698B1 (en) * 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
TWI248365B (en) * 1999-08-23 2006-02-01 Chugai Pharmaceutical Co Ltd HM1.24 antigen expression potentiators
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP2829609A1 (de) 1999-08-24 2015-01-28 E. R. Squibb & Sons, L.L.C. Humane Antikörper gegen CTLA-4-Antikörper und Verwendungen davon
US6673346B1 (en) 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
EP1207889A4 (de) 1999-09-02 2004-05-19 Univ Michigan State Vakzin zur behandlung von pferdeprotozoenmyenzephalitis in pferden
US7419668B1 (en) 1999-09-02 2008-09-02 Board Of Trustees Of Michigan State University Vaccine to control equine protozoal myeloencephalitis in horses
US7459540B1 (en) * 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US7297478B1 (en) 2000-09-22 2007-11-20 Large Scale Biology Corporation Creation of variable length and sequence linker regions for dual-domain or multi-domain molecules
DE60038252T2 (de) * 1999-09-30 2009-03-19 Kyowa Hakko Kogyo Co., Ltd. Menschlicher Antikörper gegen Gangliosid GD3 für die Transplantationskomplentarität bestimmende Region und Derivate des Antikörpers gegen das Gangliosid GD3
US7892541B1 (en) 1999-09-30 2011-02-22 Tumor Biology Investment Group, Inc. Soluble epidermal growth factor receptor isoforms
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
WO2001024823A1 (en) * 1999-10-04 2001-04-12 Chiron Corporation Cd40 antagonist for treating psoriasis
US7361338B2 (en) * 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US6790631B1 (en) * 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20090004103A1 (en) * 1999-10-08 2009-01-01 Young David S F Cytotoxicity mediation of cells evidencing surface expression of CD44
US7252821B2 (en) 1999-10-08 2007-08-07 Arius Research Inc. Cancerous disease modifying antibodies
US20080124327A1 (en) * 1999-10-08 2008-05-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) * 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
AU783776B2 (en) 1999-10-12 2005-12-01 Chemocentryx, Inc. Chemokine receptor
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
WO2001029220A2 (en) 1999-10-19 2001-04-26 Ludwig Institute For Cancer Research Mage-a12 antigenic peptides and uses thereof
KR100874280B1 (ko) * 1999-10-20 2008-12-18 제넨테크, 인크. Ｔ 헬퍼 세포 매개 질환의 치료를 위한 ｔ 세포 분화의조절
US6346249B1 (en) 1999-10-22 2002-02-12 Ludwig Institute For Cancer Research Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products
US6342587B1 (en) 1999-10-22 2002-01-29 Ludwig Institute For Cancer Research A33 antigen specific immunoglobulin products and uses thereof
SE9903895D0 (sv) * 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds
US20030103975A1 (en) * 1999-11-03 2003-06-05 Jones Jonathan C.R. Modulation of angiogenesis and endothelialization
EP1228214A2 (de) 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietinformen mit verbesserten eigenschaften
US6979546B2 (en) * 1999-11-15 2005-12-27 Universita Di Genova Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
ES2377935T3 (es) 1999-12-02 2012-04-03 Zymogenetics, Inc. Procedimiento para dirigir células que expresan receptor -3 o -2 del factor de crecimiento de fibroblastos
EP2140881B1 (de) 1999-12-16 2013-04-17 Biogen Idec MA Inc. Verfahren zur Behandlung von ischämischen oder hämorrhagischen Traumata des Zentralnervensystems unter Verwendung von Alpha4-Integrin-Antagonisten
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20060228364A1 (en) * 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
ATE337403T1 (de) * 1999-12-24 2006-09-15 Genentech Inc Verfahren und verbindungen zur verlängerung der halbwertzeiten bei der ausscheidung von biowirksamen verbindungen
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
IT1307309B1 (it) * 1999-12-30 2001-10-30 Enea Ente Nuove Tec Peptidi stabilizzanti, polipeptidi ed anticorpi che li comprendono.
BR0107613A (pt) 2000-01-12 2002-11-19 Univ Yale Bloqueio do crescimento de axÈnios mediado por receptor nogo
EP1246917B1 (de) * 2000-01-13 2009-03-04 Genentech, Inc. Menschliche stra6 polypeptide
AU2002219944B2 (en) 2000-11-28 2008-02-21 Medimmune, Llc Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6656467B2 (en) 2000-01-27 2003-12-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
WO2001055393A2 (en) 2000-01-28 2001-08-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1
WO2001056603A1 (en) * 2000-02-01 2001-08-09 Tanox, Inc. Cd40-binding apc-activating molecules
TWI373343B (en) * 2000-02-10 2012-10-01 Abbott Gmbh & Co Kg Antibodies that bind human interleukin-18 and methods of making and using
ES2269366T3 (es) 2000-02-11 2007-04-01 Merck Patent Gmbh Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos.
US7148061B2 (en) * 2000-02-11 2006-12-12 The United States Of America As Represented By The Department Of Health And Human Services Identification of a novel domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
CN1420775A (zh) 2000-02-17 2003-05-28 Cv治疗公司 鉴定及使用a2b腺苷受体拮抗剂介导哺乳动物细胞增殖的方法
TR200202799T3 (tr) * 2000-02-24 2003-03-21 Washington University St.Louis AB peptidini sekanslayan insanlaştırılmış antikorlar
ES2390761T3 (es) 2000-03-01 2012-11-16 Medimmune, Llc Anticuerpos recombinantes de alta potencia y método para producción de los mismos
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
EP1267926A2 (de) 2000-03-17 2003-01-02 Millennium Pharmaceuticals, Inc. Verfahren zur hemmung von stenose und restenose mit einer mischung von antikörpern gegen cd18 und ccr2
US6998468B2 (en) * 2000-03-23 2006-02-14 Tanox, Inc. Anti-C2/C2a inhibitors of complement activation
US7514239B2 (en) 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
BR0001078A (pt) * 2000-04-06 2003-05-13 Maria Amalia Rotolo De Moraes Método e aparelho de estìmulo positivo mental
ES2528794T3 (es) * 2000-04-11 2015-02-12 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
EP1276849A4 (de) 2000-04-12 2004-06-09 Human Genome Sciences Inc Albumin fusionsproteine
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
US7364867B2 (en) * 2000-04-17 2008-04-29 The Mount Sinai School Of Medicine Method of identifying bitter compounds by employing TRP8, a transient receptor potential channel expressed in taste receptor cells
US7094882B2 (en) * 2000-04-21 2006-08-22 Yeda Research And Development Co. Ltd. Growth factor which acts through erb b-4 rtk
US7439330B2 (en) * 2000-05-08 2008-10-21 President And Fellows Of Harvard College Anti-glycated CD59 antibodies and uses thereof
US6835545B2 (en) 2000-05-08 2004-12-28 President And Fellows Of Harvard College Methods, products and treatments for diabetes
EP1935431A3 (de) 2000-05-15 2008-08-13 Health Research, Inc. Krebsbehandlungen unter Verwendung einer Kombination aus einem HER2-Antikörper und Interleukin-2
CN1239701C (zh) * 2000-05-19 2006-02-01 梨树化学株式会社 抗表皮生长因子受体的人源化抗体
US6927320B1 (en) 2000-05-24 2005-08-09 New York University Short-root gene, promoter, and uses thereof
EP1299419A2 (de) * 2000-05-24 2003-04-09 Imclone Systems, Inc. Bispezifische immunglobulinartige antigenbindende proteine und verfahren zur deren herstellung
US6656700B2 (en) * 2000-05-26 2003-12-02 Amersham Plc Isoforms of human pregnancy-associated protein-E
US6686188B2 (en) * 2000-05-26 2004-02-03 Amersham Plc Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
EP1950297A2 (de) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und Verfahren zur Behandlung neoplastischer Erkrankungen mithilfe von Chemotherapie und Strahlungssensibilisatoren
US6649359B2 (en) 2000-06-01 2003-11-18 The Brigham & Women's Hospital, Inc. Diagnosis of endometrial precancers
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
DE60141463D1 (de) 2000-06-08 2010-04-15 Immune Disease Inst Inc Methoden und verbindungen zur hemmung immunoglobulin-vermittelter reperfusions-verletzungen
WO2001096528A2 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
PT2275449T (pt) 2000-06-16 2016-12-27 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
ATE446366T1 (de) * 2000-06-22 2009-11-15 Genentech Inc Agonistische monoklonale antikörper gegen trkc
AU2001272968C1 (en) 2000-06-22 2008-06-05 Amgen Inc. Il-17 molecules and uses thereof
WO2002000724A2 (en) 2000-06-28 2002-01-03 Amgen, Inc. Thymic stromal lymphopoietin receptor molecules and uses thereof
DE60129695T2 (de) 2000-06-29 2008-06-05 Merck Patent Gmbh Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
JP2002017361A (ja) * 2000-07-04 2002-01-22 Inst Of Physical & Chemical Res リーリンタンパク質ｃｒ−５０エピトープ領域
AU2001283062A1 (en) * 2000-08-02 2002-02-13 The Johns Hopkins University Endothelial cell expression patterns
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US20080194022A1 (en) * 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
KR100886276B1 (ko) * 2000-08-11 2009-03-04 기린 파마 가부시끼가이샤 인산 대사, 칼슘 대사, 석회화 및 비타민 ｄ 대사를조절하는 폴리펩티드 및 그것을 코딩하는 ｄｎａ
AU2001288342A1 (en) * 2000-08-21 2002-03-04 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
EP1197550A3 (de) * 2000-08-25 2002-11-20 Pfizer Products Inc. Methoden und Zusammensetzungen zur Diagnose unde Behandlung von Krankheiten an denen Angiogenese beteiligt ist
US6803211B2 (en) 2000-08-25 2004-10-12 Pfizer Inc. Methods and compositions for diagnosing and treating disorders involving angiogenesis
EP1313850B1 (de) * 2000-08-28 2008-08-06 Agensys, Inc. Nukleinsäure und korrespondierendes protein 85p1b3, nützlich zur behandlung und detektion von krebserkrankungen
JP2004529849A (ja) * 2000-09-01 2004-09-30 インターナショナル バイオイムン システムズ，インコーポレーテッド 扁平上皮癌に対する特異的モノクローナル抗体の同定と開発
DE10043481A1 (de) * 2000-09-04 2002-04-11 Vectron Therapeutics Ag Imt Humaner Antikörper gegen Endoglin (CD105) und seine Verwendung
US20040018181A1 (en) * 2000-09-11 2004-01-29 KUFE Donald W. MUC1 interference RNA compositions and methods derived therefrom
KR20030068536A (ko) * 2000-09-11 2003-08-21 다나-파버 캔서 인스티튜트 Ｍｕｃ1 세포외 도메인 및 이로부터 유래된 암 치료조성물과 방법
US7101976B1 (en) * 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
US7015008B2 (en) * 2000-09-29 2006-03-21 Merck & Co., Inc. Antibodies for human cytochrome P450 2D6
JP4271440B2 (ja) * 2000-10-02 2009-06-03 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ヒト抗ｃｄ４０抗体
US20020123474A1 (en) * 2000-10-04 2002-09-05 Shannon Mark E. Human GTP-Rho binding protein2
US7029866B1 (en) * 2000-10-10 2006-04-18 Hanswalter Zentgraf Cancer diagnosis by the measurement of Nup88 in body samples
JP2004532608A (ja) * 2000-10-13 2004-10-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド ヒト化抗ＬＴ−β−Ｒ抗体
US7666424B2 (en) * 2001-10-17 2010-02-23 Sloan-Kettering Institute For Cancer Research Methods of preparing and using single chain anti-tumor antibodies
US7737258B2 (en) * 2000-10-18 2010-06-15 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US7393532B1 (en) 2000-10-18 2008-07-01 Genentech, Inc. Modulation of T cell differentiation for the treatment of T helper cell mediated diseases
US8414892B2 (en) * 2000-10-18 2013-04-09 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US8501471B2 (en) * 2000-10-18 2013-08-06 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US7740845B2 (en) * 2000-10-18 2010-06-22 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
ES2298273T3 (es) * 2000-10-25 2008-05-16 Chugai Seiyaku Kabushiki Kaisha Agentes preventivos o terapeuticos contra la psoriasis que contienen un antagonista de il-6 como su ingrediente activo.
AU2002241556B2 (en) * 2000-11-01 2007-07-19 Elusys Therapeutics, Inc. Method of producing bispecific molecules by protein trans-splicing
WO2002043658A2 (en) * 2000-11-06 2002-06-06 The Jackson Laboratory Fcrn-based therapeutics for the treatment of auto-immune disorders
US7235643B2 (en) 2000-11-07 2007-06-26 Morphotek, Inc. Antibodies and methods for generating genetically altered antibodies with high affinity
US6808894B1 (en) 2000-11-07 2004-10-26 Morphotek, Inc. Methods for generating genetically altered antibody producing cell lines with improved antibody characteristics
EP1345495B1 (de) 2000-11-07 2009-02-25 Morphotek Inc. Verfahren zur herstellung von genetisch modifizierten antikörperproduzierenden zelllinien mit verbesserten antikörpereigenschaften
US20030092164A1 (en) 2000-11-07 2003-05-15 Gross Jane A. Human tumor necrosis factor receptor
US7608704B2 (en) 2000-11-08 2009-10-27 Incyte Corporation Secreted proteins
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US20070258987A1 (en) * 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US6855493B2 (en) * 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
GB0029360D0 (en) * 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) * 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
JP2004535765A (ja) 2000-12-07 2004-12-02 カイロン コーポレイション 前立腺癌においてアップレギュレートされた内因性レトロウイルス
US9249229B2 (en) * 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2002059280A2 (en) * 2000-12-08 2002-08-01 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line and its use for producing an antibody
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
EP2341060B1 (de) 2000-12-12 2019-02-20 MedImmune, LLC Moleküle mit längeren Halbwertszeiten, Zusammensetzungen und deren Verwendung
US20030049800A1 (en) * 2000-12-15 2003-03-13 Saravis Calvin A. Compositions and methods for producing antibodies to low molecular weight analytes
ES2390425T3 (es) 2000-12-22 2012-11-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
US20020110841A1 (en) * 2000-12-22 2002-08-15 KUFE Donald W. Regulation of cell growth by MUC1
EP1219637A1 (de) * 2000-12-27 2002-07-03 Innate Pharma Polypeptide, die NK Zellen aktivieren und deren biologische Verwendung
AR032028A1 (es) 2001-01-05 2003-10-22 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
AU2002241922B2 (en) 2001-01-17 2007-10-25 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
ATE359300T1 (de) 2001-01-19 2007-05-15 Ludwig Inst Cancer Res Flt4 (vegfr-3) als ein ziel für krebs darstellung und anti-krebs-behandlung
EP1224942A1 (de) * 2001-01-23 2002-07-24 Bernhard Dr. Nieswandt Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases
WO2002059337A1 (en) * 2001-01-26 2002-08-01 Georgetown University School Of Medicine Anti-apoptopic gene scc-s2 and diagnostic and therapeutic uses thereof
CA2444661A1 (en) 2001-01-31 2002-08-08 Idec Pharmaceutical Corporation Use of cd23 antagonists for the treatment of neoplastic disorders
AU2002251913A1 (en) * 2001-02-02 2002-08-19 Millennium Pharmaceuticals, Inc. Hybrid antibodies and uses thereof
JP3986439B2 (ja) * 2001-02-07 2007-10-03 中外製薬株式会社 造血器腫瘍の治療剤
ATE337395T1 (de) * 2001-02-07 2006-09-15 Wilex Ag Hybridomzelllinie g250 und deren verwendung zur herstellung monoklonaler antikörper
US20040077081A1 (en) * 2001-02-07 2004-04-22 Egbert Oosterwijk Hybridoma cell line g250 and its use for producing monoclonal antibodies
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
JP2005503116A (ja) 2001-02-09 2005-02-03 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド ヒトｇタンパク質ケモカインレセプター（ｃｃｒ５）ｈｄｇｎｒ１０
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US6692700B2 (en) 2001-02-14 2004-02-17 Handylab, Inc. Heat-reduction methods and systems related to microfluidic devices
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
EP1998266A3 (de) 2001-02-19 2009-02-11 Merck Patent GmbH Verfahren zur Identifizierung von T-Zell-Epitopen und Verfahren zur Herstellung von Molekülen mit verminderter Immunogenität
JP2004533997A (ja) 2001-02-20 2004-11-11 ザイモジェネティクス，インコーポレイティド Ｂｃｍａ及びｔａｃｉの両者を結合する抗体
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
WO2002067984A2 (en) 2001-02-22 2002-09-06 University Of Florida Materials and methods for detecting, preventing, and treating hiv and fiv retroviral infection
AU2002250236A1 (en) * 2001-03-02 2002-09-19 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
BR0207854A (pt) 2001-03-07 2004-08-24 Merck Patent Gmbh Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
ATE434936T1 (de) 2001-03-14 2009-07-15 Myriad Genetics Inc Tsg101-gag-wechselwirkung und ihre verwendung
ES2619313T3 (es) * 2001-03-15 2017-06-26 Precision Biologics, Inc. Terapia de anticuerpos monoclonales para el cáncer de páncreas
US20090081199A1 (en) * 2001-03-20 2009-03-26 Bioxell S.P.A. Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
CA2342376C (en) * 2001-03-20 2013-11-12 Marco Colonna A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
WO2002076499A2 (en) * 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
US20090123470A1 (en) * 2001-03-26 2009-05-14 The Macfarlane Burnet Istitute For Medical Research And Public Health Ltd. Antibodies Against Cancer
US6852287B2 (en) 2001-09-12 2005-02-08 Handylab, Inc. Microfluidic devices having a reduced number of input and output connections
US7829025B2 (en) 2001-03-28 2010-11-09 Venture Lending & Leasing Iv, Inc. Systems and methods for thermal actuation of microfluidic devices
US6575188B2 (en) 2001-07-26 2003-06-10 Handylab, Inc. Methods and systems for fluid control in microfluidic devices
US7010391B2 (en) 2001-03-28 2006-03-07 Handylab, Inc. Methods and systems for control of microfluidic devices
US7323140B2 (en) 2001-03-28 2008-01-29 Handylab, Inc. Moving microdroplets in a microfluidic device
SE0101093D0 (sv) 2001-03-28 2001-03-28 Pharmacia Diagnostics Ab Novel compound for treatment of allergy and asthma
US8895311B1 (en) 2001-03-28 2014-11-25 Handylab, Inc. Methods and systems for control of general purpose microfluidic devices
US7270786B2 (en) 2001-03-28 2007-09-18 Handylab, Inc. Methods and systems for processing microfluidic samples of particle containing fluids
US7192557B2 (en) 2001-03-28 2007-03-20 Handylab, Inc. Methods and systems for releasing intracellular material from cells within microfluidic samples of fluids
JP2005508839A (ja) 2001-03-29 2005-04-07 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド ペプチドおよびｍｕｃ１タンパク質に対する抗体
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US20030003097A1 (en) * 2001-04-02 2003-01-02 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with GnTIII
WO2002081639A2 (en) * 2001-04-06 2002-10-17 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002303262A1 (en) * 2001-04-06 2002-10-21 Georgetown University Gene shinc-1 and diagnostic and therapeutic uses thereof
JP4398644B2 (ja) * 2001-04-06 2010-01-13 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア ＥｒｂＢ界面ペプチド擬態およびその使用方法
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
US20020146753A1 (en) * 2001-04-06 2002-10-10 Henrik Ditzel Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease
WO2002081641A2 (en) * 2001-04-06 2002-10-17 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
YU80903A (sh) * 2001-04-13 2006-05-25 Biogen Inc. Antitela vla-1
DE60236646D1 (de) 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 Antikörper
US20040219632A1 (en) * 2001-04-20 2004-11-04 Robert Margolskee T1r3 a novel taste receptor
US7803982B2 (en) 2001-04-20 2010-09-28 The Mount Sinai School Of Medicine Of New York University T1R3 transgenic animals, cells and related methods
PT1390389E (pt) * 2001-04-26 2009-04-03 Biogen Idec Inc Anticorpos que bloqueiam o cripto e as utilizações dos mesmos
US7582299B2 (en) * 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
DE60229051D1 (de) * 2001-04-30 2008-11-06 Lilly Co Eli Humanisierte antikörper
ES2437875T3 (es) * 2001-04-30 2014-01-14 Eli Lilly And Company Anticuerpos humanizados que reconocen el péptido beta-amiloide
DE60239454D1 (de) * 2001-05-03 2011-04-28 Merck Patent Gmbh Rekombinanter, tumorspezifischer antikörper und dessen verwendung
US6794501B2 (en) * 2001-05-04 2004-09-21 Ludwig Institute For Cancer Research Colon cancer antigen panel
US7803382B2 (en) * 2001-05-04 2010-09-28 Ludwig Institute For Cancer Research Ltd. Method for inducing immune response to NY-CO-58
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
US7304034B2 (en) * 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
HUP0400030A3 (en) * 2001-05-18 2006-02-28 Boehringer Ingelheim Pharma Antibodies specific for cd44v6
FI112501B (fi) * 2001-05-18 2003-12-15 Valtion Teknillinen Heveiiniä sitovat monoklonaaliset vasta-aineet
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
JP2004535400A (ja) * 2001-05-22 2004-11-25 デューク ユニバーシティ 転移阻害のための組成物及び方法
US20020197253A1 (en) * 2001-05-22 2002-12-26 Cheek Dennis J. Compositions and methods for promoting or inhibiting NDPK
UY27304A1 (es) * 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
WO2002097033A2 (en) 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7745398B2 (en) * 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 and treatment of cancer
US7744882B2 (en) 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 methods of detection and antibodies
US7129261B2 (en) * 2001-05-31 2006-10-31 Medarex, Inc. Cytotoxic agents
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US7666414B2 (en) * 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
EP1392360B1 (de) * 2001-06-01 2011-11-30 Cornell Research Foundation, Inc. Modifizierte antikörper gegen prostata-spezifisches membranantigen und ihre verwendungen
US20050152902A1 (en) * 2001-06-05 2005-07-14 Advanced Biotherapy, Inc. Treatment of diabetic retinopathy
US6861056B2 (en) * 2001-06-05 2005-03-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US20040062768A1 (en) * 2001-06-05 2004-04-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US6534059B2 (en) * 2001-06-05 2003-03-18 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US20040086508A1 (en) * 2001-06-05 2004-05-06 Advanced Biotherapy, Inc. Treatment of organ transplant rejection
AU2002313194B9 (en) * 2001-06-12 2008-06-05 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human-type anti-blood coagulation factor VIII antibody
IL159177A0 (en) * 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
JP2005508298A (ja) * 2001-06-20 2005-03-31 イムクローン システムズ インコーポレイティド アテローム性動脈硬化症及び他の炎症性疾患を処置する方法
WO2003002187A2 (en) * 2001-06-26 2003-01-09 Photomed Technologies, Inc. Multiple wavelength illuminator
WO2003002144A1 (en) * 2001-06-26 2003-01-09 Imclone Systems Incorporated Bispecific antibodies that bind to vegf receptors
AU2002318960B2 (en) * 2001-06-26 2008-05-15 Agen Biomedical Limited Humanized antibodies derived from DD-3B6/22, specific for the D-dimer fragment of fibrin
US20030013081A1 (en) 2001-06-26 2003-01-16 Olson William C. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
PL222211B1 (pl) 2001-06-26 2016-07-29 Amgen Fremont Inc Przeciwciało przeciwko OPGL, kompozycja je zawierająca, jego zastosowanie i sposób jego wytwarzania, sposób wykrywania poziomu OPGL, kompozycja obejmująca polinukleotydy i komórka gosodarza
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
EP1422243B1 (de) 2001-06-28 2008-04-23 Kyowa Hakko Kogyo Co., Ltd Humanisierter antikörper gegen fibroblastenwachstumsfaktor 8 und fragment des antikörpers
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
DE60237282D1 (de) * 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
KR20040049830A (ko) * 2001-07-09 2004-06-12 애프톤 코포레이션 간, 폐 및 식도의 암 및 전암 상태의 치료 및 예방
US7393656B2 (en) 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
US20060269548A1 (en) * 2001-07-12 2006-11-30 Kari Alitalo Lymphatic endothelial cells materials and methods
WO2004006955A1 (en) * 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
WO2003007881A2 (en) * 2001-07-16 2003-01-30 The Trustees Of Columbia University In The City Of New York Antibodies specific for nanotubes and related methods and compositions
US6884619B2 (en) 2001-07-17 2005-04-26 Yale University Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
JP2005522192A (ja) * 2001-07-19 2005-07-28 パーラン セラピューティクス， インコーポレイテッド マルチマータンパク質およびマルチマータンパク質を作製および使用する方法
US20050075488A1 (en) * 2001-07-26 2005-04-07 Bright Stuart Willis Interleukin-1 beta antibodies
US6867189B2 (en) * 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
US6833441B2 (en) * 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US20040078837A1 (en) * 2001-08-02 2004-04-22 Shannon Mark E. Four human zinc-finger-containing proteins: MDZ3, MDZ4, MDZ7 and MDZ12
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
WO2003014142A2 (en) * 2001-08-03 2003-02-20 University Of Virginia Patent Foundation Phosphorylated histone h2b as an apoptosis marker
JP4729717B2 (ja) * 2001-08-03 2011-07-20 株式会社医学生物学研究所 ＧＭ１ガングリオシド結合型アミロイドβタンパク質を認識する抗体、及び該抗体をコードするＤＮＡ
JP2005526482A (ja) * 2001-08-10 2005-09-08 イムクローン システムズ インコーポレイティド Ｖｅｇｆｒ−１を発現する幹細胞の単離および動員
US20030035802A1 (en) * 2001-08-14 2003-02-20 Dewan Zeng Localization of A2B AdoR on human normal and diseased tissue: the use of anti-A2B antibody to diagnose and treat human tumors
DK1944040T3 (da) * 2001-08-17 2012-10-29 Univ Washington Analysefremgangsmåde for Alzheimers sygdom
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
IL145279A0 (en) * 2001-09-04 2002-06-30 Yeda Res & Dev Antibodies against caspase-8, their preparation and use
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20070082337A1 (en) * 2004-01-27 2007-04-12 Compugen Ltd. Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered thereby
WO2003024480A2 (en) * 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
CN1589403B (zh) 2001-09-18 2011-06-01 法布罗根股份有限公司 测定结缔组织生长因子的方法
US20030219839A1 (en) * 2001-09-20 2003-11-27 Katherine Bowdish Anti-PDGF antibodies and methods for producing engineered antibodies
CA2460587A1 (en) * 2001-09-20 2003-03-27 Alexion Pharmaceuticals, Inc. Anti-pdgf antibodies and methods for producing engineered antibodies
US20030124132A1 (en) * 2001-09-27 2003-07-03 Board Of Regents, The University Of Texas System Combined compositions for tumor vasculature coaguligand treatment
ES2629395T3 (es) 2001-10-04 2017-08-09 Genetics Institute, Llc Métodos y composiciones para modular la actividad de la interleucina-21
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
AU2002340167A1 (en) * 2001-10-11 2003-06-17 Protein Design Labs Inc. Anti-hla-dr antibodies and the methods of using thereof
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US8165535B2 (en) * 2006-06-04 2012-04-24 Samsung Electro-Mechanics Systems, methods and apparatuses for complementary metal oxide semiconductor (CMOS) antenna switches using switched resonators
EP1444267B1 (de) * 2001-10-15 2016-08-10 Immunomedics, Inc. Affinitätsverstärkende mittel
CN1604966A (zh) * 2001-10-15 2005-04-06 免疫医疗公司 直接靶定的结合蛋白
US20050238650A1 (en) * 2002-04-17 2005-10-27 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US20040151721A1 (en) * 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
KR101159061B1 (ko) 2001-10-22 2012-06-22 더 스크립스 리서치 인스티튜트 항체 표적화 화합물
US20040166490A1 (en) * 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
US20040126762A1 (en) * 2002-12-17 2004-07-01 Morris David W. Novel compositions and methods in cancer
JP2005289809A (ja) * 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
US20030190705A1 (en) * 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
JP2005508171A (ja) * 2001-11-02 2005-03-31 タノックス インコーポレーテッド Ｂ細胞悪性病変の診断及び予防に用いるためのｂ細胞リンパ腫特異抗原
CA2505129A1 (en) * 2001-11-09 2003-05-15 Transition Therapeutics Inc. Pharmaceutical compositions of marine sponge microciona prolifera
EA200400658A1 (ru) * 2001-11-09 2004-10-28 Неофарм, Инк. Способ лечения опухолей, экспрессирующих рецептор для ил-13 (варианты)
CN100374457C (zh) 2001-11-14 2008-03-12 森托科尔公司 抗il-6抗体、组合物、方法和用途
US20030157641A1 (en) * 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
ATE420964T1 (de) 2001-11-16 2009-01-15 Biogen Idec Inc Polycistronische expression von antikörpern in cho zellen
WO2003043583A2 (en) * 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
US7390885B2 (en) * 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
CA2468950A1 (en) * 2001-11-27 2003-06-05 Mochida Pharmaceutical Co., Ltd. Anti-il13 receptor .alpha.1 neutralizing antibody
US20040197778A1 (en) * 2002-12-26 2004-10-07 Sagres Discovery, Inc. Novel compositions and methods in cancer
ATE517855T1 (de) 2001-11-30 2011-08-15 Biogen Idec Inc Antikörper gegen chemotaktische monozytenproteine
US20060040262A1 (en) * 2002-12-27 2006-02-23 Morris David W Novel compositions and methods in cancer
US20040180344A1 (en) * 2003-03-14 2004-09-16 Morris David W. Novel therapeutic targets in cancer
ATE550352T1 (de) * 2001-12-03 2012-04-15 Alexion Pharma Inc Verfahren zur herstellung von hybridantikörper
US7393648B2 (en) * 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
ES2381025T3 (es) 2001-12-04 2012-05-22 Merck Patent Gmbh Inmunocitocinas con selectividad modulada
WO2003047633A2 (en) * 2001-12-04 2003-06-12 Nanospectra Biosciences, Inc. Treatment of angiogenesis disorders using targeted nanoparticles
EP1542719A4 (de) 2001-12-05 2006-06-21 Baylor College Medicine Verfahren und zusammensetzungen zur steuerung der knochenbildung über modulation des sympathikotonus
JP4822490B2 (ja) * 2001-12-07 2011-11-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 腫瘍形成形質転換に関連する内因性レトロウイルスポリペプチド
US7935338B2 (en) * 2001-12-11 2011-05-03 University Of Massachusetts Antibodies to treat cancer
US20030180296A1 (en) * 2001-12-20 2003-09-25 Theodora Salcedo Antibodies that immunospecifically bind to trail receptors
US7261890B2 (en) * 2001-12-21 2007-08-28 Idexx Laboratories, Inc. Methods for using canine immunoglobulin variable domains and caninized antibodies
EP2277889B1 (de) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusionsproteine von Albumin und Interferon beta
KR20040091616A (ko) * 2001-12-26 2004-10-28 이뮤노메딕스, 인코오포레이티드 Ｖｈ 및 ｖｌ 도메인으로부터 멀티특이성, 다원자가제제를 제조하는 방법
ATE441666T1 (de) * 2001-12-28 2009-09-15 Kyowa Hakko Kirin Co Ltd Antikírper gegen den fibroblastenwachstumsfaktor 23
US6578724B1 (en) * 2001-12-29 2003-06-17 United States Can Company Connector for use in packaging aerosol containers
US20050288487A1 (en) * 2002-01-03 2005-12-29 Kang Li Human mast cell-expressed membrane proteins
WO2003057916A2 (en) 2002-01-09 2003-07-17 Riken Cancer profiles
US20040009498A1 (en) * 2002-01-14 2004-01-15 Diversa Corporation Chimeric antigen binding molecules and methods for making and using them
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
AU2003209340A1 (en) * 2002-01-18 2003-09-02 Bristol-Myers Squibb Company Predictor sets for tyrosine kinase pathways
US7092957B2 (en) * 2002-01-18 2006-08-15 Boundary Solutions Incorporated Computerized national online parcel-level map data portal
US20080063639A1 (en) * 2002-01-18 2008-03-13 Pierre Fabre Medicament Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
US20080193445A1 (en) * 2002-01-18 2008-08-14 Liliane Goetsch Novel anti-IGF-IR antibodies and uses thereof
ATE401390T1 (de) 2002-01-18 2008-08-15 Zymogenetics Inc Zytokin (zcytor17-ligand)
AU2003210802B2 (en) 2002-02-05 2009-09-10 Genentech Inc. Protein purification
ES2373547T3 (es) 2002-02-13 2012-02-06 American Diagnostica, Inc. Métodos para seleccionar regímenes de tratamiento y predecir resultados en pacientes con cáncer de mama.
US20050281813A1 (en) * 2002-02-14 2005-12-22 Nuvelo, Inc. Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
CA2476166C (en) * 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
US8287864B2 (en) * 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
WO2003070889A2 (en) * 2002-02-19 2003-08-28 Idec Pharmaceuticals Corporation Prostate specific genes and the use thereof in design or therapeutics
JP2005526501A (ja) * 2002-02-21 2005-09-08 デューク・ユニヴァーシティ 自己免疫疾患用の試薬および治療方法
US7662924B2 (en) * 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
JP2006508631A (ja) 2002-02-22 2006-03-16 プロジェニクス・ファーマスーティカルズ・インコーポレイテッド 抗ｃｃｒ５抗体
AU2003217693A1 (en) * 2002-02-22 2003-09-09 Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
PT2336184E (pt) 2002-02-25 2015-03-09 Biogen Idec Inc Administração de agentes para o tratamento da inflamação
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
US7282567B2 (en) * 2002-06-14 2007-10-16 Immunomedics, Inc. Monoclonal antibody hPAM4
US8491896B2 (en) * 2002-06-14 2013-07-23 Immunomedics, Inc. Anti-pancreatic cancer antibodies
US20040018557A1 (en) * 2002-03-01 2004-01-29 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US8361464B2 (en) 2002-03-01 2013-01-29 Immunomedics, Inc. Anthracycline-Antibody Conjugates for Cancer Therapy
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20090042291A1 (en) * 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
US20080254027A1 (en) * 2002-03-01 2008-10-16 Bernett Matthew J Optimized CD5 antibodies and methods of using the same
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US9770517B2 (en) * 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
DE60325184D1 (de) * 2002-03-01 2009-01-22 Immunomedics Inc Rs7 antikörper
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
EP2865688A1 (de) * 2002-03-01 2015-04-29 Immunomedics, Inc. Internalisierung von Anti-CD74-Antikörpern und Verfahren zur Verwendung
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20100311954A1 (en) * 2002-03-01 2010-12-09 Xencor, Inc. Optimized Proteins that Target Ep-CAM
US9745380B2 (en) * 2002-03-01 2017-08-29 Immunomedics, Inc. RS7 antibodies
ATE475431T1 (de) * 2002-03-04 2010-08-15 Imclone Llc Kdr-spezifische humane antikörper und deren anwendung
CA2478636A1 (en) * 2002-03-04 2003-09-12 Nymox Corporation Spheron components useful in determining compounds capable of treating symptoms of alzheimer's disease, and treatments and animal models produced therefrom
JP2005536186A (ja) * 2002-03-07 2005-12-02 ルードビッヒ、インスティテュート、フォー、キャンサー、リサーチ リンパ管および血管内皮細胞遺伝子
ES2431040T3 (es) * 2002-03-08 2013-11-22 Shanghai Institutes For Biological Sciences, Cas Detección y modulación de la angiogénesis mediada por Slit y Roundabout (Robo), y sus usos
US7351547B2 (en) * 2002-10-31 2008-04-01 Health Research, Inc. Diagnostic test for West Nile virus
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
CN102659946A (zh) 2002-03-13 2012-09-12 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
AU2002316574B2 (en) * 2002-03-15 2008-05-01 Brandeis University Central airway administration for systemic delivery of therapeutics
JP2005520543A (ja) 2002-03-21 2005-07-14 サイグレス ディスカバリー， インコーポレイテッド 癌における新規組成物および方法
WO2003085093A2 (en) * 2002-04-01 2003-10-16 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
GB0207533D0 (en) 2002-04-02 2002-05-08 Oxford Glycosciences Uk Ltd Protein
WO2003087763A2 (en) 2002-04-03 2003-10-23 Celltech R & D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
PL375041A1 (en) * 2002-04-05 2005-11-14 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
US7357928B2 (en) * 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
SI1997512T1 (sl) 2002-04-09 2014-03-31 Biogen Idec Ma Inc. Postopki za zdravljenje stanj, povezanih s TWEAK-om
US7244565B2 (en) * 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en) * 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US20050260208A1 (en) * 2002-04-11 2005-11-24 Altarex Medical Corp. Binding agents and their use in targeting tumor cells
JP2005535572A (ja) 2002-04-12 2005-11-24 メディミューン，インコーポレーテッド 組換え抗インターロイキン−９抗体
WO2003086459A1 (en) * 2002-04-12 2003-10-23 Medarex, Inc. Methods of treatement using ctla-4 antibodies
EP1354600A1 (de) * 2002-04-19 2003-10-22 Affimed Therapeutics AG Antikörperkombination verwendbar für Tumortherapie
EP1507557A4 (de) * 2002-04-23 2006-06-14 Meir Strahilevitz Verfahren und vorrichtungen zum anzielen eines situs in einem säugetier und zur entfernung von spezies aus einem säugetier
CA2478925C (en) 2002-04-26 2016-06-07 Robert Lee Fahrner Non-affinity purification of proteins
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
HUE030806T2 (hu) 2002-05-02 2017-05-29 Wyeth Holdings Llc Calicheamicin származék-hordozó konjugátumok
US20070207142A1 (en) * 2002-05-08 2007-09-06 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US7670769B2 (en) 2002-05-09 2010-03-02 The Brigham And Women's Hospital, Inc. IL1RL-1 as a cardiovascular disease marker and therapeutic target
JP4557714B2 (ja) * 2002-05-10 2010-10-06 メディミューン，エルエルシー ＥｐｈＡ２モノクローナル抗体およびその使用法
WO2004014292A2 (en) * 2002-05-10 2004-02-19 Purdue Research Foundation EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
GB0210783D0 (en) * 2002-05-10 2002-06-19 Polonelli Luciano Anti-microbial polypeptides
US20040005671A1 (en) * 2002-05-17 2004-01-08 Amrad Operations Pty Ltd. Immunointeractive molecules
JP2005529152A (ja) 2002-05-17 2005-09-29 プロテイン デザイン ラブス インコーポレイティド 抗インターフェロンγ抗体を用いたクローン病又は乾癬の治療
US20030228317A1 (en) * 2002-05-22 2003-12-11 Prafulla Gokhale Gene BRCC-1 and diagnostic and therapeutic uses thereof
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
JP4440767B2 (ja) * 2002-05-31 2010-03-24 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ 潜在的抗白血病薬としての薬草分子
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
JP2005534647A (ja) 2002-06-07 2005-11-17 ダイアックス、コープ 失血の予防及び軽減
US20070071744A1 (en) * 2002-06-07 2007-03-29 Gotz Munch Agents which bind to epitopes of glycoprotein VI
NZ537579A (en) 2002-06-10 2006-10-27 Vaccinex Inc C35 peptide epitopes and their analogs
US6904341B2 (en) * 2002-06-12 2005-06-07 Sea-Watch Technologies, Inc. Integrated vessel monitoring and control system
EP2302039A1 (de) * 2002-06-13 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Virusähnliche Partikel mit HML-2 gag Polypeptid
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20030232387A1 (en) * 2002-06-14 2003-12-18 Millennium Pharmaceuticals, Inc. Antibodies that bind alphaE integrin
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US8034904B2 (en) * 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US8821868B2 (en) * 2002-06-14 2014-09-02 Immunomedics, Inc. Anti-pancreatic cancer antibodies
US9599619B2 (en) * 2002-06-14 2017-03-21 Immunomedics, Inc. Anti-pancreatic cancer antibodies
US7456260B2 (en) * 2002-06-17 2008-11-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Humanized antibody
WO2004003554A1 (en) * 2002-06-26 2004-01-08 University Of Louisville Research Foundation, Inc. A method for the detection of apoptosis
CA2490261A1 (en) 2002-06-27 2004-01-08 The University Of Queensland Differentiation modulating agents and uses therefor
US7569673B2 (en) * 2002-06-28 2009-08-04 The United States Of America As Represented By The Department Of Health And Human Services Humanized anti-tag 72 cc49 for diagnosis and therapy of human tumors
AU2002368055B2 (en) * 2002-06-28 2008-09-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist
PT1517921E (pt) * 2002-06-28 2006-09-29 Domantis Ltd Ligandos duplamente especificos com semi-vida no soro aumentada
EP1572952B1 (de) 2002-06-28 2010-09-29 Imclone LLC Neue polynukleotid- und polypeptidsequenzen und deren verwendungen
JP2005532051A (ja) * 2002-07-01 2005-10-27 バイオジェン， インコーポレイテッド ヒト化抗リンホトキシンβレセプター抗体
US7632496B2 (en) * 2002-07-01 2009-12-15 Wilex Ag Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas
BR0312692A (pt) 2002-07-15 2007-06-26 Univ Texas anticorpos selecionados e peptìdeos de duramicina que se ligam a fosfolipìdios aniÈnicos e aminofosfolipìdios e seus usos no tratamento de infecções virais e cáncer
JP2006505510A (ja) * 2002-07-16 2006-02-16 ウーメラ セラピューティックス， インク． プロバソプレシン発現癌細胞の同定および治療のための組成物およびその利用
EP1525311A2 (de) * 2002-07-19 2005-04-27 Cellzome Ag Proteinkomplexe des transkriptionellen aktivatorproteins tip60
CA2493679A1 (en) * 2002-07-19 2004-01-29 Morphotek, Inc. Methods for generating enhanced antibody-producing cell lines with improved growth characteristics
CA2494485A1 (en) * 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
JP2006500921A (ja) * 2002-07-30 2006-01-12 ブリストル−マイヤーズ　スクイブ　カンパニー ヒト４−１ｂｂに対するヒト化抗体
EP1545613B9 (de) * 2002-07-31 2012-01-25 Seattle Genetics, Inc. Auristatin-konjugate und ihre verwendung zur behandlung von krebs, einer autoimmunkranheit oder einer infektionskrankheit
WO2004013311A2 (en) * 2002-08-06 2004-02-12 Diadexus, Inc. Compositions and methods relating to ovarian specific genes and proteins
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
EP1534335B9 (de) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
US8187593B2 (en) * 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) * 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8044180B2 (en) * 2002-08-14 2011-10-25 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8530627B2 (en) * 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en) * 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8193318B2 (en) * 2002-08-14 2012-06-05 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
CA2492524A1 (en) * 2002-08-15 2004-02-26 Epitomics, Inc. Humanized rabbit antibodies
CA2496272A1 (en) 2002-08-20 2004-03-04 Millennium Pharmaceuticals, Inc. Integrin b6 markers for compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer
US7166576B2 (en) * 2002-08-28 2007-01-23 Dyax Corp. Methods for preserving organs and tissues
WO2004019886A2 (en) 2002-08-29 2004-03-11 Cytocure Llc Methods for up-regulating antigen expression in tumors
US20040265315A1 (en) * 2002-09-05 2004-12-30 Christine Dingivan Methods of preventing or treating T cell malignancies by administering CD2 antagonists
NZ593428A (en) 2002-09-06 2013-01-25 Amgen Inc Therapeutic human anti-il-1r1 monoclonal antibody
CA2499081A1 (en) * 2002-09-16 2004-04-22 Elusys Therapeutics, Inc. Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment
US20040052790A1 (en) * 2002-09-18 2004-03-18 Advanced Biotherapy, Inc. Treatment of schizophrenia
US7226755B1 (en) * 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US7507568B2 (en) * 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US20090217404A1 (en) * 2002-09-27 2009-08-27 Lowe Scott W Cell-based RNA interference and related methods and compositions
WO2004031400A2 (en) * 2002-10-01 2004-04-15 Northwestern University Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof
WO2004030685A2 (en) * 2002-10-04 2004-04-15 F. Hoffmann-La Roche Ag Use of il-2 receptor antibodies to prevent toxicity associated with amphotericin b antimycotic therapy
CA2500901A1 (en) * 2002-10-04 2004-04-22 Rinat Neuroscience Corp. Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
ES2357948T3 (es) * 2002-10-08 2011-05-04 Rinat Neuroscience Corp. Procedimientos para tratar dolor postquirúrgico mediante la administración de un anticuerpo frente al factor de crecimiento nervioso y composiciones que contienen el mismo.
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
CA2501616C (en) 2002-10-08 2015-05-12 Immunomedics, Inc. Antibody therapy
CA2501945A1 (en) * 2002-10-09 2004-04-22 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
US7217797B2 (en) * 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7365168B2 (en) * 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
PT1562972E (pt) 2002-10-15 2010-11-10 Facet Biotech Corp Alteração de afinidades de ligação ao fcrn ou semi-vidas séricas de anticorpos por mutagénese
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1551876B1 (de) 2002-10-16 2011-03-16 Purdue Pharma L.P. Antikörper, die an zellassoziiertes ca 125/0722p binden, und verfahren zu deren anwendung
WO2004034988A2 (en) * 2002-10-16 2004-04-29 Amgen Inc. Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
JP4033390B2 (ja) * 2002-10-30 2008-01-16 独立行政法人科学技術振興機構 不死化ナチュラルキラー細胞株
US20050106139A1 (en) * 2002-10-31 2005-05-19 Ivan Svendsen Humanized tissue factor antibodies
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
WO2008103472A2 (en) 2007-02-23 2008-08-28 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic and amyloidogenic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
EP1629090B1 (de) * 2002-11-06 2014-03-05 iBio, Inc. Expression von fremdsequenzen in pflanzen unter verwendung eines trans-aktivierungssystems
WO2005044858A1 (en) 2003-11-07 2005-05-19 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
JP2006524036A (ja) 2002-11-08 2006-10-26 アブリンクス エン．ヴェー． 腫瘍壊死因子αを標的とする単一ドメイン抗体およびその使用
US7683238B2 (en) * 2002-11-12 2010-03-23 iBio, Inc. and Fraunhofer USA, Inc. Production of pharmaceutically active proteins in sprouted seedlings
US7692063B2 (en) * 2002-11-12 2010-04-06 Ibio, Inc. Production of foreign nucleic acids and polypeptides in sprout systems
GB0226731D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Method for generating immunoglobulin genes
AU2003291549A1 (en) * 2002-11-15 2004-06-15 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
CN1787837A (zh) 2002-11-15 2006-06-14 希龙公司 防止和治疗癌转移以及与癌转移相关的骨质损失的方法
US9233120B2 (en) 2002-11-15 2016-01-12 Jyant Technologies Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration
AU2003295471B2 (en) 2002-11-15 2011-08-25 Genmab A/S Human monoclonal antibodies against CD25
US20110091451A1 (en) * 2002-11-15 2011-04-21 Kavanaugh William M Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
US8512701B2 (en) 2002-11-15 2013-08-20 Morehouse School Of Medicine Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
WO2004046330A2 (en) 2002-11-15 2004-06-03 Morphotek, Inc. Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
US8658377B2 (en) 2002-11-15 2014-02-25 Morehouse School Of Medicine Detecting cancer with anti-CCL25 and anti-CCR9 antibodies
NZ540562A (en) 2002-11-26 2008-04-30 Pdl Biopharma Inc Therapeutic chimeric and humanized antibodies directed against alpha5beta1 integrin, methods for purification of these antibodies, and their use in treating conditions comprising undesirable tissue angiogenesis
US7285268B2 (en) * 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
EP2363410B1 (de) 2002-11-27 2017-10-11 Minerva Biotechnologies Corporation MUC1-Isoformen
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
AU2003298794A1 (en) * 2002-12-02 2004-06-23 Us Gov Health & Human Serv Recombinant immunotoxin and use in treating tumors
EP1581629B1 (de) 2002-12-06 2015-04-01 Millennium Pharmaceuticals, Inc. Verfahren zur identifizierung,beurteilung und behandlung von patienten mit einer proteasomen inhibitions therapie
US20040115204A1 (en) 2002-12-11 2004-06-17 Fanger Gary R. Antibodies to treat cancer
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
DE60332957D1 (de) * 2002-12-16 2010-07-22 Genentech Inc Immunoglobulinvarianten und deren verwendungen
JP4494977B2 (ja) * 2002-12-17 2010-06-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質
PL377611A1 (pl) * 2002-12-20 2006-02-06 Biogen Idec Ma Inc. Czynniki dla receptora limfotoksyny beta w połączeniu z czynnikami chemioterapeutycznymi
US20040120950A1 (en) * 2002-12-20 2004-06-24 Kari Alitalo Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis
AU2003299984A1 (en) * 2002-12-20 2004-07-22 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
WO2004058171A2 (en) 2002-12-20 2004-07-15 Protein Design Labs, Inc. Antibodies against gpr64 and uses thereof
CA2886504C (en) 2002-12-20 2019-01-08 Celera Corporation Wdr12 polymorphisms associated with myocardial infarction, methods of detection and uses thereof
AU2003303384A1 (en) * 2002-12-23 2004-07-22 Schering Corporation Uses of mammalian cytokine; related reagents
JP2006513187A (ja) * 2002-12-23 2006-04-20 ライナット ニューロサイエンス コーポレイション タキソール誘発性感覚性ニューロパシーを処置するための方法
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
PT1575517E (pt) 2002-12-24 2012-05-28 Rinat Neuroscience Corp Anticorpos anti-ngf e métodos de utilização dos mesmos
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
EP1587831A2 (de) * 2002-12-26 2005-10-26 Applied Research Systems ARS Holding N.V. Gespleisste varianten von lgr6
US7960512B2 (en) * 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP2368578A1 (de) 2003-01-09 2011-09-28 Macrogenics, Inc. Identifizierung und Herstellung von Antikörpern mit abweichenden FC-Regionen und Anwendungsverfahren dafür
EP1585815A4 (de) * 2003-01-21 2006-02-22 Bristol Myers Squibb Co Ein neues acyl-coenzym a, monoacylglycerin-acyltransferase-3 (mgat3), codierendes polynukleotid sowie verwendungen davon
CA2513113A1 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
EP1592387A4 (de) 2003-01-24 2009-05-06 Elan Pharm Inc Zusammensetzung für und behandlung von entmyelinierenden erkrankungen und paralyse durch verabreichung von remyelinierenden mitteln
MXPA05007940A (es) * 2003-01-27 2007-06-14 Biogen Idec Inc Composiciones y metodos para el tratamiento del cancer usando igsf9 y liv-1.
US20080014594A1 (en) * 2003-01-31 2008-01-17 Kevin Hestir Lung-Expressed Polypeptides
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
ES2566778T3 (es) 2003-02-01 2016-04-15 Tanox, Inc. Anticuerpos anti-IgE de humano de alta afinidad
US20050169909A1 (en) * 2004-02-02 2005-08-04 Sanjaya Singh Identification of novel IgE epitopes
KR20050118669A (ko) * 2003-02-01 2005-12-19 뉴랄랩 리미티드 가용성 ａ-베타에 대한 항체를 생성하기 위한 능동 면역화
EP1594956A4 (de) 2003-02-03 2007-08-01 Fraunhofer Usa Inc System zur expression von genen in pflanzen
US8206704B2 (en) 2003-02-10 2012-06-26 Thomas Jefferson University Use of GCC ligands
CA2515708A1 (en) 2003-02-11 2004-08-26 Transkaryotic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
TW200418829A (en) * 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
EP1638587A4 (de) 2003-02-14 2007-04-18 Univ Missouri Empfängnisverhütende verfahren und zusammensetzungen betreffend proteasomale störung
CA2516138A1 (en) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Therapeutic gpcr targets in cancer
US20040219528A1 (en) * 2003-04-15 2004-11-04 Morris David W. Novel therapeutic targets in cancer
US20070218071A1 (en) * 2003-09-15 2007-09-20 Morris David W Novel therapeutic targets in cancer
DK1599573T3 (da) * 2003-02-17 2013-07-08 Cold Spring Harbor Lab Model til at studere genernes rolle i tumorresistens over for kemoterapi
US20090186839A1 (en) * 2003-02-17 2009-07-23 Cold Spring Harbor Laboratory Model for studying the role of genes in chemoresistance
PL379983A1 (pl) * 2003-02-19 2006-11-27 Rinat Neuroscience Corp. Sposoby leczenia bólu polegające na podaniu antagonisty czynnika wzrostu nerwów i niesteroidowego leku przeciwzapalnego oraz zawierające je kompozycje
WO2006113909A2 (en) * 2005-04-19 2006-10-26 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof
JP5356648B2 (ja) 2003-02-20 2013-12-04 シアトル ジェネティックス， インコーポレイテッド 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
AU2004220459B2 (en) * 2003-03-12 2010-08-05 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2004083387A2 (en) * 2003-03-13 2004-09-30 Corixa Corporation Anti-ganglioside antibodies and methods of use
US7741065B2 (en) * 2003-03-13 2010-06-22 Ramot At Tel Aviv University Ltd. Non-invasive marker for liver function and disease
PT2248899E (pt) 2003-03-19 2015-09-23 Biogen Ma Inc Proteína de ligação do receptor nogo
AU2004224390A1 (en) 2003-03-19 2004-10-07 Abgenix, Inc. Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof
US20070014786A1 (en) * 2003-03-20 2007-01-18 Rinat Neuroscience Corp. Methods for treating taxol-induced gut disorder
EP1460088A1 (de) 2003-03-21 2004-09-22 Biotest AG Humanisierter Antikörper gegen CD4 mit immunsuppressiven Merkmalen
AU2003901325A0 (en) * 2003-03-21 2003-04-03 Stephen Locarnini Therapeutic, prophylactic and diagnostic agents
EP1606316A2 (de) * 2003-03-24 2005-12-21 ZymoGenetics, Inc. Anti-il-20 antikörper und bindungspartner und verwendungsmethode bei entzündung
WO2004087758A2 (en) * 2003-03-26 2004-10-14 Neopharm, Inc. Il 13 receptor alpha 2 antibody and methods of use
US7235376B2 (en) * 2003-03-28 2007-06-26 Receptor Biologix, Inc. Gastrin hormone immunoassays
US8003765B2 (en) * 2003-04-09 2011-08-23 Stony Brook Anaesthesiology, University Faculty Practice Corporation Methods, antibodies and kits for detecting cerebrospinal fluid in a sample
US20070003992A1 (en) * 2003-04-09 2007-01-04 Pentyala Srinivas N Methods and kits for detecting cerebrospinal fluid in a sample
US20040203079A1 (en) * 2003-04-09 2004-10-14 Research Foundation Of The State University Of New York Methods and kits for detecting cerebrospinal fluid in a sample
US20110042260A1 (en) * 2003-04-10 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
JP4685764B2 (ja) * 2003-04-10 2011-05-18 アボット バイオセラピューティクス コーポレイション 変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変
WO2004092339A2 (en) * 2003-04-11 2004-10-28 Ilex Products, Inc. Modulation of muc1 mediated signal transduction
WO2004091375A2 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Epha2 and non-neoplastic hyperproliferative cell disorders
KR101224235B1 (ko) 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
AU2004230539A1 (en) * 2003-04-11 2004-10-28 Medimmune, Llc EphA2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
SE0301087D0 (sv) 2003-04-14 2003-04-14 Cartela Ab New monoclonal antibody
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US7189694B2 (en) * 2003-04-18 2007-03-13 University Of Florida Research Foundation, Inc. Inhibitors of autophosphorylation protein kinases
US7321065B2 (en) * 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US20050008640A1 (en) * 2003-04-23 2005-01-13 Wendy Waegell Method of treating transplant rejection
NZ542988A (en) * 2003-04-23 2008-07-31 Medarex Inc Humanised antibodies directed against the IFNAR-1 receptor in which murine CDR sequences have been grafted directly into unmodified human framework sequences, resulting in high affinity, functional antibodies
WO2004093908A2 (en) * 2003-04-23 2004-11-04 Medarex, Inc. Compositions and methods for the therapy of inflammatory bowel disease
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
AU2004234191A1 (en) * 2003-04-30 2004-11-11 University Of Zurich Methods for treating cancer using an immunotoxin
EP1624846A2 (de) * 2003-05-06 2006-02-15 Syntonix Pharmaceuticals, Inc. Hemmung der arzneimittelbindung an serumalbumin
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
SI2298347T1 (sl) * 2003-05-06 2016-03-31 Biogen Hemophilia Inc. Himerni proteini s faktorjem strjevanja krvi za zdravljenje hemostatske motnje
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7658927B2 (en) * 2003-05-12 2010-02-09 University Of Florida Research Foundation, Inc. Materials and methods for immunizing against FIV infection
CN100387301C (zh) * 2003-05-12 2008-05-14 佛罗里达大学研究基金公司 针对fiv感染的免疫接种材料和方法
HUE024996T2 (en) 2003-05-12 2016-01-28 Helion Biotech Aps Anti-MASP-2 antibodies
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
KR101424624B1 (ko) * 2003-05-14 2014-07-31 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
PT1633189T (pt) 2003-05-19 2017-10-04 Prothena Biosciences Ltd Fragmentos truncados de alfa-sinucleína em doença com corpos de lewy
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
AU2004272972A1 (en) 2003-05-22 2005-03-24 Fraunhofer Usa, Inc. Recombinant carrier molecule for expression, delivery and purification of target polypeptides
WO2004106515A1 (ja) * 2003-05-28 2004-12-09 Scimedia Ltd. 抗ｂａｍｂｉ抗体、及びそれを含有する大腸癌及び肝臓癌の診断剤又は治療剤
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
TWI374893B (en) * 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
WO2004108159A2 (en) * 2003-06-05 2004-12-16 The University Of Iowa Research Foundation Gb virus c (hepatitis g virus) for the treatment of hiv
US20050232926A1 (en) * 2003-06-06 2005-10-20 Oncomax Acquisition Corp. Antibodies specific for cancer associated antigen SM5-1 and uses thereof
CN1279056C (zh) * 2003-06-06 2006-10-11 马菁 肿瘤相关抗原sm5－1的特异性抗体及其应用
EP1639090A4 (de) 2003-06-09 2008-04-16 Univ Michigan Zusammensetzungen und verfahren zur behandlung und diagnose von krebs
US20060241288A1 (en) * 2003-06-10 2006-10-26 Ace Biosciences A/S Extracellular aspergillus polypeptides
DE602004029252D1 (de) 2003-06-13 2010-11-04 Biogen Idec Inc Aglycosyl-anti-cd154 (cd40-ligand) antikörper und deren verwendungen
US9005613B2 (en) 2003-06-16 2015-04-14 Immunomedics, Inc. Anti-mucin antibodies for early detection and treatment of pancreatic cancer
NZ544618A (en) 2003-06-16 2009-02-28 Celltech R & D Inc Antibodies specific for sclerostin and methods for increasing bone mineralization
IL156495A0 (en) * 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
KR100912381B1 (ko) * 2003-06-19 2009-08-19 타녹스 인코퍼레이티드 응고 관련 질병을 치료하기 위한 조성물 및 방법
BRPI0411852A (pt) 2003-06-27 2006-05-23 Abgenix Inc anticorpos dirigidos aos mutantes de deleção de receptor de fator de crescimento epidérmico e seu usos
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
WO2005046573A2 (en) * 2003-06-27 2005-05-26 Diadexus, Inc. Pro104 ANTIBODY COMPOSITIONS AND METHODS OF USE
US20050033029A1 (en) * 2003-06-30 2005-02-10 Jin Lu Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
GB0315450D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
JP5026072B2 (ja) * 2003-07-01 2012-09-12 イミューノメディクス、インコーポレイテッド 二重特異性抗体の多価キャリヤー
GB0315457D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
KR101325023B1 (ko) * 2003-07-02 2013-11-04 노보 노르디스크 에이/에스 Ｎｋ 세포 활성을 조절하기 위한 조성물 및 방법
WO2005010163A2 (en) * 2003-07-15 2005-02-03 Barros Research Institute Compositions and methods for immunotherapy of human immunotherapy of human immunodeficiency virus (hiv)
WO2005010040A1 (en) * 2003-07-15 2005-02-03 Barros Research Institute Eimeria tenella antigen for immunotherapy of coccidiosis
JP5105874B2 (ja) 2003-07-18 2012-12-26 アムジエン・インコーポレーテツド 肝細胞増殖因子に対する特異的結合因子
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
ES2786568T3 (es) 2003-07-28 2020-10-13 Genentech Inc Reducción de la lixiviación de la proteína A durante la cromatografía de afinidad con proteína A
US7696322B2 (en) * 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
CA2445420A1 (en) 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7619059B2 (en) 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
CA2534077A1 (en) * 2003-07-29 2005-02-10 Morphotek Inc. Antibodies and methods for generating genetically altered antibodies with enhanced effector function
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
WO2005010039A1 (en) * 2003-07-31 2005-02-03 Pfizer Products Inc. Bsep polypeptide variants and uses thereof
EP2402089A1 (de) 2003-07-31 2012-01-04 Handylab, Inc. Verarbeitung partikelhaltiger Proben
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
KR20060069825A (ko) * 2003-08-01 2006-06-22 제넨테크, 인크. 제한된 다양성을 갖는 항체 ｃｄｒ 폴리펩티드 서열
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CA2534661A1 (en) 2003-08-08 2005-02-17 Genenews Inc. Osteoarthritis biomarkers and uses thereof
JP2007528721A (ja) * 2003-08-14 2007-10-18 ダイアックス コーポレイション エンドセリアーゼ−２リガンド
EP2272566A3 (de) 2003-08-18 2013-01-02 MedImmune, LLC Humanisierung von antikörpern
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
AU2004267802B2 (en) * 2003-08-18 2011-03-17 Tethys Bioscience, Inc. Methods for reducing complexity of a sample using small epitope antibodies
CN1839133A (zh) * 2003-08-22 2006-09-27 阿文尼尔药品公司 作为巨噬细胞移动抑制因子的抑制剂的取代的二氮杂萘衍生物及其在治疗人类疾病中的应用
EP1660534A2 (de) * 2003-08-22 2006-05-31 MedImmune, Inc. Humanisierung von antikörpern
US7589181B2 (en) * 2003-08-29 2009-09-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use
US7604994B2 (en) * 2003-09-03 2009-10-20 Morphotek, Inc. Genetically altered antibody-producing cell lines with improved antibody characteristics
WO2005074417A2 (en) * 2003-09-03 2005-08-18 Salk Institute For Biological Studies Multiple antigen detection assays and reagents
ES2291917T3 (es) * 2003-09-05 2008-03-01 Cellzome Ag Tratamiento de enfermedades neurodegenerativas.
WO2005026362A2 (en) * 2003-09-08 2005-03-24 Ludwig Institute For Cancer Reserach Lymphatic and blood endothelial cell genes
GB0321100D0 (en) 2003-09-09 2003-10-08 Celltech R&D Ltd Biological products
US7046714B2 (en) * 2003-09-10 2006-05-16 Intel Corporation Method and apparatus for Raman ring resonator based laser/wavelength converter
WO2005025509A2 (en) * 2003-09-11 2005-03-24 Board Of Regents, The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
EP1668035A2 (de) * 2003-09-11 2006-06-14 Critical Therapeutics, Inc. Monoklonale antikörper gegen hmgb1
NZ545968A (en) * 2003-09-18 2010-01-29 Raven Biotechnologies Inc KID3 and KID3 antibodies that bind thereto
BRPI0414688A (pt) * 2003-09-23 2006-11-28 Pdl Biopharma Inc tratamento de doença respiratória com anti-receptor de il-2
US8623353B1 (en) * 2003-09-23 2014-01-07 Technische Universitat Munchen TLR2 antagonistic antibody and use thereof
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US20050282168A1 (en) * 2003-09-29 2005-12-22 Wyeth Cell surface molecules as markers and therapeutic agents against kidney cancers
US20070281896A1 (en) * 2003-09-30 2007-12-06 Morris David W Novel compositions and methods in cancer
EP1670350A4 (de) 2003-10-07 2008-02-13 Millennium Pharm Inc Nukleinsäuremoleküle und proteine für die identifizierung, beurteilung, prävention und behandlung von ovarialkrebs
EP1678195A4 (de) * 2003-10-08 2008-04-23 The Feinstein Inst Medical Res Verfahren und zusammensetzungen zur diagnose und behandlung von chronischer lymphocytischer b-zellen-leukämie
US20050239700A1 (en) * 2003-10-14 2005-10-27 Biogen Idec Inc. Treatment of cancer using antibodies to LRRC15
CA2545539A1 (en) * 2003-10-15 2005-04-28 Pdl Biopharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
WO2005042573A1 (en) 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
PL1680141T3 (pl) 2003-11-04 2011-04-29 Novartis Vaccines & Diagnostics Inc Sposoby leczenia guzów litych wykazujących ekspresję antygenu powierzchniowego CD40
ATE447412T1 (de) 2003-11-04 2009-11-15 Novartis Vaccines & Diagnostic Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren
PL1684805T3 (pl) 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostics Inc Sposoby leczenia szpiczaka mnogiego z zastosowaniem antagonistycznych monoklonalnych przeciwciał przeciwko CD40
EP2243491A1 (de) 2003-11-04 2010-10-27 Novartis Vaccines and Diagnostics, Inc. Verwendung von antagonistischen anti-CD40-Antikörpern zur Behandlung von chronischer lymphatischer Leukämie
JP4810431B2 (ja) 2003-11-04 2011-11-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｂ細胞に関連する癌に対する治療方法
GB0325836D0 (en) * 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
EA036531B1 (ru) * 2003-11-05 2020-11-19 Роше Гликарт Аг Гуманизированное антитело типа ii к cd20 (варианты), фармацевтическая композиция, содержащая эти варианты антитела, и их применение
KR101520209B1 (ko) 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
EP1691835A1 (de) * 2003-11-06 2006-08-23 Icos Corporation Verfahren zur behandlung von chronischem schmerz unter verwendung von spezifisch and cd11d (alpha-d) integrin bindenden zusammensetzungen
PE20090047A1 (es) 2003-11-10 2009-01-26 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
KR20060121150A (ko) 2003-11-11 2006-11-28 추가이 세이야쿠 가부시키가이샤 인간화 항-ｃｄ47 항체
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
JP2007514413A (ja) * 2003-11-12 2007-06-07 プロジェニクス・ファーマスーティカルズ・インコーポレイテッド Ｃ型肝炎ウイルス糖タンパク質をコードする新規配列
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
US8454963B2 (en) * 2003-11-13 2013-06-04 Musc Foundation For Research Development Tissue targeted complement modulators
KR100772800B1 (ko) 2003-11-17 2007-11-01 주식회사유한양행 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자
JP4833850B2 (ja) 2003-11-21 2011-12-07 ユセベ ファルマ ソシエテ アノニム Ｉｌ−１７活性阻害による多発性硬化症を治療するための方法
ES2343965T3 (es) 2003-11-25 2010-08-13 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Anticuerpos anti-cd22 e inmunocongujados mutados.
CA3050151C (en) 2003-11-26 2023-03-07 Celera Corporation Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof
JP4949038B2 (ja) 2003-12-01 2012-06-06 ダコ デンマーク アクティーゼルスカブ 免疫組織化学的検出のための方法および組成物
US20050158323A1 (en) * 2003-12-04 2005-07-21 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
WO2005060457A2 (en) 2003-12-04 2005-07-07 Pdl Biopharma, Inc. Treatment of inflammatory bowel diseases with anti-ip-10 antibodies
AU2004297988A1 (en) * 2003-12-04 2005-06-23 Laboratoires Serono Sa Methods for identifying modulators of active KIT tyrosine kinase receptor
EP2221315A1 (de) 2003-12-04 2010-08-25 Xencor, Inc. Verfahren zur Erzeugung von Proteinvarianten mit erhöhtem Wirtsstranginhalt und Zusammensetzungen davon
US20060095211A1 (en) * 2003-12-05 2006-05-04 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System and method for modulating a cell mediated immune response
US20060047435A1 (en) * 2004-08-24 2006-03-02 Ishikawa Muriel Y System and method related to augmenting an immune system
US20060116824A1 (en) * 2004-12-01 2006-06-01 Ishikawa Muriel Y System and method for modulating a humoral immune response
US20060047434A1 (en) * 2004-08-24 2006-03-02 Ishikawa Muriel Y System and method related to improving an immune system
US20060047436A1 (en) * 2004-08-25 2006-03-02 Ishikawa Muriel Y System and method for magnifying an immune response
US20060182742A1 (en) * 2004-08-24 2006-08-17 Ishikawa Muriel Y System and method for magnifying a humoral immune response
US20060047437A1 (en) * 2004-08-25 2006-03-02 Ishikawa Muriel Y System and method for heightening an immune response
US20060122783A1 (en) * 2004-08-24 2006-06-08 Ishikawa Muriel Y System and method for heightening a humoral immune response
US20060122784A1 (en) * 2004-12-03 2006-06-08 Ishikawa Muriel Y System and method for augmenting a humoral immune response
US20060003412A1 (en) * 2003-12-08 2006-01-05 Xencor, Inc. Protein engineering with analogous contact environments
US20070249809A1 (en) * 2003-12-08 2007-10-25 Xencor, Inc. Protein engineering with analogous contact environments
DE602004031870D1 (de) 2003-12-09 2011-04-28 Engeneic Molecular Delivery Pty Ltd Gezielte genabgabe an nicht-phagozytische säugetierzellen über bakteriell erhaltene intakte minizellen
CA2546054C (en) 2003-12-10 2014-05-13 Medarex, Inc. Interferon alpha antibodies and their uses
JP2007521248A (ja) 2003-12-10 2007-08-02 ミレニアム ファーマシューティカルズ， インコーポレイテッド ヒト化抗ｃｃｒ２抗体および該抗体を使用する方法
PL1691837T3 (pl) 2003-12-10 2012-11-30 Squibb & Sons Llc IP-10 przeciwciała i ich zastosowanie
WO2005058961A2 (en) * 2003-12-12 2005-06-30 Amgen Inc. Antibodies specific for human galanin, and uses thereof
CA2549800A1 (en) 2003-12-15 2005-06-30 Alexion Pharmaceuticals, Inc. Novel anti-dc-sign antibodies
US20070248605A1 (en) * 2003-12-19 2007-10-25 Five Prime Therapetutics, Inc. Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
WO2005077981A2 (en) * 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
EP1704160B1 (de) 2003-12-22 2010-11-10 The Trustees of The University of Pennsylvania Verfahren und zusammensetzungen zur identifikation von rna-bindenden proteinen
GB0329825D0 (en) * 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
JP4943161B2 (ja) 2003-12-23 2012-05-30 ジェネンテック， インコーポレイテッド 新規抗ｉｌ１３モノクローナル抗体での癌の処置
US7968690B2 (en) * 2003-12-23 2011-06-28 Rinat Neuroscience Corp. Agonist anti-trkC antibodies and methods using same
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
PT1699821E (pt) 2003-12-31 2012-08-23 Merck Patent Gmbh Proteína de fusão fc-eritropoietina com farmacocinética melhorada
DK1704166T3 (en) 2004-01-07 2015-06-01 Novartis Vaccines & Diagnostic M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF
SV2006001990A (es) 2004-01-09 2006-01-30 Pfizer Anticuerpos contra madcam
EP1712566A4 (de) * 2004-01-19 2007-09-12 Medical & Biol Lab Co Ltd Inhibitor von enzündlichem cytokin
AU2005207003C1 (en) * 2004-01-20 2013-06-13 Humanigen, Inc. Antibody specificity transfer using minimal essential binding determinants
WO2005070967A2 (en) * 2004-01-22 2005-08-04 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
US20060147946A1 (en) * 2004-01-27 2006-07-06 Pinchas Akiva Novel calcium channel variants and methods of use thereof
CN1925869A (zh) * 2004-01-29 2007-03-07 塞尔卓姆股份公司 使用gpr49治疗神经变性疾病
ES2300852T3 (es) * 2004-01-29 2008-06-16 Cellzome Ag Tratamiento de enfermedades neurogenerativas mediante el uso de gpr49.
SI1718338T1 (sl) 2004-02-02 2015-09-30 Engeneic Molecular Delivery Pty Ltd. Sestavki in metode za ciljno usmerjeno in vitro in in vivo dostavo zdravila v celice sesalcev preko bakterijsko pridobljenih intaktnih minicelic
SG183683A1 (en) * 2004-02-02 2012-09-27 Tanox Inc Identification of novel ige epitopes
EP1718967B1 (de) 2004-02-03 2013-04-24 Diadexus, Inc. Verfahren zum nachweis von lp-pla2-aktivität
WO2005074633A2 (en) * 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
ES2533492T3 (es) 2004-02-06 2015-04-10 University Of Massachusetts Anticuerpos contra toxinas de Clostridium difficile y usos de los mismos
US20050226883A1 (en) * 2004-02-06 2005-10-13 Paul Averback Humanized antibody
BRPI0507026A (pt) 2004-02-09 2007-04-17 Human Genome Sciences Inc proteìnas de fusão de albumina
DE602005020743D1 (de) * 2004-02-11 2010-06-02 Warner Lambert Co Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
US8562988B2 (en) * 2005-10-19 2013-10-22 Ibc Pharmaceuticals, Inc. Strategies for improved cancer vaccines
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US8435539B2 (en) * 2004-02-13 2013-05-07 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US20110020273A1 (en) * 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
US8652484B2 (en) 2004-02-13 2014-02-18 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8551480B2 (en) 2004-02-13 2013-10-08 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US20110064754A1 (en) * 2005-03-03 2011-03-17 Center For Molecular Medicine And Immunology Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
US8491914B2 (en) * 2004-02-13 2013-07-23 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA
US9481878B2 (en) 2004-02-13 2016-11-01 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US20110171126A1 (en) * 2010-01-11 2011-07-14 Center For Molecular Medicine And Immunology Enhanced Cytotoxicity of Anti-CD74 and Anti-HLA-DR Antibodies with Interferon-Gamma
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
SI1716178T1 (sl) * 2004-02-16 2010-11-30 Micromet Ag Manj imunogene vezne molekule
AU2005214988A1 (en) * 2004-02-17 2005-09-01 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
EP2168986A3 (de) * 2004-02-19 2010-07-28 Genentech, Inc. Antikörper mit korrigiertem CDR
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
EP1769068B1 (de) * 2004-02-20 2014-12-31 iBio, Inc. Systeme und verfahren zur klonalen expression in pflanzen
US20070202134A1 (en) * 2004-02-23 2007-08-30 Kufe Donald W Muc1 Antagonist Enhancement of Death Receptor Ligand-Induced Apoptosis
US20040260068A1 (en) * 2004-02-26 2004-12-23 Naoya Tsurushita Humanized chicken antibodies
JP5557982B2 (ja) 2004-03-01 2014-07-23 イミューン ディズィーズ インスティテュート インコーポレイテッド 天然ＩｇＭ抗体およびその阻害剤
WO2005094882A1 (en) * 2004-03-03 2005-10-13 Millennium Pharmaceuticals, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US20050282233A1 (en) * 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
WO2005087177A2 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same
WO2005086875A2 (en) * 2004-03-11 2005-09-22 City Of Hope A humanized anti-cea t84.66 antibody and uses thereof
CN102746401A (zh) 2004-03-12 2012-10-24 瓦斯基因治疗公司 结合ephb4、抑制血管发生和肿瘤生长的抗体
AU2005224081B2 (en) * 2004-03-12 2011-06-30 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
CN1980957A (zh) * 2004-03-23 2007-06-13 比奥根艾迪克Ma公司 受体偶联剂及其治疗用途
ES2384176T3 (es) * 2004-03-23 2012-07-02 Eli Lilly & Company Anticuerpos anti-miostatina
EP2053062A1 (de) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobinvarianten außerhalb der Fc-Region
AR048335A1 (es) * 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
JP4857259B2 (ja) * 2004-03-24 2012-01-18 アボット バイオセラピューティクス コーポレイション 癌細胞増殖を阻害するための抗α５β１抗体の使用
DE602004025291D1 (de) * 2004-03-26 2010-03-11 Cellzome Ag Behandlung von neurodegenerativen erkrankungen durch verwendung von laptm4b
US7973139B2 (en) * 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
AU2005228897B2 (en) * 2004-03-29 2009-12-10 Cancer Advances, Inc. Monoclonal antibodies to gastrin hormone
WO2005103720A1 (en) * 2004-03-29 2005-11-03 Medstar Research Institute, Inc. Methods of diagnosing cardiovascular disease
AU2005228426B2 (en) * 2004-03-29 2010-07-15 North Shore-Long Island Jewish Research Institute Treatment of type 1 diabetes with inhibitors of macrophage migration inhibitory factor
US7557193B2 (en) * 2004-03-31 2009-07-07 Universite De La Mediterranee Glycopeptides derived from pancreatic structures, antibodies and applications thereof in diagnostics and therapeutics
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
EP2394662B1 (de) 2004-04-02 2018-03-21 The Regents of The University of California Verfahren und zusammensetzungen für die behandlung und vorbeugung von mit alpha v beta 5-integrin assoziierten krankheiten
US20070237717A1 (en) * 2004-04-05 2007-10-11 Roland Martin Methods for Selection of Subjects for Multiple Sclerosis Therapy
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
DK2206728T3 (en) 2004-04-07 2018-04-23 Rinat Neuroscience Corp METHODS OF TREATING BONE CANCER PAIN BY SUBMITTING A NERVOUS FACTOR-ANTAGONISTIC ANTIBODY
WO2005103086A1 (en) 2004-04-23 2005-11-03 Bundesrepublik Deutschland letztvertreten durch das Robert-Koch-Institut vertreten durch seinen Präsidenten Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo
US7776564B2 (en) * 2004-04-30 2010-08-17 Five Prime Therapeutics, Inc. Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use
JP4836942B2 (ja) * 2004-04-30 2011-12-14 コーセラ， インコーポレイテッド リラキシンの調節による胎仔の発育の制御のための方法および組成物
US7976841B2 (en) * 2004-04-30 2011-07-12 Institut National De La Sante Et De La Recherche Anti TfR antibody
WO2005108620A2 (en) 2004-05-03 2005-11-17 Handylab, Inc. Processing polynucleotide-containing samples
US8852862B2 (en) 2004-05-03 2014-10-07 Handylab, Inc. Method for processing polynucleotide-containing samples
EP1745154B1 (de) 2004-05-07 2012-08-01 Celera Corporation Genetische polymorphismen assoziiert mit leberfibrose, verfahren zur detektion und verwendung davon
AU2005244058B2 (en) * 2004-05-10 2011-07-28 Macrogenics, Inc. Humanized FcgammaRIIB specific antibodies and methods of use thereof
US7691962B2 (en) * 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
RU2006138704A (ru) * 2004-05-19 2008-06-27 Вайет (Us) Модуляция производства иммуноглобулина и атопические расстройства
EP1747021B1 (de) * 2004-05-19 2015-09-09 E. R. Squibb & Sons, L.L.C. Selbstimmolative verbinder und arzneimittelkonjugate
US9228008B2 (en) 2004-05-28 2016-01-05 Idexx Laboratories, Inc. Canine anti-CD20 antibodies
WO2005116071A2 (en) * 2004-05-28 2005-12-08 University Of Massachusetts Snares for pathogenic or infectious agents and uses related thereto
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
CA2569240A1 (en) 2004-06-01 2005-12-15 Domantis Limited Drug fusion comprising a polypeptide drug and an immunoglobulin heavy chain variable domain specific for serum albumin
US7728114B2 (en) 2004-06-03 2010-06-01 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
PL1753456T3 (pl) 2004-06-10 2017-01-31 Omeros Corporation Sposoby leczenia stanów związanych z aktywacją dopełniacza zależną od masp-2
GB0412966D0 (en) 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20060018896A1 (en) * 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP1781826A4 (de) * 2004-06-12 2009-04-29 Univ Oregon Health & Science Zusammensetzungen und verfahren zur diagnose und behandlung von orthopoxviren
US20050276807A1 (en) * 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of acne
US20050276806A1 (en) * 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of autism
CA2570823C (en) 2004-06-21 2015-02-24 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
ES2395094T3 (es) 2004-06-24 2013-02-08 Biogen Idec Ma Inc. Tratamiento de afecciones que implican la desmielinización
EP1768662A2 (de) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Immunstimulatoren kleiner moleküle und assays für deren nachweis
US7973134B2 (en) * 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
ES2673972T3 (es) 2004-07-09 2018-06-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Formas solubles de la glicoproteína G de los virus hendra y nipah
ATE486610T1 (de) * 2004-07-09 2010-11-15 Chugai Pharmaceutical Co Ltd Anti-glypican-3-antikörper
EP1814876A2 (de) * 2004-07-15 2007-08-08 The General Hospital Corporation Heterozyklische farbstoffverbindungen für in-vivo-bilderzeugung und diagnose von alzheimer-krankheit
EP1919950A1 (de) 2004-07-15 2008-05-14 Xencor, Inc. Optimierte fc-varianten
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
US6986264B1 (en) * 2004-07-15 2006-01-17 Carrier Corporation Economized dehumidification system
EP1817294A1 (de) * 2004-07-15 2007-08-15 Amgen Inc. 1,2,3,4-tetrahydropyrazin-2-ylacetamide und deren verwendung als bradykininantagonisten zur behandlung von entzündlichen erkrankungen
CA2573821A1 (en) * 2004-07-16 2006-01-26 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
EP1791563A4 (de) 2004-07-26 2009-07-08 Biogen Idec Inc Anti-cd154-antikörper
US20060024768A1 (en) 2004-07-29 2006-02-02 Saladax Biomedical, Inc. Taxol immunoassay
EA016357B1 (ru) * 2004-07-30 2012-04-30 Ринат Ньюросайенс Корп. Антитела, направленные против бета-амилоидного пептида, и способы их применения
US7846438B2 (en) 2004-08-03 2010-12-07 Biogen Idec Ma Inc. Methods of promoting neurite outgrowth with soluble TAJ polypeptides
WO2006135382A2 (en) * 2004-08-04 2006-12-21 Chemocentryx, Inc. Enzymatic activities in chemokine-mediated inflammation
WO2006015373A2 (en) 2004-08-04 2006-02-09 Amgen Inc Antibodies to dkk-1
JP2008508885A (ja) * 2004-08-05 2008-03-27 ワイス インターロイキン−２１受容体活性を中和すること
CA2575190A1 (en) * 2004-08-09 2006-02-16 Cellzome Ag Treatment of neurodegenerative diseases by the use of scd4 inhibitors
MX2007001679A (es) 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
JP4468989B2 (ja) 2004-08-16 2010-05-26 クアーク・ファーマスーティカルス、インコーポレイテッド Ｒｔｐ８０１阻害剤の治療への使用
US20060177445A1 (en) * 2004-08-16 2006-08-10 Boris Skurkovich Treatment of inflammatory skin diseases
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
WO2006021955A2 (en) * 2004-08-23 2006-03-02 Mor Research Applications Ltd. Use of bat monoclonal antibody for immunotherapy
US20070265817A1 (en) * 2004-08-24 2007-11-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems and methods relating to fortifying an immune system
US20070207492A1 (en) * 2004-08-24 2007-09-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems to adjust a humoral immune response
US20070265818A1 (en) * 2004-08-24 2007-11-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems for heightening cell-mediated immune response
US20070265787A1 (en) * 2004-08-24 2007-11-15 Searete Llc,A Limited Liability Corporation Of The State Of Delaware Computational methods and systems for magnifying cell-mediated immune response
US20070196362A1 (en) * 2004-08-24 2007-08-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems to bolster an immune response
US20060047439A1 (en) * 2004-08-24 2006-03-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System and method for improving a humoral immune response
US20070265819A1 (en) * 2004-08-24 2007-11-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems for improving cell-mediated immune response
EP1800693B1 (de) * 2004-08-24 2013-07-17 Chugai Seiyaku Kabushiki Kaisha Adjuvante therapie mit verwendung von anti-glypican-3-antikörper
US20070288173A1 (en) * 2004-08-24 2007-12-13 Searete Llc, A Limited Liability Corporation Of The State Of Delware Computational methods and systems to reinforce a humoral immune response
US20070265788A1 (en) * 2004-08-24 2007-11-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems for augmenting cell-mediated immune response
US20070198196A1 (en) * 2004-08-24 2007-08-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems and methods relating to ameliorating an immune system
JP4965447B2 (ja) 2004-08-26 2012-07-04 エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド 細菌由来のインタクトなミニセルを介した哺乳動物細胞への機能性核酸の送達
CA2486285C (en) * 2004-08-30 2017-03-07 Viktor S. Goldmakher Immunoconjugates targeting syndecan-1 expressing cells and use thereof
US7662926B2 (en) * 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) * 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
JP2008515780A (ja) * 2004-09-02 2008-05-15 ジェネンテック・インコーポレーテッド 抗ＦｃγＲＩＩＢレセプター抗体およびその使用
US20070275874A1 (en) * 2004-09-03 2007-11-29 Yale University Use of Leptin in Wound Healing
RS57636B1 (sr) * 2004-09-03 2018-11-30 Genentech Inc Humanizovani anti-beta7 antagonisti i njihova upotreba
US7432359B2 (en) 2004-09-06 2008-10-07 Kirin Pharma Kabushiki Kaisha Anti-A33 antibody
CN101010427B (zh) * 2004-09-06 2011-07-27 协和发酵麒麟株式会社 抗a33抗体
JP2008518586A (ja) * 2004-09-09 2008-06-05 ユニバーシティ オブ ワシントン オールトランスレチノールすなわちオールトランス１３，１４−ジヒドロレチノールサチュラーゼ及びその使用方法
PA8645301A1 (es) * 2004-09-10 2006-07-03 Wyeth Corp Anticuerpo anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
GB0420466D0 (en) 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
EP3073267A1 (de) 2004-09-21 2016-09-28 Medimmune, Inc. Antikörper gegen und verfahren zur herstellung von impfstoffen für respiratorische synzytialvirus
KR101333168B1 (ko) * 2004-09-22 2013-11-28 리셉터 바이오로직스 인크 프로가스트린에 대한 모노클로날 항체
US20060194220A1 (en) * 2004-09-23 2006-08-31 Vasgene Therapeutics, Inc. Compositions and methods for detecting and treating tumors
EP1791565B1 (de) 2004-09-23 2016-04-20 Genentech, Inc. Zystein-modifizierte Antikörper und Konjugate
US20060204512A1 (en) * 2004-09-23 2006-09-14 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US7999077B2 (en) * 2004-09-30 2011-08-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services IRTA2 antibodies and methods of use
US7935790B2 (en) * 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
WO2006041641A2 (en) * 2004-10-05 2006-04-20 Genentech, Inc. Therapeutic agents with decreased toxicity
AU2005294373B2 (en) * 2004-10-05 2011-12-08 Janssen Alzheimer Immunotherapy Methods and compositions for improving recombinant protein production
US7462454B2 (en) * 2004-10-12 2008-12-09 Advanced Biotherapy, Inc. Treatment of herpes
WO2006040153A2 (en) * 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
AU2005295595C1 (en) * 2004-10-15 2012-06-21 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US8337838B2 (en) * 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US20120294863A1 (en) * 2004-10-15 2012-11-22 Seattle Genetics, Inc. Anti-CD70 Antibody and Its Use for the Treatment and Prevention of Cancer and Immune Disorders
JP2008516614A (ja) * 2004-10-18 2008-05-22 メディミューン，インコーポレーテッド リステリア増殖のための高細胞密度法
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006047249A1 (en) 2004-10-22 2006-05-04 Zymogenetics, Inc. Anti-il-22ra antibodies and binding partners and methods of using in inflammation
WO2006055178A2 (en) * 2004-10-25 2006-05-26 Merck & Co., Inc. Anti-addl antibodies and uses thereof
TWI468514B (zh) * 2004-10-26 2015-01-11 Chugai Pharmaceutical Co Ltd Sugar chain modified phosphatidylinositol glyphosyl 3 antibody
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
EP1812068A4 (de) * 2004-10-29 2010-06-09 Medimmune Inc Verfahren zur prävention und behandlung von rsv-infektionen und verwandten leiden
EP1814918A1 (de) * 2004-10-29 2007-08-08 Elusys Therapeutics, Inc. Verwendung von cr1-bindenden molekülen bei der clearance und der induktion von immunreaktionen
JP2008519028A (ja) * 2004-11-04 2008-06-05 フィブロン リミテッド Ｂ細胞悪性腫瘍の治療
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
EP1809671B1 (de) * 2004-11-09 2014-07-16 University Of Southern California CpG/Antikörper Konjugat gegen Krebs
US7632497B2 (en) * 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US20060222653A1 (en) * 2004-11-12 2006-10-05 Xencor, Inc. Antibodies operably linked to selected chemoattractants
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8288352B2 (en) 2004-11-12 2012-10-16 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the N terminus
CN102746404B (zh) 2004-11-12 2016-01-20 赞科股份有限公司 对FcRn的结合被改变的Fc变体
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
ES2744149T3 (es) 2004-11-16 2020-02-21 Humanigen Inc Intercambio de casetes de la región variable de la inmunoglobulina
ES2523457T3 (es) * 2004-11-18 2014-11-26 Imclone Llc Anticuerpos contra el receptor 1 del factor de crecimiento endotelial vascular
AU2005306399B2 (en) 2004-11-19 2012-02-09 Biogen Ma Inc. Treatment for multiple sclerosis
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
JP4993645B2 (ja) 2004-12-01 2012-08-08 ジェネンテック， インコーポレイテッド 抗体薬剤結合体および方法
CN101128487B (zh) 2004-12-02 2012-10-10 杜门蒂斯有限公司 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
NZ581497A (en) * 2004-12-03 2012-07-27 Biogen Idec Inc Delaying or preventing onset of multiple sclerosis by vla-4 ginding antibody
US7517870B2 (en) 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
WO2006060419A2 (en) 2004-12-03 2006-06-08 Schering Corporation Biomarkers for pre-selection of patients for anti-igf1r therapy
WO2006061723A2 (en) 2004-12-06 2006-06-15 Kirin Beer Kabushiki Kaisha Human monoclonal antibodies to influenza m2 protein and methods of making and using same
US8030003B2 (en) 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
WO2006063292A1 (en) * 2004-12-08 2006-06-15 Icos Corporation Recombinant method for making multimeric proteins
EP2395108A1 (de) 2004-12-08 2011-12-14 Aventis Pharmaceuticals Inc. Verfahren zur Messung der Resistenz oder Sensitivität gegenüber Docetaxel
CA2590180A1 (en) 2004-12-10 2006-06-15 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Binding partners of antibodies specific for dendritic cell antigens
TW200635607A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized Aβ antibodies for use in improving cognition
TW200636066A (en) * 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
PE20061401A1 (es) * 2004-12-15 2006-12-23 Neuralab Ltd ANTICUERPOS Aß PARA MEJORAR LA COGNICION
KR20070095949A (ko) * 2004-12-16 2007-10-01 제넨테크, 인크. 자가면역 장애의 치료 방법
KR20070086218A (ko) * 2004-12-17 2007-08-27 제넨테크, 인크. 자가면역 질환에 대한 이전 요법에 실패했던 환자에서의,자가면역 질환의 항-혈관신생 요법
US20060134698A1 (en) * 2004-12-20 2006-06-22 Evanston Northwestern Healthcare Research Institute Methods for treating cardiac disease by modifying an N-terminal domain of troponin I
US7807789B2 (en) * 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
EP1674479A1 (de) * 2004-12-22 2006-06-28 Memorial Sloan-Kettering Cancer Center Modulierung von Fc-gamma-Rezeptoren zur Optimierung einer Immunotherapie
ES2557325T5 (es) 2004-12-28 2023-11-15 Innate Pharma Sa Anticuerpos monoclonales contra NKG2A
US8137907B2 (en) * 2005-01-03 2012-03-20 Cold Spring Harbor Laboratory Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
SG173313A1 (en) 2005-01-05 2011-08-29 Biogen Idec Inc Cripto binding molecules
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
US7833725B2 (en) 2005-01-06 2010-11-16 President And Fellows Of Harvard College Mass spectrometric methods and products
WO2006076594A2 (en) * 2005-01-12 2006-07-20 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
WO2006081171A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
US20080226619A1 (en) * 2005-01-28 2008-09-18 Ramot At Tel Aviv University, Ltd. Anti-Muc1 Alpha/Beta Antibodies
EP1846032A4 (de) * 2005-01-31 2009-01-28 Raven Biotechnologies Inc Luca2 und daran bindende antikörper
US20060174362A1 (en) 2005-02-01 2006-08-03 Origen Therapeutics, Inc. Long-term culture of avian primordial germ cells (PGCs)
US7402730B1 (en) 2005-02-03 2008-07-22 Lexicon Pharmaceuticals, Inc. Knockout animals manifesting hyperlipidemia
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
NZ556286A (en) 2005-02-07 2010-11-26 Glycart Biotechnology Ag Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
EP2520669A3 (de) 2005-02-07 2013-02-27 GeneNews Inc. Biomarker für milde Arthrose und Verwendungen davon
US20060177883A1 (en) 2005-02-08 2006-08-10 Saladax Biomedical Inc. 5-Fluoro-uracil immunoassay
CA2596390A1 (en) 2005-02-08 2006-08-17 Zymogenetics, Inc. Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
AU2006213662B2 (en) 2005-02-11 2010-08-05 Immunogen, Inc. Process for preparing stable drug conjugates
JP2008530132A (ja) * 2005-02-14 2008-08-07 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１ｒａアンタゴニストを用いて皮膚障害を治療する方法
CN103920142A (zh) 2005-02-14 2014-07-16 爱荷华大学研究基金会 治疗和诊断年龄相关性黄斑变性的方法和试剂
WO2006088925A2 (en) * 2005-02-14 2006-08-24 Wyeth Use of il17-f in diagnosis and therapy of airway inflammation
AU2006214473A1 (en) 2005-02-14 2006-08-24 Wyeth Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
US8444973B2 (en) * 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
US20060233791A1 (en) 2005-02-15 2006-10-19 Duke University Anti-CD19 antibodies and uses in oncology
US20090124993A1 (en) 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
AU2006214031A1 (en) * 2005-02-18 2006-08-24 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen (PSMA)
US20060193849A1 (en) * 2005-02-25 2006-08-31 Antisoma Plc Biological materials and uses thereof
US8048992B2 (en) 2005-02-28 2011-11-01 Institute For Antibodies Co., Ltd. Anti-IgSF4 antibody and utilization of the same
DE602006016413D1 (de) 2005-03-02 2010-10-07 Biogen Idec Inc Kim-1-antikörper zur behandlung von th2-vermittelten erkrankungen
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP3332808B1 (de) * 2005-03-03 2020-09-09 Immunomedics Inc. Humanisierte l243-antikörper
JP2008531730A (ja) * 2005-03-04 2008-08-14 キュアーディーエム、インク． Ｉ型真性糖尿病及び他の症状を治療するための方法及び薬学的組成物
AU2006220709B2 (en) * 2005-03-04 2012-09-06 Biogen Ma Inc. Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
WO2006099365A2 (en) 2005-03-11 2006-09-21 Applera Corporation Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
KR20060097526A (ko) * 2005-03-11 2006-09-14 (주) 에이프로젠 탄저독소에 특이적인 단일클론 항체
JP5153613B2 (ja) 2005-03-18 2013-02-27 メディミューン，エルエルシー 抗体のフレームワーク・シャッフル
JP2008532559A (ja) 2005-03-19 2008-08-21 メディカル リサーチ カウンシル ウイルス感染の治療及び予防又は治療及び予防の改善
US20060216767A1 (en) 2005-03-22 2006-09-28 Saladax Biomedical Inc. Docetaxel immunoassay
SG10201912554TA (en) 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
US7431927B2 (en) 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
EP2384767B1 (de) 2005-03-24 2016-03-09 Millennium Pharmaceuticals, Inc. OV064-bindende Antikörper und Verfahren zu deren Verwendung
EP1861407A1 (de) * 2005-03-24 2007-12-05 Avanir Pharmaceuticals Thienopyridinonderivate als hemmer des makrophagenmigrationshemmfaktors
EP1866339B8 (de) 2005-03-25 2021-12-01 GITR, Inc. Gitr-bindende moleküle und ihre verwendung
US20060223096A1 (en) * 2005-03-25 2006-10-05 Glycart Biotechnology Ag Antigen binding molecules directed to MCSP and having increased Fc receptor binding affinity and effector function
EP2322624B1 (de) 2005-03-25 2015-09-23 National Research Council Of Canada Verfahren zur Isolation von löslichen Polypeptiden
WO2006105448A2 (en) 2005-03-30 2006-10-05 Minerva Biotechnologies Corporation Proliferation of muc1 expressing cells
WO2006104970A1 (en) 2005-03-30 2006-10-05 Saladax Biomedical Inc. Doxorubicin immunoassay
ES2720288T3 (es) 2005-03-30 2019-07-19 Minerva Biotechnologies Corp Proliferación de células que expresan MUC1
CN101189023B (zh) 2005-03-31 2013-01-30 通用医疗公司 监测和调制hgf/hgfr活性
PT2645106T (pt) 2005-04-04 2017-09-18 Biogen Ma Inc Método para avaliar uma resposta imune a um agente terapêutico
GB0506912D0 (en) 2005-04-05 2005-05-11 Celltech R&D Ltd Biological products
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
EP1865981A2 (de) 2005-04-07 2007-12-19 Chiron Corporation Cacna1e in der diagnose und nachweis von sowie als therapeutisches mittel gegen krebs
EP1871911A2 (de) 2005-04-07 2008-01-02 Chiron Corporation Gene in verbindung mit krebs (prlr)
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
PT3321359T (pt) 2005-04-11 2021-03-11 Horizon Pharma Rheumatology Llc Formas variantes de urato-oxidase e a sua utilização
US9534013B2 (en) * 2006-04-12 2017-01-03 Horizon Pharma Rheumatology Llc Purification of proteins with cationic surfactant
US20090099340A1 (en) * 2007-10-12 2009-04-16 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
CA2605024C (en) * 2005-04-15 2018-05-22 Macrogenics, Inc. Covalent diabodies and uses thereof
EP1871417B1 (de) 2005-04-15 2013-09-11 Precision Biologics, Inc. Rekombinante monoklonale antikörper und entsprechende antigene für kolon- und pankreaskarzinom
WO2008157379A2 (en) 2007-06-21 2008-12-24 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) * 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2006113209A1 (en) * 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
US20060269556A1 (en) * 2005-04-18 2006-11-30 Karl Nocka Mast cell activation using siglec 6 antibodies
US20070003557A1 (en) * 2005-04-21 2007-01-04 Andres Forero Method for treating cancer using premedication
AU2006241235B2 (en) * 2005-04-22 2012-04-05 Eisai, Inc. Antibodies with immune effector activity and that internalize in endosialin-positive cells
ITMI20050739A1 (it) * 2005-04-22 2006-10-23 Effebi Spa Piastrina di connsessione valvola-attuatore
BRPI0608096A2 (pt) 2005-04-26 2009-11-10 Pfizer anticorpos p-caderina
AR054260A1 (es) * 2005-04-26 2007-06-13 Rinat Neuroscience Corp Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos
MY148086A (en) * 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
JO3058B1 (ar) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
EP1885396A2 (de) * 2005-05-04 2008-02-13 Quark Pharmaceuticals, Inc. Rekombinante antikörper gegen cd55 und cd59 und ihre verwendungen
EP1885755A4 (de) 2005-05-05 2009-07-29 Univ Duke Cd19-antikörper-therapie für autoimmunerkrankungen
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
US20130216542A1 (en) 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
MX2007013609A (es) 2005-05-06 2008-01-24 Zymogenetics Inc Anticuerpos monoclonales de il-31 y meodos de uso.
EP1888649A2 (de) * 2005-05-09 2008-02-20 GlycArt Biotechnology AG Antigen-bindungsmoleküle mit modifizierten fc-regionen und veränderte bindung an fc-rezeptoren
LT2439273T (lt) 2005-05-09 2019-05-10 Ono Pharmaceutical Co., Ltd. Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais
AU2006244068B9 (en) 2005-05-10 2012-10-25 Incyte Holdings Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
WO2006122187A2 (en) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006124667A2 (en) 2005-05-12 2006-11-23 Zymogenetics, Inc. Compositions and methods for modulating immune responses
DK1889065T3 (da) 2005-05-18 2013-09-02 Xoma Technology Ltd Metoder til diagnostisering og behandling af sygdomme med en autoimmun- og/eller inflammationskomponent
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
ES2527428T3 (es) 2005-05-18 2015-01-23 Morphosys Ag Anticuerpos anti-GM-CSF y usos de los mismos
DE102005023617A1 (de) * 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
US7393919B2 (en) * 2005-05-25 2008-07-01 Cure Dm, Inc. Peptides, derivatives and analogs thereof, and methods of using same
US8303955B2 (en) * 2005-05-26 2012-11-06 Seattle Genetics, Inc. Humanized anti-CD40 antibodies and their methods of use
CN102441163A (zh) * 2005-05-27 2012-05-09 比奥根艾迪克Ma公司 结合tweak的抗体
WO2007053184A2 (en) 2005-05-31 2007-05-10 Cold Spring Harbor Laboratory Methods for producing micrornas
US7767789B2 (en) * 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
US20070020660A1 (en) * 2005-06-06 2007-01-25 Burczynski Michael E Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
EP2390267B1 (de) 2005-06-07 2013-06-05 ESBATech - a Novartis Company LLC Stabile und lösliche Antikörper zur Hemmung von TNF(alpha)
WO2006133450A2 (en) * 2005-06-08 2006-12-14 Duke University Anti-cd19 antibody therapy for the transplantation
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
AU2006259583A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
EP2937360A1 (de) 2005-06-17 2015-10-28 Merck Sharp & Dohme Corp. Ilt3-bindende moleküle und verwendungen davon
JP2008543449A (ja) * 2005-06-17 2008-12-04 アボット・ラボラトリーズ 変性脊椎疾患の改良型治療方法
CA2611814A1 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
WO2007094842A2 (en) * 2005-12-02 2007-08-23 Genentech, Inc. Binding polypeptides and uses thereof
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
AU2006261824A1 (en) * 2005-06-24 2007-01-04 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain (PLAD) of tumor necrosis factor receptors
US20100129288A1 (en) * 2005-06-28 2010-05-27 Elior Peles Gliomedin, Fragments Thereof and Methods of Using Same
JP2009501006A (ja) 2005-06-30 2009-01-15 セントカー・インコーポレーテツド 抗ｉｌ−２３抗体、組成物、方法および用途
US7700739B2 (en) * 2005-06-30 2010-04-20 Abbott Laboratories IL-12/p40 binding proteins
CN105330741B (zh) 2005-07-01 2023-01-31 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
CA2614436C (en) 2005-07-07 2016-05-17 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
WO2007008848A2 (en) * 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
MX2008000253A (es) 2005-07-08 2008-04-02 Biogen Idec Inc Anticuerpos de sp35 y usos de los mismos.
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
US7482124B2 (en) * 2005-07-08 2009-01-27 Bristol-Myers Squibb Company Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema
EP2497496A3 (de) * 2005-07-11 2013-02-20 Macrogenics, Inc. Verfahren zur Behandlung von Autoimmunerkrankungen mithilfe von immunsuppressiven monoklonalen Antikörpern mit reduzierter Toxizität
AU2006269940C1 (en) 2005-07-18 2013-11-07 Seagen Inc. Beta-glucuronide-linker drug conjugates
EP2388277A3 (de) 2005-07-18 2013-03-20 Amgen, Inc Humane Anti-B7RP1-neutralisierende Antikörper
ES2438019T3 (es) * 2005-07-22 2014-01-15 Cytodyn, Inc. Procedimientos para reducir la carga viral en pacientes infectados por el VIH-1
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
DK1912675T3 (en) 2005-07-25 2014-03-24 Emergent Product Dev Seattle B-cell reduction using specific and cd37-cd20-specific binding molecules
BRPI0614119B8 (pt) * 2005-07-28 2017-04-11 Pah Usa 15 Llc vacina para imunizar gatos contra calicivírus de felino
JP5457671B2 (ja) * 2005-07-28 2014-04-02 ノバルティス アーゲー Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用
JP5657862B2 (ja) * 2005-07-28 2015-01-21 ノバルティス アーゲー Ｍ−ｃｓｆに対する抗体の使用
AU2006278838B2 (en) * 2005-07-29 2010-12-23 Life Sciences Research Partners Vzw Human inhibitory anti-factor VIII antibodies binding to the A2 domain
CN109187944A (zh) * 2005-08-02 2019-01-11 埃克斯生物科技公司 使用IL-1α自身抗体诊断、治疗和预防血管疾病
FR2889533B1 (fr) * 2005-08-03 2007-10-12 Lab Francais Du Fractionnement Anticorps diriges contre le recepteur du ldl
NZ623901A (en) * 2005-08-03 2015-10-30 Immunogen Inc Immunoconjugate formulations
EP1919504B1 (de) * 2005-08-03 2013-10-16 iBio, Inc. Antikörper gegen bacillus anthracis protektiv antigen
FR2889534B1 (fr) * 2005-08-04 2012-11-02 Lab Francais Du Fractionnement Anticorps anti-idiotypique neutralisant l'activite inhibitrice d'un anticorps inhibiteur du facteur viii
EP1945257A4 (de) * 2005-08-08 2009-05-06 Onconon Llc Antikörperzusammensetzungen, verfahren zur behandlung von neoplastischer erkrankung und verfahren zur regulierung der fertilität
CA2618763A1 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
EP1922080A2 (de) * 2005-08-09 2008-05-21 ZymoGenetics, Inc. Verfahren zur behandlung von b-zell-malignomen mittels taci-ig-fusionsmolekül
SI2573114T1 (sl) * 2005-08-10 2016-08-31 Macrogenics, Inc. Identifikacija in inženiring protiteles z variantnimi fc regijami in postopki za njih uporabo
AU2006281980A1 (en) * 2005-08-15 2007-02-22 Cephalon Australia Pty Ltd Engineered antibodies with new world primate framework regions
ATE497392T1 (de) * 2005-08-18 2011-02-15 Genmab As Therapie mit anti-cd4-antikörpern und bestrahlung
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US20070202512A1 (en) * 2005-08-19 2007-08-30 Bristol-Myers Squibb Company Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
RU2515108C2 (ru) 2005-08-19 2014-05-10 Эббви Инк Иммуноглобулин с двойными вариабельными доменами и его применения
EP2500356A3 (de) 2005-08-19 2012-10-24 Abbott Laboratories Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20070048325A1 (en) * 2005-08-24 2007-03-01 Dennis Van Epps Combination therapies for inhibiting integrin-extracellular matrix interactions
AU2006283726C1 (en) 2005-08-24 2015-05-07 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
US20070071745A1 (en) 2005-08-26 2007-03-29 Pablo Umana Modified antigen binding molecules with altered cell signaling activity
WO2007027906A2 (en) * 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2007027748A2 (en) * 2005-08-31 2007-03-08 Medimmune, Inc. C/clp antagonists and methods of use thereof
US20100151495A9 (en) * 2005-08-31 2010-06-17 Cell Signaling Technolgy, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US20080234213A1 (en) * 2005-09-02 2008-09-25 Matthias Wabl Oncogenic regulatory RNAs for diagnostics and therapeutics
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
WO2007030560A2 (en) * 2005-09-08 2007-03-15 Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine Identification of modulators of serine protease inhibitor kazal and their use as anti-cancer and anti-viral agents
WO2007033230A2 (en) * 2005-09-12 2007-03-22 Novimmune S.A. Anti-cd3 antibody formulations
JP5512125B2 (ja) 2005-09-12 2014-06-04 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌における再発性遺伝子融合
WO2007037910A2 (en) 2005-09-14 2007-04-05 Fred Hutchinson Cancer Research Center Specific removal of activated immune cells
CA2620362A1 (en) * 2005-09-14 2007-03-22 Ucb Pharma S.A. Comb polymers
WO2007035406A1 (en) * 2005-09-16 2007-03-29 Orthologic Corp. Antibodies to complementary peptides of thrombin or portions thereof
EP1934605B1 (de) * 2005-09-22 2014-03-26 Prosci Incorporated In hefemutanten produzierte glykosylierte polypeptide und verwendungsverfahren dafür
CA2623387A1 (en) * 2005-09-23 2007-04-05 Vasgene Therapeutics, Inc. Use of ephrinb2 directed agents for the treatment or prevention of viral infections
US7799530B2 (en) 2005-09-23 2010-09-21 Celera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
CN101312748A (zh) 2005-09-26 2008-11-26 梅达莱克斯公司 抗体-药物轭合物和使用方法
EP1934261B1 (de) 2005-09-26 2014-10-29 Medarex, L.L.C. Humane monoklonale antikörper gegen cd70
US8906864B2 (en) 2005-09-30 2014-12-09 AbbVie Deutschland GmbH & Co. KG Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
EP1931709B1 (de) * 2005-10-03 2016-12-07 Xencor, Inc. Fc-varianten mit optimierten rezeptorbindungseigenschaften
US7422899B2 (en) * 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US7526409B2 (en) * 2005-10-07 2009-04-28 Oracle International Corporation Automatic performance statistical comparison between two periods
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
CA2625773C (en) * 2005-10-14 2015-05-12 Fukuoka University Inhibition of interleukin-6 (il-6) receptor promotes pancreatic islet transplantation
US20070087005A1 (en) * 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
US8652467B2 (en) * 2005-10-14 2014-02-18 The Regents Of The University Of Michigan Dek protein compositions and methods of using the same
GB0521139D0 (en) 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
US7794951B2 (en) * 2005-10-18 2010-09-14 University Of Massachusetts Medical School SREBP2gc transcription factors and uses thereof
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
BRPI0617664B8 (pt) * 2005-10-21 2021-05-25 Chugai Pharmaceutical Co Ltd uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio
EP2532679B1 (de) 2005-10-21 2017-04-12 Novartis AG Menschliche Antikörper gegen IL13 und therapeutische Verwendungen
ATE518007T1 (de) 2005-10-21 2011-08-15 Genenews Inc Verfahren und vorrichtung zur korrelierung der ebenen von biomarker-produkten mit erkrankungen
PE20070796A1 (es) * 2005-10-24 2007-08-15 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
ES2375843T3 (es) 2005-10-26 2012-03-06 Medarex, Inc. Procedimientos y compuestos para la preparación de an�?logos de cc-1065.
US7695911B2 (en) 2005-10-26 2010-04-13 Celera Corporation Genetic polymorphisms associated with Alzheimer's Disease, methods of detection and uses thereof
US20090074720A1 (en) * 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
US20080213274A1 (en) * 2005-10-28 2008-09-04 Sabbadini Roger A Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
WO2007053524A2 (en) * 2005-10-28 2007-05-10 The Florida International University Board Of Trustees Horse: human chimeric antibodies
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
JP5129149B2 (ja) 2005-10-31 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を処置および診断するための組成物および方法
JP2009513708A (ja) 2005-10-31 2009-04-02 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
EP1948235B1 (de) 2005-11-01 2013-08-28 AbbVie Biotechnology Ltd Methoden zur bestimmung der wirksamkeit von adalimumab bei patienten mit morbus bechterew mit ctx-ii und mmp3 als biomarker
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
US20090291437A1 (en) * 2005-11-02 2009-11-26 O'brien Sean Methods for targeting quadruplex sequences
WO2007055902A1 (en) 2005-11-03 2007-05-18 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Immunogenic peptides and methods of use for treating and preventing cancer
US20070099246A1 (en) * 2005-11-03 2007-05-03 Sandy John D Antibodies, assays and kits to quantitate cartilage destruction
PL2500030T5 (pl) 2005-11-04 2019-02-28 Genentech, Inc. Zastosowanie inhibitorów drogi aktywacji dopełniacza w leczeniu chorób oczu
MX2008005764A (es) 2005-11-04 2008-11-18 Biogen Idec Inc Metodos para promover el crecimiento de neuritas y la supervivencia en neuronas dopaminergicas.
JP5191392B2 (ja) 2005-11-07 2013-05-08 ザ スクリプス リサーチ インスティチュート 組織因子シグナル伝達の特異性を調節するための組成物及び方法
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
JP2009515897A (ja) 2005-11-10 2009-04-16 キュラジェン コーポレイション Ｔ細胞の免疫グロブリンドメインおよびムチンドメイン１（ｔｉｍ−１）抗原に対する抗体を用いて卵巣癌および腎臓癌を処置する方法
WO2007059404A2 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
AR056806A1 (es) 2005-11-14 2007-10-24 Amgen Inc Moleculas quimericas de anticuerpo rankl- pth/ pthrp
ES2664421T3 (es) 2005-11-14 2018-04-19 Teva Pharmaceuticals International Gmbh Anticuerpo antagonista dirigido contra un péptido relacionado con el gen de la calcitonina
AR057582A1 (es) * 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
EP1952147A2 (de) 2005-11-16 2008-08-06 Novartis AG Biomarker zur anti-nogo-a-antikörperbehandlung bei rückenmarksverletzung
JP2009515552A (ja) * 2005-11-17 2009-04-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリン反応性ヒト化免疫グロブリン
CN101360826B (zh) * 2005-11-18 2014-04-30 格兰马克药品股份有限公司 抗α2整联蛋白抗体及它们的用途
EP1957541A2 (de) * 2005-11-21 2008-08-20 Laboratoires Serono SA Zusammensetzungen und verfahren zur herstellung von antigenbindenden hybridmolekülen und anwendungen davon
CA2630964A1 (en) 2005-11-22 2007-05-31 The Trustees Of The University Of Pennsylvania Antibody treatment of alzheimer's and related diseases
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
WO2007061029A1 (ja) * 2005-11-25 2007-05-31 Keio University 前立腺癌治療剤
EP2805971A1 (de) 2005-11-28 2014-11-26 ZymoGenetics, Inc. IL-21-Antagonisten
CN103710430B (zh) 2005-11-29 2016-03-30 剑桥企业有限公司 乳腺癌标志物
KR101439828B1 (ko) 2005-11-30 2014-09-17 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
AU2006319358B2 (en) 2005-11-30 2012-01-19 AbbVie Deutschland GmbH & Co. KG Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
US9829494B2 (en) 2005-12-01 2017-11-28 Adrenomed Ag Methods of treatment using ADM antibodies
JP5312039B2 (ja) 2005-12-02 2013-10-09 バイオジェン・アイデック・エムエイ・インコーポレイテッド 脱髄の関与する状態の処置
AU2006321593B2 (en) 2005-12-07 2012-10-04 E. R. Squibb & Sons, L.L.C. CTLA-4 antibody dosage escalation regimens
PT1960434E (pt) 2005-12-08 2012-10-02 Medarex Inc Anticorpos monoclonais humanos para fucosil-gm1 e métodos para a utilização de anti-fucosil-gm1
DK1960430T3 (da) * 2005-12-09 2015-01-05 Ucb Pharma Sa Antistofmolekyler der har specificitet for humant il-6
RU2015111675A (ru) * 2005-12-12 2015-08-10 Ац Иммуне Са Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами
GB0525214D0 (en) * 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
KR101158959B1 (ko) 2005-12-13 2012-07-09 일라이 릴리 앤드 캄파니 항-ｉｌ-17 항체
US20070264687A1 (en) 2005-12-15 2007-11-15 Min-Yuan Chou Recombinant triplex scaffold-based polypeptides
US7763245B2 (en) 2005-12-15 2010-07-27 Genentech, Inc. Methods and compositions for targeting polyubiquitin
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
WO2008060369A2 (en) 2006-09-29 2008-05-22 Translational Therapeutics, Inc. Eif4e regulon-based diagnostics
HUE034269T2 (en) 2005-12-29 2018-02-28 Janssen Biotech Inc Human anti-IL-23 antibodies, preparations, methods and applications
JP2009522302A (ja) 2005-12-30 2009-06-11 ダイアックス コーポレーション マトリックスメタロプロテイナーゼ結合タンパク質
JP2009521912A (ja) 2005-12-30 2009-06-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 低減された免疫原性を有する抗ｃｄ１９抗体
CN106124765A (zh) * 2006-01-04 2016-11-16 富士瑞必欧美国公司 He4与其它生化标记物在卵巢癌评估中的应用
RU2450020C2 (ru) 2006-01-05 2012-05-10 Дженентек, Инк. АНТИТЕЛА ПРОТИВ EphB4 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP2594585A1 (de) 2006-01-10 2013-05-22 Zymogenetics, Inc. Verfahren zur Behandlung von Schmerzen und Entzündungen im Nervengewebe mithilfe von IL-31-Antagonisten
KR20140091765A (ko) 2006-01-12 2014-07-22 알렉시온 파마슈티칼스, 인코포레이티드 Ｏｘ-2/ｃｄ200에 대한 항체 및 이들의 용도
US20090175886A1 (en) 2006-01-17 2009-07-09 Medarex, Inc. Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
US20070166306A1 (en) * 2006-01-17 2007-07-19 Fey Georg H M Anti-CD19 antibody composition and method
ES2396440T3 (es) 2006-01-18 2013-02-21 The General Hospital Corporation Métodos de aumentar la función linfática
WO2009051846A2 (en) 2007-10-18 2009-04-23 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
NL2000439C2 (nl) 2006-01-20 2009-03-16 Quark Biotech Therapeutische toepassingen van inhibitoren van RTP801.
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
CN103215293B (zh) 2006-01-27 2015-10-28 比奥根Ma公司 Nogo受体拮抗剂
EP1990060B1 (de) * 2006-01-27 2016-09-28 Keio University Therapeutische mittel zur behandlung von krankheiten im zusammenhang mit choroidaler neovaskularisation
US20070178103A1 (en) * 2006-01-30 2007-08-02 Fey Georg H CD19-specific immunotoxin and treatment method
EP1987361A4 (de) * 2006-01-30 2009-03-04 Invitrogen Corp Zusammensetzungen und verfahren zur erkennung und quantifizierung toxischer substanzen in krankheitsstadien
US7498142B2 (en) * 2006-01-31 2009-03-03 Yeda Research And Development Co., Ltd. Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
EA017417B1 (ru) * 2006-02-01 2012-12-28 Сефалон Астралия Пти Лтд. КОНСТРУКТ ОДНОДОМЕННОГО АНТИТЕЛА, КОТОРЫЙ СВЯЗЫВАЕТСЯ С ЧЕЛОВЕЧЕСКИМ TNF-α, И ЕГО ПРИМЕНЕНИЕ
EP1994043A4 (de) 2006-02-10 2009-05-20 Univ Cincinnati Phosphatasehemmer-protein 1 als regulator der herzfunktion
US20080279877A1 (en) * 2006-02-13 2008-11-13 Fraunhofer U.S.A. Inc. HPV antigens, vaccine compositions, and related methods
JP2009526526A (ja) * 2006-02-13 2009-07-23 フラウンホーファー ユーエスエー， インコーポレイテッド インフルエンザ抗原、ワクチン組成物、および関連する方法
US8277816B2 (en) * 2006-02-13 2012-10-02 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
US7820174B2 (en) 2006-02-24 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services T cell receptors and related materials and methods of use
US7459280B2 (en) * 2006-02-27 2008-12-02 Picobella, Llc Methods for diagnosing and treating kidney cancer
US7985548B2 (en) * 2006-03-03 2011-07-26 The United States Of America As Represented By The Department Of Health And Human Services Materials and methods directed to asparagine synthetase and asparaginase therapies
EP2540741A1 (de) 2006-03-06 2013-01-02 Aeres Biomedical Limited Humanisierte Anti-CD22-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
WO2007103470A2 (en) * 2006-03-06 2007-09-13 Medimmune, Inc. Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP1996942A1 (de) * 2006-03-10 2008-12-03 Tethys Bioscience, Inc. Multiplex-protein-fraktionierung
JP2009529331A (ja) * 2006-03-10 2009-08-20 マクロジェニクス，インコーポレーテッド 変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法
EP4316465A3 (de) 2006-03-15 2024-04-24 Alexion Pharmaceuticals, Inc. Behandlung paroxysmaler nächtlicher hämoglobinurie-patienten mit einem komplementhemmer
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
GB0605689D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic compounds
US20080208486A1 (en) * 2006-03-23 2008-08-28 Jari Natunen Integrated System, Device and Use Thereof
JP4294082B2 (ja) * 2006-03-23 2009-07-08 協和発酵キリン株式会社 ヒトトロンボポエチン受容体に対するアゴニスト抗体
US11806718B2 (en) 2006-03-24 2023-11-07 Handylab, Inc. Fluorescence detector for microfluidic diagnostic system
US7998708B2 (en) 2006-03-24 2011-08-16 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
US8088616B2 (en) 2006-03-24 2012-01-03 Handylab, Inc. Heater unit for microfluidic diagnostic system
US10900066B2 (en) 2006-03-24 2021-01-26 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
JP5415253B2 (ja) 2006-03-24 2014-02-12 ハンディラブ・インコーポレーテッド 微小流体サンプルを処理するための一体化システム及びその使用方法
CN103641915B (zh) 2006-03-27 2017-04-12 医学免疫有限公司 Gm‑csf受体结合元件
RU2429014C2 (ru) 2006-03-31 2011-09-20 Массачусетс Инститьют Оф Текнолоджи Лечение опухолей, экспрессирующих мутантные рецепторы egf
JPWO2007119623A1 (ja) 2006-03-31 2009-08-27 独立行政法人理化学研究所 Ｇ蛋白質共役型受容体およびそのリガンドの新規用途
CA2638774C (en) * 2006-03-31 2015-11-24 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
DE102006015341A1 (de) * 2006-04-03 2007-10-04 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Behandlung von multipler Sklerose und/oder rheumatoider Arthritis
NZ611859A (en) 2006-04-05 2014-12-24 Abbvie Biotechnology Ltd Antibody purification
SMP200800060B (it) 2006-04-07 2009-07-14 Procter & Gamble Anticorpi che legano la proteina umana tirosina fosfatasi beta (hptbeta) e loro usi
WO2007116962A1 (ja) * 2006-04-07 2007-10-18 Osaka University 筋再生促進剤
KR20090029184A (ko) * 2006-04-07 2009-03-20 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 항체 조성물 및 신생물성 질병의 치료 방법
CA2564435A1 (en) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
EP2666478A3 (de) 2006-04-10 2014-10-22 AbbVie Biotechnology Ltd Anwendungen und Zusammensetzungen zur Behandlung von Schuppenflechte
US9624295B2 (en) 2006-04-10 2017-04-18 Abbvie Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
JP2009541208A (ja) 2006-04-13 2009-11-26 ノバルティス・バクシーンズ・アンド・ダイアグノスティクス・インコーポレイテッド がんを処置し、診断しもしくは検出する方法
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
MX2008013363A (es) 2006-04-20 2009-03-26 Jackson H M Found Military Med Metodos y composiciones basados en la proteina tipo 1 de la toxina shiga.
MEP39508A (en) 2006-04-21 2011-02-10 Novartis Ag Antagonist anti-cd40 antibody pharmaceutical compositions
US20070254338A1 (en) * 2006-04-24 2007-11-01 Amgen Inc. Method for making recombinant protein using complementation dependent DHFR mutants
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
CA2650730A1 (en) 2006-04-27 2007-11-08 Pikamab, Inc. Methods and compositions for antibody therapy
US20090298093A1 (en) * 2006-04-27 2009-12-03 Roberto Polakiewicz Reagents for the Detection of Protein Phosphorylation in ATM & ATR Kinase Signaling Pathways
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
CN101489573B (zh) * 2006-05-15 2013-05-22 阿雷斯贸易股份有限公司 用TACI-Ig融合分子治疗自身免疫疾病的方法
US20070269422A1 (en) * 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
EP1918302A3 (de) * 2006-05-18 2009-11-18 AvantGen, Inc. Verfahren zur Identifikation und Isolation von epitopspezifischen Antikörpern
US20070269442A1 (en) * 2006-05-19 2007-11-22 Robert J. Webber Chimeric monoclonal antibody recognizing iNOS
CN102580086A (zh) * 2006-05-22 2012-07-18 埃克斯生物科技公司 使用抗IL-1α抗体治疗癌症
US20100196336A1 (en) 2006-05-23 2010-08-05 Dongsu Park Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
US10119979B2 (en) 2006-05-25 2018-11-06 Biogen Ma Inc. Methods of treating stroke and traumatic brain injury using humanized AQC2 anti-VLA-1 antibodies
WO2008105886A2 (en) * 2006-05-26 2008-09-04 Macrogenics, Inc. HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
AR060978A1 (es) * 2006-05-30 2008-07-23 Genentech Inc Anticuerpos e inmunoconjugados y sus usos
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
WO2008042024A2 (en) 2006-06-01 2008-04-10 Elan Pharmaceuticals, Inc. Neuroactive fragments of app
JP4686634B2 (ja) 2006-06-02 2011-05-25 アベオ ファーマシューティカルズ， インコーポレイテッド 肝細胞成長因子（ｈｇｆ）結合蛋白質
AR061170A1 (es) 2006-06-02 2008-08-06 Aveo Pharmaceuticals Inc Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf)
GB0611116D0 (en) 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
CA2652703C (en) 2006-06-07 2018-08-28 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
AT503690A1 (de) 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
JP2009539413A (ja) 2006-06-12 2009-11-19 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド エフェクター機能を有する単鎖多価結合タンパク質
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
SG177907A1 (en) * 2006-06-14 2012-02-28 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
US20080015465A1 (en) * 2006-06-15 2008-01-17 Scuderi Gaetano J Methods for diagnosing and treating pain in the spinal cord
US8101721B2 (en) * 2006-06-15 2012-01-24 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
JP5597793B2 (ja) * 2006-06-19 2014-10-01 メルク・シャープ・アンド・ドーム・コーポレーション Ｉｌｔ３結合分子およびその使用
CA2656918A1 (en) * 2006-06-22 2007-12-27 Vaccinex, Inc. Anti-c35 antibodies for treating cancer
US20100159450A1 (en) 2006-06-23 2010-06-24 Susanne Wagner Dpyd gene variants and use thereof
HUE033007T2 (en) 2006-06-23 2017-11-28 Engeneic Molecular Delivery Pty Ltd Targeted drug, therapeutic nucleic acid and functional nucleic acid delivery to mammalian cells via intact killed bacterial cells
EP2032159B1 (de) 2006-06-26 2015-01-07 MacroGenics, Inc. Kombination aus fcgammariib-antikörpern und cd20-spezifischen antikörpern sowie verwendungsverfahren dafür
LT2029173T (lt) 2006-06-26 2016-11-10 Macrogenics, Inc. Fc riib specifiniai antikūnai ir jų panaudojimo būdai
US7589212B2 (en) * 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
TWI498137B (zh) 2006-06-30 2015-09-01 Abbvie Biotechnology Ltd 自動注射裝置
RU2499001C2 (ru) 2006-06-30 2013-11-20 Ново Нордиск А/С Антитела к nkg2a и их применения
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
EP2032989B2 (de) 2006-06-30 2015-10-28 Merck Sharp & Dohme Corp. Igfbp2-biomarker
JP5382692B2 (ja) 2006-07-10 2014-01-08 学校法人藤田学園 抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途
CA2662905A1 (en) 2006-07-10 2008-01-17 Biogen Idec Ma Inc. Compositions and methods for inhibiting growth of smad4-deficient cancers
DK2447275T3 (en) 2006-07-13 2015-06-29 Univ Iowa Res Found Methods and reagents for the treatment of age-related macular degeneration
RS56986B1 (sr) 2006-07-14 2018-05-31 Ac Immune Sa Humanizovana antitela na beta amiloid
KR101605207B1 (ko) * 2006-07-14 2016-03-22 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
CN101622276B (zh) * 2006-07-18 2015-04-22 赛诺菲-安万特 用于治疗癌症的抗epha2的拮抗抗体
WO2008011157A2 (en) 2006-07-20 2008-01-24 The General Hospital Corporation Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
CA2659820A1 (en) 2006-08-04 2008-02-14 Novartis Ag Ephb3-specific antibody and uses thereof
CA2660330A1 (en) 2006-08-08 2008-02-14 Kyoto University Novel monoclonal antibody and use of the same
AR062223A1 (es) 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
WO2008022035A2 (en) * 2006-08-10 2008-02-21 The Scripps Research Institute Methods for identifying cellular modulators of disaggregation activity or aggregation activity in an animal
US9415111B2 (en) 2006-08-11 2016-08-16 Rutgers, The State University Of New Jersey Dual-sensitizer-containing luminescent compounds, conjugates, and uses thereof
ES2506065T3 (es) * 2006-08-11 2014-10-13 Csl Limited Tratamiento de estados patológicos pulmonares
WO2008018641A1 (en) 2006-08-11 2008-02-14 Ono Pharmaceutical Co., Ltd. Monoclonal antibodies against stromal derived factor-1 (sdf-1)
US7939636B2 (en) * 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
DK2383297T5 (da) 2006-08-14 2022-07-04 Xencor Inc Optimerede antistoffer rettet mod CD19
WO2008020586A1 (en) 2006-08-14 2008-02-21 Forerunner Pharma Research Co., Ltd. Diagnosis and treatment of cancer using anti-desmoglein-3 antibody
US8497246B2 (en) * 2006-08-18 2013-07-30 Armagen Technologies, Inc. Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
GEP20125612B (en) 2006-08-18 2012-08-27 Novartis Ag Prlr-specific antibody and usage thereof
US9580515B2 (en) * 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
EP2064243A2 (de) 2006-08-28 2009-06-03 Kyowa Hakko Kirin Co., Ltd. Antagonistische lichtspezifische menschliche monoklonale antikörper
US8636995B2 (en) * 2006-08-31 2014-01-28 Cardiac Pacemakers, Inc. Methods and devices to regulate stem cell homing
US20080058922A1 (en) * 2006-08-31 2008-03-06 Cardiac Pacemakers, Inc. Methods and devices employing vap-1 inhibitors
US20090258442A1 (en) * 2006-08-31 2009-10-15 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US8372399B2 (en) * 2006-08-31 2013-02-12 Cardiac Pacemakers, Inc. Bispecific antibodies and agents to enhance stem cell homing
CN101522713A (zh) 2006-09-01 2009-09-02 津莫吉尼蒂克斯公司 Il-31单克隆抗体的可变区序列和使用方法
US20110182904A1 (en) 2006-09-05 2011-07-28 Deborah Zimmerman Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
EP2061810B1 (de) 2006-09-05 2014-11-12 Alexion Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur behandlung antikörper-vermittelter nervenleiden
EP2783700A1 (de) * 2006-09-07 2014-10-01 Stemline Therapeutics, Inc. Auf Krebsstammzellen gerichtete Krebstherapie
ES2902063T3 (es) 2006-09-08 2022-03-24 Abbvie Bahamas Ltd Proteínas de unión a interleucina-13
US20080261216A1 (en) * 2006-09-08 2008-10-23 The Regents Of The University Of Michigan HERV Group II Viruses In Lymphoma And Cancer
MX2009002414A (es) 2006-09-08 2009-05-20 Medimmune Llc Anticuerpos anti-cd19 humanizados y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunitaria.
US20100297103A1 (en) 2006-09-14 2010-11-25 Medical & Biological Laboratories Co., Ltd. Antibody having enhanced adcc activity and method for production thereof
WO2008036688A2 (en) 2006-09-18 2008-03-27 Xencor, Inc. Optimized antibodies that target hm1.24
CA2664423A1 (en) 2006-09-22 2008-03-27 St. Jude Children's Research Hospital Modulating regulatory t cell activity via interleukin 35
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
FR2906533B1 (fr) 2006-09-28 2013-02-22 Pf Medicament Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
US8093360B2 (en) 2006-09-28 2012-01-10 Elusys Therapeutics, Inc. Antibodies that bind B. anthracis exotoxin, formulations thereof, and methods of use
PL2066694T3 (pl) 2006-09-29 2016-04-29 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworu
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
SG178712A1 (en) 2006-10-02 2012-03-29 Medarex Inc Human antibodies that bind cxcr4 and uses thereof
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
EP2067041A2 (de) 2006-10-03 2009-06-10 Biogen Idec MA, Inc. Biomarker und testreihen zur behandlung von krebs
CA2664567C (en) 2006-10-04 2016-04-26 Dana-Farber Cancer Institute, Inc. Tumor immunity
CA3163418A1 (en) 2006-10-06 2008-05-22 Jeffrey S. Isenberg Prevention of tissue ischemia, related methods and compositions
US20080112961A1 (en) * 2006-10-09 2008-05-15 Macrogenics, Inc. Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
PL2698166T3 (pl) 2006-10-10 2016-03-31 Regenesance B V Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów
EP2076287A2 (de) * 2006-10-12 2009-07-08 Wyeth Verfahren und zusammensetzungen mit verringerter opaleszenz
JP2010506842A (ja) 2006-10-16 2010-03-04 メディミューン，エルエルシー 半減期が短縮された分子、その組成物および使用
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
EP1914242A1 (de) 2006-10-19 2008-04-23 Sanofi-Aventis Neue Antikörper gegen CD38 zur Behandlung von Krebs
ES2388567T3 (es) 2006-10-19 2012-10-16 Csl Limited Anticuerpos anti-il-13r alfa 1 y usos de los mismos
CA2915679C (en) 2006-10-20 2017-12-12 Celera Corporation Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof
WO2008066626A2 (en) * 2006-10-25 2008-06-05 The Rockefeller University METHODS FOR THE TREATMENT OF Aβ RELATED DISORDERS AND COMPOSITIONS THEREFOR
JP5399710B2 (ja) * 2006-10-26 2014-01-29 株式会社ジーンテクノサイエンス 細胞外マトリックスタンパク質のアミノ酸配列ｒｇｄに対する抗体およびその製法と用途
FI20060946A0 (fi) * 2006-10-26 2006-10-26 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
EP1916259A1 (de) 2006-10-26 2008-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-Glycoprotein VI SCFV Fragment zur Thrombosebehandlung
JP5795833B2 (ja) 2006-10-27 2015-10-14 エルパス・インコーポレイテッドＬｐａｔｈ， Ｉｎｃ． スフィンゴシン−１−リン酸と結合させるための組成物および方法
SI2502938T1 (sl) 2006-10-27 2015-05-29 Genentech, Inc. Protitelesa in imunokonjugati in njihove uporabe
WO2008055072A2 (en) 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
CA2667502A1 (en) * 2006-10-31 2008-06-19 Immunogen, Inc. Methods for improving antibody production
US8618248B2 (en) 2006-10-31 2013-12-31 President And Fellows Of Harvard College Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
ES2663080T3 (es) 2006-11-01 2018-04-11 Ventana Medical Systems, Inc. Haptenos, conjugados de haptenos, composiciones de los mismos y método para su preparación y uso
JP2010509234A (ja) * 2006-11-02 2010-03-25 シアトル ジェネティックス， インコーポレイテッド 新生物疾患、自己免疫疾患および炎症性疾患を処置する方法
MX2009004519A (es) 2006-11-03 2009-05-12 Wyeth Corp Sustancias que inhiben la glucolisis en un cultivo de celulas.
EP2097450A2 (de) * 2006-11-10 2009-09-09 Amgen Inc. Diagnostika und therapeutika auf antikörperbasis
US20100015665A1 (en) * 2006-11-10 2010-01-21 Ucb Pharma S.A. Antibodies and diagnostics
WO2008060604A2 (en) 2006-11-14 2008-05-22 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
WO2008061165A2 (en) 2006-11-14 2008-05-22 Handylab, Inc. Microfluidic cartridge and method of making same
MX2009005189A (es) 2006-11-15 2009-06-30 Medarex Inc Anticuerpos humanos monoclonales para btla y metodos de uso.
EP2094282A4 (de) * 2006-11-15 2010-05-05 Functional Genetics Inc Antikörper gegen tsg101 und verwendungen davon zur behandlung von virusinfektionen
CA2670368C (en) 2006-11-21 2018-05-29 Abbott Laboratories Neutralizing monoclonal antibodies against the nogo-66 receptor (ngr) and uses thereof
WO2008064306A2 (en) * 2006-11-22 2008-05-29 Curedm, Inc. Methods and compositions relating to islet cell neogenesis
WO2008065053A1 (en) * 2006-11-27 2008-06-05 Dkfz Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Multi-modal cancer therapy using viral hitch-hiking
EP2431053A1 (de) 2006-11-27 2012-03-21 Patrys Limited Neues glykosyliertes Zielpeptid in neoplastischen Zellen
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
US8945565B2 (en) 2006-12-01 2015-02-03 Selexys Pharmaceuticals Corporation Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies
US20110212096A1 (en) 2006-12-01 2011-09-01 Scott Rollins Anti-p-selectin antibodies and methods of their use and identification
WO2008069999A2 (en) * 2006-12-01 2008-06-12 Selexys Pharmaceuticals Corporation Anti-p-selectin antibodies and methods of using the same to treat inflammatory diseases
US8455622B2 (en) 2006-12-01 2013-06-04 Seattle Genetics, Inc. Variant target binding agents and uses thereof
MX2009005776A (es) 2006-12-01 2009-06-10 Medarex Inc Anticuerpos humanos que se enlazan al cd 22 y sus usos.
US8288110B2 (en) * 2006-12-04 2012-10-16 Perkinelmer Health Sciences, Inc. Biomarkers for detecting cancer
US20090010929A1 (en) * 2006-12-04 2009-01-08 Good Michael F Therapeutic Antibodies, Antibody Fragments and Antibody Conjugates
EP2687232A1 (de) 2006-12-06 2014-01-22 MedImmune, LLC Verfahren zur Behandlung von systemischem Lupus erythematodes
WO2008070780A1 (en) 2006-12-07 2008-06-12 Novartis Ag Antagonist antibodies against ephb3
US20080139790A1 (en) * 2006-12-08 2008-06-12 Jennings Philip A Chimeric antibodies
PT2121751T (pt) 2006-12-08 2017-04-18 Lexicon Pharmaceuticals Inc Anticorpos monoclonais contra angptl3
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
GB0624687D0 (en) * 2006-12-11 2007-01-17 Univ Aston Treatment of cachexia
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
WO2008074004A2 (en) 2006-12-14 2008-06-19 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
EP2628752A1 (de) * 2006-12-14 2013-08-21 Merck Sharp & Dohme Corp. Entwickelter Antikörper gegen TSLP
US7935791B2 (en) 2006-12-18 2011-05-03 Genentech, Inc. Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
WO2008079280A1 (en) * 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) * 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US20100015142A1 (en) * 2006-12-21 2010-01-21 Macrogenics Inc. Methods for the treatment of lada and other adult- onset autoimmune using immunosuppressive monoclonal antibodies with reduced toxicity
CN101678101B (zh) * 2006-12-26 2012-11-07 分子免疫中心 可用于诊断和治疗b细胞慢性淋巴细胞白血病的能够在肿瘤细胞中诱导凋亡的药物组合物
WO2008083169A2 (en) * 2006-12-26 2008-07-10 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders
US20090142342A1 (en) * 2006-12-27 2009-06-04 Johns Hopkins University B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
WO2008083239A2 (en) * 2006-12-27 2008-07-10 The Johns Hopkins University Compositions and methods for stimulating an immune response
CN101663323A (zh) 2006-12-27 2010-03-03 埃默里大学 用于治疗传染病和肿瘤的组合物和方法
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
PL3345607T3 (pl) 2006-12-29 2023-01-09 Ossifi-Mab Llc Sposoby modyfikowania wzrostu kości poprzez podanie antagonisty lub agonisty sost lub wise
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
CN103408661B (zh) 2007-01-05 2016-04-06 苏黎世大学 提供疾患特异性结合分子和靶的方法
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
DK2740744T3 (da) 2007-01-09 2018-04-23 Biogen Ma Inc Sp35-antistoffer og anvendelser deraf
AU2008206442B2 (en) 2007-01-12 2012-10-18 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services gp100-specific T cell receptors and related materials and methods of use
NZ578065A (en) 2007-01-16 2012-09-28 Abbott Lab Methods for treating psoriasis with an antibody which binds to an epitope
PT2842967T (pt) 2007-01-18 2017-01-13 Lilly Co Eli Fab beta amilóide peguilado
AU2008205457A1 (en) * 2007-01-18 2008-07-24 University Of Southern California Gene polymorphisms predictive for dual TKI therapy
WO2008087258A1 (en) 2007-01-18 2008-07-24 Suomen Punainen Risti, Veripalvelu Novel carbohydrate from human cells and methods for analysis and modification thereof
WO2008087260A1 (en) 2007-01-18 2008-07-24 Suomen Punainen Risti, Veripalvelu Novel specific cell binders
ES2426158T3 (es) 2007-01-22 2013-10-21 Genentech, Inc. Precipitación con polielectrolito y purificación de anticuerpos
TWI438208B (zh) * 2007-01-23 2014-05-21 Chugai Pharmaceutical Co Ltd 抑制慢性排斥反應之藥劑
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
CA2676008A1 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US20100196355A1 (en) * 2007-01-29 2010-08-05 Wyeth Immunophilin Ligands and Methods for Modulating Immunophilin and Calcium Channel Activity
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
TW201206954A (en) * 2007-02-02 2012-02-16 Amgen Inc Hepcidin, hepcidin antagonists and methods of use
US7871784B2 (en) * 2007-02-02 2011-01-18 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
CA2676766A1 (en) 2007-02-09 2008-08-21 Genentech, Inc. Anti-robo4 antibodies and uses therefor
EP1958645A1 (de) 2007-02-13 2008-08-20 Biomay AG Peptide abgeleitet vom Hauptallergens von Traubenkraut (Ambrosia artemisiifolia) und deren Anwendung
US7883705B2 (en) * 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
WO2008100995A1 (en) 2007-02-14 2008-08-21 Vaccinex, Inc. Humanized anti-cd100 antibodies
US20090208491A1 (en) * 2007-02-14 2009-08-20 Austin Gurney Compositions and Methods for Diagnosing and Treating Cancer
JP2010519194A (ja) * 2007-02-15 2010-06-03 アストラゼネカ・アクチエボラーグ ＩｇＥ分子に対する結合要素
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
US8114606B2 (en) * 2007-02-16 2012-02-14 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies
US8685666B2 (en) * 2007-02-16 2014-04-01 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies and uses thereof
WO2008103693A2 (en) * 2007-02-21 2008-08-28 Medarex, Inc. Chemical linkers with single amino acids and conjugates thereof
JP2010519256A (ja) 2007-02-23 2010-06-03 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 免疫疾患を治療するために、ＨＬＡ−Ｅ／Ｑａ−１拘束性ＣＤ８＋Ｔ細胞制御性経路を活性化または遮断する方法
DK2118300T3 (en) 2007-02-23 2015-07-13 Prothena Biosciences Ltd PREVENTION AND TREATMENT OF SYNUCLEINOPATHIC AND AMYLOIDOGENIC DISEASE
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US20090081659A1 (en) 2007-03-07 2009-03-26 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP2134738A4 (de) 2007-03-14 2010-04-21 Univ Washington Diagnoseverfahren für diabetes und therapeutika für adipositas
JP2010521180A (ja) 2007-03-14 2010-06-24 ノバルティス アーゲー 癌を処置、診断または検出するためのａｐｃｄｄ１阻害剤
NZ580245A (en) 2007-03-22 2012-01-12 Biogen Idec Inc Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
EP2121008A4 (de) * 2007-03-22 2010-03-31 Sloan Kettering Inst Cancer Verwendung des monoklonalen antikörpers 8h9
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
PL2308514T3 (pl) 2007-03-23 2013-11-29 To Bbb Holding B V Koniugaty do ukierunkowanego dostarczania leku poprzez barierę krew-mózg
EP1975184A3 (de) 2007-03-26 2008-11-26 Cell Signaling Technology, Inc. Serin- oder Threonin-Phosphorylationsorte
WO2008118324A2 (en) 2007-03-26 2008-10-02 Macrogenics, Inc. Composition and method of treating cancer with an anti-uroplakin ib antibody
TW200902064A (en) * 2007-03-28 2009-01-16 Wyeth Corp Methods and compositions for modulating IL-17F/IL-17A biological activity
US20080238709A1 (en) * 2007-03-28 2008-10-02 Faramarz Vaziri One-way communication apparatus with dynamic key generation
NZ598881A (en) * 2007-03-29 2013-11-29 Abbvie Inc Crystalline anti-human il-12 antibodies
US8455189B2 (en) * 2007-03-29 2013-06-04 Jeffrey W. Allard Use of HE4 for assessment of breast cancers
SG10201507969PA (en) 2007-03-30 2015-10-29 Engeneic Molecular Delivery Pty Ltd Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells
JP5456658B2 (ja) 2007-03-30 2014-04-02 メディミューン，エルエルシー 抗体製剤
WO2008120107A2 (en) 2007-04-03 2008-10-09 Oxyrane (Uk) Limited Glycosylation of molecules
US7807168B2 (en) * 2007-04-10 2010-10-05 Vaccinex, Inc. Selection of human TNFα specific antibodies
US20100261640A1 (en) 2007-04-10 2010-10-14 Branco Luis M Soluble and membrane anchored forms of lassa virus subunit proteins
CA2682390A1 (en) * 2007-04-17 2008-10-30 Imclone Llc Pdgfr.beta.-specific inhibitors
RU2523894C2 (ru) * 2007-04-18 2014-07-27 Янссен Альцгеймер Иммунотерапи Предупреждение и лечение церебральной амилоидной ангиопатии
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP1983003A3 (de) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosinphosphorylationsstellen und spezifische Antikörper
EP1983002A3 (de) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosinphosphorylations-Stellen und spezifische Antikörper
WO2008130668A2 (en) * 2007-04-20 2008-10-30 Mt. Sinai School Of Medicine Of New York University Mo-1, a gene associated with morbid obesity
MX2009011366A (es) * 2007-04-23 2009-11-05 Wyeth Corp Metodos y composiciones para tratar y monitorear el tratamiento de trastornos asociados con il-13.
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
EP2377952A1 (de) 2007-04-26 2011-10-19 Ludwig Institute For Cancer Research Verfahren zur Diagnostizierung und Behandlung von Astrozytoma
US20080267977A1 (en) * 2007-04-26 2008-10-30 Friedrich-Alexander University Of Erlangen-Nuremberg Combined immunological agent and sensitizing agent for the treatment of cancer
US20100143336A1 (en) 2007-04-26 2010-06-10 Opsona Therapeutics Limited Toll-like receptor binding epitope and compositions for binding thereto
WO2008134643A2 (en) * 2007-04-28 2008-11-06 Fraunhofer Usa, Inc. Trypanosoma antigens, vaccine compositions, and related methods
CA2685875C (en) 2007-05-01 2015-10-06 Hill's Pet Nutrition, Inc. Methods and compositions for diagnosing osteoarthritis in a feline
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
EP2164868B1 (de) 2007-05-04 2015-03-25 Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA Gentechnisch gewonnene variable domänen von kaninchen-antikörpern und deren verwendung
EP2162552A4 (de) 2007-05-11 2010-06-30 Univ Johns Hopkins Biomarker für melanome
JP5683948B2 (ja) * 2007-05-14 2015-03-11 バンクーバー バイオテク リミテッド 糖を含有する全ての（ｐａｎ）癌のマーカー
EP2068927B1 (de) 2007-05-14 2015-10-21 MedImmune, LLC Verfahren zur reduzierung eosinophiler spiegel
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
DK2164514T3 (en) 2007-05-21 2017-02-27 Alderbio Holdings Llc Antibodies to IL-6 and its use
EP1995309A1 (de) * 2007-05-21 2008-11-26 Vivalis Rekombinante Proteinproduktion in EBx -Vogelzellen
WO2008142693A2 (en) * 2007-05-22 2008-11-27 Yeda Research And Development Co. Ltd. Regulation of myelination by nectin-like (necl) molecules
ES2731432T3 (es) 2007-05-23 2019-11-15 Ventana Med Syst Inc Transportadores poliméricos para inmunohistoquímica e hibridación in situ
WO2008147526A1 (en) 2007-05-23 2008-12-04 The Trustees Of The University Of Pennsylvania Targeted carriers for intracellular drug delivery
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
ES2585702T3 (es) * 2007-05-30 2016-10-07 Lpath, Inc Composiciones y métodos para la unión al ácido lisofosfatídico
US20110064744A1 (en) * 2007-05-30 2011-03-17 Sabbadini Roger A Prevention and treatment of pain using antibodies to lysophosphatidic acid
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
PE20090329A1 (es) * 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
LT2176298T (lt) 2007-05-30 2018-04-10 Xencor, Inc. Būdai ir kompozicijos, skirti cd32b ekspresuojančių ląstelių slopinimui
US7709215B2 (en) 2007-06-01 2010-05-04 Cytonics Corporation Method for diagnosing and treating acute joint injury
EP1997830A1 (de) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
KR20100040840A (ko) * 2007-06-06 2010-04-21 도만티스 리미티드 폴리펩티드，항체 가변 도메인 및 길항제
US20110008343A1 (en) * 2007-06-08 2011-01-13 Lambris John D Method Of Reducing Tissue Loss In Pancreatic Islet Cell Transplantation
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
CN101820911B (zh) * 2007-06-12 2015-05-06 Ac免疫有限公司 β淀粉样蛋白的人源化抗体
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
BRPI0812484A2 (pt) * 2007-06-12 2018-06-05 Ac Immune Sa anticorpo monoclonal, regiões variáveis de cadeia leve e de cadeia pesada, cdr isolada, polinucleotídeo, composição terapêutica, métodos para tratar doenças e distúrbios, para produzir um anticorpo, para tratar ou aliviar os efeitos de doenças e distúrbios, para reduzir a carga de placas no cérebro de um indivíduo, para reduzir a quantidade de placas no cérebro de um indivíduo, para diminuir a quantidade total de abeta solúvel no cérebro de um indivíduo, para reter ou aumentar a capacidade de memória cognitiva em um indivíduo, de diagnose de ou para diagnosticar uma predisposição para uma doença associada com amilóide ou condição em um paciente, para determinar a extensão de carga de placa amiloidogênica em um tecido de um indivíduo, para monitorar doença residual mínima em um indivíduo e para prever responsividade de um indivíduo, linhagem de células, kit de teste, epítopo abeta
CN103977404A (zh) * 2007-06-14 2014-08-13 比奥根艾迪克Ma公司 抗体制剂
CA2691075C (en) * 2007-06-15 2017-04-11 Daniela Gast Treatment of tumors using specific anti-l1 antibody
US8097422B2 (en) 2007-06-20 2012-01-17 Salk Institute For Biological Studies Kir channel modulators
US20080317768A1 (en) 2007-06-21 2008-12-25 Boeing Company Bioconjugated nanoparticles
ATE550648T1 (de) * 2007-06-22 2012-04-15 Genera Istrazivanja D O O Adamts4 als blut-biomarker und therapeutisches ziel bei chronischem nierenversagen
US10745701B2 (en) 2007-06-28 2020-08-18 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
US20090324596A1 (en) 2008-06-30 2009-12-31 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
US8563259B2 (en) * 2007-06-29 2013-10-22 The Trustees Of The University Of Pennsylvania Complement-mediated thrombophilic assay
CA2691378A1 (en) 2007-07-02 2009-01-08 Oncomed Pharmaceuticals, Inc. Antibody against human r-spondin (rspo) and use thereof for inhibition of beta-catenin signaling and treatment of cancer
EP3018216B1 (de) 2007-07-06 2018-09-12 The Regents Of The University Of Michigan Rezidivierende genfusionen bei prostatakrebs
SI3597659T1 (sl) 2007-07-09 2023-04-28 Genentech, Inc. Preprečevanje redukcije disulfidne vezi med rekombinantno proizvodnjo polipeptidov
WO2009009759A2 (en) 2007-07-11 2009-01-15 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
EP2014681A1 (de) 2007-07-12 2009-01-14 Pierre Fabre Medicament Neue Antikörper zur Hemmung der C-Met-Dimerisation und Verwendungen davon
ES2591281T3 (es) 2007-07-12 2016-11-25 Gitr, Inc. Terapias de combinación que emplean moléculas de enlazamiento a GITR
US8182763B2 (en) 2007-07-13 2012-05-22 Handylab, Inc. Rack for sample tubes and reagent holders
US8287820B2 (en) 2007-07-13 2012-10-16 Handylab, Inc. Automated pipetting apparatus having a combined liquid pump and pipette head system
US20090136385A1 (en) 2007-07-13 2009-05-28 Handylab, Inc. Reagent Tube
US8105783B2 (en) 2007-07-13 2012-01-31 Handylab, Inc. Microfluidic cartridge
CA2693654C (en) 2007-07-13 2018-02-13 Handylab, Inc. Polynucleotide capture materials, and methods of using same
US8133671B2 (en) 2007-07-13 2012-03-13 Handylab, Inc. Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples
US9186677B2 (en) 2007-07-13 2015-11-17 Handylab, Inc. Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples
US9618139B2 (en) 2007-07-13 2017-04-11 Handylab, Inc. Integrated heater and magnetic separator
USD621060S1 (en) 2008-07-14 2010-08-03 Handylab, Inc. Microfluidic cartridge
TW200918089A (en) 2007-07-16 2009-05-01 Genentech Inc Humanized anti-CD79b antibodies and immunoconjugates and methods of use
JP5469600B2 (ja) 2007-07-16 2014-04-16 ジェネンテック， インコーポレイテッド 抗ＣＤ７９ｂ抗体及びイムノコンジュゲートとその使用方法
WO2009014633A1 (en) * 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
WO2009014650A2 (en) 2007-07-20 2009-01-29 The General Hospital Corporation Recombinant vibrio cholerae exotoxins
US8986684B2 (en) * 2007-07-25 2015-03-24 Alexion Pharmaceuticals, Inc. Methods and compositions for treating autoimmune disease
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
US8974791B2 (en) 2007-07-27 2015-03-10 Armagen Technologies, Inc. Methods and compositions for increasing α-L-iduronidase activity in the CNS
US20090041767A1 (en) * 2007-07-27 2009-02-12 Vanitha Ramakrishnan Pharmaceutical combinations
JP2010534719A (ja) * 2007-07-27 2010-11-11 ファイザー・リミテッド 沈殿化による抗体精製方法
US8734788B2 (en) 2007-08-03 2014-05-27 Opsona Therapeutics Ltd Composition and method for treatment of reperfusion injury and tissue damage
EP2022848A1 (de) 2007-08-10 2009-02-11 Hubrecht Institut Verfahren zur Identifikation, Vermehrung und Entfernung erwachsener Stammzellen und Krebsstammzellen
CA2696164C (en) * 2007-08-13 2018-06-12 Vasgene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to ephb4
EP2597464B1 (de) 2007-08-16 2015-02-25 The Regents of the University of Michigan Metabolomische Profilierung von Prostatakrebs
US20110059130A1 (en) * 2007-08-20 2011-03-10 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions and methods
CL2008002444A1 (es) 2007-08-21 2009-09-04 Amgen Inc Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente.
EP2179037A4 (de) 2007-08-21 2010-12-22 Nodality Inc Diagnose-, prognose- und behandlungsverfahren
EP2615114B1 (de) 2007-08-23 2022-04-06 Amgen Inc. Antigenbindende Proteine an Proprotein-Konvertase-Subtilisin/Kexin vom Typ 9 (PCSK9)
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
CA2698203C (en) 2007-08-29 2018-09-11 Sanofi-Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their use
NZ599756A (en) * 2007-08-30 2013-09-27 Curedm Group Holdings Llc Compositions and methods of using proislet peptides and analogs thereof
US8415455B2 (en) 2007-09-04 2013-04-09 Compugen Ltd Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
EP2033971A1 (de) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
US8039597B2 (en) * 2007-09-07 2011-10-18 Agensys, Inc. Antibodies and related molecules that bind to 24P4C12 proteins
SG188136A1 (en) 2007-09-13 2013-03-28 Delenex Therapeutics Ag HUMANIZED ANTIBODIES AGAINST THE ß-AMYLOYD PEPTIDE
EP2193146B1 (de) 2007-09-14 2016-05-25 Adimab, LLC Synthetische antikörperbibliotheken mit rationalem design und ihre verwendung
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
US20090136427A1 (en) 2007-09-18 2009-05-28 La Jolla Institute For Allergy And Immunology LIGHT Inhibitors For Asthma, Lung and Airway Inflammation, Respiratory, Interstitial, Pulmonary and Fibrotic Disease Treatment
US9377465B2 (en) * 2007-09-18 2016-06-28 Dako Denmark A/S Rapid and sensitive method for detection of biological targets
US8728477B2 (en) * 2007-09-19 2014-05-20 Immune Pharmaceuticals Ltd. Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and uses thereof
EP2573104A1 (de) 2007-09-24 2013-03-27 Cornell University Immunogene Proteine aus der genombasierten äußeren Membran von Leptospira sowie darauf basierende Zusammensetzungen und Verfahren
EP2195341B1 (de) 2007-09-26 2017-03-22 UCB Biopharma SPRL Fusionsantikörper mit dualer spezifität
AU2008304313B2 (en) 2007-09-26 2013-01-10 Oregon Health & Science University Cyclic undecapeptides and derivatives as multiple sclerosis therapies
EP2205249B1 (de) 2007-09-28 2018-11-07 Intrexon Corporation Therapeutische genschalterkonstrukte und bioreaktoren zur expression biotherapeutischer moleküle und ihre verwendung
JP2010540498A (ja) * 2007-09-28 2010-12-24 ウニヴェルズィテーツシュピタール バーゼル 癌の治療のための免疫リポソーム
EP2915564B1 (de) 2007-09-28 2020-11-04 Portola Pharmaceuticals, Inc. Gegenmittel für Faktor-XA-Hemmer und Verfahren zur Verwendung davon
SG10201606120XA (en) 2007-10-02 2016-09-29 Theranos Inc Modular Point-Of-Care Devices And Uses Thereof
EP2209498A2 (de) 2007-10-03 2010-07-28 Cornell University Behandlung von proliferativen erkrankungen mit psma-antikörpern
WO2009046407A2 (en) 2007-10-04 2009-04-09 Zymogenetics, Inc. B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS
US8114681B2 (en) 2007-10-05 2012-02-14 Affymetrix, Inc. Highly multiplexed particle-based assays
RU2542967C2 (ru) 2007-10-05 2015-02-27 Дженентек, Инк. Применение антитела против амилоида бета при глазных заболеваниях
EP2238166B1 (de) 2007-10-05 2013-11-27 Genentech, Inc. Verwendung eines anti-amyloid-beta-antikörpers bei augenkrankheiten
JP5674469B2 (ja) * 2007-10-11 2015-02-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド ＬＩＮＧＯ−１アンタゴニストおよびＴｒｋＢアゴニストの投与を介して圧力誘導性の視神経障害を処置し、神経変性を防ぎ、ニューロン細胞の生存を促進する方法
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
EP2209810A1 (de) * 2007-10-15 2010-07-28 King's College London Virales therakpeutikum
EP2050764A1 (de) 2007-10-15 2009-04-22 sanofi-aventis Neues polyvalentes bispezifisches Antikörperformat und Verwendung
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
HUE031533T2 (hu) 2007-10-19 2017-07-28 Seattle Genetics Inc CD19-kötõszerek valamint alkalmazásuk
US8143224B2 (en) 2007-10-23 2012-03-27 The Cleveland Clinic Foundation Oxidant resistant apolipoprotein A-1 and mimetic peptides
US20100297115A1 (en) 2007-10-23 2010-11-25 Novartis Ag Use of trkb antibodies for the treatment of respiratory disorders
CN101970498A (zh) 2007-10-25 2011-02-09 维文蒂阿生物技术公司 针对变体HnRNPG的癌相关表位的抗体及其应用
CN101970486A (zh) * 2007-10-25 2011-02-09 布里斯托尔大学 特异于血管内皮生长因子(vegf)的促血管发生同工型的抗体
WO2009055656A2 (en) 2007-10-26 2009-04-30 Centocor, Inc. Vectors, host cells, and methods of production and uses
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
RS53850B2 (sr) 2007-10-30 2018-07-31 Genentech Inc Pročišćavanje antitela hromatografijom izmene katjona
EP2851432B1 (de) 2007-11-01 2019-01-09 University of Iowa Research Foundation RCA-Locus-Analyse zur Beurteilung der Anfälligkeit für AMD
DK2567709T3 (en) 2007-11-02 2018-03-12 Novartis Ag Molecules and Methods for Modulating Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6)
US8039212B2 (en) 2007-11-05 2011-10-18 Celera Corporation Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
AU2008324800B2 (en) 2007-11-05 2014-03-27 Astrazeneca Ab Methods of treating scleroderma
CN101918540B (zh) * 2007-11-08 2016-05-11 比奥根Ma公司 Lingo-4拮抗剂在治疗涉及脱髓鞘的疾患中的应用
CA2700197C (en) 2007-11-08 2020-09-08 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
US7828840B2 (en) * 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
US8637435B2 (en) * 2007-11-16 2014-01-28 Merck Sharp & Dohme Corp. Eukaryotic cell display systems
US8715941B2 (en) 2007-11-16 2014-05-06 Arca Biopharma, Inc. Antibodies to LRP6
JP5580205B2 (ja) 2007-11-19 2014-08-27 セレラ コーポレーション 肺癌マーカーとその使用
JP5474809B2 (ja) 2007-11-21 2014-04-16 ロスキレ ユニバーシティ 氷結合活性を備えたポリペプチド
EP2062920A3 (de) 2007-11-21 2009-06-17 Peter Hornbeck Proteinphosphorylation durch basophilische Serin-/Threonin-Kinasen in Insulinsignalisierungspfaden
US8236316B2 (en) 2007-11-21 2012-08-07 Oregon Health & Science University Anti-factor XI monoclonal antibodies and methods of use thereof
CN101925364B (zh) 2007-11-27 2014-04-30 不列颠哥伦比亚大学 用于预防和治疗关节炎的14-3-3拮抗剂
WO2015164330A1 (en) 2014-04-21 2015-10-29 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
JP5490714B2 (ja) * 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
US8470979B2 (en) 2007-12-07 2013-06-25 Zymogenetics, Inc. Humanized antibody molecules specific for IL-31
WO2009079922A1 (fr) * 2007-12-13 2009-07-02 Shanghai Guojian Bio-Tech Institute Anticorps monoclonal anti-cd34 humanisé, sa préparation et ses utilisations
CN105001333B (zh) 2007-12-14 2019-05-17 诺沃—诺迪斯克有限公司 抗人nkg2d抗体及其用途
AU2008338464A1 (en) * 2007-12-14 2009-06-25 Amgen Inc. Method for treating bone fracture with anti-sclerostin antibodies
AU2008338313B2 (en) 2007-12-18 2014-01-16 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
US8795667B2 (en) * 2007-12-19 2014-08-05 Macrogenics, Inc. Compositions for the prevention and treatment of smallpox
US20090169549A1 (en) * 2007-12-19 2009-07-02 The Board Of Regents Of The University Of Texas System Conformational isomers of alpha-synuclein, antibodies thereto and methods of their manufacture and use
US8414893B2 (en) 2007-12-21 2013-04-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
WO2009080054A1 (en) * 2007-12-21 2009-07-02 Ifxa A/S Protease inhibitor
JP2011508738A (ja) * 2007-12-26 2011-03-17 バイオテスト・アクチエンゲゼルシヤフト Ｃｄ１３８発現腫瘍細胞のターゲティングを向上させる方法及び剤
PT2242772E (pt) * 2007-12-26 2015-02-09 Biotest Ag Imunoconjugados dirigidos contra cd138 e as suas utilizações
SI2808343T1 (sl) 2007-12-26 2019-10-30 Xencor Inc Fc-variante s spremenjeno vezavo na FcRn
EP2801584B1 (de) 2007-12-26 2019-07-10 Biotest AG Wirkstoffe für CD138-Targeting und Verwendungen davon
CA2710680C (en) 2007-12-26 2018-10-16 Vaccinex, Inc. Anti-c35 antibody combination therapies and methods
US9011864B2 (en) * 2007-12-26 2015-04-21 Biotest Ag Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
JP5611834B2 (ja) * 2007-12-27 2014-10-22 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ 抗Ｔ．ｃｒｕｚｉ抗体及び使用方法
ES2544679T3 (es) 2007-12-28 2015-09-02 Prothena Biosciences Limited Tratamiento y profilaxis de la amiloidosis
GB0800277D0 (en) 2008-01-08 2008-02-13 Imagination Tech Ltd Video motion compensation
CN101918555B (zh) 2008-01-11 2013-11-06 株式会社遗传科技 人源化抗整联蛋白α9抗体及其应用
AU2009205995B2 (en) 2008-01-18 2014-04-03 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation
WO2009093263A1 (en) * 2008-01-23 2009-07-30 Department Of Biotechnology A humanized high affinity recombinant antibody against hepatitis b surface antigen
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
EP2247619A1 (de) 2008-01-24 2010-11-10 Novo Nordisk A/S Humanisierter monoklonaler anti-human-nkg2a-antikörper
AU2009206306B2 (en) 2008-01-25 2013-06-06 Amgen Inc. Ferroportin antibodies and methods of use
ES2848323T3 (es) 2008-01-31 2021-08-06 Inst Nat Sante Rech Med Anticuerpos contra CD39 humano y uso de los mismos para inhibir la actividad de las células T reguladoras
EP2245055A2 (de) * 2008-01-31 2010-11-03 Compugen Ltd. Polypeptide und polynukleotide und deren verwendung als arzneimittel-target zur herstellung von arzneimitteln und biologika
SI2657253T1 (sl) 2008-01-31 2017-10-30 Genentech, Inc. Protitelesa proti CD79b in imunokonjugati in postopki za uporabo
AU2009212747B2 (en) 2008-01-31 2013-11-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Engineered antibody constant domain molecules
PL2252633T3 (pl) * 2008-02-04 2014-02-28 Lay Line Genomics Spa Przeciwciała anty-TrkA i ich pochodne
US8039596B2 (en) 2008-02-05 2011-10-18 Bristol-Myers Squibb Company Alpha 5-beta 1 antibodies and their uses
CN101952454B (zh) 2008-02-08 2014-06-04 米迪缪尼有限公司 具有减弱的Fc配体亲和性的抗IFNAR1抗体
PL2246427T3 (pl) 2008-02-08 2017-06-30 Immunas Pharma, Inc. Przeciwciała zdolne do wiązania się swoiście do oligomerów amyloidu beta i ich stosowanie
WO2009105217A2 (en) * 2008-02-19 2009-08-27 The Trustees Of The University Of Pennsylvania Complement inhibitors as therapeutic agents for treatment of cancer
JO2913B1 (en) * 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US20090221620A1 (en) 2008-02-20 2009-09-03 Celera Corporation Gentic polymorphisms associated with stroke, methods of detection and uses thereof
US20090220991A1 (en) * 2008-02-29 2009-09-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
US8962803B2 (en) * 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
CA2715212A1 (en) * 2008-03-03 2009-09-11 Glycofi, Inc. Surface display of recombinant proteins in lower eukaryotes
US8293239B2 (en) 2008-03-04 2012-10-23 Pfizer Limited Methods of treating chronic pain
WO2009111644A2 (en) * 2008-03-05 2009-09-11 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating pancreatic cancer
EP2262837A4 (de) * 2008-03-12 2011-04-06 Merck Sharp & Dohme Pd-1-bindende proteine
WO2009121690A1 (en) * 2008-03-13 2009-10-08 Biotest Ag Agent for treating disease
SG190627A1 (en) * 2008-03-13 2013-06-28 Biotest Ag Agent for treating disease
MX2010010026A (es) * 2008-03-13 2011-03-21 Biotest Ag Agente para tratar enfermedad.
NZ587765A (en) 2008-03-18 2013-02-22 Abbott Lab Methods for treating psoriasis
NO2842575T3 (de) 2008-03-18 2018-02-24
EP2260102A1 (de) 2008-03-25 2010-12-15 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tumorbehandlung mittels herunterregelung von frizzled-4 und/oder frizzled-1
JP2011515497A (ja) 2008-03-26 2011-05-19 セレラント セラピューティクス インコーポレイテッド 骨髄性血液学的増殖性疾患と関連する免疫グロブリンおよび／またはＴｏｌｌ様受容体タンパク質ならびにその使用
DK2274008T3 (da) 2008-03-27 2014-05-12 Zymogenetics Inc Sammensætninger og fremgangsmåder til hæmning af PDGFRBETA og VEGF-A
EP2274009B1 (de) 2008-03-28 2013-11-13 GlaxoSmithKline LLC Behandlungsverfahren
ES2654937T3 (es) 2008-04-02 2018-02-15 Macrogenics, Inc. Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos
WO2009123894A2 (en) 2008-04-02 2009-10-08 Macrogenics, Inc. Her2/neu-specific antibodies and methods of using same
WO2009121948A2 (en) 2008-04-03 2009-10-08 Vib Vzw Single domain antibodies capable of modulating bace activity
US9908943B2 (en) 2008-04-03 2018-03-06 Vib Vzw Single domain antibodies capable of modulating BACE activity
CA2720526C (en) 2008-04-04 2017-11-28 Massachusetts Institute Of Technology Cellular production of glucaric acid
SG10201402815VA (en) 2008-04-09 2014-09-26 Genentech Inc Novel compositions and methods for the treatment of immune related diseases
US20110191868A1 (en) 2008-04-10 2011-08-04 Massachusetts Institute Of Technology Methods for identification and use of agents targeting cancer stem cells
EP2274437B1 (de) 2008-04-10 2015-12-23 Cell Signaling Technology, Inc. Zusammensetzungen und verfahren zur erkennung von egfr-mutationen bei krebs
KR102469853B1 (ko) 2008-04-11 2022-11-22 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP2288715B1 (de) 2008-04-11 2014-09-24 Merrimack Pharmaceuticals, Inc. Humanserumalbumin-linker und konjugate davon
ES2368700T3 (es) * 2008-04-11 2011-11-21 Emergent Product Development Seattle, Llc Agente inmunoterapéutico para cd37 y combinación con un agente quimioterapéutico bifuncional del mismo.
EP3062106B1 (de) 2008-04-16 2020-11-11 The Johns Hopkins University Verfahren zur bestimmung von varianten des andorgen rezeptors in prostatakrebs
AU2008201871A1 (en) * 2008-04-16 2009-11-26 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Inhibition of angiogenesis and tumor metastasis
WO2009129374A2 (en) * 2008-04-18 2009-10-22 Trustees Of Boston University Methods and compositions for preventing adhesion
US8314213B2 (en) * 2008-04-18 2012-11-20 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
US9365644B2 (en) * 2008-04-23 2016-06-14 Epitomics, Inc. Anti-TNFα antibody
WO2009131256A1 (en) 2008-04-24 2009-10-29 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof
US20090269786A1 (en) * 2008-04-25 2009-10-29 The Board Of Trustees Of The University Of Illinois RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies
CA2722082C (en) 2008-04-25 2021-11-09 Christopher Tenhoor Fc receptor binding proteins
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
EP2816059A1 (de) 2008-05-01 2014-12-24 Amgen, Inc Anti-Hepcidin-Antikörper und Verfahren zu ihrer Verwendung
ES2458541T3 (es) 2008-05-02 2014-05-06 Seattle Genetics, Inc. Métodos y composiciones para elaborar anticuerpos y derivados de anticuerpos con fucosilación del núcleo reducida
EP2274331B1 (de) 2008-05-02 2013-11-06 Novartis AG Verbesserte bindemoleküle auf fibronectin-basis und ihre verwendung
MY159667A (en) 2008-05-09 2017-01-13 Abbvie Inc Antibodies to receptor of advanced glycation end products (rage) and uses thereof
US8673644B2 (en) 2008-05-13 2014-03-18 Battelle Memorial Institute Serum markers for type II diabetes mellitus
JP6219556B2 (ja) * 2008-05-16 2017-10-25 ジェネンテック， インコーポレイテッド ベータ７インテグリンアンタゴニストを用いた消化管炎症性障害の治療評価のためのバイオマーカーの使用
EP2789684B1 (de) * 2008-05-23 2016-12-21 Siwa Corporation Verfahren und Zusammensetzungen zur erleichterten Regeneration
EP2304439A4 (de) 2008-05-29 2012-07-04 Nuclea Biotechnologies Llc Anti-phospho-akt-antikörper
CA2726131C (en) 2008-05-29 2018-03-13 Baoming Jiang Expression and assembly of human group c rotavirus-like particles and uses thereof
WO2009148928A1 (en) 2008-05-29 2009-12-10 Galaxy Biotech, Llc Monoclonal antibodies to basic fibroblast growth factor
NZ590033A (en) 2008-05-30 2011-08-26 Xbiotech Inc Interleukin-1alpha antibodies and methods of use
CA2726804C (en) 2008-06-02 2021-12-28 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides
US20090297439A1 (en) * 2008-06-02 2009-12-03 Metheresis Translational Research Sa, Anti-met monoclonal antibody, fragments and derivatives thereof for use in tumor diagnosis, corresponding compositions and kits
RU2010153578A (ru) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойными вариабельными доменами и их применение
CA2726087A1 (en) * 2008-06-03 2009-12-10 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
WO2010033279A2 (en) * 2008-06-04 2010-03-25 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
CA2728243C (en) * 2008-06-05 2020-03-10 National Cancer Center Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer
US8999702B2 (en) * 2008-06-11 2015-04-07 Emd Millipore Corporation Stirred tank bioreactor
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
ES2595362T3 (es) 2008-06-16 2016-12-29 Patrys Limited Anticuerpos LM, fragmentos funcionales, antígeno diana LM-1 y métodos para prepararlos y usarlos
US8188235B2 (en) * 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
US8410251B2 (en) * 2008-06-20 2013-04-02 National University Corporation Okayama University Antibody against calcified globule and use of the same
EP2319869B1 (de) 2008-06-20 2016-08-17 National University Corporation Okayama University ANTIKÖRPER GEGEN DEN OXIDIERTES LDL/ß²GPI-KOMPLEX UND ANWENDUNG DAVON
WO2009156994A1 (en) * 2008-06-24 2009-12-30 Hadasit Medical Research Services And Development Ltd. Ccl20-specific antibodies for cancer therapy
CN110372792A (zh) 2008-06-25 2019-10-25 艾斯巴技术-诺华有限责任公司 抑制vegf的稳定和可溶的抗体
RU2653753C1 (ru) 2008-06-25 2018-05-14 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα
CN104004094B (zh) 2008-06-25 2017-09-22 艾斯巴技术-诺华有限责任公司 使用通用抗体构架进行的兔抗体的人源化
MX2011000052A (es) 2008-06-25 2011-07-29 Esbatech Alcon Biomed Res Unit Humanizacion de anticuerpos de conejos usando una estructura de anticuerpos universal.
EP2671891A3 (de) 2008-06-27 2014-03-05 Amgen Inc. Ang-2-Hemmung zur Behandlung von Multipler Sklerose
FR2933702A1 (fr) * 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
MY155603A (en) 2008-07-08 2015-11-13 Oncomed Pharm Inc Notch-binding agents and antagonists and methods of use thereof
RU2011104348A (ru) * 2008-07-08 2012-08-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
US8834875B2 (en) 2010-01-13 2014-09-16 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
TW201014602A (en) 2008-07-08 2010-04-16 Abbott Lab Prostaglandin E2 binding proteins and uses thereof
KR101783004B1 (ko) 2008-07-08 2017-09-28 인사이트 홀딩스 코포레이션 인돌아민 ２,３-디옥시게나아제의 억제제로서의 １,２,５-옥사디아졸
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
EP2310525B1 (de) 2008-07-09 2014-02-26 Celera Corporation Mit herz-kreislauf-erkrankungen assoziierte genetische polymorphismen, nachweisverfahren und ihre verwendung
US8067339B2 (en) 2008-07-09 2011-11-29 Merck Sharp & Dohme Corp. Surface display of whole antibodies in eukaryotes
USD618820S1 (en) 2008-07-11 2010-06-29 Handylab, Inc. Reagent holder
USD787087S1 (en) 2008-07-14 2017-05-16 Handylab, Inc. Housing
JP5986745B2 (ja) 2008-07-15 2016-09-06 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｐｔｆｅ様のアルミニウム・コート・ガラススライド上のグリカンアレイおよび関連する方法
WO2010008051A1 (ja) 2008-07-16 2010-01-21 株式会社医学生物学研究所 抗ヒトclcp1抗体とその用途
US8148088B2 (en) * 2008-07-18 2012-04-03 Abgent Regulation of autophagy pathway phosphorylation and uses thereof
NZ590330A (en) * 2008-07-21 2012-08-31 Immunomedics Inc Structural variants of anti-cd20 antibodies for improved therapeutic characteristics
US20100021472A1 (en) * 2008-07-25 2010-01-28 Geetha Srikrishna Methods for diagnosing and treating cancer
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
EA027575B1 (ru) 2008-08-05 2017-08-31 Новартис Аг Антитело или его антигенсвязывающий фрагмент, связывающий человеческий белок с5, содержащая их композиция, нуклеиновая кислота, кодирующая антитело или его антигенсвязывающий фрагмент, содержащие эту кислоту вектор и клетка-хозяин и применение антитела или его антигенсвязывающего фрагмента
CN102137681B (zh) * 2008-08-08 2014-12-03 埃姆诺医药有限公司 抗胰腺癌抗体
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010019702A2 (en) 2008-08-12 2010-02-18 Oncomed Pharmaceuticals, Inc. Ddr1-binding agents and methods of use thereof
US20120034157A1 (en) * 2010-08-03 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
US20100042072A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
US20100041133A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
US20100040546A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
HUE047316T2 (hu) 2008-08-14 2020-04-28 Genentech Inc Eljárások szennyezés eltávolítására indigén fehérjekiszorításos ioncserés membrán kromatográfia alkalmazásával
US8563697B2 (en) 2008-08-14 2013-10-22 Cephalon Australia Pty. Ltd. Anti-IL-12/IL-23 antibodies
AU2009282830B2 (en) * 2008-08-20 2013-11-28 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) vaccines for cancer therapy
US9180160B2 (en) 2008-08-20 2015-11-10 The Trustees Of The University Of Pennsylvania Complement inhibitors for treatment of injury from intracerebral hemorrhage
US20120128684A1 (en) 2008-08-25 2012-05-24 Burnham Institute For Medical Research Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use
CA2730909A1 (en) * 2008-08-28 2010-03-04 Abbott Biotherapeutics Corp. Method for treating multiple sclerosis patients with anti-il2r antibodies
CA2735433C (en) 2008-09-07 2016-02-16 Glyconex Inc. Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
WO2010029343A2 (en) * 2008-09-10 2010-03-18 University Of Bradford Compositions and methods
US20110171225A1 (en) * 2008-09-12 2011-07-14 The Board Of Trustees Of The University Of Illinois Novel Plasmodium Falciparum Gene Encoding Signal Peptide Peptidase and Method of Using Inhibitors Thereof for Inhibiting Malarial Infection
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
EP2326347A4 (de) * 2008-09-12 2013-03-06 Xbiotech Inc Targeting krankheitserregender monozyten
WO2010029534A1 (en) 2008-09-15 2010-03-18 Yeda Research And Development Co. Ltd. Antibody combinations and use of same for treating cancer
EP2853545B8 (de) 2008-09-17 2023-04-05 Xencor, Inc. Antikörper gegen IgE
BRPI0917888A2 (pt) 2008-09-19 2014-02-25 Pfizer Formulação de anticorpo líquida estável
CA2737758C (en) * 2008-09-19 2017-10-31 Soldano Ferrone Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma
CA2739357A1 (en) 2008-09-23 2010-04-08 Wyeth Llc Methods for predicting production of activating signals by cross-linked binding proteins
EP2334300B1 (de) * 2008-09-24 2016-02-17 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Zusammensetzung und verfahren zur behandlung von vorzeitigen wehen
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
AU2009296246B2 (en) 2008-09-26 2015-07-30 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
WO2010037046A1 (en) 2008-09-28 2010-04-01 Fraunhofer Usa, Inc. Humanized neuraminidase antibody and methods of use thereof
SG194362A1 (en) * 2008-09-29 2013-11-29 Biotest Ag Composition for treating disease
US8445190B2 (en) 2008-09-30 2013-05-21 The Trustees Of The University Of Pennsylvania Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
EP2172485A1 (de) 2008-10-01 2010-04-07 Pierre Fabre Medicament Neuartige Anti-CXCR4-Antikörper und ihre Verwendung bei der Krebsbehandlung
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
WO2010040766A1 (en) 2008-10-07 2010-04-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (pf4v1)
KR20170110740A (ko) 2008-10-09 2017-10-11 미네르바 바이오테크놀로지 코포레이션 세포내에서 다능성을 유도하기 위한 방법
EA032727B1 (ru) 2008-10-10 2019-07-31 Амген Инк. Мутантный резистентный к протеолизу полипептид fgf21 и его применение
CA2740440A1 (en) 2008-10-14 2010-04-22 Dyax Corp. Use of igf-ii/igf-iie binding proteins for the treatment and prevention of systemic sclerosis-associated pulmonary fibrosis
CA2737597C (en) 2008-10-16 2017-03-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
CA2932207A1 (en) 2008-10-20 2010-12-09 Abbvie Inc. Isolation and purification of antibodies using protein a affinity chromatography
EP2350270B1 (de) 2008-10-24 2018-03-07 The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services Menschliche ebolavirus-spezies sowie zusammensetzungen und verfahren dafür
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
CA2739352C (en) 2008-10-29 2021-07-13 Wyeth Llc Methods for purification of single domain antigen binding molecules
KR101581986B1 (ko) 2008-10-29 2016-01-04 아블린쓰 엔.브이. 단일 도메인 항원 결합 분자의 제형
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2356251A1 (de) 2008-11-07 2011-08-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Teneurin und krebs
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
ES2523740T3 (es) 2008-11-07 2014-12-01 Galaxy Biotech, Llc Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2
WO2010054379A2 (en) 2008-11-10 2010-05-14 The United States Of America, As Represensted By The Secretary, Department Of Health And Human Services Gene signature for predicting prognosis of patients with solid tumors
NZ602369A (en) 2008-11-11 2015-02-27 Univ Michigan Anti-cxcr1 compositions and methods
US8309306B2 (en) * 2008-11-12 2012-11-13 Nodality, Inc. Detection composition
BRPI0921665A2 (pt) * 2008-11-13 2019-04-16 Femta Pharmaceuticals, Inc. humanizado anti-il-6 anticorpos
US8323652B2 (en) * 2008-11-14 2012-12-04 Canadian Blood Services Antibodies against GPIbα
WO2010059315A1 (en) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
WO2010065079A2 (en) 2008-11-25 2010-06-10 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
WO2010062896A1 (en) * 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
EP2191843A1 (de) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumorkombinationen mit Antikörpern, die insbesondere CD38 und Cyclophosphamid erkennen
EP2191842A1 (de) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumorkombinationen mit Antikörpern, die insbesondere CD38 und Cytarabin erkennen
DK2370593T3 (en) 2008-11-28 2016-07-04 Univ Emory A method for determining the effect of PD-1 Antagonists
EP2191841A1 (de) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumorkombinationen mit Antikörpern, die insbesondere CD38 und Vincristin erkennen
EP2191840A1 (de) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumorkombinationen mit Antikörpern, die insbesondere CD38 und Melphalan erkennen
AR074439A1 (es) 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
US9469691B2 (en) 2008-12-02 2016-10-18 Pierre Fabre Medicament Anti-cMET antibody
EP2193790A1 (de) * 2008-12-04 2010-06-09 Klinikum der Universität Regensburg IL-3-Inhibitoren zur Verwendung bei der Behandlung von rheumatoider Arthritis im Frühstadium
BRPI0922807A2 (pt) * 2008-12-04 2015-12-22 Abbott Lab imonuglobulinas de domínio variável duplo e usos dos mesmos
US8183346B2 (en) * 2008-12-05 2012-05-22 Eli Lilly And Company Anti-ferroportin 1 monoclonal antibodies and uses thereof
EP2374001A4 (de) * 2008-12-05 2013-03-13 Lpath Inc Antikörperdesign unter verwendung von anti-lipid-antikörper-kristallstrukturen
US8401799B2 (en) * 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
AU2009325878B2 (en) 2008-12-08 2014-01-16 Compugen Ltd. TMEM154 polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
CA2747244A1 (en) 2008-12-12 2010-06-17 University Of Florida Research Foundation, Inc. Cell-based detection of apf through its interaction with ckap4 for diagnosis of interstitial cystitis
CN105037535A (zh) 2008-12-16 2015-11-11 Emd密理博公司 搅拌槽反应器及方法
JP2012512244A (ja) * 2008-12-16 2012-05-31 イー・エム・デイー・ミリポア・コーポレイシヨン タンパク質の精製
EP2198884A1 (de) 2008-12-18 2010-06-23 Centre National de la Recherche Scientifique (CNRS) Gegen die LG4-5-Domäne der alpha3-Kette von Humanlaminim-5 gerichtete monoklonale Antikörper
US8497358B2 (en) 2008-12-19 2013-07-30 Takeda Pharmaceutical Company Limited Antibody purification method
SI2786762T1 (sl) 2008-12-19 2019-07-31 Macrogenics, Inc. Kovalentna diatelesa in njihove uporabe
US20100159485A1 (en) * 2008-12-19 2010-06-24 Centre For Dna Fingerprinting And Diagnostics Detection of mycobacterium tuberculosis
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
WO2010075417A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
WO2010075303A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
US20120003235A1 (en) 2008-12-31 2012-01-05 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
WO2010081001A2 (en) 2009-01-09 2010-07-15 The Regents Of The University Of Michigan Recurrent gene fusions in cancer
GB0900425D0 (en) 2009-01-12 2009-02-11 Ucb Pharma Sa Biological products
US20110300068A1 (en) 2009-01-12 2011-12-08 Takeda Pharmaceutical Company Limited Agent for prophylaxis or treatment of cancer
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
CA2749572A1 (en) 2009-01-14 2010-07-22 Iq Therapeutics Bv Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
PT2387627E (pt) 2009-01-15 2016-06-03 Adaptive Biotechnologies Corp Determinação do perfil de imunidade adaptativa e métodos de geração de anticorpos monoclonais
WO2010083044A1 (en) 2009-01-16 2010-07-22 Massachusetts Institute Of Technology Diagnosis and treatment of autism spectrum disorders
US9181341B2 (en) 2009-01-19 2015-11-10 Innate Pharma Anti-KIR3D antibodies
BRPI1007345A2 (pt) 2009-01-20 2019-04-16 H. ZADEH Homayoun regeneração óssea de anticorpo mediado
CA2750581A1 (en) 2009-01-21 2010-07-29 Oxford Biotherapeutics Ltd. Pta089 protein
EP2210903A1 (de) 2009-01-21 2010-07-28 Monoclonal Antibodies Therapeutics Monoklonale Antikörper gegen CD160 und Anwendungen davon
WO2010085345A1 (en) 2009-01-22 2010-07-29 Ludwig Institute For Cancer Research Ltd. Methods and compositions for diagnosis and treatment of malignant and non-malignant gammopathies
WO2010085590A1 (en) 2009-01-23 2010-07-29 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid gram positive bacteria
KR20110110349A (ko) * 2009-01-29 2011-10-06 아보트 러보러터리즈 Ｉｌ-1 결합 단백질
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
WO2010087994A2 (en) 2009-01-30 2010-08-05 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US9085795B2 (en) * 2009-02-04 2015-07-21 Molecular Innovations, Inc. Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin and antibodies
US8309530B2 (en) * 2009-02-04 2012-11-13 Washington State University Compositions and methods for modulating ghrelin-mediated conditions
US9079942B2 (en) * 2009-02-09 2015-07-14 Epitomics, Inc. CDR-anchored amplification method
WO2010091328A1 (en) 2009-02-09 2010-08-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Diagnostic and therapeutic uses of gnptab, gnptg, and nagpa in stuttering
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
DK2396652T3 (da) 2009-02-11 2018-01-29 Cedars Sinai Medical Center Diagnose af inflammatorisk tarmsyndrom baseret på cytoletalt udspilende toksin
EP2396035A4 (de) 2009-02-12 2012-09-12 Human Genome Sciences Inc Verwendung von antagonisten des b-lymphozyten-stimulatorproteins zur förderung von transplantationstoleranz
US9364477B2 (en) 2009-02-12 2016-06-14 Cell Signaling Technology, Inc. Mutant ROS expression in human cancer
WO2010093872A2 (en) 2009-02-13 2010-08-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Molecular-based method of cancer diagnosis and prognosis
HUE033661T2 (en) 2009-02-16 2017-12-28 Cerenis Therapeutics Holding Sa Apolipoprotein A-1 mimetics
WO2010096486A1 (en) 2009-02-17 2010-08-26 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
LT2398498T (lt) * 2009-02-17 2019-01-10 Ucb Biopharma Sprl Antikūno molekulės, pasižyminčios specifiškumu žmogaus ox40
US9671400B2 (en) * 2009-02-19 2017-06-06 Dako Denmark A/S Conjugate molecules
GB0902916D0 (en) 2009-02-20 2009-04-08 Fusion Antibodies Ltd Antibody therapy
US20120045773A1 (en) 2009-02-24 2012-02-23 University Of Miyazaki Cell adhesion inhibitor and applications thereof
US8030026B2 (en) * 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
WO2010098863A1 (en) * 2009-02-26 2010-09-02 Lpath, Inc. Humanized platelet activating factor antibody design using anti-lipid antibody templates
US20100248265A1 (en) * 2009-02-27 2010-09-30 The Salk Institute For Biological Studies Compositions and methods for diagnosis and treatment of cancer
US8435488B2 (en) 2009-02-27 2013-05-07 Genentech, Inc. Methods and compositions for protein labelling
BRPI1009232B1 (pt) 2009-03-05 2022-05-03 E.R. Squibb & Sons, Llc. Anticorpo monoclonal isolado ou uma porção de ligação de antígeno do mesmo, ou um fragmento de anticorpo, composição que os compreende, molécula de ácido nucleico, hibridoma e métodos para a preparação de um anticorpo anti-cadm1
EP2810652A3 (de) 2009-03-05 2015-03-11 AbbVie Inc. IL-17-bindende Proteine
WO2010100247A1 (en) 2009-03-06 2010-09-10 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Novel therapy for anxiety
CA2754531A1 (en) 2009-03-06 2010-09-30 Seattle Genetics, Inc. Antibody drug conjugates (adc) that bind to 24p4c12 proteins
KR101667227B1 (ko) 2009-03-10 2016-10-18 가부시키가이샤 진 테크노 사이언스 인간화된 ｋ33ｎ 단일 클론 항체의 제조, 발현 및 해석
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
EP2228059A1 (de) 2009-03-12 2010-09-15 Universitätsspital Basel Chemotherapeutische Zusammensetzung für die Krebsbehandlung
EA024695B1 (ru) 2009-03-16 2016-10-31 Сефалон Острэйлиа Пти Лтд. Гуманизированные антитела с противоопухолевой активностью
EP3002296B1 (de) 2009-03-17 2020-04-29 Université d'Aix-Marseille Btla-antikörper und ihre verwendung
WO2010108048A2 (en) 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
WO2010106542A2 (en) 2009-03-19 2010-09-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. USE OF NKp46 FOR PREVENTING DIABETES
ES2572728T3 (es) 2009-03-20 2016-06-02 F. Hoffmann-La Roche Ag Anticuerpos anti-HER biespecíficos
EP2233500A1 (de) 2009-03-20 2010-09-29 LFB Biotechnologies Optimierte Fc Varianten
JP5830460B2 (ja) 2009-03-23 2015-12-09 クォーク ファーマシューティカルズ インコーポレーティッドＱｕａｒｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 癌および線維性疾患を治療する化合物、組成物、および方法
US8242248B2 (en) * 2009-03-23 2012-08-14 Nodality, Inc. Kits for multiparametric phospho analysis
EP2411412B1 (de) 2009-03-24 2015-05-27 Teva Biopharmaceuticals USA, Inc. Humanisierte antikörper gegen licht und anwendungen davon
CA2754163C (en) 2009-03-25 2019-04-09 Genentech, Inc. Anti-fgfr3 antibodies and methods using same
EP2233502A1 (de) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylierte antigenspezifische Antikörper zur Behandlung oder Vorbeugung von ungewollten entzündlichen Immunreaktionen und Verfahren zu deren Herstellung
EP3121271B1 (de) 2009-03-30 2019-07-24 Portola Pharmaceuticals, Inc. Gegenmittel für faktor-xa-hemmer und verfahren zur verwendung davon
EP2899212B1 (de) 2009-03-30 2017-07-19 Edimer Biotech S.a. Herstellung von isolierten monoklonalen Agonist-Anti-EDAR-Antikörpern
WO2010112033A2 (en) 2009-03-31 2010-10-07 Østjysk Innovation A/S Method for estimating the risk of having or developing multiple sclerosis using sequence polymorphisms in a specific region of chromosome x
WO2010120566A2 (en) * 2009-04-01 2010-10-21 Cornell University METHODS FOR TREATING IgE-MEDIATED DISORDER
HU0900195D0 (en) * 2009-04-01 2009-06-29 Debreceni Egyetem Diagnosis and treatment of gluten-induced autoimmune diseases
AR075989A1 (es) 2009-04-10 2011-05-11 Lilly Co Eli Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria
EP2417984B1 (de) 2009-04-10 2016-03-30 Kyowa Hakko Kirin Co., Ltd. Verfahren zur behandlung von blutkrebs mittels anti-tim-antikörper
EP2241323A1 (de) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W und Hirnkrebs
US8722860B2 (en) 2009-04-16 2014-05-13 Abbvie Biotherapeutics Inc. Anti-TNF-α antibodies and their uses
AU2010236257A1 (en) * 2009-04-17 2011-11-03 Biogen Idec Ma Inc. Compositions and methods to treat acute myelogenous leukemia
ES2641612T3 (es) * 2009-04-17 2017-11-10 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a oligómeros de beta A y uso de los mismos
EP2419446A4 (de) * 2009-04-17 2013-01-23 Lpath Inc Humanisierte antikörperzusammensetzungen und verfahren zur bindung von lysophosphatidsäure
US20120052064A1 (en) 2009-04-17 2012-03-01 Yuuki Ito Anti-hgf antibody combinational cancer therapies
SG10201401604VA (en) 2009-04-20 2014-08-28 Oxford Biotherapeutics Ltd Antibodies Specific To Cadherin-17
US9062116B2 (en) 2009-04-23 2015-06-23 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
JP5766179B2 (ja) 2009-04-27 2015-08-19 ノバルティス アーゲー 筋肉増殖を増加させるための組成物および方法
WO2010126890A1 (en) * 2009-04-27 2010-11-04 Facet Biotech Corporation Methods for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients
US9074002B2 (en) 2009-04-27 2015-07-07 Cold Spring Harbor Laboratory PTP1B inhibitors
MX2011011338A (es) 2009-04-27 2012-04-19 Novartis Ag Composiciones y metodos de uso para anticuerpos terapeuticos especificos para la subunidad beta1 del receptor de il-12.
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
WO2010126066A1 (ja) 2009-04-27 2010-11-04 協和発酵キリン株式会社 血液腫瘍治療を目的とした抗IL-3Rα抗体
WO2010125566A2 (en) 2009-04-27 2010-11-04 Technion Research And Development Foundation Ltd. Markers for cancer detection
JP5677411B2 (ja) 2009-04-29 2015-02-25 アッヴィ バイオテクノロジー リミテッド 自動注入機器
EP2246364A1 (de) 2009-04-29 2010-11-03 Pierre Fabre Médicament Antikörper gegen CXCR4 zur Behandlung von HIV
EP2424891B1 (de) 2009-04-29 2014-06-11 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Monoklonale erg-antikörper
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
HRP20240135T1 (hr) 2009-05-05 2024-04-12 Amgen Inc. Fgf21 mutanti i njihove upotrebe
PE20160652A1 (es) 2009-05-05 2016-07-09 Novimmune Sa Anticuerpos que se unen a il-17f
US9187568B2 (en) 2009-05-07 2015-11-17 Stallergenes S.A. Use of IgG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and manifestations via the mucosal route
US9309325B2 (en) 2009-05-07 2016-04-12 The Regents Of The University Of California Antibodies and methods of use thereof
CN108912228B (zh) 2009-05-08 2022-03-15 瓦西尼斯公司 抗-cd100抗体和其使用方法
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
EP2429582A4 (de) 2009-05-13 2013-01-23 Genzyme Corp Anti-human-cd52-immunglobuline
WO2010138709A1 (en) 2009-05-28 2010-12-02 Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Anti-tnf induced apoptosis (atia) diagnostic markers and therapies
ES2726945T3 (es) 2009-06-03 2019-10-10 Immunogen Inc Métodos de conjugación
WO2010142603A1 (en) 2009-06-08 2010-12-16 Vib Vzw Screening for compounds that modulate gpr3-mediated beta-arrestin signaling and amyloid beta peptide generation
US20100317539A1 (en) * 2009-06-12 2010-12-16 Guo-Liang Yu Library of Engineered-Antibody Producing Cells
CA2764545C (en) 2009-06-15 2019-05-14 Katholieke Universiteit Leuven, K.U.Leuven R&D Bace1 inhibitory antibodies
CA2765287C (en) 2009-06-15 2018-12-11 Bayer Bioscience N.V. Nicotiana benthamiana plants deficient in xylosyltransferase activity
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
WO2010148142A1 (en) 2009-06-17 2010-12-23 Amgen Inc. Chimeric fgf19 polypeptides and uses thereof
MX346002B (es) 2009-06-17 2017-03-01 Abbvie Biotherapeutics Inc Anticuerpos anti-vegf y sus usos.
CA2765989C (en) 2009-06-18 2016-11-29 Pfizer Inc. Anti notch-1 antibodies
WO2011005481A1 (en) 2009-06-22 2011-01-13 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
US20120101262A1 (en) 2009-06-25 2012-04-26 Bristol-Myers Squibb Company Protein purification by caprylic acid (octanoic acid) precipitation
US8399625B1 (en) 2009-06-25 2013-03-19 ESBATech, an Alcon Biomedical Research Unit, LLC Acceptor framework for CDR grafting
TWI513465B (zh) 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
SG10201408480RA (en) 2009-06-25 2015-02-27 Crealta Pharmaceuticals Llc Methods for preventing or predicting infusion reactions or antibody-mediated loss of response, by monitoring serum uric acid levels during pegylated uricase therapy
EP2448966B1 (de) 2009-07-03 2018-11-14 Avipep Pty Ltd Immunkonjugate und verfahren zu ihrer herstellung
EA022788B1 (ru) 2009-07-03 2016-03-31 Бионор Иммуно Ас Новые терапевтические и диагностические средства
PL2451279T3 (pl) 2009-07-06 2019-09-30 Aerpio Therapeutics, Inc. Pochodne benzosulfonamidowe, ich kompozycje i ich zastosowanie w zapobieganiu przerzutom komórek nowotworowych
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
CA2766861A1 (en) 2009-07-09 2011-01-13 F. Hoffmann-La Roche Ag In vivo tumor vasculature imaging
WO2011008959A1 (en) 2009-07-15 2011-01-20 Abbott Laboratories Enhancement of cellular production through mechanotransduction
WO2011008885A1 (en) 2009-07-15 2011-01-20 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same
EP2456787A4 (de) 2009-07-24 2013-01-30 Univ Leland Stanford Junior Zytokinzusammensetzungen und verfahren zu ihrer verwendung
AU2010275367B2 (en) 2009-07-24 2015-09-03 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with avB5 integrin
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
HUE048980T2 (hu) 2009-08-11 2020-08-28 Hoffmann La Roche Fehérjék elõállítása glutaminmentes sejttenyésztõ táptalajban
US8568719B2 (en) 2009-08-13 2013-10-29 Crucell Holland B.V. Antibodies against human respiratory syncytial virus (RSV) and methods of use
WO2011020024A2 (en) 2009-08-13 2011-02-17 The Johns Hopkins University Methods of modulating immune function
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
US20180057602A1 (en) * 2009-08-17 2018-03-01 Tracon Pharmaceuticals, Inc. Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents
KR101553740B1 (ko) * 2009-08-17 2015-09-17 트라콘 파마수티칼즈, 인코포레이티드 항엔도글린 항체 및 항ｖｅｇｆ 제제를 사용한 암 치료를 위한 병용 요법
WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies
WO2011025826A1 (en) * 2009-08-26 2011-03-03 Research Development Foundation Methods for creating antibody libraries
EP2292266A1 (de) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Behandlung von Krebs durch Modulation von Copine III
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
WO2011024113A1 (en) 2009-08-28 2011-03-03 Rinat Neuroscience Corporation Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
CN102002104A (zh) 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
TWI412375B (zh) 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體
DK2470671T3 (en) 2009-08-28 2015-02-09 Regeneron Pharma ANTIKIN- ANTIBODIES BINDING TO MULTIPLE CC chemokines
EP3029070A1 (de) 2009-08-29 2016-06-08 AbbVie Inc. Therapeutische dll4-bindende proteine
BR112012003983A2 (pt) * 2009-08-31 2021-09-14 Roche Glycart Ag Molecula de ligação abm moleculas de ligação de antigenos abm variante polipeptideo isolado molecula de ligação de antigeneos humanizada anticorpo polinucleotideo isolado composição vetor celula hospedeira metodo de produção de abm metodo de indução da lise celular de tumor, metodo de diagnostico de doença em pacientes que possuem um cancer metodo de aumento de tempo de sobrevivencia em pacientes que possuem um cancer metodo de indução em pacientes de regressão de um motor uso abm e invenção
US8454956B2 (en) * 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
WO2011025542A1 (en) 2009-08-31 2011-03-03 Ludwig Institute For Cancer Research Ltd. Seromic analysis of ovarian cancer
WO2011026122A2 (en) 2009-08-31 2011-03-03 Amplimmune, Inc. B7-h4 fusion proteins and methods of use thereof
EP2473851A1 (de) 2009-08-31 2012-07-11 Abbott Biotherapeutics Corp. Verwendung einer immunregulatorischen nk-zellenpopulation zur überwachung der wirksamkeit von anti-il-2r-antikörpern bei patienten mit multipler sklerose
US20110059111A1 (en) 2009-09-01 2011-03-10 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
US9428548B2 (en) 2009-09-01 2016-08-30 Genentech, Inc. Enhanced protein purification through a modified protein A elution
KR20120060877A (ko) * 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US9321823B2 (en) 2009-09-02 2016-04-26 Genentech, Inc. Mutant smoothened and methods of using the same
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
JP2013504585A (ja) 2009-09-09 2013-02-07 セントローズ， エルエルシー 細胞外標的化薬物複合体
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
EP2475398B1 (de) 2009-09-11 2015-05-20 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Verbessertes pseudomonas-exotoxin a mit verminderter immunogenität
US8293483B2 (en) 2009-09-11 2012-10-23 Epitomics, Inc. Method for identifying lineage-related antibodies
KR20140048229A (ko) * 2009-09-14 2014-04-23 애브비 인코포레이티드 건선을 치료하는 방법
EP2305717A1 (de) 2009-09-21 2011-04-06 Koninklijke Nederlandse Akademie van Wetenschappen Hemmung von TNIK zur Behandlung von Darmkrebs
WO2011038004A1 (en) 2009-09-22 2011-03-31 The Trustees Of The University Of Pennsylvania Methods and compositions for in-vivo enzyme capture
EP2480573A1 (de) 2009-09-22 2012-08-01 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Behandlung von krebs durch modulation von mex-3
WO2011037983A1 (en) 2009-09-23 2011-03-31 Medarex, Inc. Cation exchange chromatography
US20120183546A1 (en) 2009-09-23 2012-07-19 Amgen Inc. Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
JP5781504B2 (ja) 2009-09-24 2015-09-24 株式会社ジーンテクノサイエンス 細胞外マトリックスタンパク質のアミノ酸配列ｒｇｄに特異的なヒト化抗体およびそれらの使用
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
WO2011038290A2 (en) 2009-09-25 2011-03-31 The U. S. A., As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use
WO2011039634A2 (en) 2009-09-29 2011-04-07 Universiteit Gent Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose
EP2483307A1 (de) 2009-09-29 2012-08-08 Fraunhofer USA, Inc. Influenza-hämagglutinin-antikörper, zusammensetzungen daraus und zugehörige verfahren
US8697073B2 (en) * 2009-09-30 2014-04-15 Fujifilm Ri Pharma Co., Ltd. Anti-podoplanin antibody, and pharmaceutical composition containing anti-podoplanin antibody
WO2011041093A1 (en) 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
EP2308895A1 (de) 2009-10-01 2011-04-13 Universität Duisburg-Essen Anti-HSV-Antikörper
US9005926B2 (en) 2009-10-02 2015-04-14 Biogen Idec Ma Inc. Methods of preventing and removing trisulfide bonds
AR078470A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis Anticuerpos que se unen especificamente al receptor epha2
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
US9096877B2 (en) 2009-10-07 2015-08-04 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
SI2485761T1 (sl) 2009-10-09 2019-05-31 Armagen, Inc. Postopki in sestavki za povečanje aktivnosti iduronat-2-sulfataze v CŽS
EP2308897A1 (de) 2009-10-09 2011-04-13 Pierre Fabre Medicament Chimäre Antikörper spezifisch für CD151 und deren Verwendung zur Behandlung von Krebs
US20130064788A1 (en) 2009-10-10 2013-03-14 Eleven Biotherapeutics, Inc. Il-17 family cytokine compositions and uses
AU2010303156B2 (en) 2009-10-11 2016-02-04 Biogen Ma Inc. Anti-VLA-4 related assays
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
EP2470569A1 (de) 2009-10-13 2012-07-04 Oxford Biotherapeutics Ltd. Antikörper gegen epha10
WO2011054644A1 (en) 2009-10-14 2011-05-12 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. A low density lipoprotein-related protein 1 splice variant as cancer marker
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
AU2010306677B2 (en) 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
PT2488551T (pt) 2009-10-16 2018-10-31 Inst Nat Sante Rech Med Anticorpos monoclonais contra a progastrina e suas utilizações
PL3072526T3 (pl) 2009-10-16 2019-04-30 Oncomed Pharm Inc Kombinacja terapeutyczna i zastosowanie przeciwciał antagonistycznych względem DLL4 i środków antyhipertensyjnych
BR112012008970A2 (pt) 2009-10-16 2019-12-10 Omeros Corp uso de uma composição, e, composição
JP5889794B2 (ja) 2009-10-19 2016-03-22 ジェネンテック， インコーポレイテッド 肝細胞増殖因子アクチベーターの調節
EP2491390B1 (de) 2009-10-20 2014-03-26 Dako Denmark A/S Immunochemischer nachweis von single-target-einheiten
RS60577B1 (sr) 2009-10-20 2020-08-31 Abbvie Inc Izolacija i prečišćavanje anti-il-13 antitela upotrebom protein a afinitetne hromatografije
BR112012009409A2 (pt) 2009-10-22 2017-02-21 Genentech Inc método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
NZ599337A (en) 2009-10-22 2013-05-31 Genentech Inc Anti-hepsin antibodies and methods using same
IN2012DN02604A (de) 2009-10-23 2015-09-04 Millennium Pharm Inc
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
WO2011056561A1 (en) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
US20110098862A1 (en) 2009-10-27 2011-04-28 ExxonMobil Research Engineering Company Law Department Multi-stage processes and control thereof
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
CN102781963B (zh) 2009-10-27 2018-02-16 Ucb医药有限公司 功能修饰性NAv1.7抗体
TW201122101A (en) 2009-10-28 2011-07-01 Facet Biotech Corp Anti-EGFR antibodies and their uses
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
BR112012011463A2 (pt) * 2009-10-30 2017-05-02 Abbott Biotherapeutics Corp uso de populações imunorregulatórias de célula nk para prognosticar a eficácia de anticorpos anti-il-2r em pacientes com esclerose múltipla.
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
WO2011053707A1 (en) 2009-10-31 2011-05-05 Abbott Laboratories Antibodies to receptor for advanced glycation end products (rage) and uses thereof
WO2011054007A1 (en) 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
CN102782149B (zh) 2009-11-04 2014-11-12 默沙东公司 经工程改造的抗-tslp抗体
CN102740885B (zh) 2009-11-05 2015-04-01 梯瓦制药澳大利亚私人有限公司 涉及突变的kras或braf基因的癌症的治疗
WO2011055550A1 (ja) 2009-11-05 2011-05-12 国立大学法人大阪大学 自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法
RU2585488C2 (ru) 2009-11-05 2016-05-27 Дженентек, Инк. Способы и композиция для секреции гетерологичных полипептидов
US9260517B2 (en) 2009-11-17 2016-02-16 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
DK2501822T3 (da) 2009-11-17 2017-11-27 Squibb & Sons Llc Fremgangsmåder til forbedret proteinproduktion
EP2501805B1 (de) 2009-11-19 2019-02-20 Oxyrane UK Limited Hefe stämme die säugetier-ähnliche n-glykane produzieren
SG177025A1 (en) 2010-06-21 2012-01-30 Agency Science Tech & Res Hepatitis b virus specific antibody and uses thereof
WO2011063198A2 (en) 2009-11-20 2011-05-26 St. Jude Children's Research Hospital Methods and compositions for modulating the activity of the interleukin-35 receptor complex
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
CN102711829B (zh) 2009-11-30 2016-03-16 生物测试股份公司 治疗系统性红斑狼疮(sle)的人源化抗il-10抗体
US9428586B2 (en) 2009-12-01 2016-08-30 Compugen Ltd Heparanase splice variant
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
JP2013512672A (ja) 2009-12-02 2013-04-18 アムジエン・インコーポレーテツド ヒトＦＧＦＲ１ｃ、ヒトβ−クロト−、ならびにヒトＦＧＦＲ１ｃおよびヒトβ−クロト−の両方に結合する結合タンパク質
US8790887B2 (en) 2009-12-04 2014-07-29 Vib Vzw Screening methods for compounds that modulate ARF-6 mediated endosomal redistribution
US8324352B2 (en) 2009-12-07 2012-12-04 Decimmune Therapeutics, Inc. Anti-inflammatory antibodies and uses therefor
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
SG181563A1 (en) 2009-12-08 2012-07-30 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
MX2012006443A (es) 2009-12-09 2012-06-28 Inst Nat Sante Rech Med Anticuerpos monoclonales que se enlazan a b7h6 y usos de los mismos.
EP2332995A1 (de) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralisierende Prolactinrezeptor-Antikörper und deren therapeutische Verwendung
TWI505836B (zh) 2009-12-11 2015-11-01 Genentech Inc 抗－ｖｅｇｆ－ｃ抗體及其使用方法
US20110150885A1 (en) 2009-12-11 2011-06-23 Atyr Pharma, Inc. Aminoacyl trna synthetases for modulating hematopoiesis
RU2582401C2 (ru) 2009-12-15 2016-04-27 Эббви Байотекнолоджи Лтд Усовершенствованная пусковая кнопка для автоматического инъекционного устройства
AU2010330907A1 (en) 2009-12-16 2012-06-14 Bosch, Phillip Methods of treating interstitial cystitis
EP2513148B1 (de) 2009-12-16 2016-08-31 AbbVie Biotherapeutics Inc. Anti-her2-antikörper und ihre verwendung
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
US9023996B2 (en) 2009-12-23 2015-05-05 Synimmune Gmbh Anti-FLT3 antibodies
US20110165161A1 (en) * 2009-12-23 2011-07-07 Shih-Yao Lin Anti-epcam antibodies that induce apoptosis of cancer cells and methods using same
CA2784610C (en) 2009-12-23 2020-07-14 Avipep Pty Ltd Immuno-conjugates and methods for producing them
SI2516465T1 (sl) 2009-12-23 2016-08-31 F. Hoffmann-La Roche Ag Protelesa proti bv8 in uporaba le-teh
WO2011080322A1 (en) 2009-12-30 2011-07-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of prognosing the outcome of acquired hemophilia and of treatment of hemophilia
SI2521568T1 (sl) 2010-01-06 2019-01-31 Dyax Corp. Proteini, ki vežejo plazemski kalikrein
US8900817B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
US9217032B2 (en) 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
US8900588B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Methods for treating breast cancer
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
US9221759B2 (en) 2010-01-13 2015-12-29 Rutgers, The State University Of New Jersey Fluorophore chelated lanthanide luminescent probes with improved quantum efficiency
DK2523688T3 (en) 2010-01-15 2017-12-04 Kirin-Amgen Inc ANTIBODY FORMULATION AND THERAPEUTIC REGIMENS
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
AR079944A1 (es) * 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
WO2011091181A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
WO2011091177A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Anti-ilt5 antibodies and ilt5-binding antibody fragments
US20130096281A1 (en) 2010-01-21 2013-04-18 Oxyrane Uk Limited Methods and compositions for displaying a polypeptide on a yeast cell surface
WO2011089211A1 (en) 2010-01-22 2011-07-28 Synimmune Gmbh Anti-cd133 antibodies and methods of using the same
EP2526421B1 (de) 2010-01-22 2018-11-21 Immunomedics, Inc. Erkennung von bauchspeicheldrüsen-adenokarzinomen im frühstadium
CA3101636A1 (en) 2010-01-26 2011-08-04 National Jewish Health Diagnosis and prognosis of idiopathic interstitial pneumonia by rs35705950 snp in muc5b gene promoter
US20120014956A1 (en) 2010-02-02 2012-01-19 Hartmut Kupper Methods and compositions for predicting responsiveness to treatment with tnf-alpha inhibitor
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
US20110189178A1 (en) * 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
US20120309056A1 (en) 2010-02-04 2012-12-06 Leon Arnaud Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
EP2531210A1 (de) 2010-02-04 2012-12-12 The United States Of America As Represented By The Office of Technology Transfer, National Institutes Of Health Impfstoff und verfahren zur verwendung gegen infektionen mit strongyloides stercoralis
WO2011097511A1 (en) 2010-02-05 2011-08-11 The United States Of America, As Represented By The Secretary Department Of Health & Human Services REGULATORY B CELLS (tBREGS) AND THEIR USE
KR101510413B1 (ko) 2010-02-08 2015-04-08 어젠시스 인코포레이티드 １６１ｐ２ｆ１０ｂ 단백질에 결합하는 항체 약물 컨쥬게이트
CN102933231B (zh) 2010-02-10 2015-07-29 伊缪诺金公司 Cd20抗体及其用途
MX2012009318A (es) 2010-02-10 2012-09-07 Novartis Ag Metodos y compuestos para el crecimiento muscular.
KR20120117931A (ko) 2010-02-12 2012-10-24 온코메드 파마슈티칼스, 인크. 폴리펩타이드를 발현하는 세포를 확인 및 분리하는 방법
AU2011217848B8 (en) 2010-02-18 2015-09-24 The Regents Of The University Of California Integrin aVB8 neutralizing antibody
EP2536761B1 (de) 2010-02-19 2017-09-20 The Board Of Regents Of The University Of Oklahoma Monoklonale antikörper zur hemmung des wnt-signalisierungspfades sowie verfahren zu seiner herstellung und verwendung
SA114360064B1 (ar) 2010-02-24 2016-01-05 رينات نيوروساينس كوربوريشن طرق وأجسام مضادة معارضة ضد مستقبل il-7
TW202348631A (zh) 2010-02-24 2023-12-16 美商免疫遺傳股份有限公司 葉酸受體１抗體類和免疫共軛物類及彼等之用途
EP2538965B1 (de) 2010-02-25 2017-04-12 Schepens Eye Research Institute Therapeutische zusammensetzungen zur behandlung des syndroms des trockenen auges
US9358266B2 (en) 2010-02-25 2016-06-07 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
US20110212088A1 (en) * 2010-02-26 2011-09-01 Sabbadini Roger A Anti-paf antibodies
EP2542582A4 (de) 2010-03-02 2013-12-04 Abbvie Inc Therapeutische dll4-bindende proteine
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
ME03447B (de) 2010-03-04 2020-01-20 Macrogenics Inc Mit b7-h3 reagierende antikörper, immunologisch wirkende fragmente davon und verwendungen davon
EP2542578A1 (de) 2010-03-05 2013-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Smoc1, tenascin-c und hirnkrebs
JP5920929B2 (ja) 2010-03-11 2016-05-18 ユセベ ファルマ ソシエテ アノニム Ｐｄ−１抗体
WO2011111007A2 (en) 2010-03-11 2011-09-15 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CN102971012B (zh) 2010-03-12 2016-05-04 伊缪诺金公司 Cd37结合分子及其免疫缀合物
WO2011116026A2 (en) 2010-03-15 2011-09-22 The Board Of Trustees Of The University Of Illinois Inhibitors of beta integrin-g protein alpha subunit binding interactions
PL2550018T3 (pl) 2010-03-22 2019-08-30 F.Hoffmann-La Roche Ag Kompozycje i sposoby użyteczne do stabilizowania preparatów zawierających białko
PL2550294T3 (pl) 2010-03-24 2020-03-31 Progastrine Et Cancers S.À R.L. Profilaktyka nowotworu jelita grubego i nowotworu przewodu pokarmowego
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
ES2717883T3 (es) 2010-03-25 2019-06-26 Ucb Biopharma Sprl Moléculas de DVD-LG estabilizadas con disulfuro
WO2011119906A1 (en) 2010-03-26 2011-09-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HUMAN POLYOMAVIRUS 6 (HPyV6) AND HUMAN POLYOMAVIRUS 7 (HPyV7)
US9631018B2 (en) 2010-03-26 2017-04-25 The Trustees Of Dartmouth College Vista regulatory T cell mediator protein, vista binding agents and use thereof
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
EP2371863A1 (de) 2010-03-30 2011-10-05 Pierre Fabre Médicament Menschlische Antikörper gegen CXCR4 zur Behandlung von Krebs
SI2552961T1 (en) 2010-03-30 2018-02-28 Janssen Biotech, Inc. Humanized antibodies against IL-25
US20130109645A1 (en) 2010-03-31 2013-05-02 The united States of America,as represented by Secretary,Dept.,of Health and Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
CN102971337B (zh) 2010-04-01 2016-09-21 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
JP2013523153A (ja) * 2010-04-07 2013-06-17 アッヴィ・インコーポレイテッド ＴＮＦ−α結合タンパク質
EP2560994B1 (de) 2010-04-08 2016-10-12 JN Biosciences LLC Antikörper gegen cd122
WO2011127412A2 (en) 2010-04-09 2011-10-13 Critical Care Diagnostics, Inc. Soluble human st-2 antibodies and assays
CA2795799C (en) 2010-04-09 2018-09-25 Aveo Pharmaceuticals, Inc. Anti-erbb3 antibodies
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
WO2011129379A1 (ja) 2010-04-13 2011-10-20 独立行政法人理化学研究所 新規抗ｈｓｐ９０モノクローナル抗体
EP2558503B1 (de) 2010-04-14 2015-12-09 National Research Council of Canada Zusammensetzungen und verfahren zur freisetzung schmerzstillender peptide im hirn
KR101820987B1 (ko) 2010-04-15 2018-01-22 프로제닉스 파머슈티컬스, 인코포레이티드 클로스트리듐 디피실리 관련 감염 및 질병의 치료를 위한 항체
US8383793B2 (en) 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
AU2011239689A1 (en) 2010-04-15 2012-11-08 Amgen Inc. Human FGF receptor and beta-Klotho binding proteins
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
US9226960B2 (en) 2010-04-16 2016-01-05 Andrew B. Bush FGF modulation of in vivo antibody production and humoral immunity
SG10201502967RA (en) 2010-04-16 2015-05-28 Biogen Ma Inc Anti-vla-4 antibodies
WO2011130611A2 (en) 2010-04-16 2011-10-20 National Cheng Kung University Treating disorders associated with il-20 receptor-mediated signaling pathway by blocking il-20 receptor activity
US8435525B1 (en) 2010-04-16 2013-05-07 Andrew B. Bush FGF modulation of in vivo antibody production and humoral immunity
US20110269735A1 (en) 2010-04-19 2011-11-03 Celera Corporation Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
WO2011131611A1 (en) 2010-04-19 2011-10-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulating xrn1
BR112012026837B1 (pt) 2010-04-20 2020-04-07 Univ Cornell método in vitro e kit para diagnosticar proliferações melanocíticas
SG10201503130UA (en) 2010-04-21 2015-06-29 Abbvie Biotechnology Ltd Wearable automatic injection device for controlled delivery of therapeutic agents
AU2011248625B2 (en) 2010-04-26 2017-01-05 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
EP2380909A1 (de) 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. An Brustkrebs beteiligtes Protein PTK-7
JP6294074B2 (ja) 2010-04-27 2018-03-14 エータイアー ファーマ， インコーポレイテッド イソロイシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
WO2011139853A2 (en) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
CA2797393C (en) 2010-04-29 2020-03-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
US9068177B2 (en) 2010-04-29 2015-06-30 Atyr Pharma, Inc Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
CA2797374C (en) 2010-04-29 2021-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
CN103096925A (zh) 2010-05-03 2013-05-08 Atyr医药公司 与精氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN103096912A (zh) 2010-05-03 2013-05-08 Atyr医药公司 与苯丙氨酰-α-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
EP2566510A1 (de) 2010-05-03 2013-03-13 F. Hoffmann-La Roche AG Zusammensetzungen und verfahren zur reduzierung der viskosität von proteinhaltigen formulierungen
CA2797978C (en) 2010-05-03 2019-12-03 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
WO2011140182A2 (en) 2010-05-04 2011-11-10 Medimmune, Llc Optimized degenerative muscle disease diagnostics and treatments
US8206715B2 (en) 2010-05-04 2012-06-26 Five Prime Therapeutics, Inc. Antibodies that bind colony stimulating factor 1 receptor (CSF1R)
CN102985103A (zh) 2010-05-04 2013-03-20 Atyr医药公司 与p38多-tRNA合成酶复合物相关的治疗、诊断和抗体组合物的创新发现
ES2949159T3 (es) 2010-05-06 2023-09-26 Novartis Ag Composiciones y métodos de uso para anticuerpos terapéuticos de proteína 6 relacionada con lipoproteínas de baja densidad (LRP6)
KR20130066631A (ko) 2010-05-06 2013-06-20 노파르티스 아게 치료적 저밀도 지단백질-관련 단백질 ６ （ｌｒｐ６） 다가 항체에 대한 조성물 및 사용 방법
SI2571532T1 (sl) 2010-05-14 2017-10-30 Abbvie Inc. Proteini, ki vežejo IL-1
HUE060541T2 (hu) * 2010-05-14 2023-03-28 Univ Leland Stanford Junior Humanizált és kiméra monoklonális CD47 elleni ellenanyagok
CA2798331C (en) 2010-05-14 2022-03-15 Baxter International Inc. Ospa chimeras and use thereof in vaccines
EA027039B1 (ru) 2010-05-14 2017-06-30 Эмджен Инк. Композиции с высокой концентрацией антител
JP6396656B2 (ja) 2010-05-14 2018-09-26 エータイアー ファーマ， インコーポレイテッド フェニルアラニルβｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
EP2571903B1 (de) 2010-05-17 2019-09-04 EMD Millipore Corporation Stimulusreaktive polymere zur aufreinigung von biomolekülen
WO2011146727A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of treating interstitial cystitis
WO2011145085A2 (en) 2010-05-21 2011-11-24 Procognia (Israel) Ltd Novel antibodies and methods of use for the treatment and diagnosis of cancer
JP6050226B2 (ja) 2010-05-28 2016-12-21 ジェネンテック， インコーポレイテッド Ｌｄｈ及びｐｄｈｋ発現を下方制御することによる乳酸レベルの低下及びポリペプチド生産の増加
EP4115906A1 (de) 2010-05-28 2023-01-11 Chugai Seiyaku Kabushiki Kaisha Verstärker der antitumor t-zellenantwort
BR112012029866A2 (pt) 2010-06-03 2017-03-07 Genentech Inc método para a determinação da presença de uma proteína steap-1
WO2011161545A2 (en) 2010-06-04 2011-12-29 The Netherlands Cancer Institute Non-hydrolyzable protein conjugates, methods and compositions related thereto
WO2011156617A2 (en) 2010-06-09 2011-12-15 Aveo Pharmaceuticals, Inc. Anti-egfr antibodies
US20130089538A1 (en) 2010-06-10 2013-04-11 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh Treating cancer by modulating mammalian sterile 20-like kinase 3
AR081434A1 (es) 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
TR201807750T4 (tr) * 2010-06-11 2018-06-21 Kyowa Hakko Kirin Co Ltd Anti-TIM-3 antikoru.
ES2611479T3 (es) 2010-06-16 2017-05-09 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Anticuerpos contra endoplasmina y su uso
AU2011268310A1 (en) 2010-06-16 2013-01-10 Abbvie Inc. Comparison of protein samples
KR20180086297A (ko) 2010-06-18 2018-07-30 엑스바이오테크, 인크. 관절염 치료
NZ603581A (en) 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
CA2803391C (en) 2010-06-22 2021-11-09 Neogenix Oncology, Inc. Npc1 antibodies that bind a muc5ac epitope
WO2011163466A1 (en) 2010-06-23 2011-12-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Regulation of skin pigmentation by neuregulin-1 (nrg-1)
CA2802756C (en) 2010-06-24 2021-05-04 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
AU2011268780A1 (en) 2010-06-25 2013-02-07 Aston University Glycoproteins having lipid mobilizing properties and therapeutic uses thereof
JPWO2012002472A1 (ja) * 2010-06-30 2013-08-29 オリンパス株式会社 Ａｃｆ検出方法
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
WO2012003472A1 (en) 2010-07-02 2012-01-05 Aveo Pharmaceuticals, Inc. Anti-notch1 antibodies
JP2013533746A (ja) 2010-07-06 2013-08-29 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｒｏｎ抗体
WO2012006500A2 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EA027835B1 (ru) 2010-07-09 2017-09-29 Круселл Холланд Б.В. Антитела против респираторно-синцитиального вируса (рсв) и способы их применения
EA201390085A1 (ru) 2010-07-09 2013-06-28 Экселиксис, Инк. Композиции ингибиторов киназ для лечения рака
WO2013009475A1 (en) 2011-07-11 2013-01-17 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Photosensitizing antibody-phuorophore conjugates
CA2804416C (en) 2010-07-12 2020-04-28 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
WO2012007880A2 (en) 2010-07-16 2012-01-19 Ablynx Nv Modified single domain antigen binding molecules and uses thereof
EP4219805A1 (de) 2010-07-16 2023-08-02 Adimab, LLC Antikörperbibliotheken
JP5972871B2 (ja) 2010-07-20 2016-08-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｉｌ−２３ヘテロ二量体特異的抗体
WO2012010696A1 (en) 2010-07-23 2012-01-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for cancer management targeting co-029
CA2806157C (en) 2010-07-26 2016-11-22 Les Laboratoires Servier Methods and compositions for liver cancer therapy
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
EP2412724A1 (de) 2010-07-29 2012-02-01 Centre National de la Recherche Scientifique (C.N.R.S) Regulierung der Glypican-4-Aktivität zur Modulierung des Schicksals von Stammzellen und Verwendungen davon
JP5953303B2 (ja) 2010-07-29 2016-07-20 ゼンコア インコーポレイテッド 改変された等電点を有する抗体
NZ605928A (en) 2010-07-29 2015-02-27 Eleven Biotherapeutics Inc Chimeric il-1 receptor type i agonists and antagonists
AU2011283646B2 (en) 2010-07-30 2015-07-09 Novartis Ag Fibronectin cradle molecules and libraries thereof
EP2598126A2 (de) 2010-07-30 2013-06-05 Saint Louis University Verfahren zur behandlung von schmerz
SG187173A1 (en) 2010-07-30 2013-02-28 Ac Immune Sa Safe and functional humanized anti beta-amyloid antibody
CA2807127C (en) 2010-08-02 2019-02-12 Leslie S. Johnson Covalent diabodies and uses thereof
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
US20120034225A1 (en) * 2010-08-03 2012-02-09 National Cheng Kung University Suppressing Bone Loss with Anti-IL-19 Antibody
US8377441B2 (en) 2010-08-03 2013-02-19 National Cheng Kung University Treating breast cancer with anti-IL-19 antibody
US20120034224A1 (en) * 2010-08-03 2012-02-09 National Cheng Kung University Treating Rheumatoid Arthritis with Anti-IL-19 Antibody
WO2012019024A2 (en) 2010-08-04 2012-02-09 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
US20130210663A1 (en) 2010-08-04 2013-08-15 Cizzle Biotechnology Limited Methods and compounds for the diagnosis and treatment of cancer
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
EP3578205A1 (de) 2010-08-06 2019-12-11 ModernaTX, Inc. Pharmazeutische zusammensetzungen enthaltenbearbeitete nukleinsäuren und ihre medizinische verwendung
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
EP2420250A1 (de) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4-Antikörper
CN103068848B (zh) 2010-08-12 2015-11-25 伊莱利利公司 抗N3pGlu淀粉样蛋白BETA肽抗体及其用途
BR112013003279A2 (pt) 2010-08-13 2016-06-14 Genentech In “métodos para tratar uma doença, método para neutralizar ou bloquear a atividade de il-1ß e/ou il-18, anticorpo, usos de um anticorpo e usos de um anticorpo monoclonal”
EP3533803B1 (de) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antikörper
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
HUE058226T2 (hu) 2010-08-19 2022-07-28 Zoetis Belgium S A NGF elleni antitestek és alkalmazásuk
CU24094B1 (es) 2010-08-20 2015-04-29 Novartis Ag Anticuerpos para el receptor 3 del factor de crecimiento epidérmico(her3)
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
EP3443985B1 (de) 2010-08-23 2020-12-16 XBiotech, Inc Behandlung von neoplasieerkrankungen
US11077212B2 (en) 2010-08-24 2021-08-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Molecular imaging of cancer cells in vivo
WO2012027494A1 (en) 2010-08-24 2012-03-01 Regents Of The University Of Minnesota Bispecific targeting reagents
WO2012027555A2 (en) 2010-08-25 2012-03-01 President And Fellows Of Harvard College Glycated cd59 peptides, their preparation, and uses thereof
AU2011293294B2 (en) 2010-08-25 2016-03-24 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
CA2809433A1 (en) 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
NZ608318A (en) 2010-09-02 2015-03-27 Vaccinex Inc Anti-cxcl13 antibodies and methods of using the same
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US20130171159A1 (en) 2010-09-10 2013-07-04 Brian Arthur Hemmings Phosphorylated twist1 and metastasis
WO2012037095A1 (en) 2010-09-13 2012-03-22 Abbott Laboratories A highly sensitive monoclonal antibody residual detection assay
WO2012035518A1 (en) 2010-09-17 2012-03-22 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
US20120122076A1 (en) 2010-09-20 2012-05-17 Abbott Laboratories Purification of antibodies using simulated moving bed chromatography
ES2734889T3 (es) 2010-09-21 2019-12-12 Us Health Receptores de células T anti-SSX-2 y materiales relacionados y métodos de uso
US9362094B2 (en) 2010-09-22 2016-06-07 The Board Of Trustees Of The University Of Arkansas Biomarkers for determining breast cancer bone metastasis
ES2719624T3 (es) 2010-09-23 2019-07-11 Prec Biologics Inc Peptidomiméticos de cáncer de colon y de páncreas
CA2812644A1 (en) 2010-09-27 2012-04-05 Zestagen, S.A. Compositions and methods for treating neoplasia
ES2725852T3 (es) 2010-09-27 2019-09-27 Siwa Corp Eliminación selectiva de células modificadas por AGE para el tratamiento de la aterosclerosis
CA2812870C (en) 2010-09-29 2020-06-09 Oxyrane Uk Limited Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
BR112013007263A2 (pt) 2010-09-29 2016-06-14 Oxyrane Uk Ltd desmanosilação de n-glicanos fosforilados
PT2621526T (pt) 2010-09-29 2018-08-02 Seattle Genetics Inc Conjugados de anticorpo com fármaco (adc) que se ligam a proteínas 191pad12
CA2813133C (en) 2010-10-01 2023-10-31 National Research Council Of Canada Anti-ceacam6 antibodies and uses thereof
US9228023B2 (en) 2010-10-01 2016-01-05 Oxford Biotherapeutics Ltd. Anti-ROR1 antibodies and methods of use for treatment of cancer
US20120237975A1 (en) 2010-10-01 2012-09-20 Jason Schrum Engineered nucleic acids and methods of use thereof
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
CN103154037A (zh) 2010-10-05 2013-06-12 诺瓦提斯公司 抗IL12Rβ1抗体及它们在治疗自身免疫病和炎性疾病中的用途
WO2012047968A2 (en) 2010-10-05 2012-04-12 Genentech, Inc. Mutant smoothened and methods of using the same
CA2817973C (en) * 2010-10-15 2019-06-25 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
WO2012054825A1 (en) 2010-10-22 2012-04-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mage-a3 t cell receptors and related materials and methods of use
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
JP6121906B2 (ja) 2010-10-22 2017-04-26 シアトル ジェネティクス，インコーポレーテッド アウリスタチン系抗体薬物複合体とＰＩ３Ｋ−ＡＫＴｍＴＯＲ経路インヒビターの間の相乗効果
WO2012055030A1 (en) 2010-10-25 2012-05-03 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
EP3326645B1 (de) 2010-10-25 2020-03-18 Biogen MA Inc. Verfahren zur bestimmung von unterschieden in einer alpha-4-integrin-aktivität durch korrelation von unterschieden in svcam- und/oder smadcam-ebenen
RU2013122770A (ru) 2010-10-27 2014-12-10 Пьер Фабр Медикамент Антитела для лечения вич
TWI636994B (zh) 2010-10-27 2018-10-01 安美基公司 Ｄｋｋ１抗體及使用方法
EP3404043B1 (de) 2010-10-29 2022-10-26 Perseus Proteomics Inc. Anti-cdh3-antikörper mit hoher internalisierungskapazität
US20120108651A1 (en) 2010-11-02 2012-05-03 Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL) Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof
US9068993B2 (en) 2010-11-04 2015-06-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Diagnostic assays and methods of use for detection of filarial infection
US20130224116A1 (en) 2010-11-05 2013-08-29 TransBio Ltd. Markers of Endothelial Progenitor Cells and Uses Thereof
WO2012062318A1 (en) 2010-11-08 2012-05-18 Dako Denmark A/S Quantification of single target molecules in histological samples
US9309322B2 (en) * 2010-11-12 2016-04-12 Scott & White Healthcare (Swh) Antibodies to tumor endothelial marker 8
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012065937A1 (en) 2010-11-15 2012-05-24 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Anti-fungal agents
CN103874707B (zh) 2010-11-19 2017-04-19 卫材R&D管理有限公司 中和抗‑ccl20抗体
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
WO2012071554A2 (en) 2010-11-23 2012-05-31 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of oral mucositis
EP2643353A1 (de) 2010-11-24 2013-10-02 Novartis AG Multispezifische moleküle
AU2011337704B2 (en) 2010-11-30 2017-06-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
CN103534392A (zh) 2010-12-01 2014-01-22 默沙东公司 表面锚定的fc-诱饵抗体展示系统
AU2011336470B8 (en) 2010-12-01 2017-09-14 Alderbio Holdings Llc Anti-NGF compositions and use thereof
WO2012074097A1 (ja) * 2010-12-03 2012-06-07 協和発酵キリン株式会社 抗ｃｄ３３抗体
SG190938A1 (en) 2010-12-06 2013-07-31 Seattle Genetics Inc Humanized antibodies to liv-1 and use of same to treat cancer
WO2012076010A1 (en) 2010-12-06 2012-06-14 Dako Denmark A/S Combined histological stain
EP2648754A4 (de) 2010-12-07 2016-02-24 Philadelphia Health & Educatio Verfahren zur hemmung von krebs-metastasen
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
EP2651975B1 (de) 2010-12-14 2017-08-09 National University of Singapore Menschlicher monoklonaler antikörper mit spezifität für das dengue-virus-serotyp-1e-protein und verwendungen davon
WO2012080769A1 (en) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
KR20150088334A (ko) 2010-12-15 2015-07-31 와이어쓰 엘엘씨 항-노치1 항체
EP2465928A1 (de) 2010-12-16 2012-06-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Behandlung von Th17-vermittelten Krankheiten
EP2655401B1 (de) 2010-12-20 2016-03-09 The Regents of the University of Michigan Hemmer der bindeinteraktion des epidermalen wachstumsfaktor-rezeptor-wärmeschock-proteins 90
KR20140003467A (ko) 2010-12-20 2014-01-09 메디뮨 리미티드 항il-18 항체 및 그의 용도
KR20130133247A (ko) 2010-12-21 2013-12-06 애브비 인코포레이티드 Ｉｌ-1-알파 및 -베타 이특이적 이원 가변 도메인 면역글로불린 및 이의 용도
US20120275996A1 (en) 2010-12-21 2012-11-01 Abbott Laboratories IL-1 Binding Proteins
PT2654781T (pt) 2010-12-21 2018-05-02 Oklahoma Med Res Found Anticorpos anti-p-selectina e métodos para a sua utilização e identificação
JP6147670B2 (ja) 2010-12-22 2017-06-14 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 改善された半減期を有する修飾された抗体
US20130273062A1 (en) 2010-12-22 2013-10-17 Orega Biotech Antibodies against human cd39 and use thereof
KR101889119B1 (ko) 2010-12-27 2018-08-16 고에키자이단호진 휴먼 사이언스 신코우자이단 인간 파필로마 바이러스 (hpv) l2 단백질을 인식하는 모노클로널 항체와 그것을 사용한 hpv 중화 항체가 측정법
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
MX344595B (es) 2010-12-31 2016-12-20 Bioatla Llc Humanizacion rapida de anticuerpos.
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
US20120171195A1 (en) 2011-01-03 2012-07-05 Ravindranath Mepur H Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
CN103635489B (zh) 2011-01-06 2016-04-13 戴埃克斯有限公司 血浆前激肽释放酶结合蛋白
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
BR112013017951B1 (pt) 2011-01-14 2022-09-27 UCB Biopharma SRL Anticorpo de neutralização, sequência de dna isolada, vetor de clonagem ou expressão, processo para a produção do anticorpo, composição farmacêutica, uso de anticorpo e uso da composição farmacêutica
EP2663578A2 (de) 2011-01-14 2013-11-20 Five Prime Therapeutics, Inc. Il-27 antagonisten zur behandlung von entzündungserkrankungen
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
US9211302B2 (en) 2011-01-17 2015-12-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulation of LRCH4 activity and therapeutic application thereof
CA2824885A1 (en) 2011-01-19 2012-07-26 Bayer Intellectual Property Gmbh Binding proteins to inhibitors of coagulation factors
EP2665749B1 (de) * 2011-01-19 2016-01-13 Cantargia AB Anti-il1rap antikörper und ihre vervendung zur behandlung von melanomen
CN106248582B (zh) 2011-01-21 2020-10-20 拉布拉多诊断有限责任公司 样品使用最大化的系统和方法
WO2012101125A1 (en) 2011-01-24 2012-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific antibodies against human cxcl4 and uses thereof
MX337208B (es) 2011-01-24 2016-02-17 Abbvie Biotechnology Ltd Dispositivos de inyeccion automaticos que tienen superficies de agarre sobremoldeadas.
JP6294079B2 (ja) 2011-01-25 2018-03-14 ミノル シル ホン コー 膵臓幹細胞及び前駆細胞のためのマーカーとしてのｚｓｃａｎ４及びその使用
WO2012103240A2 (en) 2011-01-25 2012-08-02 Eleven Biotherapeutics, Inc. Receptor binding agents
EP2668210B1 (de) 2011-01-26 2020-06-17 Celldex Therapeutics, Inc. Anti-kit-antikörper und ihre verwendungen
US9669092B2 (en) 2011-02-02 2017-06-06 Emory University Antagonism of the VIP signaling pathway
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
CA3146962A1 (en) 2011-02-11 2012-08-16 The Rockefeller University Treatment of angiogenesis disorders
US9803210B2 (en) 2011-02-11 2017-10-31 Research Corporation Technologies, Inc. Fusion proteins comprising immunoglobulin constant domain-derived scaffolds
CN103429263A (zh) 2011-02-15 2013-12-04 免疫医疗公司 用于胰腺癌早期检测和治疗的抗粘蛋白抗体
WO2012110500A1 (en) 2011-02-15 2012-08-23 Vib Vzw Means and methods for improvement of synaptic dysfunction disorders
WO2012112842A2 (en) 2011-02-17 2012-08-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for treating poliovirus
WO2012110843A1 (en) 2011-02-18 2012-08-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for promoting fibrinolysis and thrombolysis
WO2012110824A1 (en) 2011-02-18 2012-08-23 Astrazeneca Ab Binding agents with specificity for a nucleic acid modification
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
US20140105898A1 (en) 2011-02-28 2014-04-17 Istituto Di Ricovero E Cura A Carattere Scientific Materno-Infantile Burlo Garo Apoptosis-inducing molecules and uses therefor
WO2012118903A2 (en) 2011-03-01 2012-09-07 Amgen Inc. Bispecific binding agents
CN103501859B (zh) 2011-03-02 2017-08-25 博格有限责任公司 基于细胞的探询式分析及其应用
NZ614125A (en) 2011-03-02 2015-07-31 Roche Glycart Ag Cea antibodies
US10139420B2 (en) 2011-03-09 2018-11-27 ISNERM (Institut National de la Sante et de la Recherche Medicale) Methods for treating vaso-occlusive crisis using non-modified annexin V
EP2683736B1 (de) 2011-03-09 2018-01-17 Cell Signaling Technology, Inc. Verfahren und reagenzien zur erzeugung monoklonaler antikörper
WO2012122528A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Bispecific three-chain antibody-like molecules
PT2683406T (pt) 2011-03-11 2019-07-08 Beth Israel Deaconess Medical Ct Inc Anticorpos anti-cd40 e utilização dos mesmos
WO2012122590A1 (en) 2011-03-14 2012-09-20 Cellmid Limited Antibody recognizing n-domain of midkine
WO2012125735A1 (en) 2011-03-15 2012-09-20 Abott Laboratories An integrated approach to the isolation and purification of antibodies
EP3235508B1 (de) 2011-03-16 2020-12-30 Sanofi Zubereitungen enthaltend ein antikörperähnliches protein mit dualer v-region
CN103561771B (zh) 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
TW201239355A (en) 2011-03-23 2012-10-01 Abbott Lab Methods and systems for the analysis of protein samples
US9555108B2 (en) 2011-03-24 2017-01-31 Texas Tech University System TCR mimic antibodies as vascular targeting tools
CN103517920B (zh) 2011-03-25 2018-04-17 安进公司 抗硬化蛋白(sclerostin)抗体晶体及其制剂
WO2012135517A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
ME03353B (de) 2011-03-29 2019-10-20 Immunogen Inc Herstellung von maytansinoid-antikörperkonjugaten anhand eines einstufigen verfahrens
CN103547592A (zh) 2011-03-30 2014-01-29 埃博灵克斯股份有限公司 使用针对TNFα的单结构域抗体治疗免疫病症的方法
MA34978B1 (fr) 2011-03-30 2014-03-01 Boehringer Ingelheim Int Antidotes pour anticoagulants
EP2691101A2 (de) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
EP3590969A1 (de) 2011-03-31 2020-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Gegen icos gerichtete antikörper und verwendungen davon
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
US20140219999A1 (en) 2011-04-01 2014-08-07 The Trustees Of The University Of Pennsylvania Treatment of colon cancer using complement inhibitors
KR20190090046A (ko) 2011-04-01 2019-07-31 엑스바이오테크, 인크. 피부과학적 병리의 치료
CN103619881B (zh) 2011-04-07 2017-07-28 安姆根有限公司 新的egfr结合蛋白
WO2012138694A2 (en) 2011-04-07 2012-10-11 Emory University Compositions comprising saccharide binding moieties and methods for targeted therapy
MX355648B (es) 2011-04-08 2018-04-26 Univ Leicester El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2.
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP2694549B1 (de) 2011-04-08 2018-08-15 The United States of America, as represented by The Secretary, Department of Health and Human Services Chimäre antigenrezeptoren des anti-egf-rezeptors variante iii und ihre verwendung zur behandlung von krebs
EP2508176A1 (de) 2011-04-08 2012-10-10 Lipotarg Gmbh Neues Kombinatonsbehandlung für Krebs
EP2697394A4 (de) 2011-04-12 2015-01-14 Electronic Biosciences Inc Ortsspezifische chemisch modifizierte nanoporenvorrichtungen
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
GB201106395D0 (en) 2011-04-14 2011-06-01 Hubrecht Inst Compounds
WO2012142233A1 (en) 2011-04-14 2012-10-18 St. Jude Children's Research Hospital Methods and compositions for detecting and modulating a novel mtor complex
CA3082652A1 (en) 2011-04-15 2012-10-18 Becton, Dickinson And Company Scanning real-time microfluidic thermocycler and methods for synchronized thermocycling and scanning optical detection
WO2012140627A1 (en) 2011-04-15 2012-10-18 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
CN103596985B (zh) 2011-04-19 2016-06-08 美国政府(由卫生和人类服务部的部长所代表) 对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途
EP2699691B1 (de) 2011-04-19 2017-10-18 Dako Denmark A/S Neues verfahren zur enzymbasierenden signalamplifikation
LT2699264T (lt) 2011-04-20 2018-07-10 Medimmune, Llc Antikūnai ir kitos molekulės, kurios jungiasi prie b7-h1 ir pd-1
EP3020428A1 (de) 2011-04-21 2016-05-18 AbbVie Inc. Tragbare automatische injektionsvorrichtung zur gesteuerten verabreichung von therapeutika
WO2012142662A1 (en) 2011-04-21 2012-10-26 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using them b
SI2699587T1 (sl) 2011-04-22 2019-08-30 Wyeth Llc Sestavek, povezan z mutantskim clostridium difficile toksinom, in metode omenjenega sestavka
WO2012149334A2 (en) 2011-04-27 2012-11-01 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
EP2702077A2 (de) 2011-04-27 2014-03-05 AbbVie Inc. Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
EP2701700A4 (de) 2011-04-27 2015-10-21 Univ Yale Inc Arzneimitteltherapie zur hemmung chemotherapie-induzierter nebenwirkungen sowie entsprechende pharmazeutische zusammensetzungen, diagnostika, screening-verfahren und kits
JP2014515759A (ja) 2011-04-29 2014-07-03 ノバルティス アーゲー 扁平上皮がんを治療する方法関連出願
MX367097B (es) 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
EP2705366B1 (de) 2011-05-04 2017-07-12 Pop Test LLC Diagnosevorrichtung
CA2835094C (en) * 2011-05-06 2020-12-22 David Gearing Anti-nerve growth factor antibodies and methods of preparing and using the same
PE20141454A1 (es) 2011-05-06 2014-10-23 Us Gov Health & Human Serv Inmunotoxina recombinante dirigida a la mesotelina
US9598496B2 (en) 2011-05-09 2017-03-21 Perseus Proteomics Inc. Antibody capable of specifically recognizing transferrin receptor
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US9562252B2 (en) 2011-05-13 2017-02-07 Biogen Ma Inc. Methods of preventing and removing trisulfide bonds
CN103842383B (zh) 2011-05-16 2017-11-03 健能隆医药技术（上海）有限公司 多特异性fab融合蛋白及其使用方法
EP2710038B1 (de) 2011-05-16 2018-01-17 Yeda Research and Development Co. Ltd. Kombinationen aus erbb-antikörpern zur behandlung von krebs
CA2840175C (en) 2011-05-19 2021-11-16 The Regents Of The University Of Michigan Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
US9127065B2 (en) 2011-05-19 2015-09-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-human HER3 antibodies and uses thereof
CN103957935B (zh) 2011-05-20 2018-04-03 奥尔德生物控股有限责任公司 抗cgrp或抗cgrp‑r抗体或抗体片段用于治疗或预防慢性和急性形式的腹泻的用途
KR102098546B1 (ko) 2011-05-20 2020-04-07 앨더바이오 홀딩스 엘엘씨 필요한 대상체, 특히 편두통 환자의 광선공포증 또는 광선 혐오증을 예방 또는 억제하기 위한 항-cgrp 항체 및 항체 단편의 용도
CN108373502B (zh) 2011-05-20 2022-03-22 H.伦德贝克公司 抗cgrp组合物及其用途
WO2012162215A1 (en) 2011-05-20 2012-11-29 The Trustees Of The University Of Pennsylvania Promotion of fracture healing using complement inhibitors
KR102030531B1 (ko) 2011-05-21 2019-10-10 마크로제닉스, 인크. 탈면역화된 혈청-결합 도메인 및 혈청 반감기를 연장하기 위한 그것의 용도
EP2714738B1 (de) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalente und monovalente multispezifische komplexe und ihre verwendungen
US8426143B2 (en) 2011-05-24 2013-04-23 Saladax Biomedical Inc. Gemcitabine immunoassay
AR086543A1 (es) 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
EP2714741B1 (de) 2011-05-25 2019-10-30 Innate Pharma, S.A. Anti-kir-antikörper zur behandlung entzündlicher erkrankungen
WO2012163848A1 (en) 2011-05-27 2012-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of crohn's disease
EP2714094B1 (de) 2011-06-02 2016-02-24 The University of Louisville Research Foundation, Inc. An einen anti-nucleolin-wirkstoff konjugierte nanopartikel
EP2714084B1 (de) 2011-06-02 2019-05-22 Dyax Corp. Fc-REZEPTOR-BINDENDE PROTEINE
CA2836373A1 (en) 2011-06-06 2012-12-13 Neotope Biosciences Limited Mcam antagonists and methods of treatment
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
WO2012168259A1 (en) 2011-06-06 2012-12-13 Novartis Forschungsstiftung, Zweigniederlassung Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
WO2012170929A2 (en) * 2011-06-08 2012-12-13 Indiana University Research And Technology Corporation Monoclonal antibody and antigens for diagnosing and treating lung disease and injury
CN103748107B (zh) 2011-06-09 2020-06-02 美利坚合众国, 由健康及人类服务部部长代表 具有免疫原性较小的t细胞和/或b细胞表位的假单胞菌外毒素a
AU2012266363A1 (en) 2011-06-10 2014-01-09 Corimmun Gmbh Binding compounds to human beta1-adrenoreceptor (beta1-AR) and their use in the measurement of auto-anti-beta1-AR antibodies
WO2012170969A2 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
DK3006464T3 (en) 2011-06-10 2018-09-17 Canada Minister Nat Defence ANTIRICIN ANTIBODIES AND APPLICATIONS THEREOF
HUE038509T2 (hu) 2011-06-10 2018-10-29 Medimmune Ltd Pseudomonas PSL elleni kötõmolekula és alkalmazása
WO2012174055A1 (en) 2011-06-13 2012-12-20 The Trustees Of The University Of Pennsylvania Wound healing using complement inhibitors
AU2012269720B2 (en) 2011-06-13 2015-01-22 Csl Limited Antibodies against G-CSFR and uses thereof
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
CA2838340A1 (en) 2011-06-17 2012-12-20 Amgen Inc. Method of treating or ameliorating metabolic disorders using clec-2
US20140120555A1 (en) 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
EP2723376B1 (de) 2011-06-22 2018-12-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl-antikörper und verwendungen damit
CN103747803B (zh) 2011-06-22 2016-10-12 国家医疗保健研究所 抗axl抗体及其用途
WO2012175735A1 (en) 2011-06-23 2012-12-27 Vib Vzw A20 inhibitors for the treatment of respiratory viral infections
WO2012178188A2 (en) 2011-06-23 2012-12-27 Children's Hospital Medical Center Molecular diagnostic panel of eosinophilic gastrointestinal disorders
EP2537933A1 (de) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) Auf IL-15- und IL-15Ralpha-Sushi-Domäne basierende Immunozytokine
EP2537864B1 (de) 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies FC-Varianten mit reduzierten Effektorfunktionen
CN103764665A (zh) 2011-06-28 2014-04-30 怀特黑德生物医学研究所 使用分选酶安装用于蛋白质连接的点击化学柄
PE20140756A1 (es) 2011-06-28 2014-07-04 Oxford Biotherapeutics Ltd Anticuerpos que se unen a bst1
ME02632B (de) 2011-06-28 2017-06-20 Oxford Biotherapeutics Ltd Therapeutisches und diagnostisches ziel
WO2013001372A2 (en) 2011-06-30 2013-01-03 University Of Oslo Methods and compositions for inhibition of activation of regulatory t cells
AU2012277376B2 (en) 2011-06-30 2016-11-24 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
ES2692519T3 (es) 2011-07-01 2018-12-04 Novartis Ag Método para tratar trastornos metabólicos
ES2592628T3 (es) 2011-07-06 2016-11-30 Sykehuset Sorlandet Hf Terapia dirigida al receptor del factor de crecimiento epidérmico (EGFR)
EP2543677A1 (de) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antikörper zur Behandlung und Vorbeugung von Thrombose
EP2543679A1 (de) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antikörper zur Behandlung und Vorbeugung von Thrombose
EP2543678A1 (de) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antikörper zur Behandlung und Vorbeugung von Thrombose
US9475858B2 (en) 2011-07-08 2016-10-25 Momenta Pharmaceuticals, Inc. Cell culture process
LT2731677T (lt) 2011-07-11 2018-07-10 Glenmark Pharmaceuticals S.A. Antikūnai, kurie prisiriša prie ox40, ir jų panaudojimas
EP2734236A4 (de) 2011-07-13 2015-04-15 Abbvie Inc Verfahren und zusammensetzungen zur behandlung von asthma mit anti-il-13-antikörpern
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
WO2013012747A1 (en) 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
WO2013010955A1 (en) 2011-07-15 2013-01-24 Morphosys Ag Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
US8591892B2 (en) 2011-07-18 2013-11-26 The Ohio State University FTY720 increases CD74 expression and sensitizes cancer cells to anti-CD74 antibody-mediated cell death
EP2734546A1 (de) 2011-07-18 2014-05-28 Amgen Inc. Apelinantigen-bindende proteine und verwendungen davon
JP6253578B2 (ja) 2011-07-22 2017-12-27 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 阻害性抗第ｘｉｉ／ｘｉｉａ因子モノクローナル抗体及びそれらの使用
WO2013015821A1 (en) 2011-07-22 2013-01-31 The Research Foundation Of State University Of New York Antibodies to the b12-transcobalamin receptor
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
US20150125533A1 (en) 2011-07-25 2015-05-07 American University In Cairo Single-domain antibodies and graphene coated magnetic metal nanoparticles conjugate and methods for using the same
EP2737083A1 (de) 2011-07-27 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Scientifique) Verfahren zur diagnose und behandlung des myhre-syndroms
EP2551348B1 (de) 2011-07-29 2014-09-24 Icon Genetics GmbH Produktion von galactosylierten N-Glycanen in Pflanzen
EP2739975B1 (de) 2011-08-03 2015-06-17 Quidel Corporation N-acetyl-d-glucosamin für verbesserte spezifität von streptokokken in einem immunoassay
PT2739311T (pt) 2011-08-04 2018-03-26 Amgen Inc Método para tratamento de defeitos de lacunas ósseas
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
WO2013022972A1 (en) 2011-08-08 2013-02-14 Abbott Biotherapeutics Corporation Methods of treating progressive forms of multiple sclerosis
ES2893855T3 (es) 2011-08-11 2022-02-10 Ono Pharmaceutical Co Agente terapéutico para enfermedades autoinmunes que comprende agonista de PD-1
US9694049B2 (en) 2011-08-11 2017-07-04 Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The Unitversity Of Nevada, Reno Methods for treating muscular dystrophy
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
AU2012296613B2 (en) 2011-08-15 2016-05-12 Amplimmune, Inc. Anti-B7-H4 antibodies and their uses
EP2744828A4 (de) 2011-08-16 2014-12-31 Univ Emory Jaml-spezifische bindungsmittel, antikörper und verwendungen davon
CN103857696B (zh) 2011-08-17 2017-07-04 加利福尼亚大学董事会 结合整合素αVβ8的抗体
JP6244301B2 (ja) 2011-08-18 2017-12-06 アフィニティ バイオサイエンス ピーティーワイ リミテッド 可溶性ポリペプチド
CA2845884A1 (en) 2011-08-22 2013-02-28 Cangene Corporation Clostridium difficile antibodies
US9435812B2 (en) 2011-08-31 2016-09-06 Ventana Medical Systems, Inc. Expression of ETS related gene (ERG) and phosphatase and tensin homolog (PTEN) correlates with prostate cancer capsular penetration
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
US20140234903A1 (en) 2011-09-05 2014-08-21 Eth Zurich Biosynthetic gene cluster for the production of peptide/protein analogues
CA2846667A1 (en) 2011-09-06 2013-03-14 Guy L. Reed Serpinf2-binding molecules and methods of use
CA2847245A1 (en) 2011-09-09 2013-03-14 Amgen Inc. Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients
AU2012306341B2 (en) 2011-09-09 2017-08-31 Cambridge Enterprise Limited Anti-Siglec-15 antibodies and uses thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US8475739B2 (en) 2011-09-25 2013-07-02 Theranos, Inc. Systems and methods for fluid handling
US9664702B2 (en) 2011-09-25 2017-05-30 Theranos, Inc. Fluid handling apparatus and configurations
US20140170735A1 (en) 2011-09-25 2014-06-19 Elizabeth A. Holmes Systems and methods for multi-analysis
US8435738B2 (en) 2011-09-25 2013-05-07 Theranos, Inc. Systems and methods for multi-analysis
US9619627B2 (en) 2011-09-25 2017-04-11 Theranos, Inc. Systems and methods for collecting and transmitting assay results
US8840838B2 (en) 2011-09-25 2014-09-23 Theranos, Inc. Centrifuge configurations
US9268915B2 (en) 2011-09-25 2016-02-23 Theranos, Inc. Systems and methods for diagnosis or treatment
US9632102B2 (en) 2011-09-25 2017-04-25 Theranos, Inc. Systems and methods for multi-purpose analysis
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
IL290105B2 (en) 2011-09-15 2024-04-01 Us Health MAGE-recognizing T cell receptors are restricted to 1HLA–A or HLA–CW7
AU2012308240A1 (en) 2011-09-15 2013-05-02 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Immunotherapy and diagnosis of mucormycosis using CotH
MX2014002769A (es) 2011-09-16 2014-06-11 Ucb Pharma Sa Anticuerpos neutralizantes para las exotoxinas principales tcda y tcdb de clostridium difficile.
EP2755993B1 (de) 2011-09-16 2017-11-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Pseudomonas exotoxin a mit weniger immunogenen b-zellepitopen
EP2759551B1 (de) 2011-09-21 2019-05-22 Fujirebio Inc. Antikörper die an einen affinitätskomplex binden der 25oh-vitamin d2 oder d3 und einen dagegen gerichteten antikörper enthält
MX353958B (es) 2011-09-22 2018-02-07 Amgen Inc Proteinas de union al antigeno cd27l.
MX356808B (es) 2011-09-23 2018-06-14 Xbiotech Inc Uso de una composición farmacéutica que comprende un anticuerpo anti-il-1a para el tratamiento de la caquexia.
LT3485903T (lt) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
EP2758422A1 (de) 2011-09-23 2014-07-30 Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA Modifizierte albuminbindende domänen und ihre verwendung zur verbesserung der pharmakokinetik
WO2013041687A1 (en) 2011-09-23 2013-03-28 Amgen Research (Munich) Gmbh Bispecific binding molecules for 5t4 and cd3
US10012664B2 (en) 2011-09-25 2018-07-03 Theranos Ip Company, Llc Systems and methods for fluid and component handling
US9250229B2 (en) 2011-09-25 2016-02-02 Theranos, Inc. Systems and methods for multi-analysis
US9810704B2 (en) 2013-02-18 2017-11-07 Theranos, Inc. Systems and methods for multi-analysis
EP3628329B1 (de) 2011-09-30 2022-08-10 Dana-Farber Cancer Institute, Inc. Therapeutische peptide mit antikörpern, die an mhc-klasse-1-polypeptid-verwandte sequenz a (mica) binden
USD692162S1 (en) 2011-09-30 2013-10-22 Becton, Dickinson And Company Single piece reagent holder
CA2850549C (en) 2011-09-30 2023-03-14 Teva Pharmaceuticals Australia Pty Ltd. Antibodies against tl1a and uses thereof
DK2761305T3 (da) 2011-09-30 2017-11-20 Becton Dickinson Co Forenet reagensstrimmel
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
CA2850624A1 (en) 2011-10-03 2013-04-11 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US10196664B2 (en) 2011-10-04 2019-02-05 Icon Genetics Gmbh Nicotiana benthamiana plants deficient in fucosyltransferase activity
AR088048A1 (es) 2011-10-04 2014-05-07 Univ Columbia Señuelos notch1 humanos
EP3275902A1 (de) 2011-10-04 2018-01-31 IGEM Therapeutics Limited Ige anti-hmw-maa antikörper
WO2013050441A1 (en) 2011-10-05 2013-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation
WO2013052933A2 (en) 2011-10-06 2013-04-11 The Board Of Trustees Of The University Of Illinois Myosin binding protein-c for use in methods relating to diastolic heart failure
JP2014530360A (ja) 2011-10-07 2014-11-17 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ 診断マーカーとしてのｏｘＭＩＦ
JP6239517B2 (ja) 2011-10-10 2017-11-29 メディミューン リミテッド 関節リウマチの治療法
JP6310394B2 (ja) 2011-10-10 2018-04-11 ゼンコア インコーポレイテッド 抗体を精製する方法
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
US20140234308A1 (en) 2011-10-13 2014-08-21 The Regents Of The University Of California Treatment of breast cancer with companion diagnostic
JP2014530816A (ja) 2011-10-14 2014-11-20 ノバルティスアーゲー Ｗｎｔ経路関連疾患のための抗体および方法
CA2851795C (en) 2011-10-20 2018-11-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
EP2768971A1 (de) 2011-10-20 2014-08-27 Institut National de la Sante et de la Recherche Medicale (INSERM) Verfahren zur erkennung und behandlung von kardialer remodellierung
WO2013056377A1 (en) 2011-10-21 2013-04-25 Augurex Life Sciences Corporation Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis
MX2014004977A (es) 2011-10-24 2014-09-11 Abbvie Inc Inmunoaglutinantes dirigidos contra esclerostina.
US9265817B2 (en) 2011-10-28 2016-02-23 Patrys Limited PAT-LM1 epitopes and methods for using same
EP3559049A4 (de) 2011-10-28 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd Polypeptidkonstrukte und anwendungen davon
WO2013063419A2 (en) 2011-10-28 2013-05-02 The Trustees Of The University Of Pennsylvania A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
EP2771031B1 (de) 2011-10-28 2018-04-18 Prothena Biosciences Limited Alpha-synuklein erkennende humanisierte antikörper
AU2012328980A1 (en) 2011-10-28 2014-04-24 Genentech, Inc. Therapeutic combinations and methods of treating melanoma
EP2773667A1 (de) 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49-antikörper
ES2697674T3 (es) 2011-11-01 2019-01-25 Bionomics Inc Procedimientos para bloquear el crecimiento de células madre cancerosas
AU2012332590B2 (en) 2011-11-01 2016-10-20 Bionomics, Inc. Anti-GPR49 antibodies
JP2014533247A (ja) 2011-11-01 2014-12-11 バイオノミクス インコーポレイテッド 抗体および癌を治療する方法
ES2861435T3 (es) 2011-11-03 2021-10-06 Univ Pennsylvania Composiciones específicas de B7-H4 aisladas y métodos de uso de las mismas
EP2589609A1 (de) 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigenbindendes Protein und dessen Verwendung als Adressierungsprodukt bei der Behandlung von Krebs
EP2773892B1 (de) 2011-11-04 2020-10-07 Handylab, Inc. Vorrichtung zur vorbereitung von polynukleotidproben
CA3161431A1 (en) 2011-11-07 2013-05-16 Medimmune Limited Combination therapies using anti-pseudomonas psl and pcrv binding molecules
EP2776022A1 (de) 2011-11-08 2014-09-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Neue behandlung für neurodegenerative erkrankungen
WO2013070821A1 (en) 2011-11-08 2013-05-16 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
EP2776838A1 (de) 2011-11-08 2014-09-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Frühe diagnose neurodegenerativer erkrankungen
WO2013070468A1 (en) 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
WO2013071233A1 (en) 2011-11-10 2013-05-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for detecting infectious agents and a novel virus detected thereby
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
PT2776466T (pt) 2011-11-11 2017-11-30 Ucb Biopharma Sprl Anticorpos de ligação a albumina e seus fragmentos de ligação
EP2776470A2 (de) 2011-11-11 2014-09-17 Rinat Neuroscience Corporation Für trop-2 spezifische antikörper und ihre verwendungen
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
US20130156766A1 (en) 2011-11-15 2013-06-20 Allergan, Inc. Treatment of dry age related macular degeneration
ES2617211T3 (es) 2011-11-16 2017-06-15 Sphingotec Gmbh Ensayos de adrenomedulina y métodos para determinar la adrenomedulina madura
BR122019027917B1 (pt) 2011-11-16 2023-05-09 Adrenomed Ag Uso de um anticorpo anti-adrenomedulina (adm) enxertado em cdr humano ou humanizado ou fragmento de anticorpo anti-adm do mesmo
EP2594587B1 (de) 2011-11-16 2014-05-21 AdrenoMed AG Anti-Adrenomedullin-Antikörper (ADM) oder Anti-ADM-Antikörperfragment oder non-Ig Anti-ADM-Proteingerüst zur Reduzierung des Sterblichkeitsrisikos bei einem Patienten mit chronischer oder akuter Erkrankung oder in einem akuten Zustand
PL2780370T3 (pl) 2011-11-16 2020-01-31 Adrenomed Ag Przeciwciało przeciwko adrenomedulinie (adm) lub fragment przeciwciała przeciwko adp lub szkielet przeciwko adm inny niż ig do zastosowania do stabilizacji krążenia w terapii ostrej choroby lub ostrego stanu pacjenta
PT2780371T (pt) 2011-11-16 2019-01-30 Adrenomed Ag Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou uma estrutura não ig anti-adm para a regulação do equilíbrio de fluidos num doente com uma doença aguda ou crónica
US20140328853A1 (en) 2011-11-16 2014-11-06 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
SI2780039T1 (en) 2011-11-17 2018-06-29 Pfizer Inc. Cytotoxic peptides and their conjugates between the antibody and the drug
WO2013078122A1 (en) 2011-11-22 2013-05-30 President And Fellows Of Harvard College Diabetes diagnosis through the detection of glycated proteins in urine
EP2782933A1 (de) 2011-11-22 2014-10-01 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren und pharmazeutische zusammensetzungen zur verringerung von atemwegüberreaktion
SG11201402619VA (en) 2011-11-23 2014-10-30 Igenica Biotherapeutics Inc Anti-cd98 antibodies and methods of use thereof
US9220775B2 (en) 2011-11-23 2015-12-29 Medimmune Llc Binding molecules specific for HER3 and uses thereof
EP2785365B1 (de) 2011-11-28 2017-07-19 Institut National de la Sante et de la Recherche Medicale (INSERM) Pharmazeutische zusammensetzung zur verwendung bei der behandlung von dysfunktion in zusammenhang mit der alterung
WO2013081143A1 (ja) 2011-11-30 2013-06-06 中外製薬株式会社 免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬
WO2013079606A1 (en) 2011-12-01 2013-06-06 Ventana Medical Systems, Inc. Automated dual stain of mirna and protein targets
JP6266529B2 (ja) 2011-12-02 2018-01-24 アーマジェン・インコーポレイテッドＡｒｍａｇｅｎ， Ｉｎｃ． Ｃｎｓにおけるアリールスルファターゼａ活性を増加するための方法および組成物
CN104159924B (zh) 2011-12-05 2018-03-16 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
CA2853138A1 (en) 2011-12-05 2013-06-13 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
TWI640537B (zh) 2011-12-05 2018-11-11 Ｘ 染色體有限公司 ＰＤＧＦ受體β結合多肽
EP2788382A2 (de) 2011-12-05 2014-10-15 Novartis AG Antikörper für epidermalen wachstumsfaktor-rezeptor 3 (her3) gegen domäne ii von her3
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
CA2858572C (en) 2011-12-08 2023-01-17 Amgen Inc. Human lcat antigen binding proteins and their use in therapy
BR112014013694A2 (pt) 2011-12-08 2017-06-13 Biotest Ag método para tratar uma doença, e, kit
CA2855570A1 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
US10118958B2 (en) 2011-12-14 2018-11-06 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
GB201121513D0 (en) 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
PE20150159A1 (es) 2011-12-21 2015-02-08 Novartis Ag Composiciones y metodos para anticuerpos que actuan sobre el factor p
TR201815709T4 (tr) 2011-12-22 2018-11-21 Hoffmann La Roche İyon değişim membranı kromatografisi.
EP2793944A4 (de) 2011-12-23 2015-09-02 Nicholas B Lydon Immunoglobuline und varianten gegen pathogene mikroben
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
WO2013092983A2 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
FR2984750B1 (fr) 2011-12-23 2014-01-10 Lfb Biotechnologies Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii
EP2797953B1 (de) 2011-12-28 2020-06-03 Amgen Inc. Verfahren zur behandlung von alveolarknochenverlust durch verwendung von anti-sclerostin-antikörpern
TWI443107B (zh) 2011-12-29 2014-07-01 Ind Tech Res Inst 人源化之抗人類細胞表面抗原ｃｄ３４之單株抗體及其應用
US20130171642A1 (en) 2011-12-30 2013-07-04 Ventana Medical Systems, Inc. Automated analysis of circulating tumor cells
TW201333035A (zh) 2011-12-30 2013-08-16 Abbvie Inc 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
CN104080480A (zh) 2012-01-01 2014-10-01 奇比艾企业有限公司 用于选择性递送治疗剂和诊断剂的endo180靶向微粒
EP2800583A1 (de) 2012-01-02 2014-11-12 Novartis AG Cdcp1 und brustkrebs
WO2013106489A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
WO2013106485A2 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
KR102104686B1 (ko) 2012-01-10 2020-04-24 바이오젠 엠에이 인코포레이티드 뇌혈관 장벽을 통한 치료학적 분자의 수송 개선법
US20130177574A1 (en) 2012-01-11 2013-07-11 Paul I. Terasaki Foundation Laboratory ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
US10800847B2 (en) 2012-01-11 2020-10-13 Dr. Mepur Ravindranath Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
WO2013104798A1 (en) 2012-01-12 2013-07-18 Cemm - Center For Molecular Medicine Of The Austrian Academy Of Sciences Modulators of immune responses
EP2804878B1 (de) 2012-01-20 2018-08-22 Genzyme Corporation Anti-cxcr3-antikörper
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
NZ629296A (en) 2012-01-27 2016-06-24 Prothena Biosciences Ltd Humanized antibodies that recognize alpha-synuclein
MY176695A (en) 2012-01-27 2020-08-19 Abbvie Inc Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
AU2013216320A1 (en) 2012-02-01 2014-04-03 Compugen Ltd. C10RF32 antibodies, and uses thereof for treatment of cancer
EP2809682B1 (de) 2012-02-03 2020-04-08 F.Hoffmann-La Roche Ag Bispezifische antikörpermoleküle mit antigen-transfizierten t-zellen und deren verwendung in der medizin
RU2658773C2 (ru) 2012-02-03 2018-06-22 Бектон, Дикинсон Энд Компани Система и способ выполнения автоматизированных тестов над множеством биологических проб
SI2812443T1 (sl) 2012-02-06 2019-10-30 Inhibrx Inc Protitelesa CD47 in postopki za njihovo uporabo
US9546219B2 (en) 2012-02-08 2017-01-17 North Carolina State University Treatment of allergic diseases with recombinant antibodies
WO2013119990A2 (en) 2012-02-10 2013-08-15 Seattle Genetics, Inc. Detection and treatment of cd30+ cancers
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
PT2814844T (pt) 2012-02-15 2017-09-18 Novo Nordisk As Anticorpos que se ligam e bloqueiam recetor de acionamento expresso em células mieloides-1 (trem-1)
SI2814842T1 (sl) 2012-02-15 2018-10-30 Novo Nordisk A/S Protitelesa, ki vežejo peptidoglikal prepoznan protein 1
CA2864539C (en) 2012-02-16 2022-06-07 Santarus, Inc. Antibody formulations
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
JP6401060B2 (ja) 2012-02-24 2018-10-03 アッヴィ・ステムセントルクス・エル・エル・シー 抗ｓｅｚ６抗体及び使用方法
DK2817338T3 (en) 2012-02-24 2017-10-23 Abbvie Stemcentrx Llc DLL3 modulators and methods of use
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
JP6407726B2 (ja) 2012-03-01 2018-10-24 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ 長寿命ポリペプチド結合分子
CA2865928C (en) 2012-03-02 2021-02-16 Vaccinex, Inc. Cxcl13 antagonist for the treatment of sjogren's syndrome
JP6195855B2 (ja) 2012-03-03 2017-09-13 イミュンジーン，インコーポレーテッド 工学的に作製した抗体−インターフェロン変異体融合分子
FR2987627B1 (fr) 2012-03-05 2016-03-18 Splicos Utilisation de rbm39 comme biomarqueur
EP3296320A1 (de) 2012-03-08 2018-03-21 Halozyme, Inc. Bedingt aktive antikörper gegen den epidermalen wachstumsfaktorrezeptor und verfahren zur verwendung davon
EP3628326B1 (de) 2012-03-15 2024-02-28 Oxyrane UK Limited Verfahren und materialien zur behandlung von morbus pompe
JP6200437B2 (ja) 2012-03-16 2017-09-20 ユニバーシティ ヘルス ネットワーク Ｔｏｓｏ活性を調節するための方法および組成物
EP2825557B1 (de) 2012-03-16 2017-06-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Manipuliertes lösliches monomeres fc
ES2731757T3 (es) 2012-03-20 2019-11-18 Biogen Ma Inc Anticuerpos neutralizantes de JCV
EP2828291A1 (de) 2012-03-21 2015-01-28 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Aus der d1-domäne von nkp46 abgeleitete peptide
CA2866185C (en) 2012-03-23 2021-04-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pathogenic phlebovirus isolates and compositions and methods of use
AU2013235726B2 (en) 2012-03-23 2017-04-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
DK2831587T3 (en) 2012-03-27 2018-07-23 Ventana Med Syst Inc Signaling conjugates and methods of use
DK2832363T3 (en) 2012-03-27 2019-01-07 Green Cross Corp Epitopes of epidermal growth factor receptor surface antigen and use thereof
CN109880867A (zh) 2012-03-27 2019-06-14 弗·哈夫曼-拉罗切有限公司 用于重组蛋白质的改进的收获操作
TWI605060B (zh) 2012-03-28 2017-11-11 賽諾菲公司 抗緩激肽ｂ１受體配位體之抗體
WO2013144240A1 (en) 2012-03-29 2013-10-03 Friedrich Miescher Institute For Biomedical Research Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
ES2702278T3 (es) 2012-04-01 2019-02-28 Technion Res & Dev Foundation Péptidos de inductor de metaloproteinasa de matriz extracelular (emmprin) y anticuerpos de unión
CA2868398A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
KR20200105524A (ko) 2012-04-02 2020-09-07 버그 엘엘씨 조사적 세포 기반 분석 및 이의 사용
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
MX356800B (es) 2012-04-05 2018-06-13 Ac Immune Sa Anticuerpo tau humanizado.
US20130273053A1 (en) 2012-04-06 2013-10-17 University Of Leicester Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
US10385395B2 (en) 2012-04-11 2019-08-20 The Regents Of The University Of California Diagnostic tools for response to 6-thiopurine therapy
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
DK2838998T3 (en) 2012-04-18 2018-01-15 Cell Signaling Technology Inc EGFR AND ROS1 IN CANCER
WO2013158485A1 (en) 2012-04-18 2013-10-24 Massachusetts Institute Of Technology Menainv and cancer invasion and metastasis
WO2013158217A1 (en) 2012-04-20 2013-10-24 Thomas Jefferson University Engineered antibody for inhibition of fibrosis
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013158275A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
EP2841452B1 (de) 2012-04-25 2023-04-12 Momenta Pharmaceuticals, Inc. Modifizierte glykoproteine
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
SI3431492T1 (sl) 2012-04-27 2021-07-30 Novo Nordisk A/S Antigen-vezavni proteini liganda človeškega CD30
EP2660324A1 (de) 2012-05-02 2013-11-06 Algenics Herstellung sekretierter therapeutischer Antikörper in Mikroalgen
EP2660323A1 (de) 2012-05-02 2013-11-06 Algenics Herstellung sekretierter therapeutischer Antikörper in Phaeodactylum tricornutum-Mikroalgen
WO2013164095A1 (en) 2012-05-02 2013-11-07 Algenics Production of secreted therapeutic antibodies in microalgae
US9980942B2 (en) 2012-05-02 2018-05-29 Children's Hospital Medical Center Rejuvenation of precursor cells
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
WO2013166290A1 (en) 2012-05-04 2013-11-07 Abbvie Biotherapeutics Inc. P21 biomarker assay
US9273140B2 (en) 2012-05-10 2016-03-01 Fujita Health University Antibody for detecting DNA damage in cells utilizing cell membrane surface antigen Ly6D
EP2847220A1 (de) 2012-05-11 2015-03-18 Five Prime Therapeutics, Inc. Verfahren zur behandlung von erkrankungen mit antikörpern zur bindung des koloniestimulationsfaktor-1-rezeptors (csf1r)
EP2847368B1 (de) 2012-05-11 2020-08-19 Merck Sharp & Dohme Corp. Oberflächenverankertes leichtketten-köder-antikörperdisplaysystem
WO2013173364A2 (en) 2012-05-14 2013-11-21 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
JP6122948B2 (ja) 2012-05-15 2017-04-26 モルフォテック， インコーポレイテッド 胃癌の治療のための方法
KR102433686B1 (ko) 2012-05-15 2022-08-19 씨젠 인크. 자가-안정화 링커 접합체
JO3623B1 (ar) 2012-05-18 2020-08-27 Amgen Inc البروتينات المرتبطة بمولد المستضاد st2
BR112014028600B1 (pt) 2012-05-18 2022-11-22 Genentech, Inc Formulações de suspensão compreendendo anticorpo monoclonal de alta concentração, seu método de preparação, seu uso e dispositivo para sua administração subcutânea, e método para produção de um artigo de fabricação
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
WO2013177115A2 (en) 2012-05-21 2013-11-28 Abbvie Inc. Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
JP2015520373A (ja) 2012-05-22 2015-07-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 巣状分節性糸球体硬化症を診断及び処置するための方法
WO2013177247A1 (en) 2012-05-22 2013-11-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Murine anti-ny-eso-1 t cell receptors
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
CN104603149B (zh) 2012-05-24 2017-06-30 万机集团有限公司 与预防和治疗狂犬病感染相关的组合物和方法
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
WO2013177473A1 (en) 2012-05-25 2013-11-28 The University Of Vermont And State Agriculture College Compositions and methods for assaying platelet reactivity and treatment selection
JP6494507B2 (ja) 2012-06-01 2019-04-03 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ グリピカン−３に対する高親和性モノクローナル抗体およびその使用
EP2859018B1 (de) 2012-06-06 2021-09-22 Zoetis Services LLC Anti-ngf-antikörper für hunde und verfahren dafür
US20150174235A1 (en) 2012-06-06 2015-06-25 Bionor Immuno As Vaccine
CA2875980A1 (en) 2012-06-06 2013-12-12 Oncomed Pharmaceuticals, Inc. Binding agents that modulate the hippo pathway and uses thereof
AU2013270684B2 (en) 2012-06-08 2018-04-19 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US20130344064A1 (en) 2012-06-08 2013-12-26 Glenmark Pharmaceuticals S.A. Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof
AU2013274347B2 (en) 2012-06-11 2018-03-08 Amgen Inc. Dual receptor antagonistic antigen-binding proteins and uses thereof
RU2709351C2 (ru) 2012-06-18 2019-12-17 Омерос Корпорейшн Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения различных заболеваний и нарушений
US20150204873A1 (en) 2012-06-18 2015-07-23 Electonic Biosciences, Inc. Cell-free assay device and methods of use
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
FI3421486T3 (fi) 2012-06-22 2023-12-15 Dartmouth College Uusia vista-ig-rakenteita ja vista-ig:n käyttö autoimmuuni-, allergia- ja tulehdushäiriöiden hoitamiseksi
EP4008270A1 (de) 2012-06-22 2022-06-08 Preprogen LLC Verfahren zur gewinnung fötaler zellen und fötaler zellkomponenten
WO2014039983A1 (en) 2012-09-07 2014-03-13 The Trustees Of Dartmouth College Vista modulators for diagnosis and treatment of cancer
US9676847B2 (en) 2012-06-25 2017-06-13 Orega Biotech IL-17 antagonist antibodies
WO2014001557A1 (en) 2012-06-28 2014-01-03 Ucb Pharma S.A. A method for identifying compounds of therapeutic interest
BR112014032916A2 (pt) 2012-06-28 2017-08-01 Pfizer anticorpos anti-fármacos e usos destes para o monitoramento de fármaco
US9457071B2 (en) 2012-06-28 2016-10-04 Hiroshima University Histamine releaser contained in human sweat
WO2014001482A1 (en) 2012-06-29 2014-01-03 Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research Treating diseases by modulating a specific isoform of mkl1
JP6246199B2 (ja) 2012-07-02 2017-12-13 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド パラミクソウイルスおよび使用方法
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
EP2870242A1 (de) 2012-07-05 2015-05-13 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Neue behandlung für neurodegenerative erkrankungen
US10656156B2 (en) 2012-07-05 2020-05-19 Mepur Ravindranath Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
AU2013285488B2 (en) 2012-07-05 2018-03-22 Ucb Pharma S.A. Treatment for bone diseases
WO2014006115A1 (en) 2012-07-06 2014-01-09 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
EP2873422A4 (de) 2012-07-10 2015-12-30 Takeda Pharmaceutical Pharmazeutische zubereitung zur injektion
WO2014011908A1 (en) 2012-07-11 2014-01-16 Esperion Therapeutics, Inc. Apolipoprotein mixtures
WO2014011955A2 (en) 2012-07-12 2014-01-16 Abbvie, Inc. Il-1 binding proteins
MX2015000426A (es) 2012-07-13 2015-07-14 Univ Pennsylvania Incremento de actividad de celulas t car mediante cointroduccion de un anticuerpo biespecifico.
WO2014009426A2 (en) 2012-07-13 2014-01-16 Innate Pharma Screening of conjugated antibodies
HUE061555T2 (hu) 2012-07-13 2023-07-28 Univ Pennsylvania CAR-ok tumorellenes hatásának toxicitáskezelése
PL2875049T3 (pl) 2012-07-18 2019-07-31 Institut National De La Santé Et De La Recherche Médicale (Inserm) Sposoby zapobiegania i leczenia przewlekłej choroby nerek (ckd)
WO2014014821A1 (en) 2012-07-19 2014-01-23 Redwood Biosciences, Inc. Antibody specific for cd22 and methods of use thereof
US9221904B2 (en) 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
DK2877494T3 (da) 2012-07-23 2020-09-21 La Jolla Inst Allergy & Immunology PTPRS og proteoglycaner i autoimmun sygdom
WO2014016737A1 (en) 2012-07-24 2014-01-30 Pfizer Inc. Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof
US9334332B2 (en) 2012-07-25 2016-05-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
KR20150038380A (ko) 2012-07-27 2015-04-08 백스터 인터내셔널 인코포레이티드 키메라 ospa 분자를 포함하는 조성물 및 이의 사용 방법
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
US20150197574A1 (en) 2012-08-02 2015-07-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of transferrin receptor antagonist for the treatment of thalassemia
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
WO2014026033A1 (en) 2012-08-08 2014-02-13 University Of Florida Research Foundation, Inc. Cross-reactive t cell epitopes of hiv, siv, and fiv for vaccines in humans and cats
JP6320382B2 (ja) 2012-08-13 2018-05-09 ザ ロックフェラー ユニヴァーシティ メラノーマの処置および診断
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
SG10201701165TA (en) 2012-08-14 2017-03-30 Univ Nanyang Tech Angiopoietin-like 4 antibody and a method of its use in cancer treatment
US9989538B2 (en) 2012-08-17 2018-06-05 Hiroshima University Monoclonal IgE antibody that binds to sweat allergy antigen protein
US9645151B2 (en) 2012-08-17 2017-05-09 California Institute Of Technology Targeting phosphofructokinase and its glycosylation form for cancer
AU2013306098A1 (en) 2012-08-18 2015-02-12 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
US20140056901A1 (en) 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
EP3327037B1 (de) 2012-08-21 2019-10-09 The U.S.A. as represented by the Secretary, Department of Health and Human Services Domänenspezifische monoklonale mesothelin-antikörper und verwendung davon
SG10201701424QA (en) 2012-08-23 2017-04-27 Agensys Inc Antibody drug conjugates (adc) that bind to 158p1d7 proteins
US9345766B2 (en) 2012-08-30 2016-05-24 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-ERBB3 agents
JP6233932B2 (ja) 2012-08-30 2017-11-22 国立大学法人広島大学 ＢＢＦ２Ｈ７（ＢＢＦ２ ｈｕｍａｎ ｈｏｍｏｌｏｇｕｅ ｏｎ ｃｈｒｏｍｏｓｏｍｅ７）部分アミノ酸配列を有するペプチドまたはそれに結合する抗体を含む細胞増殖調節用組成物
NZ726258A (en) 2012-08-31 2019-07-26 Immunogen Inc Antibodies and uses thereof to detect folate receptor 1
EP2897631A4 (de) 2012-08-31 2016-10-05 Univ Virginia Patent Found Zielpeptide für immuntherapie und diagnostik
AU2013308635A1 (en) 2012-08-31 2015-03-12 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
WO2014033327A1 (en) 2012-09-03 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies directed against icos for treating graft-versus-host disease
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
EP2892544A4 (de) 2012-09-05 2016-11-02 Univ Virginia Patent Found Target-peptide für therapie und diagnostik von kolorektalkarzinomen
UA105278C2 (ru) 2012-09-06 2014-04-25 Інститут Біології Клітини Нан України Способ получения каталитически активных антител (абзимов) с сиалидазной активностью
US9718887B2 (en) 2012-09-06 2017-08-01 Adelaide Research & Innovation Pty Ltd Methods and products for preventing and/or treating metastatic cancer
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
TWI595007B (zh) 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗ｍｃａｍ抗體及相關使用方法
WO2014041544A1 (en) * 2012-09-12 2014-03-20 Ramot At Tel-Aviv University Ltd. Immunoparticles and methods of generating and using same
DK3636665T3 (da) 2012-09-14 2022-10-03 Us Health T-cellereceptorer, som genkender mhc klasse ii-begrænset mage-a3
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
CA2885761C (en) 2012-09-27 2021-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
WO2014055442A2 (en) 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
NO2760138T3 (de) 2012-10-01 2018-08-04
KR102296017B1 (ko) 2012-10-04 2021-09-01 얀센 바이오테크 인코포레이티드 혈관 질환 및 이에 따른 합병증 치료
NZ707091A (en) 2012-10-04 2018-12-21 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
WO2014055771A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
CN104870014A (zh) 2012-10-09 2015-08-26 比奥根Ma公司 联合治疗及用于治疗脱髓鞘病症的用途
KR102308915B1 (ko) 2012-10-15 2021-10-06 메디뮨 리미티드 아밀로이드 베타에 대한 항체
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CA2887711A1 (en) 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
CN104822705B (zh) 2012-10-24 2019-07-12 美国卫生和人力服务部 M971嵌合抗原受体
KR20150073211A (ko) 2012-10-24 2015-06-30 내셔날 리서치 카운실 오브 캐나다 항―캄필로박터 제주니 항체 및 그의 용도
CA2889765C (en) 2012-10-26 2021-06-22 Minna D. BALBAS Androgen receptor variants and methods for making and using
US20150246118A1 (en) 2012-10-26 2015-09-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
EP3736022A3 (de) 2012-10-31 2021-01-20 The Rockefeller University Behandlung und diagnose von darmkrebs
CA2890263C (en) 2012-11-01 2020-03-10 Abbvie Inc. Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
US10189906B2 (en) 2012-11-01 2019-01-29 Max-Delrück-Centrum Für Molekulare Medizin Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
EP2914343B1 (de) 2012-11-02 2019-03-06 TG Therapeutics, Inc. Kombination von anti-cd20-antikörpern und pi3-kinaseselektivem inhibitor
US8975033B2 (en) 2012-11-05 2015-03-10 The Johns Hopkins University Human autoantibodies specific for PAD3 which are cross-reactive with PAD4 and their use in the diagnosis and treatment of rheumatoid arthritis and related diseases
CN105377288B (zh) 2012-11-05 2019-11-15 达纳-法伯癌症研究所股份有限公司 Xbp1、cd138和cs1肽的组合物制备药物的用途
PT2917195T (pt) 2012-11-05 2018-02-09 Pfizer Análogos de spliceostatina
JP6445444B2 (ja) 2012-11-05 2018-12-26 ピエール、ファーブル、メディカマン 新規抗原結合タンパク質および癌の治療のためのアドレッシング産物（ａｄｄｒｅｓｓｉｎｇｐｒｏｄｕｃｔ）としてのそれらの使用
EP2917240A1 (de) 2012-11-07 2015-09-16 Pfizer Inc. Antikörper gegen notch-3 und antikörper-wirkstoff-konjugate
SG10201608703SA (en) 2012-11-08 2016-12-29 Eleven Biotherapeutics Inc Il-6 antagonists and uses thereof
LT2918603T (lt) 2012-11-08 2018-10-25 University Of Miyazaki Antikūnas, galintis specifiškai atpažinti transferino receptorių
EP2917347B1 (de) 2012-11-08 2019-01-02 Institut National de la Sante et de la Recherche Medicale (INSERM) Verfahren und pharmazeutische zusammensetzungen zur behandlung von knochenmetastasen
CN108424453B (zh) 2012-11-09 2021-08-06 基因先端领域株式会社 用于治疗癌症的抗adam28抗体
EP3564259A3 (de) 2012-11-09 2020-02-12 Innate Pharma Kennungen für tgase-vermittelte konjugation
AU2013341711A1 (en) 2012-11-12 2015-05-21 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
TW201438736A (zh) 2012-11-14 2014-10-16 Regeneron Pharma 以ｄｌｌ４拮抗劑治療卵巢癌之方法
EP2733153A1 (de) 2012-11-15 2014-05-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur Herstellung von Immunkonjugaten und Verwendungen davon
JP2016505528A (ja) 2012-11-16 2016-02-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア タンパク質の化学修飾のためのピクテ−スペングラーライゲーション
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
US20140161790A1 (en) 2012-11-19 2014-06-12 Xencor, Inc. Engineered immunoglobulins with extended in vivo half-life
EP2920207B1 (de) 2012-11-19 2018-03-21 Temasek Life Sciences Laboratory Limited Monoklonale antikörper gegen neutralisierende epitopen auf h7-influenzaviren
CN104956224B (zh) 2012-11-20 2017-12-12 美国政府卫生与公共服务部 测量中期因子或多效生长因子水平用于诊断生长的测定
WO2014079886A1 (en) 2012-11-20 2014-05-30 Sanofi Anti-ceacam5 antibodies and uses thereof
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
JP6144355B2 (ja) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 化学修飾ｍＲＮＡ
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
WO2014083379A1 (en) 2012-11-30 2014-06-05 Institut Pasteur Use of anti-fcyri and/or anti-fcyriia antibodies for treating arthritis, inflammation, thrombocytopenia and allergic shock
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
AU2013355414B2 (en) 2012-12-05 2017-02-02 Novartis Ag Compositions and methods for antibodies targeting EPO
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
UA118255C2 (uk) 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
US9383357B2 (en) 2012-12-07 2016-07-05 Northwestern University Biomarker for replicative senescence
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
ES2780398T3 (es) 2012-12-10 2020-08-25 Biogen Ma Inc Anticuerpo anti-antígeno 2 de células dendríticas sanguíneas y uso de los mismos
AU2013359398B2 (en) 2012-12-11 2019-08-15 Cornell University Methods for diagnosing and treating prostate cancer
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
CA2894885A1 (en) 2012-12-13 2014-06-19 University Of Virginia Patent Foundation Target peptides for ovarian cancer therapy and diagnostics
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
HRP20220399T1 (hr) 2012-12-13 2022-05-13 Immunomedics, Inc. Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
EP2931749B1 (de) 2012-12-17 2019-04-24 Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme Verwendung monoklonaler antikörper zur behandlung von entzündungen und bakteriellen infektionen
WO2014099997A1 (en) 2012-12-18 2014-06-26 Novartis Ag Compositions and methods that utilize a peptide tag that binds to hyaluronan
WO2014100439A2 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
CN104994885B (zh) 2012-12-19 2017-09-29 基因泰克公司 用于放射性卤素蛋白质标记的方法和组合物
DK2935330T3 (da) 2012-12-19 2019-07-22 Aveo Pharmaceuticals Inc Anti-notch3-antistoffer
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
JP6359031B2 (ja) 2012-12-21 2018-07-18 メディミューン，エルエルシー 抗ｈ７ｃｒ抗体
AU2013362134B2 (en) 2012-12-21 2018-07-05 Sykehuset Sorlandet Hf EGFR targeted therapy of neurological disorders and pain
DK2934584T3 (da) 2012-12-21 2020-05-18 Aveo Pharmaceuticals Inc Anti-gdf15-antistoffer
US9550986B2 (en) 2012-12-21 2017-01-24 Abbvie Inc. High-throughput antibody humanization
CN104994874B (zh) 2012-12-26 2017-04-12 安科协同公司 抗整联蛋白β1抗体组合物及其使用方法
EA201690004A1 (ru) 2012-12-27 2016-07-29 Санофи Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
NZ709828A (en) * 2012-12-28 2019-07-26 Prec Biologics Inc Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
PE20151289A1 (es) 2013-01-02 2015-10-05 Glenmark Pharmaceuticals Sa Anticuerpos que se unen al tl1a y sus usos
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
AU2014205086B2 (en) 2013-01-14 2019-04-18 Xencor, Inc. Novel heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
EP2945969A1 (de) 2013-01-15 2015-11-25 Xencor, Inc. Schnelle beseitigung von antigenkomplexen unter verwendung neuartiger antikörper
PL2946206T3 (pl) 2013-01-20 2019-07-31 Dyax Corp. Ocena, testy i leczenie zaburzeń mediowanych przez PKAL
DK2948479T3 (en) 2013-01-20 2018-11-26 Dyax Corp EVALUATION AND TREATMENT OF BRADYKINE-MEDIATED DISORDERS
WO2014118705A1 (en) 2013-01-31 2014-08-07 Novartis Ag Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
EP2951199A4 (de) 2013-01-31 2016-07-20 Univ Jefferson Fusionsproteine zur modulation von regulatorischen und effektor-t-zellen
EP2951589A1 (de) 2013-02-01 2015-12-09 INSERM - Institut National de la Santé et de la Recherche Médicale Verfahren zur vorhersage und vorbeugung von metastasen in dreifach negativen brustkrebsen
CA2899960C (en) 2013-02-01 2022-05-03 Transbio Ltd Anti-cd83 antibodies and use thereof
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
KR102276974B1 (ko) 2013-02-06 2021-07-13 인히브릭스, 인크. 비-혈소판 및 비-적혈구 세포 격감성 cd47 항체 및 이를 이용하는 방법
US9340618B2 (en) 2013-02-07 2016-05-17 Csl Limited IL-11R binding proteins
US8877202B2 (en) 2013-02-07 2014-11-04 Immunomedics, Inc. Pro-drug form (P2PDOX) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
SI2953969T1 (sl) 2013-02-08 2020-01-31 Novartis Ag Protitelesa proti-IL-17A in njihova uporaba v zdravljenju avtoimunskih in vnetnih motenj
EP2956169B1 (de) 2013-02-12 2018-04-11 THE UNITED STATES OF AMERICA, represented by the S Monoklonale antikörper zur neutralisierung von noroviren
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
CN104884470A (zh) 2013-02-15 2015-09-02 艾斯巴技术-诺华有限责任公司 用于cdr移植的接受体框架
EP2957632B1 (de) 2013-02-15 2020-09-30 Perseus Proteomics Inc. Humanisierter anti-cdh3-antikörper, arzneimittelkonjugat daraus und verwendung davon
US9745558B2 (en) 2013-02-18 2017-08-29 Vegenics Pty Limited VEGFR-3 ligand binding molecules and uses thereof
US9573988B2 (en) 2013-02-20 2017-02-21 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
PT2958943T (pt) 2013-02-20 2019-12-17 Novartis Ag Tratamento do cancro usando recetor de antigénios quiméricos anti-egfrviii humanizados
WO2014127811A1 (en) 2013-02-20 2014-08-28 Esbatech - A Novartis Company Llc Acceptor framework for cdr grafting
MX2015010682A (es) 2013-02-22 2016-05-31 Stemcentrx Inc Nuevos conjugados de anticuerpos y usos de los mismos.
US20150366890A1 (en) 2013-02-25 2015-12-24 Trustees Of Boston University Compositions and methods for treating fungal infections
FR3004184B1 (fr) 2013-02-26 2016-03-18 Agronomique Inst Nat Rech Anticorps anti-gluten desamide et utilisations.
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
WO2014137355A1 (en) 2013-03-08 2014-09-12 Vaccinex, Inc. Anti-cxcl13 antibodies and associated epitope sequences
EP2830651A4 (de) 2013-03-12 2015-09-02 Abbvie Inc An humanes tnf-alpha bindende humane antikörper und verfahren zur herstellung davon
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
JP6450364B2 (ja) 2013-03-13 2019-01-09 セセン バイオ， インコーポレイテッド 眼送達のためのキメラサイトカイン製剤
KR102241868B1 (ko) 2013-03-13 2021-04-20 사노피 항-cd38 항체 및 카르필조밉을 포함하는 조성물
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
AU2014248515B2 (en) 2013-03-13 2019-03-07 Prothena Biosciences Limited Tau immunotherapy
JP6739329B2 (ja) 2013-03-14 2020-08-12 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ Ｈｃｖコア脂質結合ドメインモノクローナル抗体
CA2906688A1 (en) 2013-03-14 2014-09-25 Parkash S. Gill Cancer treatment using antibodies that bind cell surface grp78
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
PL2968520T3 (pl) 2013-03-14 2022-01-03 Macrogenics, Inc. Dwuspecyficzne cząsteczki, które są immunoreaktywne wobec immunologicznych komórek efektorowych wykazujących ekspresję receptora aktywującego
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP2968526A4 (de) 2013-03-14 2016-11-09 Abbott Lab Hcv-antigen-antikörper-kombinationstest sowie verfahren und zusammensetzungen zur verwendung darin
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
WO2014159554A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing the same using displacement chromatography
US10081673B2 (en) 2013-03-14 2018-09-25 Ffe Therapeutics Llc Compositions and methods for treating angiogenesis-related disorders
CA2916421A1 (en) 2013-03-14 2014-09-25 Bayer Healthcare Llc Monoclonal antibodies against antithrombin beta complexed with heparin
SG11201504260UA (en) 2013-03-14 2015-10-29 Abbvie Inc Low acidic species compositions and methods for producing and using the same
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US20140271629A1 (en) 2013-03-14 2014-09-18 Amgen Inc. Chrdl-1 antigen binding proteins and methods of treatment
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
JP2016512241A (ja) 2013-03-14 2016-04-25 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ 改良された抗体検出のためのｈｃｖｎｓ３組換え抗原およびこの突然変異体
WO2014142882A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Protein purification using displacement chromatography
EP2970479B1 (de) 2013-03-14 2019-04-24 Novartis AG Antikörper gegen notch 3
SG11201507093WA (en) 2013-03-14 2015-10-29 Univ Maryland Baltimore Office Of Technology Transfer Androgen receptor down-regulating agents and uses thereof
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9090697B2 (en) * 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
KR102207859B1 (ko) 2013-03-15 2021-01-27 메모리얼 슬로안 케터링 캔서 센터 고 친화도 항-gd2 항체
EP2968582B1 (de) 2013-03-15 2020-07-01 Innate Pharma Festphasen-tgase-vermittelte konjugation von antikörpern
US9446105B2 (en) 2013-03-15 2016-09-20 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor specific for folate receptor β
WO2014143739A2 (en) * 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
CA2899089C (en) 2013-03-15 2021-10-26 Biogen Ma Inc. Factor ix polypeptide formulations
WO2014144466A1 (en) * 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
AP2015008732A0 (en) * 2013-03-15 2015-09-30 Amgen Inc Human pac1 antibodies
WO2014168734A1 (en) 2013-03-15 2014-10-16 Cedars-Sinai Medical Center Time-resolved laser-induced fluorescence spectroscopy systems and uses thereof
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
US9850297B2 (en) 2013-03-15 2017-12-26 Amgen Inc. Secreted frizzle-related protein 5 (SFRP5) binding proteins
CA2903546A1 (en) 2013-03-15 2014-09-25 Biogen Ma Inc. Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
CN105143257B (zh) 2013-03-15 2020-10-27 艾伯维生物医疗股份有限公司 Fc变体
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
CN111138543A (zh) 2013-03-15 2020-05-12 Xencor股份有限公司 异二聚体蛋白
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
EP3421495A3 (de) 2013-03-15 2019-05-15 Xencor, Inc. Modulation von t-zellen mit bispezifischen antikörpern und fc-fusionen
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
EP2970426B1 (de) 2013-03-15 2019-08-28 Michael C. Milone Anzielung zytotoxischer zellen mit chimären rezeptoren für eine adoptive immuntherapie
RU2015144033A (ru) 2013-03-15 2017-04-26 Эббви Байотекнолоджи Лтд. Антитела против cd25 и их применения
CN105283196B (zh) 2013-03-15 2018-10-12 贝丝以色列女执事医疗中心 用于产生和使用构象-特异性抗体的方法和组合物
US9920377B2 (en) 2013-03-15 2018-03-20 Sutter West Bay Hospitals FALZ for use as a target for therapies to treat cancer
WO2014144791A2 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
JP2016515524A (ja) 2013-03-15 2016-05-30 アッヴィ バイオテクノロジー リミテッド 抗ｃｄ２５抗体およびそれらの使用
EA201890895A1 (ru) 2013-03-15 2019-02-28 Зинджения, Инк. Мультивалентные и моновалентные мультиспецифические комплексы и их применение
MY174813A (en) 2013-03-15 2020-05-16 Zymeworks Inc Cytotoxic and anti-mitotic compounds, and methods of using the same
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
CN105102985B (zh) 2013-03-20 2018-05-18 斯弗因高泰克有限公司 用于指导血压下降疗法的肾上腺髓质素
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
CN112870368A (zh) 2013-03-27 2021-06-01 西达-赛奈医疗中心 通过抑制tl1a的功能和相关信号传导途径来减轻并逆转纤维化和炎症
US9452228B2 (en) 2013-04-01 2016-09-27 Immunomedics, Inc. Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2)
ES2823648T3 (es) 2013-04-01 2021-05-07 Univ California Métodos y composiciones para tratar y prevenir enfermedades asociadas con la integrina AVB8
US11267868B2 (en) 2013-04-02 2022-03-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
US20140308751A1 (en) * 2013-04-12 2014-10-16 Siemens Healthcare Diagnostics Inc. Assays for Analyte Homologs
EP2986326B1 (de) 2013-04-15 2018-09-05 Cedars-Sinai Medical Center Verfahren zum nachweis von krebsmetastasen
CA2909576C (en) 2013-04-19 2023-07-18 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
US20160083698A1 (en) 2013-04-19 2016-03-24 The Regents Of The University Of California Lone star virus
IL291122B2 (en) 2013-04-23 2024-01-01 Cedars Sinai Medical Center Methods and systems for simultaneous recording of a visible light image and an infrared light image FLUOROPHORES
US10745489B2 (en) 2013-04-29 2020-08-18 Ogd2 Pharma Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy for Cancer Stem Cells cancer
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
EP2992013B1 (de) 2013-04-29 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38-antikörper und fusionen davon mit abgeschwächtem interferon-alpha-2b
CA2910855C (en) 2013-04-29 2024-04-02 Ogd2 Pharma Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy for cancer stem cells cancer
CA2910553A1 (en) 2013-04-30 2014-11-06 Universite De Montreal Novel biomarkers for acute myeloid leukemia
EP2991666B1 (de) 2013-05-02 2020-03-25 Momenta Pharmaceuticals, Inc. Sialylierte glycoproteine
SG10201913751RA (en) 2013-05-06 2020-03-30 Scholar Rock Inc Compositions and methods for growth factor modulation
WO2014182532A1 (en) 2013-05-07 2014-11-13 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Mesothelin-specific immunocytokine and use thereof
AR096236A1 (es) 2013-05-09 2015-12-16 The Us Secretary Dept Of Health And Human Services Nat Inst Of Health Office Of Tech Transfer Anticuerpos de dominio simple vhh dirigidos a norovirus gi.1 y gii.4 y sus usos
WO2014183066A2 (en) 2013-05-10 2014-11-13 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
EP3988673A3 (de) 2013-05-17 2022-08-03 Cedars-Sinai Medical Center Varianten von tnfsf15 und dcr3 im zusammenhang mit morbus crohn
US10005839B2 (en) 2013-05-17 2018-06-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antagonist of the BTLA/HVEM interaction for use in therapy
AU2014268298B2 (en) 2013-05-24 2019-01-17 Medlmmune, Llc Anti-B7-H5 antibodies and their uses
EA201592285A1 (ru) 2013-05-30 2016-05-31 Байоджен Ма Инк. Антигенсвязывающие белки к рецептору онкостатина м
SG11201509982UA (de) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
ES2753419T3 (es) 2013-06-07 2020-04-08 Univ Duke Inhibidores del factor H del complemento
JP6696896B2 (ja) 2013-06-13 2020-05-20 ユニバーシティ オブ サウス オーストラリアＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｓｏｕｔｈ Ａｕｓｔｒａｌｉａ 前立腺癌を検出する方法
US9499628B2 (en) 2013-06-14 2016-11-22 Children's Hospital Medical Center Method of boosting the immune response in neonates
WO2014202089A2 (en) 2013-06-18 2014-12-24 Roskilde Universitet Variants of anti-freeze polypeptides
WO2014205187A1 (en) 2013-06-20 2014-12-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cytolethal distending toxin subunit b conjugated or fused to bacillus anthracis toxin lethal factor
US10071169B2 (en) 2013-06-20 2018-09-11 Innate Pharma Enzymatic conjugation of polypeptides
UY35620A (es) 2013-06-21 2015-01-30 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
JP6744212B2 (ja) 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． ポリペプチドの酵素的結合
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
MX2015017485A (es) 2013-06-25 2016-03-31 Vaccinex Inc Uso de moleculas inhibidoras de semaforina-4d en combinacion con una terapia de modulacion inmune para inhibir crecimiento tumoral y metastasis.
SG10201811017QA (en) * 2013-06-26 2019-01-30 Numab Innovation Ag Novel antibody frameworks
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
EP3013347B1 (de) 2013-06-27 2019-12-11 Academia Sinica Glykankonjugate und verwendung davon
US10221239B2 (en) 2013-06-28 2019-03-05 Singapore Health Services Pte Ltd TRPM4 channel inhibitors for stroke treatment
AU2013396206B2 (en) 2013-06-28 2019-11-14 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
WO2015003114A1 (en) 2013-07-05 2015-01-08 University Of Washington Through Its Center For Commercialization Soluble mic neutralizing monoclonal antibody for treating cancer
US20160176943A1 (en) 2013-07-05 2016-06-23 Inserm (Insititut National De La Sante Et De La Recherche Medicale) Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
ES2658039T3 (es) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
EP2824176A1 (de) 2013-07-11 2015-01-14 Siamed'xpress Verfahren zur Herstellung von sialylierten therapeutischen Proteinen
US9951131B2 (en) 2013-07-12 2018-04-24 Prothena Biosciences Limited Antibodies that recognize IAPP
US9850302B2 (en) 2013-07-12 2017-12-26 Prothena Biosciences Limited Antibodies that recognize IAPP
US9822162B2 (en) 2013-07-15 2017-11-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human papillomavirus 16 E6 T cell receptors
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
EP3022224A2 (de) 2013-07-18 2016-05-25 Fabrus, Inc. Antikörper mit ultralangen komplementaritätsbestimmenden regionen
CN105814074B (zh) 2013-07-18 2020-04-21 图鲁斯生物科学有限责任公司 具有超长互补决定区的人源化抗体
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
EP3022295A4 (de) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signatur des tl1a (tnfsf15)-signalweges
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
WO2015010791A2 (en) 2013-07-24 2015-01-29 Klareskog, Lars Novel antibodies for the diagnosis and treatment of rheumatoid arthritis
US10196458B2 (en) * 2013-07-26 2019-02-05 The Regents Of The University Of California Anti-immunoglobulin E antibodies and methods of using thereof
DK3028048T3 (en) 2013-07-31 2019-01-21 Bioventures Llc COMPOSITIONS FOR TREATMENT AND PREVENTION OF CANCER TARGETING AGAINST TUMOR-ASSOCIATED CARBOHYDRATE ANTIGEN
JP6510518B2 (ja) 2013-08-01 2019-05-08 アジェンシス，インコーポレイテッド Ｃｄ３７タンパク質に結合する抗体薬物結合体（ａｄｃ）
US10227370B2 (en) 2013-08-02 2019-03-12 California Institute Of Technology Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity
US9770461B2 (en) 2013-08-02 2017-09-26 California Institute Of Technology Tailored glycopolymers as anticoagulant heparin mimetics
RU2675516C2 (ru) 2013-08-02 2018-12-19 Пфайзер Инк. Anti-cxcr4 антитела и конъюгаты антитело-лекарство
CA2920521A1 (en) 2013-08-07 2015-02-12 Astute Medical, Inc. Assays for timp2 having improved performance in biological samples
US20160178610A1 (en) 2013-08-07 2016-06-23 Friedrich Miescher Institute For Biomedical Research New screening method for the treatment Friedreich's ataxia
JP6649254B2 (ja) 2013-08-08 2020-02-19 サイチューン ファーマ ＩＬ−１５及びＩＬ−１５Ｒαスシドメインに基づくモジュロカイン
WO2015018529A1 (en) 2013-08-08 2015-02-12 Cytune Pharma Combined pharmaceutical composition
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
EP3030268B1 (de) 2013-08-09 2022-07-27 The Trustees Of The University Of Pennsylvania Kombination von ifn-gamma mit anti-erbb-antikörpern zur krebsbehandlung
US10093978B2 (en) 2013-08-12 2018-10-09 Genentech, Inc. Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
TW201722994A (zh) 2013-08-13 2017-07-01 賽諾菲公司 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
SG10201710013RA (en) 2013-08-13 2018-01-30 Sanofi Sa Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
US10077304B2 (en) 2013-08-14 2018-09-18 The Governing Council Of The University Of Toronto Antibodies against frizzled receptor
CN105960414A (zh) 2013-08-14 2016-09-21 诺华股份有限公司 治疗散发性包涵体肌炎的方法
EP3036320B2 (de) 2013-08-19 2024-04-03 Biogen MA Inc. Steuerung der proteinglykosylierung durch kulturmediumsupplementation und zellkulturprozessparametern
WO2015025054A1 (en) 2013-08-22 2015-02-26 Medizinische Universität Wien Dye-specific antibodies for prestained molecular weight markers and methods producing the same
EP2839842A1 (de) 2013-08-23 2015-02-25 MacroGenics, Inc. Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon
EP2840091A1 (de) 2013-08-23 2015-02-25 MacroGenics, Inc. Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser
WO2015031645A1 (en) 2013-08-28 2015-03-05 Washington University Monoclonal antibodies to human 14-3-3 epsilon and human 14-3-3 epsilon sv
EP3338793A1 (de) 2013-08-28 2018-06-27 AbbVie Stemcentrx LLC Neuartige sez6-modulatoren und verfahren zur verwendung
EP3892294A1 (de) 2013-08-28 2021-10-13 AbbVie Stemcentrx LLC Konjugationsverfahren stellenspezifischer antikörper und zusammensetzungen
CA2922698C (en) 2013-08-29 2023-01-03 City Of Hope Cell penetrating conjugates comprising non-cell penetrating antibodies covalently attached to one or more phosphorothioate nucleic acids
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
KR102585409B1 (ko) 2013-08-30 2023-10-05 이뮤노젠 아이엔씨 엽산 수용체 1의 검출을 위한 항체 및 분석
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
US10030071B2 (en) 2013-09-05 2018-07-24 University Of Miyazaki Antibody which specifically reacts with human integrin A6B4
CN105682666B (zh) 2013-09-06 2021-06-01 中央研究院 使用醣脂激活人类iNKT细胞
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
US11545241B1 (en) 2013-09-07 2023-01-03 Labrador Diagnostics Llc Systems and methods for analyte testing and data management
EP3760639A1 (de) 2013-09-08 2021-01-06 Kodiak Sciences Inc. Zwitterionische polymerkonjugate
US9481729B2 (en) 2013-09-11 2016-11-01 The University Of Hong Kong Anti-HER2 and anti-IGF-IR BI-specific antibodies and uses thereof
MX2016003256A (es) 2013-09-12 2016-06-07 Halozyme Inc Anticuerpos modificados del receptor de factor de crecimiento anti-epidermico y metodos de uso de los mismos.
US20160216262A1 (en) 2013-09-12 2016-07-28 Institut National De La Sante Et De La Recherche Medicale Method for In Vitro Quantifying Allo-Antibodies, Auto-Antibodies and/or Therapeutic Antibodies
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
EP3048899B1 (de) 2013-09-25 2021-09-08 Bioverativ Therapeutics Inc. Verfahren zur virusinaktivierung auf einer säule
EP3052106A4 (de) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynukleotide zur codierung immunmodulierender polypeptide
US10259875B2 (en) 2013-10-01 2019-04-16 Mayo Foundation For Medical Education And Research Methods for treating cancer in patients with elevated levels of BIM
WO2015051159A1 (en) * 2013-10-02 2015-04-09 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9388222B2 (en) 2013-10-06 2016-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified Pseudomonas exotoxin A
WO2015054451A1 (en) 2013-10-09 2015-04-16 The United States Of America As Represented By The Secretary Department Of Health And Human Services Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma
PT3055331T (pt) 2013-10-11 2021-04-05 Oxford Bio Therapeutics Ltd Anticorpos conjugados contra ly75 para o tratamento de cancro
MX2016003744A (es) 2013-10-11 2016-08-11 Us Health Anticuerpos tem8 y su uso.
US11103593B2 (en) 2013-10-15 2021-08-31 Seagen Inc. Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
US20160257754A1 (en) 2013-10-16 2016-09-08 Momenta Pharmaceuticals Inc. Sialylated glycoproteins
DK3057993T3 (en) 2013-10-17 2020-11-16 Omeros Corp Method for Treating Conditions Associated with MASP-2 Dependent Complement
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015057461A2 (en) 2013-10-18 2015-04-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that specifically bind ataxia telangiectasia-mutated and rad3-related kinase phosphorylated at position 1989 and their use
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US11372002B2 (en) 2013-10-21 2022-06-28 Takeda Pharmaceutical Company Limited Assays for determining plasma kallikrein system biomarkers
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
KR102295623B1 (ko) 2013-10-21 2021-08-31 다이액스 코포레이션 자가면역 질환의 진단 및 치료
CA2927968C (en) 2013-10-25 2023-02-21 Psioxus Therapeutics Limited Oncolytic adenoviruses armed with heterologous genes
EP3733868A3 (de) 2013-10-28 2021-01-13 DOTS Technology Corp. Allergennachweis
TN2016000142A1 (en) 2013-10-31 2017-10-06 Sanofi Sa Specific anti-cd38 antibodies for treating human cancers.
RU2016122041A (ru) 2013-11-06 2017-12-11 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые анти-клаудин антитела и способы их применения
US20160280798A1 (en) 2013-11-06 2016-09-29 The United States Of America, As Represented By The Secretary Department Of Health & Human Service Alk antibodies, conjugates, and chimeric antigen receptors, and their use
CN105793439B (zh) 2013-11-06 2020-09-04 阿斯图特医药公司 以生物样品进行的针对igfbp7的具有改进的性能的测定
CN105849125B (zh) 2013-11-07 2020-05-15 国家医疗保健研究所 神经调节蛋白变构抗her3抗体
US9580504B1 (en) 2013-11-07 2017-02-28 Curetech Ltd. Pidilizumab monoclonal antibody therapy following stem cell transplantation
WO2015070068A1 (en) 2013-11-07 2015-05-14 Abbvie Inc. Isolation and purification of antibodies
EP3065769A4 (de) 2013-11-08 2017-05-31 Biogen MA Inc. Prokoagulatorische fusionsverbindung
EP2871190A1 (de) 2013-11-11 2015-05-13 ATLAB Pharma Antikörper gegen acetylisiertes Gd2-O-Gangliosid mit pro-apoptotischer Aktivität
WO2015073575A2 (en) 2013-11-12 2015-05-21 Centre For Probe Development And Commercialization Residualizing linkers and uses thereof
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
WO2015073709A2 (en) 2013-11-14 2015-05-21 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Detection of atherosclerotic cardiovascular disease risk and heart failure risk
WO2015073922A2 (en) 2013-11-15 2015-05-21 Northwestern University Inhibition of oxidative stress in atrial fibrillation
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3068419A1 (de) 2013-11-15 2016-09-21 INSERM - Institut National de la Santé et de la Recherche Médicale Verfahren und pharmazeutische zusammensetzungen zur behandlung von pankreaskarzinomen
US11191832B2 (en) 2013-11-19 2021-12-07 Prothena Biosciences Limited Monitoring immunotherapy of Lewy body disease from constipation symptoms
JP6640083B2 (ja) 2013-11-21 2020-02-05 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 肺高血圧症を治療するための組成物および方法
WO2015081282A1 (en) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
EP3530286A1 (de) 2013-11-28 2019-08-28 CSL Limited Verfahren zur behandlung von diabetischer nephropathie
WO2015082446A1 (en) 2013-12-02 2015-06-11 F. Hoffmann-La Roche Ag Treatment of cancer using an anti-cdcp1 antibody and a taxane
US9321834B2 (en) 2013-12-05 2016-04-26 Leidos, Inc. Anti-malarial compositions
BR112016012358A2 (pt) 2013-12-06 2017-09-26 Dana Farber Cancer Inst Inc peptídios terapêuticos
SG11201604565WA (en) 2013-12-06 2016-07-28 Us Health Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
KR20160097294A (ko) 2013-12-09 2016-08-17 뉴욕 유니버시티 항-포도상구균 제제의 식세포 전달을 위한 조성물 및 방법
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
EP3079475B1 (de) 2013-12-11 2020-10-07 Sloan-kettering Institute For Cancer Research Glucocorticoid-inhibitoren zur behandlung von prostatakrebs
NZ721984A (en) 2013-12-12 2020-01-31 Umc Utrecht Holding Bv Immunoglobulin-like molecules directed against fibronectin-eda
US9944694B2 (en) 2013-12-13 2018-04-17 Rijksuniversiteit Groningen Antibodies against Staphylococcus aureus and uses therof
TWI700295B (zh) 2013-12-16 2020-08-01 馬來西亞商Ｍａｂ探索私人有限公司 對會感染人類之腸病毒具有專一性之抗體
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
PL3082860T3 (pl) 2013-12-18 2021-06-14 Csl Limited Sposób leczenia ran
FI3082878T3 (fi) 2013-12-19 2022-12-15 Metyleenikarbamaatin linkkerit käytettäviksi kohdennettujen lääkeaineiden konjugaattien kanssa
JP2017500017A (ja) 2013-12-20 2017-01-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
JP6793902B2 (ja) 2013-12-20 2020-12-02 ノバルティス アーゲー 調節可能キメラ抗原受容体
TW201609805A (zh) 2013-12-23 2016-03-16 美國禮來大藥廠 結合ｅｇｆｒ及ｍｅｔ之多功能抗體
PL3712174T3 (pl) 2013-12-24 2022-07-04 Janssen Pharmaceutica Nv Przeciwciała i fragmenty anty-vista
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
CA2935077C (en) 2013-12-27 2022-03-15 Geoffrey C. Winters Sulfonamide-containing linkage systems for drug conjugates
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
US10398772B2 (en) 2014-01-08 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ras pathways as markers of protection against HIV and methods to improve vaccine efficacy
CA2936346A1 (en) 2014-01-08 2015-07-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody targeting cell surface deposited complement protein c3d and use thereof
EP3091999B1 (de) 2014-01-09 2021-10-20 Hadasit Medical Research Services and Development Ltd. Verbesserte zellenzusammensetzungen und verfahren zur krebstherapie
WO2015106158A1 (en) 2014-01-09 2015-07-16 Intra-Cellular Therapies, Inc. Organic compounds
EP2893939A1 (de) 2014-01-10 2015-07-15 Netris Pharma Anti-Netrin-1-Antikörper
EP3659624B1 (de) 2014-01-15 2022-11-16 The U.S.A. as represented by the Secretary, Department of Health and Human Services Auf knorpel gerichtete wirkstoffe und deren verwendung
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
US9982041B2 (en) 2014-01-16 2018-05-29 Academia Sinica Compositions and methods for treatment and detection of cancers
EP4303229A3 (de) 2014-01-21 2024-04-17 Novartis AG Verbessertes antigen mit car-t-zellfähigkeit durch co-einführung von co-stimulatorischen molekülen
CN116585468A (zh) 2014-01-21 2023-08-15 武田药品工业株式会社 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途
EP3097123A1 (de) 2014-01-24 2016-11-30 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-ny-br-1-polypeptide, proteine und chimäre antigenrezeptoren
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
MY180257A (en) 2014-01-27 2020-11-26 Pfizer Bifunctional cytotoxic agents
US10562977B2 (en) 2014-01-29 2020-02-18 Shanghai Hengrui Pharmaceutical Co., Ltd. Ligand-cytotoxic drug conjugate, preparation method thereof, and uses thereof
US11648335B2 (en) 2014-01-31 2023-05-16 Wake Forest University Health Sciences Organ/tissue decellularization, framework maintenance and recellularization
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2015120022A1 (en) 2014-02-04 2015-08-13 Thomas Jefferson University Specific expression of half-trna in cancers
WO2015120075A2 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
WO2015120187A1 (en) 2014-02-05 2015-08-13 The University Of Chicago Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants
JP6713931B2 (ja) 2014-02-11 2020-06-24 シアトル ジェネティクス，インコーポレイティド タンパク質の選択的還元
MX2016010360A (es) 2014-02-11 2016-11-30 Visterra Inc Moleculas de anticuerpo para el virus del dengue y uso de las mismas.
JP2017506640A (ja) 2014-02-14 2017-03-09 セントローズ， エルエルシー 細胞外標的化薬物共役体
MX2016009862A (es) 2014-02-17 2016-10-31 Seattle Genetics Inc Conjugados de anticuerpo-farmaco hidrofilicos.
US20170051062A1 (en) 2014-02-18 2017-02-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling Pathway
WO2015124570A1 (en) 2014-02-18 2015-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of influenza a virus infection
US10261084B1 (en) 2014-02-19 2019-04-16 Stc.Unm Activated GTPase-based assays and kits for the diagnosis of sepsis and other infections
US9701743B2 (en) 2014-02-20 2017-07-11 Allergan, Inc. Complement component C5 antibodies
JP2017514143A (ja) 2014-02-21 2017-06-01 アッヴィ・ステムセントルクス・エル・エル・シー メラノーマに使用するための抗ｄｌｌ３抗体および薬物コンジュゲート
JP6643244B2 (ja) 2014-02-27 2020-02-12 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 補体因子Ｂｂ抗体
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
EP2915569A1 (de) 2014-03-03 2015-09-09 Cytune Pharma Reinigungsverfahren für Il-15/Il-15Ralpha-basierte Konjugate
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10106614B2 (en) 2014-03-06 2018-10-23 National Research Council Of Canada Insulin-like growth factor 1 receptor-specific antibodies and uses thereof
AU2014385801B2 (en) 2014-03-06 2020-11-12 National Research Council Of Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
CA2942154C (en) 2014-03-06 2023-06-27 National Research Council Of Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
AU2015225867B2 (en) 2014-03-07 2020-02-06 University Health Network Methods and compositions for modifying the immune response
US10611833B2 (en) * 2014-03-07 2020-04-07 Welson Pharmaceuticals, Inc. Humanized anti-human epidermal growth factor receptor antibody and application thereof
WO2015136469A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
KR20160131082A (ko) 2014-03-12 2016-11-15 프로테나 바이오사이언시즈 리미티드 Lg1-3에 특이적인 항-라미닌4 항체
EP3116907A1 (de) 2014-03-12 2017-01-18 Prothena Biosciences Limited Für lg4-5 spezifische anti-laminin4-antikörper
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
JP2017510627A (ja) 2014-03-13 2017-04-13 プロセナ バイオサイエンシーズ リミテッド 多発性硬化症の併用治療
CN106103484B (zh) 2014-03-14 2021-08-20 诺华股份有限公司 针对lag-3的抗体分子及其用途
US9738702B2 (en) 2014-03-14 2017-08-22 Janssen Biotech, Inc. Antibodies with improved half-life in ferrets
EP3925973A1 (de) 2014-03-14 2021-12-22 Dana-Farber Cancer Institute, Inc. Impfstoffzusammensetzungen und verfahren zur wiederherstellung der nkg2d-wegfunktion gegen krebs
ES2857226T3 (es) 2014-03-15 2021-09-28 Novartis Ag Receptor de antígeno quimérico regulable
EP3593812A3 (de) 2014-03-15 2020-05-27 Novartis AG Behandlung von krebs mithilfe eines chimären antigenrezeptors
WO2015140351A1 (en) 2014-03-21 2015-09-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing myelination
CA2943242A1 (en) 2014-03-21 2015-09-24 X-Body, Inc. Bi-specific antigen-binding polypeptides
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
DK3119431T3 (da) 2014-03-21 2024-03-18 Teva Pharmaceuticals Int Gmbh Antagonistantistoffer rettet mod calcitoningen-relateret peptid og fremgangsmåder til anvendelse deraf
EP3122869B2 (de) 2014-03-24 2022-08-10 Biogen MA Inc. Verfahren zur überwindung von glutamindeprivation bei einer säugetierzellkultur
EP3122181A4 (de) 2014-03-26 2018-04-25 The Brigham and Women's Hospital, Inc. Zusammensetzungen und verfahren zur ex-vivo-vermehrung von menschlichen hämatopoietischen stamm-/vorläuferzellen
TWI687428B (zh) 2014-03-27 2020-03-11 中央研究院 反應性標記化合物及其用途
CN106459210A (zh) 2014-03-27 2017-02-22 戴埃克斯有限公司 用于治疗糖尿病黄斑性水肿的组合物和方法
EP3122768A2 (de) 2014-03-27 2017-02-01 Yeda Research and Development Co. Ltd. T-zell-rezeptor-cdr3-peptide und -antikörper
EP3954713A3 (de) 2014-03-28 2022-03-30 Xencor, Inc. Bispezifische, an cd38 und cd3 bindende antikörper
EP3126392B1 (de) 2014-03-31 2019-09-11 Kirin-Amgen, Inc. Verfahren zur behandlung von nagel- und kopfhautpsoriasis
DK3126384T3 (da) 2014-04-01 2021-01-18 Adimab Llc Multispecifikke antistofanaloger omfattende en fælles letkæde, og fremgangsmåder til deres fremstilling og anvendelse
CN106536556B (zh) * 2014-04-04 2020-02-07 生态学有限公司 结合lgr5的人源化抗体
IL293603B2 (en) 2014-04-07 2024-03-01 Novartis Ag Cancer treatment using chimeric antigen receptor (CAR) against CD19
US10562973B2 (en) 2014-04-08 2020-02-18 Prothena Bioscience Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
KR102546611B1 (ko) 2014-04-08 2023-06-22 보스턴 파마슈티칼즈, 아이엔씨. Il-21에 특이적인 결합 분자 및 이들 용도
WO2015157629A2 (en) 2014-04-10 2015-10-15 Obi Pharma Inc. Antibodies, pharmaceutical compositions and uses thereof
US10160812B2 (en) 2014-04-11 2018-12-25 Medimmune, Llc Bispecific HER2 antibodies
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
EP3131929B1 (de) 2014-04-16 2022-06-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antikörper zur prophylaxe oder behandlung von blutungsepisoden
US11058768B2 (en) 2014-04-16 2021-07-13 Biocon Ltd. Stable protein formulations comprising a molar excess of sorbitol
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
WO2015164364A2 (en) 2014-04-25 2015-10-29 The Brigham And Women's Hospital, Inc. Methods to manipulate alpha-fetoprotein (afp)
DK3134095T3 (da) 2014-04-25 2020-06-29 Bluebird Bio Inc Forbedrede fremgangsmåder til fremstilling af adoptive celleterapier
CN106536549B (zh) 2014-04-25 2020-01-17 蓝鸟生物公司 Mnd启动子嵌合抗原受体
SI3134124T1 (sl) 2014-04-25 2019-06-28 Pierre Fabre Medicament Konjugat protitelesa zdravila IGF-1R in uporaba le-tega za zdravljenje raka
MX2016013999A (es) 2014-04-25 2017-05-30 Pf Medicament Conjugado farmaco-anticuerpo y su uso para el tratamiento contra el cancer.
AU2015249666A1 (en) 2014-04-25 2016-11-17 The Brigham And Women's Hospital, Inc. Compositions and methods for treating subjects with immune-mediated diseases
KR102357032B1 (ko) 2014-04-25 2022-02-08 피에르 파브르 메디카먼트 Igf-1r 항체 및 암 치료를 위한 운반체를 어드레싱하는 그의 용도
EP3137502B1 (de) 2014-04-27 2020-07-29 FameWave Ltd. Humanisierte antikörper gegen ceacam1
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
US10087259B1 (en) 2014-04-28 2018-10-02 Memorial Sloan Kettering Cancer Center Depleting tumor-specific tregs
LT3137114T (lt) 2014-04-30 2021-03-25 Pfizer Inc. Anti-ptk7 antikūnų ir vaistų konjugatai
BR112016025312A2 (pt) 2014-05-01 2017-10-17 Genentech Inc variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
SG11201609014TA (en) 2014-05-08 2016-12-29 Chugai Pharmaceutical Co Ltd Gpc3 -targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
WO2015176010A1 (en) 2014-05-15 2015-11-19 The United States Of America, As Represented By The Secretary, Departmentof Health & Human Services Treatment or prevention of an intestinal disease or disorder
CN106413750B (zh) 2014-05-16 2022-04-29 免疫医疗有限责任公司 具有增强的治疗和诊断特性的带有改变的新生儿Fc受体结合的分子
WO2015175861A1 (en) 2014-05-16 2015-11-19 Amgen Inc. Assay for detecting th1 and th2 cell populations
EP3146081B1 (de) 2014-05-19 2020-10-28 The Johns Hopkins University Verfahren zur identifizierung von androgenrezeptorspleissvarianten bei patienten mit kastrationsresistentem prostatakrebs
US20170198054A1 (en) 2014-05-21 2017-07-13 Dana-Farber Cancer Institute Methods for treating cancer with anti bip or anti mica antibodies
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
AU2015267045B2 (en) 2014-05-27 2021-02-25 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CN106573971A (zh) 2014-05-27 2017-04-19 中央研究院 抗cd20醣抗体及其用途
EP3149161B1 (de) 2014-05-27 2021-07-28 Academia Sinica Fucosidase aus bacteroiden und verfahren damit
EP3149049B1 (de) 2014-05-27 2022-10-26 The University Of Queensland Il-22 zur verwendung in der behandlung von stoffwechselkrankheiten
MA47849A (fr) 2014-05-28 2020-01-29 Agenus Inc Anticorps anti-gitr et leurs procédés d'utilisation
TWI732738B (zh) 2014-05-28 2021-07-11 中央研究院 抗TNF-α醣抗體及其用途
JP6742991B2 (ja) 2014-05-29 2020-08-19 アメリカ合衆国 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
JP6683628B2 (ja) 2014-06-04 2020-04-22 シーダーズ−サイナイ メディカル センター 脊椎圧迫骨折の非外科的修復のための方法
WO2015188131A1 (en) 2014-06-05 2015-12-10 Cedars-Sinai Medical Center A novel and efficient method for reprogramming immortalized lymphoblastoid cell lines to induced pluripotent stem cells
ES2846811T3 (es) 2014-06-06 2021-07-29 Bluebird Bio Inc Composiciones de células T mejoradas
EA037006B1 (ru) 2014-06-06 2021-01-26 Бристол-Майерс Сквибб Компани Антитела к индуцируемому глюкокортикоидами рецептору фактора некроза опухолей (gitr) и их применения
EP3151830A4 (de) 2014-06-06 2018-02-07 Redwood Bioscience, Inc. Anti-her2-antikörper-maytansin-konjugate und verfahren zur verwendung davon
FR3021970B1 (fr) * 2014-06-06 2018-01-26 Universite Sciences Technologies Lille Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
US9911365B2 (en) 2014-06-09 2018-03-06 Bijan SIASSI Virtual neonatal echocardiographic training system
MX2016016310A (es) 2014-06-11 2017-10-20 A Green Kathy Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral.
ES2960601T3 (es) 2014-06-12 2024-03-05 Cedars Sinai Medical Center Composiciones y métodos para el tratamiento del cáncer
WO2015189816A1 (en) 2014-06-13 2015-12-17 Friedrich Miescher Institute For Biomedical Research New treatment against influenza virus
CA2943588C (en) * 2014-06-17 2019-04-30 Academia Sinica Humanized anti-ige antibodies that crosslink cd23 on b lymphocytes but do not sensitize mast cells
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
EP3157953B1 (de) 2014-06-20 2021-12-22 Aveo Pharmaceuticals, Inc. Behandlung von chronischer nierenerkrankung und anderen nierendysfunktionen mit einem gdf15-modulator
US20170137505A1 (en) 2014-06-20 2017-05-18 Aveo Pharmaceuticals, Inc. Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
KR20170016501A (ko) 2014-06-23 2017-02-13 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체 (ｃｓｆ1ｒ)에 결합하는 항체를 이용하여 병태를 치료하는 방법
US10308935B2 (en) 2014-06-23 2019-06-04 Friedrich Miescher Institute For Biomedical Research Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small RNAS
WO2015198243A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
EP3161001A2 (de) 2014-06-25 2017-05-03 Novartis AG Il17-a spezifische antikörper die mit hyaluronan bindenden peptid-marker fusioniert sind
WO2015198240A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
CN107074935B (zh) * 2014-06-26 2021-08-03 扬森疫苗与预防公司 特异性结合微管相关蛋白tau的抗体和抗原结合片段
JP6822849B2 (ja) 2014-06-27 2021-01-27 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 多重特異的ＮＫｐ４６結合タンパク質
AU2015279321B2 (en) 2014-06-27 2021-03-04 Innate Pharma, S.A. Multispecific antigen binding proteins
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN106573038A (zh) 2014-06-30 2017-04-19 默多克儿童研究所 螺杆菌治疗剂
US20170165261A1 (en) 2014-07-01 2017-06-15 Brian Arthur Hemmings Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
JP6789124B2 (ja) 2014-07-03 2020-11-25 イエール ユニバーシティ 腫瘍形成を抑制するディコップ２（Ｄｉｃｋｋｏｐｆ２）（Ｄｋｋ２）阻害
US10414814B2 (en) 2014-07-03 2019-09-17 City Of Hope Tumor-selective CTLA-4 antagonists
US10132818B2 (en) 2014-07-08 2018-11-20 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
ES2825574T3 (es) 2014-07-09 2021-05-17 Hoffmann La Roche Ajuste del pH para mejorar la recuperación por descongelación de bancos de células
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
WO2016009017A1 (en) 2014-07-16 2016-01-21 Institut Gustave-Roussy Combination of oncolytic virus with immune checkpoint modulators
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
JP6895374B2 (ja) 2014-07-16 2021-06-30 トランジェーヌＴｒａｎｓｇｅｎｅ 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス
MY178347A (en) 2014-07-17 2020-10-08 Novo Nordisk As Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
CN112481283A (zh) 2014-07-21 2021-03-12 诺华股份有限公司 使用cd33嵌合抗原受体治疗癌症
CN106687483B (zh) 2014-07-21 2020-12-04 诺华股份有限公司 使用人源化抗-bcma嵌合抗原受体治疗癌症
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
ES2753551T3 (es) 2014-07-22 2020-04-13 Sutro Biopharma Inc Anticuerpos anti-cd74, composiciones que comprenden anticuerpos anti-CD74 y procedimientos de uso de los anticuerpos anti-CD74
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
EP3194449A1 (de) 2014-07-24 2017-07-26 Xencor, Inc. Schnelle beseitigung von antigenkomplexen unter verwendung neuartiger antikörper
JP6706244B2 (ja) 2014-07-24 2020-06-03 ブルーバード バイオ， インコーポレイテッド Ｂｃｍａキメラ抗原受容体
JP6721568B2 (ja) 2014-07-29 2020-07-15 セレクティスＣｅｌｌｅｃｔｉｓ がん免疫療法のためのｒｏｒ１（ｎｔｒｋｒ１）特異的キメラ抗原レセプター
ES2848857T3 (es) 2014-07-31 2021-08-12 Us Gov Health & Human Services Anticuerpos monoclonales humanos contra EphA4 y su uso
JP6749312B2 (ja) 2014-07-31 2020-09-02 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ 最適化された種間特異的二重特異性単鎖抗体コンストラクト
WO2016016415A1 (en) 2014-07-31 2016-02-04 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
JP2017522893A (ja) 2014-07-31 2017-08-17 セレクティスＣｅｌｌｅｃｔｉｓ Ｒｏｒ１特異的多重鎖キメラ抗原受容体
US20170209492A1 (en) 2014-07-31 2017-07-27 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
AR101669A1 (es) 2014-07-31 2017-01-04 Amgen Res (Munich) Gmbh Constructos de anticuerpos para cdh19 y cd3
PT3177644T (pt) 2014-08-05 2021-01-13 MabQuest SA Reagentes imunológicos que se ligam a pd-1
US9982052B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
CN107148428B (zh) 2014-08-07 2021-03-09 诺华股份有限公司 血管生成素样蛋白4抗体和使用方法
EP3194437B1 (de) 2014-08-07 2021-01-20 Novartis AG Antikörper gegen angiopoietinähnliches protein 4 und deren verwendung
JP6796058B2 (ja) 2014-08-08 2020-12-02 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ インビトロおよびインビボにおける標的の光制御除去
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
MY189028A (en) 2014-08-19 2022-01-20 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
IL250583B (en) 2014-08-19 2022-07-01 Merck Sharp & Dohme Anti-tigit antibodies
WO2016026978A1 (en) 2014-08-22 2016-02-25 Universite Nice Sophia Antipolis Methods and pharmaceutical compositions for treating drug addiction
EP3186393A4 (de) 2014-08-25 2018-01-10 The Johns Hopkins University Verfahren und zusammensetzungen im zusammenhang mit prostatakrebstherapeutika
MX2017002654A (es) 2014-08-28 2017-08-07 1) Cedars-Sinai Medical Center Deteccion temprana de cancer de pulmon por clasificacion fenotipica por metilacion de adn de celulas derivadas de esputo.
KR102626976B1 (ko) 2014-09-02 2024-01-18 이뮤노젠 아이엔씨 항체 약물 컨쥬게이트 조성물의 제형화 방법
AU2015310897B2 (en) 2014-09-04 2020-03-19 Cellectis Trophoblast glycoprotein (5T4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
WO2016040369A2 (en) 2014-09-08 2016-03-17 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
US10442863B2 (en) 2014-09-08 2019-10-15 Lutana Gmbh Construct for the delivery of a molecule into the cytoplasm of a cell
WO2016040767A2 (en) 2014-09-12 2016-03-17 Amgen Inc. Chrdl-1 epitopes and antibodies
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
US9993551B2 (en) 2014-09-13 2018-06-12 Novartis Ag Combination therapies of EGFR inhibitors
CA2960756C (en) 2014-09-15 2023-08-01 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
WO2016043577A1 (en) 2014-09-16 2016-03-24 Academisch Medisch Centrum Ig-like molecules binding to bmp4
DK3194443T3 (da) 2014-09-17 2021-09-27 Novartis Ag Målretning af cytotoksiske celler med kimære receptorer i forbindelse med adoptiv immunterapi
ES2875057T3 (es) 2014-09-17 2021-11-08 Us Health Anticuerpos anti-CD276 (B7H3)
DK3194421T3 (da) 2014-09-17 2022-02-14 Zymeworks Inc Cytotoksiske og antimitotiske forbindelser samt fremgangsmåder til anvendelse heraf
WO2016044736A1 (en) * 2014-09-18 2016-03-24 Cell Signaling Technology, Inc. Altered antibodies and methods of making the same
EP3194446B1 (de) 2014-09-18 2022-10-26 Cedars-Sinai Medical Center Zusammensetzungen und verfahren zur behandlung von fibrose
WO2016044252A2 (en) 2014-09-19 2016-03-24 Siwa Corporation Anti-age antibodies for treating inflammation and auto-immune disorders
US10080790B2 (en) 2014-09-19 2018-09-25 The Regents Of The University Of Michigan Staphylococcus aureus materials and methods
PL3262071T3 (pl) 2014-09-23 2020-08-10 F. Hoffmann-La Roche Ag Sposób stosowania immunokoniugatów anty-CD79b
WO2016046768A1 (en) 2014-09-24 2016-03-31 Friedrich Miescher Institute For Biomedical Research Lats and breast cancer
HUE054670T2 (hu) 2014-09-25 2021-09-28 Aveo Pharmaceuticals Inc Módszer cachexia visszafordítására és túlélés megnövelésére egy GDF15 modulátor és egy rákellenes szer adagolásával
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
CN107108721B (zh) 2014-09-29 2021-09-07 杜克大学 包含hiv-1包膜靶向臂的双特异性分子
AU2015327064B2 (en) 2014-09-30 2021-03-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Binding molecules, especially antibodies, binding to L1CAM (CD171)
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
AU2015327819B2 (en) 2014-10-03 2021-07-01 Massachusetts Institute Of Technology Antibodies that bind ebola glycoprotein and uses thereof
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
RU2706361C2 (ru) 2014-10-09 2019-11-18 Седарс-Синаи Медикал Сентер Способы и системы для отличия синдрома раздраженного кишечника от воспалительного заболевания кишечника и глютеновой болезни
CA3001724A1 (en) 2014-10-10 2016-04-14 National Research Council Of Canada Anti-tau antibody and uses thereof
AU2015333590B2 (en) * 2014-10-14 2021-03-11 Cellmid Limited Improved midkine antibody
CU20170052A7 (es) 2014-10-14 2017-11-07 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
MA41480A (fr) 2014-10-17 2017-12-19 Glenmark Pharmaceuticals Sa Anticorps qui se lient au ccr6 et leurs utilisations
MA41685A (fr) 2014-10-17 2017-08-22 Biogen Ma Inc Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
RU2017111228A (ru) 2014-10-18 2018-11-21 Пфайзер Инк. Композиции антитела против IL-7R
US10040844B2 (en) 2014-10-22 2018-08-07 The Regents Of The University Of California Proteolytic release of cell surface antigens for phage biopanning
US10870704B2 (en) 2014-10-23 2020-12-22 Kira Biotech Pty Limited CD83 binding proteins and uses thereof
MA40835A (fr) * 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
EP3209697A4 (de) 2014-10-23 2018-05-30 La Trobe University Fn14-bindende proteine und verwendungen davon
EP3209769B1 (de) 2014-10-24 2020-08-05 The Board of Trustees of the Leland Stanford Junior University Zusammensetzungen und verfahren zur induzierung der phagozytose von mhc-klasse-i-positiven zellen und verhinderung von anti-cd47/sirpa-resistenz
CN107074933B (zh) * 2014-10-24 2021-03-19 豪夫迈·罗氏有限公司 基于vh-vl域间角的抗体人源化
KR102636539B1 (ko) 2014-10-29 2024-02-13 파이브 프라임 테라퓨틱스, 인크. 암에 대한 조합 요법
AU2015337858B2 (en) 2014-10-29 2020-09-24 Teva Pharmaceuticals Australia Pty Ltd. Interferon alpha2b variants
SG11201703446RA (en) 2014-10-31 2017-05-30 Abbvie Biotherapeutics Inc Anti-cs1 antibodies and antibody drug conjugates
JP6879910B2 (ja) 2014-10-31 2021-06-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｃａｒｔ細胞における遺伝子発現の改変およびその使用
AU2015338974B2 (en) 2014-10-31 2021-08-26 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
CA2966035A1 (en) 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Compositions and methods of stimulating and expanding t cells
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
CA2966523A1 (en) 2014-11-03 2016-05-12 Genentech, Inc. Assays for detecting t cell immune subsets and methods of use thereof
WO2016073401A1 (en) 2014-11-03 2016-05-12 Bristol-Myers Squibb Company Use of caprylic acid precipitation for protein purification
US20190030071A1 (en) 2014-11-03 2019-01-31 IMMURES S.r.I. T cell receptors
CN114381521A (zh) * 2014-11-03 2022-04-22 豪夫迈·罗氏有限公司 用于ox40激动剂治疗的功效预测和评估的方法和生物标志物
WO2016073647A2 (en) 2014-11-04 2016-05-12 University Of Southern California COMPOSITIONS AND METHODS FOR TREATING HIF-1alpha OVER-EXPRESSING CANCERS
CA2961439A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention
ES2756275T3 (es) 2014-11-07 2020-04-27 Sesen Bio Inc Anticuerpos contra IL-6 mejorados
AU2015345202B2 (en) 2014-11-10 2021-05-13 Medimmune Limited Binding molecules specific for CD73 and uses thereof
JP6847037B2 (ja) 2014-11-11 2021-03-24 メディミューン リミテッド 抗ｃｄ７３抗体とａ２ａ受容体阻害薬とを含む併用治療薬及びその使用
EP4183806A3 (de) 2014-11-12 2023-08-02 Seagen Inc. Glycaninteragierende verbindungen und verfahren zur verwendung
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
JP2017537084A (ja) 2014-11-12 2017-12-14 トラコン ファーマシューティカルズ、インコーポレイテッド 抗エンドグリン抗体及びその用途
US11072644B2 (en) 2014-11-12 2021-07-27 Allogene Therapeutics, Inc. Inhibitory chimeric antigen receptors
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
EP3218397B8 (de) 2014-11-14 2021-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralisierende antikörper gegen ebola virus glykoprotein und deren verwendung
US9982057B2 (en) 2014-11-17 2018-05-29 Pelican Therapeutics, Inc. Human TNFRSF25 antibody
EA201791093A1 (ru) 2014-11-18 2018-04-30 Янссен Фармацевтика Нв Антитела к cd47, способы и применение
MA40934A (fr) 2014-11-19 2017-09-27 Immunogen Inc Procédé de préparation de conjugués agent de liaison cellulaire-agent cytotoxique
EP3220965A1 (de) 2014-11-20 2017-09-27 University of Southern California Verwendung einer alginatformulierung zur intrainzisionalen arzneimittelabgabe
US20170355755A1 (en) 2014-11-21 2017-12-14 Yale University Compositions and methods for modulating salm5 and hvem
RS60631B1 (sr) 2014-11-21 2020-09-30 Bristol Myers Squibb Co Antitela protiv cd73 i njihova upotreba
ES2832802T3 (es) 2014-11-21 2021-06-11 Univ Maryland Sistemas de administración dirigida del particulado específico de una estructura
EP3223866B1 (de) 2014-11-25 2023-03-08 Bristol-Myers Squibb Company Verfahren und zusammensetzungen zur radioaktiven markierung der fibronektin typ (iii) domäne mit 18f
WO2016086186A2 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies including binding to cd8
CA2967426A1 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
BR112017011166A2 (pt) 2014-11-26 2018-02-27 Xencor, Inc. anticorpos heterodiméricos que se ligam a cd3 e cd38
EP3227341A1 (de) 2014-12-02 2017-10-11 CeMM - Forschungszentrum für Molekulare Medizin GmbH Anti-mutante calreticulin-antikörper und deren verwendung bei der diagnose und therapie von myeloiden malignomen
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
WO2016090034A2 (en) 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
US20170319661A1 (en) 2014-12-03 2017-11-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and Pharmaceutical Compositions Using Orexins (OXA, OXB) for the Treatment of Prostate Cancers
EP3226900A4 (de) 2014-12-05 2018-09-19 Immunext, Inc. Identifizierung von vsig8 als vermeintlicher vista-rezeptor und dessen verwendung zur herstellung von vista/vsig8-modulatoren
CA2970155A1 (en) 2014-12-09 2016-06-16 Abbvie Inc. Bcl-xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same
BR112017012377A2 (pt) 2014-12-09 2018-04-24 Abbvie Inc conjugados anticorpo-fármaco com inibidores de bcl-xl permeáveis à célula
EP3229838B1 (de) 2014-12-11 2020-09-09 Pierre Fabre Medicament Anti-c10orf54-antikörper und verwendungen davon
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
SI3628687T1 (sl) 2014-12-12 2021-12-31 2Seventy Bio, Inc. BCMA himerni antigenski receptorji
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
EP3230313A2 (de) 2014-12-12 2017-10-18 Encare Biotech B.V. Gegen fibronectin-eda gerichtete immunoglobulinähnliche moleküle
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
PE20221834A1 (es) 2014-12-19 2022-11-29 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina
WO2016094962A1 (en) 2014-12-19 2016-06-23 Monash University Il-21 antibodies
EP3835319A1 (de) 2014-12-19 2021-06-16 Alder Biopharmaceuticals, Inc. Humanisierte anti-acth-antikörper und verwendungen davon
CA2971517A1 (en) 2014-12-19 2016-06-23 Universite De Nantes Anti il-34 antibodies
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
RU2746356C2 (ru) 2014-12-19 2021-04-12 Чугаи Сейяку Кабусики Кайся Антитела к с5 и способы их применения
EP3233918A1 (de) 2014-12-19 2017-10-25 Novartis AG Kombinationstherapien
US10239942B2 (en) 2014-12-22 2019-03-26 Pd-1 Acquisition Group, Llc Anti-PD-1 antibodies
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
CA2969341C (en) 2014-12-22 2023-07-04 Five Prime Therapeutics, Inc. Anti-csf1r antibodies for treating pvns
EP3789039A1 (de) 2014-12-22 2021-03-10 The Rockefeller University Anti-mertk-antikörper und verwendungen davon
WO2016103093A1 (en) 2014-12-23 2016-06-30 Pfizer Inc. Stable aqueous antibody formulation for anti tnf alpha antibodies
TWI708786B (zh) 2014-12-23 2020-11-01 美商必治妥美雅史谷比公司 針對ｔｉｇｉｔ之抗體
MX2017009038A (es) 2015-01-08 2017-10-25 Biogen Ma Inc Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes.
NL2014108B1 (en) * 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
EP3244907B1 (de) 2015-01-13 2020-02-19 City of Hope Peptid-linkermasken mit ctla4-bindenden proteinen
CA2973978A1 (en) * 2015-01-14 2016-07-21 The Brigham And Women's Hospital, Inc. Treatment of cancer with anti-lap monoclonal antibodies
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
MX2017009272A (es) 2015-01-16 2018-04-11 Anticuerpos que penetran en células.
US10689449B2 (en) 2015-01-20 2020-06-23 Igm Biosciences, Inc. Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof
GB201501004D0 (en) 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
ES2824167T3 (es) 2015-01-23 2021-05-11 Sanofi Sa Anticuerpos anti-CD3, anticuerpos anti-CD123 y anticuerpos biespecíficos que se unen específicamente a CD3 y/o CD123
WO2016118961A1 (en) 2015-01-24 2016-07-28 Academia Sinica Cancer markers and methods of use thereof
EP3248005B1 (de) 2015-01-24 2020-12-09 Academia Sinica Neuartige glycankonjugate und verfahren zur verwendung davon
JP6912386B2 (ja) 2015-01-26 2021-08-04 ザ ユニバーシティー オブ シカゴ 癌特異的なＩＬ１３Ｒα２を認識するＣＡＲ Ｔ細胞
JP7264592B2 (ja) 2015-01-26 2023-04-25 ザ ユニバーシティー オブ シカゴ ＩＬ１３Ｒα２結合剤及び癌治療におけるその使用
MX2017009181A (es) 2015-01-26 2017-11-22 Cellectis Receptores de antigenos quimericos de cadena sencilla especificos de anti-cll1 para inmunoterapia de cancer.
WO2016120753A1 (en) 2015-01-28 2016-08-04 Pfizer Inc. Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation
TWI769570B (zh) * 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
TWI718121B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI786505B (zh) 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10539572B2 (en) 2015-01-30 2020-01-21 Salk Institute For Biological Studies Compositions and methods for treating age-related diabetes and related disorders
AU2015380397B2 (en) 2015-01-31 2021-10-21 The Trustees Of The University Of Pennsylvania Compositions and methods for T cell delivery of therapeutic molecules
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
AU2016215604B2 (en) 2015-02-02 2020-08-13 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
WO2016124558A1 (en) 2015-02-03 2016-08-11 Ventana Medical Systems, Inc. Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1)
US10330683B2 (en) 2015-02-04 2019-06-25 Genentech, Inc. Mutant smoothened and methods of using the same
KR20170110129A (ko) 2015-02-05 2017-10-10 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
US10266584B2 (en) 2015-02-09 2019-04-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies specific to glycoprotein (GP) of Ebolavirus and uses for the treatment and diagnosis of ebola virus infection
CA2976074A1 (en) 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
WO2016128523A1 (en) 2015-02-12 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
AU2016223584B2 (en) 2015-02-23 2020-11-19 Enrico GIRAUDO Non-natural Semaphorins 3 and their medical use
US10301377B2 (en) 2015-02-24 2019-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
TWI805046B (zh) 2015-02-27 2023-06-11 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
WO2016139482A1 (en) 2015-03-03 2016-09-09 Kymab Limited Antibodies, uses & methods
CA2977493C (en) 2015-03-03 2023-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Display platform from bacterial spore coat proteins
KR20230130148A (ko) 2015-03-04 2023-09-11 아이쥐엠 바이오사이언스 인코포레이티드 Ｃｄ20 결합 분자 및 그의 용도
MA41629A (fr) 2015-03-04 2018-01-09 Center For Human Reproduction Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
US20180043012A1 (en) * 2015-03-06 2018-02-15 Csl Behring Recombinant Facility Ag Compounds for improving the half-life of von willebrand factor
WO2016143702A1 (ja) * 2015-03-06 2016-09-15 ジーンフロンティア株式会社 抗ヒト膜型ａｄａｍ２８抗体
EP3265483B1 (de) 2015-03-06 2019-12-11 CSL Behring Lengnau AG Modifizierter von-willebrand-faktor mit verbesserter halbwertzeit
AU2016233557B2 (en) 2015-03-13 2021-06-24 Bristol-Myers Squibb Company Use of alkaline washes during chromatography to remove impurities
EP3067062A1 (de) 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Kombination von tasquinimod oder einem pharmazeutisch zulässigen salz davon und pd1 und/oder pdl1-hemmer zur verwendung als medikament
WO2016146134A1 (en) 2015-03-16 2016-09-22 Aarhus Universitet Antibodies towards an extracellular region of nbcn1
WO2016149368A1 (en) 2015-03-17 2016-09-22 Memorial Sloan Kettering Cancer Center Anti-muc16 antibodies and uses thereof
EP3662933A1 (de) 2015-03-18 2020-06-10 Seattle Genetics, Inc. Cd48-antikörper und konjugate davon
HUE049081T2 (hu) 2015-03-20 2020-09-28 The United States Of America As GP120 elleni neutralizáló antitestek és alkalmazásuk
US20180105554A1 (en) 2015-03-20 2018-04-19 Bristol-Myers Squibb Company Use of dextran sulfate to enhance protein a affinity chromatography
US20180105555A1 (en) 2015-03-20 2018-04-19 Bristol-Myers Squibb Company Use of dextran for protein purification
WO2016151432A1 (en) 2015-03-20 2016-09-29 Pfizer Inc. Bifunctional cytotoxic agents containing the cti pharmacophore
ES2805743T3 (es) 2015-03-24 2021-02-15 Inst Nat Sante Rech Med Método y composición farmacéutica para uso en el tratamiento de la diabetes
WO2016160926A1 (en) 2015-03-30 2016-10-06 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
AU2016242866B2 (en) 2015-03-30 2021-06-03 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to FC gamma receptors
WO2016161018A1 (en) 2015-03-30 2016-10-06 City Of Hope Mechanically interlocking complexes
EP3277717B1 (de) 2015-03-31 2020-11-18 Medimmune Limited Neuartige il33-form, mutierte formen von il33, antikörper, tests und verfahren zur verwendung davon
WO2016156557A1 (en) 2015-04-03 2016-10-06 Alienor Farma Monoclonal antibody to human line-1 orf2 protein and method for early detection of transforming cells in pre-neoplastic tissues of a human subject
EP3280441B1 (de) 2015-04-07 2021-09-29 Alector LLC Anti-sortilin-antikörper und verfahren zur verwendung davon
EP3280455A1 (de) 2015-04-07 2018-02-14 INSERM - Institut National de la Santé et de la Recherche Médicale Nichtinvasive abbildung von tumor pd-l1 expression
SI3280729T1 (sl) 2015-04-08 2022-09-30 Novartis Ag Terapije CD20, terapije CD22 in kombinacija terapij s celico, ki izraža himerni antigenski receptor CD19 (CAR)
EP3280444A4 (de) 2015-04-10 2019-03-27 Adimab, LLC Verfahren zur reinigung heterodimerer multispezifischer antikörper aus elterlichen homodimeren antikörperarten
ES2841437T3 (es) 2015-04-13 2021-07-08 Inst Nat Sante Rech Med Métodos y composiciones farmacéuticas para el tratamiento de enfermedades hemorrágicas
BR112017020952A2 (pt) 2015-04-13 2018-07-10 Five Prime Therapeutics Inc método de tratamento de câncer, composição e uso da composição
CN114773476A (zh) 2015-04-13 2022-07-22 辉瑞公司 治疗性抗体和它们的用途
WO2016168769A1 (en) * 2015-04-15 2016-10-20 The California Institute For Biomedical Research Chimeric receptor t cell switches for her2
EP4276116A3 (de) 2015-04-17 2024-01-17 Amgen Research (Munich) GmbH Bispezifische antikörperkonstrukte für cdh3 und cd3
JP6811723B2 (ja) 2015-04-17 2021-01-13 アイジーエム バイオサイエンシズ インコーポレイテッド 多価ヒト免疫不全ウイルス抗原結合分子およびその使用方法
EP3285795B1 (de) 2015-04-22 2022-11-16 Cedars-Sinai Medical Center Enteral verabreichte bittere oligopeptide zur behandlung von typ-2-diabetes und fettleibigkeit
US20180298104A1 (en) 2015-04-22 2018-10-18 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of th17 mediated diseases
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
EP3286224A4 (de) 2015-04-22 2018-11-14 Immunomedics, Inc. Isolierung, detektion, diagnose und/oder charakterisierung von zirkulierenden trop-2-positiven krebszellen
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
US20180298068A1 (en) 2015-04-23 2018-10-18 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
WO2016172726A1 (en) 2015-04-24 2016-10-27 The Regents Of The University Of California Modulators of ror1-ror2 binding
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
EP3288976B1 (de) 2015-04-29 2020-04-08 Regeneron Pharmaceuticals, Inc. Behandlung von fibrodysplasia ossificans progressiva
WO2016173719A1 (en) * 2015-04-30 2016-11-03 Abcheck S.R.O. Method for mass humanization of rabbit antibodies
TW201702271A (zh) 2015-04-30 2017-01-16 哈佛大學校長及研究員協會 治療代謝病症之抗－ａｐ２抗體及抗原結合劑
US20180140694A1 (en) 2015-05-04 2018-05-24 Bionor Immuno As Dosage regimen for hiv vaccine
CA2984948A1 (en) 2015-05-04 2016-11-10 Cytomx Therapeutics, Inc. Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
AU2016258988A1 (en) * 2015-05-04 2017-12-07 Cytomx Therapeutics, Inc Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof
CA3020885A1 (en) 2015-05-05 2016-11-10 Mohammad Tariq MALIK Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
WO2016179518A2 (en) 2015-05-06 2016-11-10 Janssen Biotech, Inc. Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
SG11201708804WA (en) 2015-05-07 2017-11-29 Agenus Inc Anti-ox40 antibodies and methods of use thereof
KR20180018525A (ko) 2015-05-08 2018-02-21 젠코어 인코포레이티드 Cd3 및 종양 항원과 결합하는 이종이량체 항체
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
EP3294879A4 (de) 2015-05-14 2019-02-20 University of Southern California Optimierte geneditierung mit einem rekombinanten endonukleasesystem
WO2016187068A1 (en) 2015-05-15 2016-11-24 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
AU2016265845B2 (en) 2015-05-15 2020-10-08 City Of Hope Chimeric antigen receptor compositions
CN107995913B (zh) 2015-05-18 2022-02-11 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
WO2016185035A1 (en) 2015-05-20 2016-11-24 Cellectis Anti-gd3 specific chimeric antigen receptors for cancer immunotherapy
IL293719B2 (en) 2015-05-21 2023-07-01 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
CN107921127B (zh) 2015-05-22 2022-04-08 纪念斯隆-凯特琳癌症中心 对于prame肽具有特异性的t细胞受体样抗体
EA039951B1 (ru) 2015-05-27 2022-03-31 Юсб Биофарма Спрл Ингибитор активности csf-1r, предназначенный для лечения или профилактики эпилепсии или болезни паркинсона, и фармацевтическая композиция на его основе
JP2018080114A (ja) 2015-05-29 2018-05-24 株式会社アールテック・ウエノ 抗ヒトｖａｐ−１モノクローナル抗体
CA2987410A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
WO2016196522A1 (en) 2015-05-29 2016-12-08 Cedars-Sinai Medical Center Correlated peptides for quantitative mass spectrometry
SG10201913500TA (en) 2015-05-29 2020-03-30 Agenus Inc Anti-ctla-4 antibodies and methods of use thereof
HUE048284T2 (hu) 2015-05-29 2020-07-28 Abbvie Inc Anti-CD40 antitestek és alkalmazásuk
PE20180041A1 (es) 2015-06-05 2018-01-09 Novartis Ag Anticuerpos dirigidos a la proteina morfogenetica osea (bmp9) y metodos a partir de estos
EP3307779A2 (de) 2015-06-12 2018-04-18 Alector LLC Anti-cd33-antikörper und verfahren zur verwendung davon
JP7376977B2 (ja) 2015-06-12 2023-11-09 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
TW201709932A (zh) 2015-06-12 2017-03-16 西雅圖遺傳學公司 Ｃｄ１２３抗體及其共軛物
US10723793B2 (en) 2015-06-12 2020-07-28 Ludwig Institute For Cancer Research, Ltd. TGF-β3 specific antibodies and methods and uses thereof
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3313876A2 (de) 2015-06-23 2018-05-02 Innate Pharma Multispezifische antigenbindende proteine
US10113003B2 (en) 2015-06-23 2018-10-30 Innate Pharma Multispecific NK engager proteins
JP7026509B2 (ja) 2015-06-24 2022-02-28 ヤンセン ファーマシューティカ エヌブイ 抗ｖｉｓｔａ抗体およびフラグメント
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
EP3314250A4 (de) 2015-06-26 2018-12-05 Beth Israel Deaconess Medical Center, Inc. Auf tetraspanin 33 (tspann33) in myeloidabgeleiteten suppressorzellen abzielende krebstherapie
AU2016285920A1 (en) 2015-06-29 2018-02-01 Bristol-Myers Squibb Company Antibodies to CD40 with enhanced agonist activity
HUE053619T2 (hu) 2015-06-29 2021-07-28 Immunogen Inc Anti-CD123 antitestek és konjugátumok és ezek származékai
IL303690A (en) 2015-06-30 2023-08-01 Seagen Inc Anti–NTB–A antibodies and related preparations and methods
WO2017002934A1 (ja) 2015-07-01 2017-01-05 中外製薬株式会社 Ｇｐｃ３標的治療剤が有効である患者に投与されるｇｐｃ３標的治療剤
EP3319990A1 (de) 2015-07-07 2018-05-16 Institut National de la Sante et de la Recherche Medicale (INSERM) Antikörper mit spezifität gegen myosin 18a und verwendungen davon
US10287338B2 (en) 2015-07-10 2019-05-14 Miran NERSISSIAN Factor VIII protein compositions and methods of treating of hemophilia A
CN113350518A (zh) 2015-07-12 2021-09-07 杭州多禧生物科技有限公司 与细胞结合分子的共轭偶联的桥连接体
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
CN109641951A (zh) * 2015-07-13 2019-04-16 拉瓦尔大学 人源化抗s100a9抗体及其用途
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
RU2611685C2 (ru) * 2015-07-20 2017-02-28 Илья Владимирович Духовлинов Гуманизированное моноклональное антитело, специфичное к синдекану-1
WO2017015334A1 (en) 2015-07-21 2017-01-26 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
EP3328427A4 (de) 2015-07-27 2018-12-12 The General Hospital Corporation Antikörperderivate mit bedingt aktivierter effektorfunktion
SI3317301T1 (sl) 2015-07-29 2021-10-29 Novartis Ag Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3
EP3316902A1 (de) 2015-07-29 2018-05-09 Novartis AG Kombinationstherapien mit antikörpermolekülen gegen tim-3
WO2017023863A1 (en) 2015-07-31 2017-02-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
EP3328994A4 (de) 2015-07-31 2019-04-17 Memorial Sloan-Kettering Cancer Center Gegen cd56 gerichtete antigenbindende proteine und verwendungen davon
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
EP3328393B1 (de) 2015-07-31 2023-12-20 Centrose, Llc Auf cd20 abzielende extrazelluläre arzneimittelkonjugate
KR20180035852A (ko) 2015-08-03 2018-04-06 노파르티스 아게 Fgf21-연관 장애를 치료하는 방법
ES2944982T3 (es) 2015-08-05 2023-06-27 Janssen Biotech Inc Anticuerpos anti-CD154 y métodos para utilizarlos
JP7104462B2 (ja) 2015-08-06 2022-07-21 シティ・オブ・ホープ 細胞透過性タンパク質－抗体コンジュゲートおよび使用方法
EP3331569A1 (de) 2015-08-07 2018-06-13 Gamamabs Pharma Antikörper, antikörper-wirkstoff-konjugate und verfahren zur verwendung
MA45352A (fr) 2015-08-07 2018-06-13 Univ Birmingham Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer
EP3331913A1 (de) 2015-08-07 2018-06-13 Novartis AG Behandlung von krebs mithilfe von chimären cd3-rezeptor-proteinen
AU2016307050A1 (en) 2015-08-11 2018-02-15 Cellectis Cells for immunotherapy engineered for targeting CD38 antigen and for CD38 gene inactivation
WO2017027685A2 (en) 2015-08-13 2017-02-16 New York University Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy
PT3334761T (pt) 2015-08-13 2023-08-17 Univ New York Moléculas baseadas em anticorpo seletivo para o epítopo {p}ser404 da tau e os seus usos no diagnóstico e tratamento de tauopatias
EP3337514B8 (de) 2015-08-18 2022-04-06 Rakuten Medical, Inc. Zusammensetzung aus einem konjugat mit einem phthalocyaninfarbstoff, der mit einem zielmollekel für fotoimmunotherapie verbunden ist
SG10202011033QA (en) 2015-08-18 2020-12-30 Rakuten Medical Inc Phthalocyanine dye conjugates and their storage
WO2018036117A1 (zh) 2016-08-22 2018-03-01 复旦大学 靶向于组织因子的抗体、其制备方法和用途
EP3340995A4 (de) 2015-08-28 2019-04-03 The Trustees Of The University Of Pennsylvania Verfahren und zusammensetzungen für zellen zur expression eines chimären intrazellulären signalmoleküls
EP3340998B1 (de) 2015-08-28 2023-01-11 The Trustees of the University of Pennsylvania Verfahren und zusammensetzungen für zellen zur expression eines chimären intrazellulären signalmoleküls
US11279769B2 (en) 2015-08-31 2022-03-22 Helixmith Co., Ltd Anti-Sialyl Tn chimeric antigen receptors
AU2016315752B2 (en) 2015-08-31 2021-08-05 Cedars-Sinai Medical Center Novel blood cell biomarker for late onset Alzheimer's disease
EA201890630A1 (ru) 2015-09-01 2018-10-31 Эйдженус Инк. Антитела против pd-1 и способы их применения
EP3798234A1 (de) 2015-09-02 2021-03-31 Immutep S.A.S. Agonistische anti-lag-3 antikörper
ES2924071T3 (es) 2015-09-02 2022-10-04 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Anticuerpos específicos para inmunoglobulina de células T humanas y dominio ITIM (TIGIT)
AU2016315892B2 (en) 2015-09-02 2023-06-15 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for modulating T-cell mediated immune response
AU2016318114B2 (en) 2015-09-03 2023-04-20 The Brigham And Women's Hospital, Inc. Three-dimensional differentiation of epiblast spheroids to kidney organoids models stage-specific epithelial physiology, morphogenesis, and disease
KR20180042431A (ko) 2015-09-04 2018-04-25 헬스 리서치 인코포레이티드 암 치료용 안티-서비빈 항체
CN116063481A (zh) 2015-09-04 2023-05-05 普里玛托普医疗股份有限公司 人源化抗-cd40抗体及其用途
US10000561B2 (en) 2015-09-09 2018-06-19 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
RU2731644C2 (ru) 2015-09-09 2020-09-07 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
CA2997673A1 (en) 2015-09-15 2017-03-23 Board Of Regents, The University Of Texas System T-cell receptor (tcr)-binding antibodies and uses thereof
AU2016323440B2 (en) 2015-09-15 2023-07-13 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
JP2018530540A (ja) 2015-09-16 2018-10-18 プロセナ バイオサイエンシーズ リミテッド 巨細胞動脈炎、リウマチ性多発筋痛症又は高安動脈炎の処置又は予防のための抗ｍｃａｍ抗体の使用
WO2017052679A1 (en) 2015-09-21 2017-03-30 The United States Of America, As Represented By The Secretary, Departmnet Of Health & Human Service Monoclonal antibodies specific for heartland virus and methods of their use
EP3352760A4 (de) 2015-09-21 2019-03-06 Aptevo Research and Development LLC Cd3-bindende polypeptide
DK3353196T3 (da) 2015-09-22 2023-02-20 Inst Nat Sante Rech Med Polypeptider, der er i stand til at inhibere bindingen mellem leptin og neuropilin-1
EP3353204B1 (de) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Bi-spezifischer anti-vegf/dll4-antikörper zur verwendung bei der behandlung von platin-resistentem eierstockkrebs
RU2638457C2 (ru) 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
EP3355909B1 (de) 2015-09-28 2023-06-07 Children's Hospital Los Angeles Verfahren zur behandlung von durch erbb4-positive proinflammatorische makrophagen vermittelte erkrankungen
CN109069622A (zh) 2015-09-30 2018-12-21 詹森生物科技公司 特异性结合人cd40的拮抗性抗体和使用方法
US20180280474A1 (en) 2015-10-01 2018-10-04 Amgen Inc. Treatment of bile acid disorders
EP3359692A4 (de) 2015-10-05 2019-05-01 Cedars-Sinai Medical Center Verfahren zur klassifizierung und behandlung von krebs
AR106307A1 (es) 2015-10-07 2018-01-03 Obi Pharma Inc Anticuerpos de hidratos de carbono, composiciones farmacéuticas y usos de los mismos
CA2997809A1 (en) 2015-10-07 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
US11517590B2 (en) 2015-10-08 2022-12-06 National University Corporation Tokai National Higher Education And Research System Method for preparing genetically-modified T cells which express chimeric antigen receptor
WO2017060397A1 (en) 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from melanoma metastases
US11161912B2 (en) 2015-10-13 2021-11-02 Technion Research & Development Foundation Limited Heparanase-neutralizing monoclonal antibodies
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
WO2017064302A1 (en) 2015-10-16 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
US20180057788A1 (en) 2016-08-29 2018-03-01 EMULATE, Inc. Development of spinal cord on a microfluidic chip
GB201518675D0 (en) 2015-10-21 2015-12-02 Cellcap Technologies Ltd Detection of structural forms of proteins
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
CA3002903A1 (en) * 2015-10-23 2017-04-27 Fred Hutchinson Cancer Research Center Methods to create chemically-induced dimerizing protein systems for regulation of cellular events
KR20180064541A (ko) * 2015-10-23 2018-06-14 화이자 인코포레이티드 항-il-2 항체 및 조성물 및 이의 용도
KR20180105634A (ko) 2015-10-26 2018-09-28 피에르 파브르 메디카먼트 Igf-1r을 발현하는 암의 치료를 위한 조성물
CN108350068A (zh) 2015-10-27 2018-07-31 Ucb生物制药私人有限公司 使用抗-il-17a/f抗体的治疗方法
US20180348224A1 (en) 2015-10-28 2018-12-06 Friedrich Miescher Institute For Biomedical Resear Ch Tenascin-w and biliary tract cancers
US11267875B2 (en) 2015-10-28 2022-03-08 Yale University Humanized anti-DKK2 antibody and uses thereof
JP2019502363A (ja) * 2015-10-30 2019-01-31 エヌビーイー セラピューティクス アクチェン ゲゼルシャフト 抗ｒｏｒ１抗体
US10875923B2 (en) 2015-10-30 2020-12-29 Mayo Foundation For Medical Education And Research Antibodies to B7-H1
EP3368090A1 (de) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-faktor-d-antikörpervarianten-konjugate und verwendungen davon
EP3368074A2 (de) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-faktor-d-antikörper und -konjugate
JP6869553B2 (ja) 2015-10-30 2021-05-12 ギャラクシー バイオテック， エルエルシーＧａｌａｘｙ Ｂｉｏｔｅｃｈ， Ｌｌｃ デスレセプター４及びデスレセプター５に結合する非常に強力な抗体
TW201720459A (zh) 2015-11-02 2017-06-16 妮翠斯製藥公司 Ntn1中和劑與抑制後生控制之藥物之組合治療
WO2017079215A1 (en) 2015-11-03 2017-05-11 Glycomimetics, Inc. Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
US10618935B2 (en) 2015-11-03 2020-04-14 Industrial Technology Research Institute Antibody-drug conjugate (ADC) and method for forming the same
BR112018008904A2 (pt) 2015-11-03 2018-11-27 Janssen Biotech Inc anticorpos que se ligam especificamente a tim-3 e seus usos
WO2017079479A1 (en) 2015-11-03 2017-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Neutralizing antibodies to hiv-1 gp41 and their use
CA3003759A1 (en) 2015-11-03 2017-05-11 Merck Patent Gmbh Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
WO2017079419A1 (en) 2015-11-05 2017-05-11 The Regents Of The University Of California Cells labelled with lipid conjugates and methods of use thereof
WO2017083371A1 (en) 2015-11-09 2017-05-18 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
RU2710194C9 (ru) 2015-11-10 2020-09-14 МЕДИММЬЮН, ЭлЭлСи Связывающие молекулы, специфичные в отношении asct2, и их применения
CA3004790A1 (en) 2015-11-10 2017-05-18 Visterra, Inc. Lipopolysaccharide binding antibody-antimicrobial peptide conjugates and uses thereof
US20210011025A1 (en) 2015-11-11 2021-01-14 Serimmune Inc. Methods and compositions for assessing antibody specificities
IL258768B2 (en) 2015-11-12 2023-11-01 Siamab Therapeutics Inc Compounds interacting with glycans and methods of use
EP3377103B1 (de) 2015-11-19 2021-03-17 Revitope Limited Komplementierung eines funktionellen antikörperfragments für ein zwei-komponenten-system zur umgelenkten tötung unerwünschter zellen
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
US20190330336A1 (en) 2015-11-19 2019-10-31 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
JP2019501139A (ja) 2015-11-25 2019-01-17 イミュノジェン・インコーポレーテッド 医薬製剤及びその使用
MA43308A (fr) 2015-11-25 2018-10-03 Visterra Inc Molécules d'anticorps se liant à april et leurs utilisations
WO2017095875A1 (en) 2015-11-30 2017-06-08 Bristol-Myers Squibb Company Anti human ip-10 antibodies and their uses
WO2017095808A1 (en) 2015-11-30 2017-06-08 Abbvie Inc. ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
JP2019500327A (ja) 2015-11-30 2019-01-10 アッヴィ・インコーポレイテッド 抗ｈｕＬＲＲＣ１５抗体薬物コンジュゲート及びその使用方法
SG10201913100WA (en) 2015-11-30 2020-03-30 Medimmune Ltd Method for preventing or treating nosocomial pneumonia
KR20180100122A (ko) 2015-12-02 2018-09-07 주식회사 에스티사이언스 당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
AU2016365318B2 (en) 2015-12-02 2024-04-18 Board Of Regents, The University Of Texas System Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
CA3006477A1 (en) 2015-12-04 2017-06-08 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation
US20180271998A1 (en) 2015-12-04 2018-09-27 Merrimack Pharmaceuticals, Inc. Disulfide-stabilized fabs
AU2016365423A1 (en) 2015-12-04 2018-07-12 The Regents Of The University Of California Novel antibodies for the treatment of cancers
AU2016363013B2 (en) 2015-12-04 2022-03-10 Seagen Inc. Conjugates of quaternized tubulysin compounds
EP3387013B1 (de) 2015-12-07 2022-06-08 Xencor, Inc. Cd3 und psma bindende heterodimere antikörper
US11479755B2 (en) 2015-12-07 2022-10-25 2Seventy Bio, Inc. T cell compositions
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
CN108603037B (zh) 2015-12-10 2020-11-17 希望之城 细胞穿透花青偶联抗体
EA201891388A1 (ru) 2015-12-11 2018-11-30 Дайэкс Корп. Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека
MA43567A (fr) 2015-12-15 2018-11-14 Amgen Inc Anticorps pacap et leurs utilisations
WO2017106372A1 (en) 2015-12-15 2017-06-22 Oncoimmune, Inc. Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
CA3007671A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
JP2019502695A (ja) 2015-12-17 2019-01-31 ノバルティス アーゲー ＰＤ−１に対する抗体分子とＣ−Ｍｅｔ阻害剤との組合せおよびその使用
AU2016371034A1 (en) 2015-12-17 2018-05-31 Janssen Biotech, Inc. Antibodies specifically binding HLA-DR and their uses
CA3008102A1 (en) 2015-12-18 2017-06-22 Novartis Ag Antibodies targeting cd32b and methods of use thereof
EP3389693A4 (de) 2015-12-18 2019-08-21 Agilvax, Inc. Zusammensetzungen und verfahren im zusammenhang mit xct-peptiden
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
PE20181327A1 (es) 2015-12-23 2018-08-20 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1
EP3184544A1 (de) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotein-v-inhibitoren zur verwendung als koagulansien
KR20180103918A (ko) 2015-12-24 2018-09-19 코버스 파마슈티칼스, 인크. 암을 치료하는 방법
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
WO2017117130A1 (en) 2015-12-28 2017-07-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells
RU2744860C2 (ru) 2015-12-30 2021-03-16 Кодиак Сайенсиз Инк. Антитела и их конъюгаты
ES2861587T3 (es) 2015-12-31 2021-10-06 Progastrine Et Cancers S A R L Composiciones y métodos para detectar y tratar el cáncer de esófago
EP3954999A1 (de) 2015-12-31 2022-02-16 Progastrine et Cancers S.à r.l. Compositions and methods for detecting and treating ovarian cancer
JP6909795B2 (ja) 2015-12-31 2021-07-28 プロガストリン、エ、カンセル、エス、アー エル、エルＰｒｏｇａｓｔｒｉｎｅ Ｅｔ Ｃａｎｃｅｒｓ Ｓ．Ａ Ｒ．Ｌ． 胃癌の検出および治療のための組成物および方法
EP3397965A1 (de) 2015-12-31 2018-11-07 Syncerus S.à R.l. Zusammensetzungen und verfahren zur beurteilung des risikos des auftretens von krebs
SG11201805695SA (en) 2016-01-05 2018-07-30 Univ Leicester Methods for inhibiting fibrosis in a subject in need thereof
US10472422B2 (en) 2016-01-08 2019-11-12 Abgenomics International Inc. Tetravalent anti-PSGL-1 antibodies and uses thereof
AU2017206656B2 (en) 2016-01-10 2024-02-01 Neotx Therapeutics Ltd. Immunopotentiator enhanced superantigen mediated cancer immunotherapy
US10821094B2 (en) 2016-01-13 2020-11-03 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
CN109069627A (zh) 2016-01-14 2018-12-21 纪念斯隆-凯特琳癌症中心 对foxp3衍生肽特异性的t细胞受体样抗体
EP3851457A1 (de) 2016-01-21 2021-07-21 Novartis AG Gegen cll-1 gerichtete multispezifische moleküle
US10221242B2 (en) 2016-01-21 2019-03-05 Pfizer Inc. Antibodies specific for epidermal growth factor receptor variant III and their uses
US11214617B2 (en) 2016-01-22 2022-01-04 MabQuest SA Immunological reagents
AU2017208819B2 (en) 2016-01-22 2023-10-19 MabQuest SA PD1 specific antibodies
KR20180104106A (ko) 2016-01-27 2018-09-19 서트로 바이오파마, 인크. anti-CD74 항체 접합체, anti-CD74 항체 접합체를 포함하는 조성물 및 anti-CD74 항체 접합체의 이용 방법
WO2017129763A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
EP4035681A1 (de) 2016-01-28 2022-08-03 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren und pharmazeutische zusammensetzung zur behandlung von krebs
EP3407912B1 (de) 2016-01-28 2022-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur verbesserung der potenz immunologischer checkpoint-hemmer
CA3012960A1 (en) 2016-02-01 2017-08-10 Pfizer Inc. Tubulysin analogs and methods for their preparation
US10337032B2 (en) 2016-02-01 2019-07-02 The University Of Manchester Compositions and methods for recombinant biosynthesis of propane
CA3013357A1 (en) 2016-02-01 2017-08-10 Cedars-Sinai Medical Center Systems and methods for growth of intestinal cells in microfluidic devices
KR20180103084A (ko) 2016-02-03 2018-09-18 암젠 리서치 (뮌헨) 게엠베하 Bcma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
EP3411404B1 (de) 2016-02-03 2022-11-09 Amgen Research (Munich) GmbH Psma- und cd3-bispezifische t-zellaktivierende antikörperkonstrukte
CA3019952A1 (en) 2016-02-04 2017-08-10 Curis, Inc. Mutant smoothened and methods of using the same
CN108601848A (zh) 2016-02-05 2018-09-28 伊缪诺金公司 用于制备细胞结合剂-细胞毒性剂缀合物的有效方法
KR101843985B1 (ko) 2016-02-09 2018-03-30 오토텔릭 엘엘씨 암을 치료하기 위한 조성물과 방법
KR20180103816A (ko) 2016-02-09 2018-09-19 오토텔릭 엘엘씨 췌장암을 치료하기 위한 조성물과 방법
GB201602413D0 (en) 2016-02-10 2016-03-23 Nascient Ltd Method
CA3011372A1 (en) 2016-02-10 2017-08-17 Immunomedics, Inc. Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
CN116920085A (zh) 2016-02-12 2023-10-24 詹森药业有限公司 抗-vista（b7h5）抗体
JP7063813B2 (ja) 2016-02-15 2022-05-09 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 術後認知機能障害の処置のための方法及び医薬組成物
RU2018131123A (ru) 2016-02-17 2020-03-17 Новартис Аг Антитела к tgf-бета2
CN108778329B (zh) 2016-02-17 2022-09-16 西雅图基因公司 Bcma抗体和其用以治疗癌症和免疫病症的用途
JP6722293B2 (ja) 2016-02-19 2020-07-15 シワ コーポレーション 終末糖化産物（ａｇｅ）に対する抗体を使用して、がんを治療、転移性がん細胞を殺傷、及びがん転移を予防するための方法及び組成物
KR20180115276A (ko) 2016-02-22 2018-10-22 베링거잉겔하임베트메디카게엠베하 생체 분자의 고정화 방법
EP3419999B1 (de) 2016-02-26 2021-08-04 (INSERM) Institut National de la Santé et de la Recherche Médicale Antikörper mit spezifizität für btla und verwendungen davon
EP3423121B1 (de) 2016-02-29 2022-11-02 Cedars-Sinai Medical Center Endogene stammzellenaktivierung zur sehnen-/ligamentosseointegration
CN109476731A (zh) 2016-02-29 2019-03-15 基础医药有限公司 治疗癌症的方法
WO2017149538A1 (en) 2016-03-01 2017-09-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (pvr)
EP4299586A3 (de) 2016-03-02 2024-04-03 Idexx Laboratories, Inc. Verfahren und zusammensetzungen zur erkennung und diagnose von nierenerkrankungen und parodontalerkrankungen
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
EA201891983A8 (ru) 2016-03-04 2020-05-28 Бристол-Майерс Сквибб Компани Комбинированная терапия антителами к cd73
SG11201807677YA (en) 2016-03-04 2018-10-30 Univ Rockefeller Antibodies to cd40 with enhanced agonist activity
EP3423482A1 (de) 2016-03-04 2019-01-09 Novartis AG Zellen mit expression von mehreren chimären antigenrezeptor (car)-molekülen und verwendungen dafür
US10443054B2 (en) 2016-03-06 2019-10-15 Massachusetts Institute Of Technology Methods for identifying and treating invasive/metastatic breast cancers
EP3216458A1 (de) 2016-03-07 2017-09-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Modifizierter vaskulärer endothelialen wachstumsfaktor a (vegf-a) und dessen medizinische verwendung
US11340233B2 (en) 2016-03-07 2022-05-24 Pierre Fabre Medicament Universal method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in biological samples
TW201808978A (zh) 2016-03-08 2018-03-16 中央研究院 N-聚醣及其陣列之模組化合成方法
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
WO2017156488A2 (en) 2016-03-10 2017-09-14 Acceleron Pharma, Inc. Activin type 2 receptor binding proteins and uses thereof
SG11201807523PA (en) 2016-03-10 2018-09-27 Viela Bio Inc Ilt7 binding molecules and methods of using the same
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
KR20180119670A (ko) 2016-03-15 2018-11-02 아스트라제네카 아베 아밀로이드 베타의 축적과 관련된 질환의 치료를 위한 bace 억제제와 항체 또는 항원 결합 단편의 조합
US10947317B2 (en) 2016-03-15 2021-03-16 Mersana Therapeutics, Inc. NaPi2b-targeted antibody-drug conjugates and methods of use thereof
EP3430058A4 (de) 2016-03-15 2019-10-23 Generon (Shanghai) Corporation Ltd. Multispezifische fab-fusionsproteine und verwendungen davon
HRP20220335T1 (hr) 2016-03-15 2022-05-13 Institut National De La Santé Et De La Recherche Médicale (Inserm) Rani i neinvazivni postupak za procjenu rizika kod nekog subjekta od obolijevanja od duktalnog adenokarcinoma gušterače i postupci za liječenje takve bolesti
MA45324A (fr) 2016-03-15 2019-01-23 Seattle Genetics Inc Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
WO2017158396A1 (en) 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
KR102392746B1 (ko) 2016-03-17 2022-04-29 누맙 이노베이션 아게 항-TNFα-항체 및 이의 기능성 단편
RS61374B1 (sr) 2016-03-17 2021-02-26 Tillotts Pharma Ag Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti
WO2017161342A1 (en) 2016-03-17 2017-09-21 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through rnaset2
WO2017158084A1 (en) 2016-03-17 2017-09-21 Numab Innovation Ag ANTI-TNFα-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
US10774140B2 (en) 2016-03-17 2020-09-15 Numab Therapeutics AG Anti-TNFα-antibodies and functional fragments thereof
LT3219727T (lt) 2016-03-17 2021-02-10 Tillotts Pharma Ag Anti-tnf alfa antikūnai ir jų funkciniai fragmentai
EP3433615A1 (de) 2016-03-21 2019-01-30 Institut National de la Sante et de la Recherche Medicale (INSERM) Verfahren zur diagnose und behandlung von sonnenpigmentflecken
CN109153728A (zh) 2016-03-21 2019-01-04 埃尔斯塔治疗公司 多特异性和多功能分子及其用途
US10745487B2 (en) 2016-03-22 2020-08-18 Bionomics Limited Method of treating cancer by administering an anti-LGR5 monoclonal antibody
WO2017161976A1 (en) 2016-03-23 2017-09-28 Mabspace Biosciences (Suzhou) Co., Ltd Novel anti-pd-l1 antibodies
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
JP7155009B2 (ja) 2016-03-25 2022-10-18 ビステラ， インコーポレイテッド デングウイルスに対する抗体分子の製剤
AU2017237186A1 (en) 2016-03-25 2018-11-01 Seagen Inc. Process for the preparation of PEGylated drug-linkers and intermediates thereof
CA3019145A1 (en) 2016-03-28 2017-10-05 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors
AU2017241776A1 (en) 2016-03-29 2018-10-11 Janssen Biotech, Inc. Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody
CA3018382A1 (en) 2016-03-29 2017-10-05 University Of Southern California Chimeric antigen receptors targeting cancer
EP3436610A1 (de) 2016-03-29 2019-02-06 Geltor, Inc. Expression von proteinen in gramnegativen bakterien mit verhältnis von periplasmatischem volumen zu zytoplasmatischem volumen zwischen 0,5:1 und 10:1
CN115137816A (zh) 2016-03-31 2022-10-04 奥默罗斯公司 抑制有需要的受试者的血管发生的方法
EP3436037A4 (de) 2016-03-31 2019-12-04 University of Southern California Hochempfindlicher und spezifischer luciferasebasierter reportertest für antigennachweis
US10656089B2 (en) 2016-04-01 2020-05-19 Black Light Surgical, Inc. Systems, devices, and methods for time-resolved fluorescent spectroscopy
US10766954B2 (en) * 2016-04-06 2020-09-08 Imago Pharmaceuticals, Inc. Therapeutic antibodies for treatment of neurodegeneration
US20200330459A1 (en) 2016-04-06 2020-10-22 Inserm (Institut National De La Santé Et La Recherche Médicale) Methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
MX2018012615A (es) 2016-04-15 2019-05-30 Novartis Ag Composiciones y metodos para la expresion selectiva de proteinas.
US20170298119A1 (en) 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
MY198114A (en) 2016-04-15 2023-08-04 Macrogenics Inc Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
RU2021111187A (ru) 2016-04-15 2021-04-29 Янссен Фармасьютикалз, Инк. Антитела против человеческого vista и их применение
US10202435B2 (en) 2016-04-15 2019-02-12 Alder Biopharmaceuticals, Inc. Anti-PACAP antibodies and uses thereof
CA3057829A1 (en) 2016-04-15 2017-10-19 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
WO2017182561A1 (en) 2016-04-21 2017-10-26 Sphingotec Therapeutics Gmbh Methods for determining dpp3 and therapeutic methods
US20190125826A1 (en) 2016-04-22 2019-05-02 Inserm (Institut National De La Santé Et De La Médicale) Methods and pharmaceutical composition for the treatment of inflammatory skin diseases associated with desmoglein-1 deficiency
WO2017189483A1 (en) 2016-04-25 2017-11-02 The Johns Hopkins University Znt8 assays for drug development and pharmaceutical compositions
WO2017189353A1 (en) 2016-04-26 2017-11-02 Five Prime Therapeutics, Inc. Treating respiratory diseases by targeting interleukin 4 induced 1 (il4i1)
EP3448391A4 (de) 2016-04-27 2019-12-18 AbbVie Inc. Verfahren zur behandlung von erkrankungen mit schädlicher il-13 aktivität unter verwendung von anti-il-13-antikörpern
WO2017187183A1 (en) 2016-04-27 2017-11-02 Itara Therapeutics Methods for the identification of bifunctional compounds
WO2017189279A1 (en) 2016-04-27 2017-11-02 Immunomedics, Inc. Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
US11312766B2 (en) 2016-04-27 2022-04-26 Novartis Ag Antibodies against growth differentiation factor 15 and uses thereof
RU2750454C2 (ru) * 2016-04-29 2021-06-28 Пфайзер Инк. Антитела против интерферона бета и их применение
WO2017192589A1 (en) 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
KR102471787B1 (ko) 2016-05-02 2022-11-29 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
CN109415434B (zh) 2016-05-02 2022-12-30 普罗塞纳生物科学有限公司 识别tau的抗体
ES2933491T3 (es) 2016-05-02 2023-02-09 Prothena Biosciences Ltd Inmunoterapia tau
WO2017191100A1 (en) 2016-05-03 2017-11-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of tissue lesions
WO2017191300A1 (en) 2016-05-06 2017-11-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions for the treatment of chemoresistant acute myeloid leukemia (aml)
EP3455256A1 (de) 2016-05-09 2019-03-20 Bristol-Myers Squibb Company Tl1a-antikörper und verwendungen davon
EP3454863A1 (de) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Kombinationstherapien zur behandlung von krebs
WO2017194568A1 (en) 2016-05-11 2017-11-16 Sanofi Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
JP7084878B2 (ja) 2016-05-16 2022-06-15 武田薬品工業株式会社 抗第ＩＸ因子Ｐａｄｕａ抗体
KR20230028574A (ko) 2016-05-17 2023-02-28 애브비 바이오테라퓨틱스 인크. 항-cMet 항체 약물 컨쥬게이트 및 그들의 이용 방법
CN109600992A (zh) 2016-05-20 2019-04-09 西达-赛奈医疗中心 治疗或预防阿尔茨海默病和相关病况的方法
US20190290756A1 (en) 2016-05-20 2019-09-26 Christoph Karl Pharmaceutical compositions with anti-rankl antibodies, calcium and vitamin d
CN109476698B (zh) 2016-05-20 2023-10-17 西达-赛奈医疗中心 基于基因的炎性肠病诊断
US10100106B2 (en) 2016-05-20 2018-10-16 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EP3464357A1 (de) 2016-05-24 2019-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzungen zur behandlung von bakteriellen lungeninfektionen
CN109415441B (zh) 2016-05-24 2023-04-07 英斯梅德股份有限公司 抗体及其制备方法
WO2017202814A1 (en) 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of neuropathological disorders characterized by a loss of cortical neurons
US20190292259A1 (en) 2016-05-24 2019-09-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
JP2019523221A (ja) 2016-05-27 2019-08-22 アッヴィ・バイオセラピューティクス・インコーポレイテッド 抗ｃｄ４０抗体とその使用
KR20190015351A (ko) 2016-05-27 2019-02-13 티지 쎄라퓨틱스, 인코포레이티드 B-세포 증식성 장애를 치료하기 위한 항-cd20 항체, p13 키나제-델타 선택적 억제제 및 btk 억제제의 조합
MX2018014387A (es) 2016-05-27 2019-03-14 Agenus Inc Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
US10875921B2 (en) 2016-05-27 2020-12-29 Abbvie Biotherapeutics Inc. Anti-4-1BB antibodies and their uses
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
WO2017207694A1 (en) 2016-06-02 2017-12-07 Kohlmann Angelica Antibodies that bind to human anti-müllerian hormone (amh) and their uses
US20210177896A1 (en) 2016-06-02 2021-06-17 Novartis Ag Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
MY194619A (en) 2016-06-02 2022-12-07 Abbvie Inc Glucocorticoid receptor agonist and immunoconjugates thereof
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
US9982043B2 (en) 2016-06-03 2018-05-29 National Cheng Kung University Use of IL-20 antagonists for treating pancreatic cancer
CN109311991B (zh) 2016-06-06 2022-08-30 希望之城 Baff-r靶向嵌合抗原受体修饰的t细胞及其用途
JP7275446B2 (ja) 2016-06-06 2023-05-18 シティ・オブ・ホープ Ｂａｆｆ－ｒ抗体及びその使用
SG11201810697QA (en) 2016-06-07 2018-12-28 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Chimeric antigen receptor and car-t cells that bind bcma
CA3027103A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
CN109563167A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
WO2017214333A1 (en) 2016-06-08 2017-12-14 Intrexon Corporation Cd33 specific chimeric antigen receptors
WO2017214335A1 (en) * 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
EP3468997B1 (de) 2016-06-08 2023-09-13 Xencor, Inc. Behandlung von erkrankungen im zusammenhang mit igg4 mit anti-cd19-antikörpern mit kreuzbindung an cd32b
BR112018075222A2 (pt) 2016-06-09 2019-03-19 Pelican Therapeutics, Inc anticorpos anti-tnfrsf25
CA3026490A1 (en) 2016-06-09 2017-12-14 University Of Leicester Monoclonal antibodies, compositions and methods for detecting mucin-like protein (mlp) as a biomarker for ovarian and pancreatic cancer
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
MX2018015584A (es) 2016-06-13 2019-09-18 I Mab Anticuerpos anti-pd-l1 y usos de los mismos.
AU2017286432B2 (en) 2016-06-14 2020-09-24 Adimab, Llc Anti-coagulation factor XI antibodies
MX2018015592A (es) 2016-06-14 2019-04-24 Xencor Inc Anticuerpos inhibidores de puntos de control biespecificos.
US11098107B2 (en) 2016-06-15 2021-08-24 Sutro Biopharma, Inc. Antibodies with engineered CH2 domains, compositions thereof and methods of using the same
WO2017216724A1 (en) 2016-06-15 2017-12-21 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
US10221395B2 (en) 2016-06-16 2019-03-05 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
DK3473270T3 (da) 2016-06-20 2023-01-09 Genahead Bio Inc Konjugat af antistof-lægemiddel
WO2017222535A1 (en) 2016-06-23 2017-12-28 Siwa Corporation Vaccines for use in treating various diseases and disorders
MA45493A (fr) 2016-06-27 2019-05-01 Aicuris Anti Infective Cures Gmbh Inhibiteurs d'entrée de hcmv.
CA3029328A1 (en) 2016-06-28 2018-01-04 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
US20190263919A1 (en) 2016-07-01 2019-08-29 Five Prime Therapeutics, Inc. Combined anti tumor therapy with a gitr agonist and cpg
EP3478716A2 (de) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin-antikörper
WO2018007922A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3478715A2 (de) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin-antikörper
AU2017292172A1 (en) 2016-07-06 2019-01-03 Prothena Biosciences Limited Assay for detecting total and S129 phosphorylated alpha-synuclein
KR20190039937A (ko) 2016-07-08 2019-04-16 스태튼 바이오테크놀로지 비.브이. 항-ApoC3 항체 및 이의 사용 방법
JP2019524706A (ja) 2016-07-08 2019-09-05 ジェネンテック， インコーポレイテッド Ｍｕｃ１６陽性癌治療の応答性を評価するためのヒト精巣上体タンパク質４（ｈｅ４）の使用
ES2948446T3 (es) 2016-07-08 2023-09-12 Sphingotec Gmbh Adrenomedulina para la valoración de la congestión en un sujeto con insuficiencia cardiaca aguda
WO2018013611A1 (en) 2016-07-11 2018-01-18 Corvus Pharmaceuticals, Inc. Anti-cd73 antibodies
WO2018013509A1 (en) 2016-07-11 2018-01-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for diagnosing and treating arrhythmias
MY197836A (en) 2016-07-12 2023-07-20 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
BR112019000630A2 (pt) 2016-07-13 2019-07-09 Biogen Ma Inc regimes de dosagem dos antagonistas de lingo-1 e usos para tratamento de distúrbios desmielinizante
JP7027401B2 (ja) 2016-07-14 2022-03-01 ブリストル－マイヤーズ スクイブ カンパニー Ｔｉｍ３に対する抗体およびその使用
EP3484496B1 (de) 2016-07-14 2023-12-27 University of Southern California Verfahren und zusammensetzung zur herstellung und verwendung von immunzellen und stammzellen für zellbasierte therapien
WO2018013917A1 (en) 2016-07-15 2018-01-18 Takeda Pharmaceutical Company Limited Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
JP7219376B2 (ja) 2016-07-15 2023-02-08 ノバルティス アーゲー キメラ抗原受容体をキナーゼ阻害薬と併用して使用したサイトカイン放出症候群の治療及び予防
CN109477114A (zh) 2016-07-18 2019-03-15 赫利克斯生物药品公司 治疗癌症的针对癌胚抗原相关细胞粘附分子6的car免疫细胞
WO2018015881A1 (en) 2016-07-18 2018-01-25 Ramot At Tel-Aviv University Ltd. Modular platform for targeted therapeutics
WO2018014067A1 (en) 2016-07-19 2018-01-25 Teva Pharmaceuticals Australia Pty Ltd Anti-cd47 combination therapy
WO2018015573A2 (en) 2016-07-22 2018-01-25 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Trem2 cleavage modulators and uses thereof
KR102435801B1 (ko) 2016-07-22 2022-08-25 암젠 인크 Fc-함유 단백질의 정제 방법
US20190330318A1 (en) 2016-07-25 2019-10-31 Biogen Ma Inc. Anti-hspa5 (grp78) antibodies and uses thereof
WO2018022786A1 (en) * 2016-07-26 2018-02-01 Washington University Antibodies to zika virus and methods of use thereof
WO2018018082A1 (en) 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor
US20190271702A1 (en) 2016-07-28 2019-09-05 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods of treatement of cancer disease by targetting tumor associated macrophage
AU2017302668B9 (en) 2016-07-28 2023-06-22 Novartis Ag Combination therapies of chimeric antigen receptors and PD-1 inhibitors
CN110088133B (zh) 2016-07-29 2023-12-08 朱诺治疗学股份有限公司 抗独特型抗体及相关方法
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
BR112019001693A2 (pt) 2016-07-29 2019-07-02 Ct Hospitalier Universitaire Toulouse anticorpos direcionados a macrófagos associados a tumores e seus usos
CA3032581A1 (en) 2016-08-01 2018-02-08 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
JOP20170154B1 (ar) 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
US11858980B2 (en) 2016-08-02 2024-01-02 Visterra, Inc. Engineered polypeptides and uses thereof
WO2018026715A1 (en) 2016-08-02 2018-02-08 Vaccinex, Inc. Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
CA3032498A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
JP2018058822A (ja) 2016-08-03 2018-04-12 ファイザー・インク ヘテロアリールスルホンをベースとするコンジュゲーションハンドル、これらの調製のための方法、および抗体薬物コンジュゲートの合成におけるこれらの使用
JP7369620B2 (ja) 2016-08-03 2023-10-26 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー マクロファージ上のＦｃ受容体結合の破壊による抗ＳｌＲＰα抗体療法の効果増強
CN116251182A (zh) 2016-08-05 2023-06-13 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
EP3493834A1 (de) 2016-08-07 2019-06-12 Novartis AG Mrna-vermittelte immunisierungsverfahren
MA45945A (fr) 2016-08-09 2019-06-19 Seattle Genetics Inc Conjugués de médicaments avec des lieurs auto-stabilisants, aux propriétés physiochimiques améliorées
CN109790201A (zh) 2016-08-12 2019-05-21 百时美施贵宝公司 纯化蛋白质的方法
CN109790532B (zh) * 2016-08-15 2022-06-17 国立大学法人北海道大学 抗lag-3抗体
EP3617232A1 (de) 2016-08-17 2020-03-04 Compugen Ltd. Anti-tigit-antikörper, anti-pvrig-antikörper und kombinationen daraus
JP7213549B2 (ja) 2016-08-22 2023-01-27 シーエイチオー ファーマ インコーポレイテッド 抗体、結合性断片、および使用の方法
CN106938051B (zh) 2016-08-22 2019-10-11 复旦大学 靶向于组织因子的抗体-药物偶联物
WO2018038684A1 (en) 2016-08-26 2018-03-01 Agency For Science, Technology And Research Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
SG11201901716TA (en) 2016-08-29 2019-03-28 Psioxus Therapeutics Ltd Adenovirus armed with bispecific t cell engager (bite)
WO2018045110A1 (en) 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
TW201825674A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現雙特異性接合分子的溶瘤病毒
CA3035976A1 (en) 2016-09-09 2018-03-15 Tg Therapeutics, Inc. Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers
HUE051700T2 (hu) 2016-09-14 2021-03-29 Abbvie Biotherapeutics Inc Anti-PD-1 antitestek
WO2018052503A1 (en) 2016-09-14 2018-03-22 Teneobio, Inc. Cd3 binding antibodies
JP7256116B2 (ja) 2016-09-19 2023-04-11 アイ－エムエービー バイオファーマ （ハンジョウ） カンパニー リミテッド 抗ｇｍ－ｃｓｆ抗体およびその使用
WO2018053542A1 (en) 2016-09-19 2018-03-22 University Of Southern California Non-radioactive cytotoxicity assays
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
RU2759334C2 (ru) 2016-09-21 2021-11-12 Нексткьюр, Инк. Антитела против siglec-15 и способы их применения
BR112019005333A2 (pt) * 2016-09-21 2019-06-11 Aptevo Research And Development Llc proteínas de ligação a cd123 e composições e métodos relacionados
EP3515937A1 (de) 2016-09-23 2019-07-31 Teva Pharmaceuticals International GmbH Behandlung von refraktärer migräne
CN110023339A (zh) 2016-09-23 2019-07-16 Csl有限公司 凝血因子结合蛋白及其应用
WO2018057955A1 (en) 2016-09-23 2018-03-29 Elstar Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
MX2019003703A (es) 2016-09-30 2020-08-13 Janssen Biotech Inc Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23.
EP3519824A1 (de) 2016-10-03 2019-08-07 Abbott Laboratories Verbesserte verfahren zur beurteilung des uch-l1-status in patientenproben
JP2019537621A (ja) 2016-10-04 2019-12-26 フェアバンクス ファーマシューティカルズ，インコーポレイテッド 抗ｆｓｔｌ３抗体およびその使用
AR110676A1 (es) 2016-10-07 2019-04-24 Novartis Ag Tratamiento del cáncer utilizando receptores de antígenos quiméricos
IL302917A (en) 2016-10-07 2023-07-01 Tcr2 Therapeutics Inc Preparations and methods for reprogramming T-cell receptors using fusion proteins
TW202246349A (zh) 2016-10-11 2022-12-01 美商艾吉納斯公司 抗ｌａｇ－３抗體及其使用方法
EP3525813B1 (de) 2016-10-11 2024-04-17 Razi Holdings, Inc. Breit neutralisierende antikörper gegen die interne glycoproteinfusionsschleife des ebolavirus
US20190233512A1 (en) 2016-10-12 2019-08-01 Sutro Biopharma, Inc. Anti-folate receptor antibodies, compositions comprising anti-folate receptor antibodies and methods of making and using anti-folate receptor antibodies
WO2018071822A2 (en) 2016-10-13 2018-04-19 Massachusetts Institute Of Technology Antibodies that bind zika virus envelope protein and uses thereof
CA3040687A1 (en) 2016-10-14 2018-04-19 Childrens' Medical Center Corporation Compositions and methods for treating diseases and disorders of the central nervous system
AU2017342559B2 (en) 2016-10-14 2022-03-24 Xencor, Inc. Bispecific heterodimeric fusion proteins containing IL-15/IL-15Ralpha Fc-fusion proteins and PD-1 antibody fragments
WO2018071576A1 (en) 2016-10-14 2018-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of tumors by inhibition of cd300f
IL291810A (en) 2016-10-18 2022-06-01 Seagen Inc Targeted administration of nicotinamide adenine dinucleotide reductase pathway inhibitors
AU2017345479B2 (en) 2016-10-19 2024-03-21 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
US11286295B2 (en) 2016-10-20 2022-03-29 Sanofi Anti-CHIKV monoclonal antibodies directed against the E2 structural protein
KR102646708B1 (ko) 2016-10-21 2024-03-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) T 세포 반응을 촉진하는 방법
EP3529270A2 (de) * 2016-10-21 2019-08-28 Adimab, LLC Antikörper gegen das respiratorische synzytial-virus und verfahren zu deren erzeugung und verwendung
EP3532489A4 (de) 2016-10-26 2020-07-08 Cedars-Sinai Medical Center Neutralisierende monoklonale anti-tl1a-antikörper
MA46673A (fr) 2016-10-26 2019-09-04 Leap Therapeutics Inc Utilisation de la bêta-caténine en tant que biomarqueur pour traiter des cancers à l'aide d'un anticorps anti-dkk-1
WO2018081578A1 (en) 2016-10-28 2018-05-03 Astute Medical, Inc. Use of antibodies to timp-2 for the improvement of renal function
US11249082B2 (en) 2016-10-29 2022-02-15 University Of Miami Zika virus assay systems
WO2018085359A1 (en) 2016-11-02 2018-05-11 Immunogen, Inc. Combination treatment with antibody-drug conjugates and parp inhibitors
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2018083538A1 (en) 2016-11-07 2018-05-11 Neuracle Scienc3 Co., Ltd. Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
EP3538558A4 (de) 2016-11-09 2020-07-15 North Carolina State University Behandlung allergischer erkrankungen mit einem chimären protein
NZ752394A (en) 2016-11-14 2021-07-30 Hangzhou Dac Biotech Co Ltd Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
US11008325B2 (en) 2016-11-14 2021-05-18 Virginia Commonwealth University Inhibitors of cancer invasion, attachment, and/or metastasis
CA3043528A1 (en) 2016-11-14 2018-05-17 Amgen Inc. Bispecific or biparatopic antigen binding proteins and uses thereof
CN109996809A (zh) 2016-11-14 2019-07-09 诺华股份有限公司 与促融合蛋白minion相关的组合物、方法和治疗用途
KR102593669B1 (ko) 2016-11-15 2023-10-25 하. 룬드벡 아크티에셀스카브 시누클레인병증의 치료를 위한 제제, 용도 및 방법
JP2020504084A (ja) * 2016-11-16 2020-02-06 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 赤血球標的化第ｖｉｉｉ因子およびその使用方法
AU2017362222A1 (en) 2016-11-16 2019-05-30 Janssen Biotech, Inc. Method of treating psoriasis with anti-IL-23 specific antibody
EP3541847A4 (de) 2016-11-17 2020-07-08 Seattle Genetics, Inc. Glycaninteragierende verbindungen und verfahren zur verwendung
JP7263235B2 (ja) 2016-11-17 2023-04-24 ２セブンティ バイオ インコーポレイテッド ＴＧＦβシグナルコンバーター
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
AU2017361887B2 (en) 2016-11-21 2019-08-15 Cureab Gmbh Anti-GP73 antibodies and immunoconjugates
US11773163B2 (en) 2016-11-21 2023-10-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the prophylactic treatment of metastases
EP3544996A2 (de) 2016-11-22 2019-10-02 TCR2 Therapeutics Inc. Zusammensetzungen und verfahren zur tcr-reprogrammierung mithilfe von fusionsproteinen
WO2018098370A1 (en) 2016-11-23 2018-05-31 Immunoah Therapeutics, Inc. 4-1bb binding proteins and uses thereof
JP7227146B2 (ja) 2016-11-23 2023-02-21 バイオベラティブ セラピューティクス インコーポレイテッド 凝固第ｉｘ因子および凝固第ｘ因子に結合する二重特異性抗体
BR112019010602A2 (pt) 2016-11-23 2019-12-17 Harpoon Therapeutics Inc proteínas trispecíficas para psma e métodos de uso
MX2019006043A (es) 2016-11-23 2019-09-26 Harpoon Therapeutics Inc Proteína de unión de antígeno prostático específico de membrana.
EP3548075A4 (de) 2016-12-05 2020-11-25 The Administrators of The Tulane Educational Fund Monoklonale arenavirus-antikörper und verwendungen
US20180164221A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
MX2019006340A (es) 2016-12-07 2019-11-07 Agenus Inc Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) y métodos de uso de los mismos.
CA3046082A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Antibodies and methods of use thereof
CA3044684A1 (en) 2016-12-09 2018-06-14 Alector Llc Anti-sirp-alpha antibodies and methods of use thereof
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
US11155635B2 (en) * 2016-12-14 2021-10-26 Pangen Biotech Inc. Anti-coagulation factor VIII antibody and use thereof
CN110300761B (zh) 2016-12-15 2023-05-09 国家生物技术研究所公司 抗pcna单克隆抗体及其用途
KR20210157471A (ko) 2016-12-15 2021-12-28 애브비 바이오테라퓨틱스 인크. 항-ox40 항체 및 이의 용도
CN110167962A (zh) 2016-12-16 2019-08-23 艾德里诺医药公司 用于干预和治疗需要的患者的充血的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig支架
EP3339324A1 (de) 2016-12-22 2018-06-27 sphingotec GmbH Anti-adrenomedullin (adm)-antikörper oder anti-adm antikörperfragment oder anti-adm-nicht-ig-gerüst zur verwendung in einer intervention und therapie von verstopfung bei einem darauf angewiesenen patienten
MA47019A (fr) 2016-12-16 2021-04-21 H Lundbeck As Agents, utilisations et procédés
TW201840585A (zh) 2016-12-22 2018-11-16 法商賽諾菲公司 用於白斑病的治療的抗人cxcr3抗體
WO2018119299A1 (en) 2016-12-22 2018-06-28 Sanofi Humanized cxcr3 antibodies with depleting activity and methods of use thereof
CN106519034B (zh) 2016-12-22 2020-09-18 鲁南制药集团股份有限公司 抗pd-1抗体及其用途
JP2020503316A (ja) 2016-12-22 2020-01-30 ジェネンテック， インコーポレイテッド 凍結乾燥ポリペプチドの再構成時間を低減するための方法及び製剤
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
JOP20190134A1 (ar) 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
EP3559032A1 (de) 2016-12-23 2019-10-30 Innate Pharma Heterodimere antigenbindende proteine
EP3559047A1 (de) 2016-12-23 2019-10-30 Novartis AG Faktor xi-antikörper und verfahren zur verwendung
AU2017383537A1 (en) 2016-12-23 2019-06-27 Novartis Ag Methods of treatment with anti-factor XI/XIa antibodies
RU2019123063A (ru) 2016-12-23 2021-01-26 Вистерра, Инк. Связывающие полипептиды и способы их получения
WO2018122249A1 (en) 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
WO2018122245A1 (en) 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
CA3049105A1 (en) 2017-01-04 2018-07-12 Lauren O. Bakaletz Dnabii vaccines and antibodies with enhanced activity
TW201825515A (zh) 2017-01-04 2018-07-16 美商伊繆諾金公司 Ｍｅｔ抗體以及其免疫結合物及用途
CN110267985B (zh) 2017-01-04 2023-05-23 H.隆德贝克有限公司 用于治疗眼科疾病的特异性针对过度磷酸化τ蛋白的抗体
CA3049114A1 (en) 2017-01-04 2018-07-12 Lauren O. Bakaletz Antibody fragments for the treatment of biofilm-related disorders
EP3565596A4 (de) 2017-01-05 2020-12-16 Brown University Verfahren und zusammensetzungen in verbindung mit anti-chi3l1-antikörperreagenzien
EA039433B1 (ru) 2017-01-05 2022-01-27 Нетрис Фарма Комбинированное лечение лекарственными средствами, интерферирующими с нетрином-1, и лекарственными средствами, ингибиторами контрольных точек иммуного ответа
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
WO2018128454A1 (ko) 2017-01-06 2018-07-12 에이비엘바이오 주식회사 항 α-SYN 항체 및 그 용도
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
EP3565845A4 (de) 2017-01-06 2020-10-07 Biosion, Inc. Erbb2-antikörper und deren verwendungen
US11197928B2 (en) * 2017-01-13 2021-12-14 Board Of Regents, The University Of Texas System Sustained production of high affinity antigen specific antibody by high dose BAFF receptor-targeting mAb-siRNA conjugate
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
CA3050691A1 (en) 2017-01-17 2018-07-26 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating lysosomal storage diseases and disorders
AU2018209940A1 (en) 2017-01-18 2019-07-11 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
BR112019013238A2 (pt) 2017-01-20 2020-02-11 Tayu Huaxia Biotech Medical Group Co., Ltd. Anticorpos anti-pd-1 e usos dos mesmos
CN109476755B (zh) 2017-01-24 2020-12-04 天境生物科技(上海)有限公司 Cd73抗体及其用途
US20190345186A1 (en) 2017-01-24 2019-11-14 Pfizer Inc. Calicheamicin deratives and antibody drug conjugates thereof
WO2018140630A1 (en) 2017-01-25 2018-08-02 Northwestern University Autophagy inducers for treatment of cns conditions
WO2018140510A1 (en) 2017-01-25 2018-08-02 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders
WO2018140725A1 (en) 2017-01-26 2018-08-02 Novartis Ag Cd28 compositions and methods for chimeric antigen receptor therapy
EP3574012A1 (de) 2017-01-27 2019-12-04 Memorial Sloan Kettering Cancer Center Bispezifische her2- und cd3-bindende moleküle
SG11201906968YA (en) 2017-01-27 2019-08-27 A Clip Institute Co Prophylactic and/or therapeutic agent of infectious disease or inflammatory disease
CA3052095A1 (en) 2017-01-30 2018-08-02 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
JP7191833B2 (ja) 2017-01-30 2022-12-19 中外製薬株式会社 抗スクレロスチン抗体およびその使用
EP3577134A1 (de) 2017-01-31 2019-12-11 Novartis AG Behandlung von krebs mit chimären t-zellrezeptorproteinen mit mehreren spezifitäten
EP3354278A1 (de) 2017-01-31 2018-08-01 Sanofi Nervenzellschutzwirkung von spezifischen antikörpern für die protofibrillenform des beta-amyloid-peptids
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
MA47442A (fr) 2017-02-07 2019-12-18 Janssen Biotech Inc Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
CA3052911A1 (en) 2017-02-08 2018-08-16 Novartis Ag Fgf21 mimetic antibodies and uses thereof
CA3052291A1 (en) 2017-02-09 2018-08-16 Memorial Sloan Kettering Cancer Center Anti-kir3dl1 antibodies
US11471538B2 (en) 2017-02-10 2022-10-18 INSERM (Institut National de la Santéet de la Recherche Medicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
US11021535B2 (en) 2017-02-10 2021-06-01 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
US20200291089A1 (en) 2017-02-16 2020-09-17 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
SG11201907159SA (en) 2017-02-16 2019-09-27 Xbiotech Inc Treatment of hidradenitis suppurativa
US10626169B2 (en) 2017-02-17 2020-04-21 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
JP7304288B2 (ja) 2017-02-17 2023-07-06 サノフイ ジストログリカンおよびラミニン２に対する特異性を有する多特異性結合性分子
EP3583124A1 (de) 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antikörper gegen alpha-synuklein und verwendungen davon
EP3585813A1 (de) 2017-02-22 2020-01-01 Sutro Biopharma, Inc. Pd-1/tim-3 bi-spezifische antikörper, zusammensetzungen davon und verfahren zur herstellung und verwendung davon
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
EP3585819A4 (de) 2017-02-27 2020-10-14 Caerus Therapeutics, Inc. Antikörperkonstrukte und verfahren zur behandlung von krebs
EP3589662A4 (de) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. Induzierbares monovalentes antigenbindendes protein
WO2018158719A1 (en) 2017-03-02 2018-09-07 Novartis Ag Engineered heterodimeric proteins
WO2018158398A1 (en) 2017-03-02 2018-09-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
MA47812A (fr) 2017-03-03 2021-04-14 Seagen Inc Composés interagissant avec le glycane et méthodes d'utilisation
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
EP4095161A1 (de) 2017-03-15 2022-11-30 Tsinghua University Neuartige anti-trkb-antikörper
CA3056088A1 (en) 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
CN110382544B (zh) 2017-03-16 2023-12-22 先天制药公司 用于治疗癌症的组合物和方法
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
EP3597221B1 (de) 2017-03-17 2023-08-30 Osaka University Mittel zur behandlung von netzhautdegenerationen und von erkrankungen in zusammenhang mit lichtaufnahme
US10941178B2 (en) 2017-03-17 2021-03-09 Gilead Sciences, Inc. Method of purifying an antibody
EP3600419B1 (de) 2017-03-20 2023-08-09 Vaccinex, Inc. Behandlung von krebs mit einem semaphorin-4d-antikörper in kombination mit einem epigenetischen modulierungsmittel
TWI808963B (zh) 2017-03-22 2023-07-21 法商賽諾菲公司 使用人類化抗ｃｘｃｒ５抗體治療狼瘡
US11016092B2 (en) 2017-03-23 2021-05-25 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase L1
AU2018240117A1 (en) 2017-03-24 2019-09-19 Beth Israel Deaconess Medical Center, Inc. Methods for preventing and treating heart disease
US11730822B2 (en) 2017-03-24 2023-08-22 Seagen Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
US20200330590A1 (en) 2017-03-27 2020-10-22 Celgene Corporation Methods and compositions for reduction of immunogenicity
WO2018183041A1 (en) 2017-03-27 2018-10-04 Immunomedics, Inc. Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor
WO2018183366A1 (en) 2017-03-28 2018-10-04 Syndax Pharmaceuticals, Inc. Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
CN110678753B (zh) 2017-03-30 2023-10-24 普莱戈斯瑞恩癌症有限责任公司 用于治疗肺癌的组合物和方法
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
JP7071994B2 (ja) 2017-03-30 2022-05-19 プロガストリン、エ、カンセル、エス、アー エル、エル 前立腺がんを治療するための組成物および方法
JP7291398B2 (ja) 2017-03-30 2023-06-15 ザ ユニバーシティー オブ クイーンズランド キメラ分子およびその使用
JP2020512357A (ja) 2017-03-31 2020-04-23 ファイブ プライム セラピューティクス， インコーポレイテッド 抗ｇｉｔｒ抗体を使用した癌の併用療法
CN110914300A (zh) 2017-04-03 2020-03-24 安康乐济股份有限公司 使用ps靶向抗体与免疫肿瘤学药剂治疗癌症的方法
EP3606964A4 (de) 2017-04-03 2020-12-09 Immunomedics, Inc. Subkutane verabreichung von antikörper-arzneimittelkonjugaten zur krebstherapie
WO2018185516A1 (en) 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
JP7315466B2 (ja) 2017-04-05 2023-07-26 アスチュート メディカル，インコーポレイテッド 生体試料中において改善した性能を有する、ｔｉｍｐ２に関するアッセイ
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
JOP20190243A1 (ar) 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
BR112019017241A2 (pt) 2017-04-13 2020-04-14 Agenus Inc anticorpos anti-cd137 e métodos de uso dos mesmos
AU2018252546A1 (en) 2017-04-13 2019-10-10 Sairopa B.V. Anti-SIRPα antibodies
EP3610264A1 (de) 2017-04-13 2020-02-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur diagnose und behandlung von duktalem pankreasadenokarzinom
JP2020516648A (ja) 2017-04-13 2020-06-11 シワ コーポレーション ヒト化モノクローナル終末糖化産物抗体
WO2018189403A1 (en) 2017-04-14 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancer
AU2018250695A1 (en) 2017-04-14 2019-11-07 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
BR112019021495A8 (pt) 2017-04-14 2023-05-02 Inst Curie Compostos de ligação ao amhrii para prevenção ou tratamento de cânceres de pulmão
CA3058282A1 (en) 2017-04-14 2018-10-18 Gamamabs Pharma Amhrii-binding compounds for preventing or treating cancers
US10877048B2 (en) 2017-04-15 2020-12-29 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
JP2020517256A (ja) 2017-04-19 2020-06-18 エルスター セラピューティクス， インコーポレイテッド 多重特異性分子およびその使用
CN110506056A (zh) 2017-04-21 2019-11-26 斯塔滕生物技术有限公司 抗apoc3抗体和其使用方法
CA3059232A1 (en) 2017-04-27 2018-11-01 The Brigham And Women's Hospital, Inc. Novel alk2 inhibitors and methods for inhibiting bmp signaling
SG11201909563VA (en) 2017-04-27 2019-11-28 Seattle Genetics Inc Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
US20230140818A1 (en) 2017-04-27 2023-05-04 The University Of Hong Kong Use of hcn inhibitors for treatment of cancer
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US10877038B2 (en) 2017-04-28 2020-12-29 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
EP4328241A2 (de) 2017-04-28 2024-02-28 Marengo Therapeutics, Inc. Multispezifische moleküle mit einer nichtimmunglobulin-heterodimerisierungsdomäne und verwendungen davon
EP3618863B1 (de) 2017-05-01 2023-07-26 Agenus Inc. Anti-tigit antikörper und deren verwendung
CN110809582B (zh) 2017-05-01 2023-12-22 儿童医疗中心有限公司 涉及抗pd1抗体试剂的方法以及组合物
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
CA3061516A1 (en) 2017-05-02 2018-11-08 Prothena Biosciences Limited Antibodies recognizing tau
CN110891596A (zh) 2017-05-04 2020-03-17 希望之城 抗体可变结构域及抗体构建体
RU2019139434A (ru) 2017-05-05 2021-06-07 Сентр фор Проуб Девелопмент энд Коммерсиализэйшн Моноклональные антитела против igf-1r и их применение
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
CN111263747B (zh) 2017-05-05 2023-10-27 探针技术开发及商业化中心 双官能螯合物的药代动力学增强及其用途
KR20200004324A (ko) 2017-05-05 2020-01-13 백시넥스 인코포레이티드 인간 항-세마포린 4d 항체
WO2018204907A1 (en) 2017-05-05 2018-11-08 Amgen Inc. Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
CN110621337B (zh) 2017-05-10 2021-11-09 浙江时迈药业有限公司 抗lag3人单克隆抗体及其用途
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
WO2018209301A1 (en) 2017-05-11 2018-11-15 Cytodyn Inc. Methods for treating or preventing graft-versus-host disease involving the administration of anti-ccr5 receptor agents
US11524999B2 (en) 2017-05-12 2022-12-13 The Trustees Of The University Of Pennsylvania Fully humanized anti-platelet factor 4 antibodies that treat heparin-induced thrombocytopenia
KR102376863B1 (ko) 2017-05-12 2022-03-21 하푼 테라퓨틱스, 인크. 메소텔린 결합 단백질
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
JP7209936B2 (ja) 2017-05-12 2023-01-23 ハープーン セラピューティクス，インク． Ｍｓｌｎ標的三重特異性タンパク質及びその使用方法
WO2018213612A1 (en) 2017-05-18 2018-11-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin polypeptides and proteins
KR20240042244A (ko) 2017-05-19 2024-04-01 신닥스 파마슈티컬스, 인크. 조합 요법
WO2018217688A1 (en) 2017-05-22 2018-11-29 Dana-Farber Cancer Institute, Inc. Compositions and methods for inhibition of mica/b shedding
CA3063344A1 (en) 2017-05-23 2018-11-29 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Novel cd73 antibody, preparation and uses thereof
US20200270334A1 (en) 2017-05-24 2020-08-27 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
WO2018217940A2 (en) 2017-05-24 2018-11-29 Sutro Biopharma, Inc. Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
US20200362058A1 (en) 2017-05-24 2020-11-19 Novartis Ag Antibody-cytokine engrafted proteins and methods of use
AU2018272054A1 (en) 2017-05-25 2019-09-26 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
AR111830A1 (es) 2017-05-25 2019-08-21 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
JP7269183B2 (ja) 2017-05-30 2023-05-08 アボット・ラボラトリーズ 心臓トロポニンｉを使用する、ヒト対象における軽度外傷性脳損傷を診断及び査定する一助となるための方法
EP3630834A1 (de) 2017-05-31 2020-04-08 STCube & Co., Inc. Verfahren zur behandlung von krebs mit antikörpern und molekülen, die immunspezifisch an btn1a1 binden
JOP20190259A1 (ar) 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1
WO2018222901A1 (en) 2017-05-31 2018-12-06 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
EP3630835A1 (de) 2017-05-31 2020-04-08 STCube & Co., Inc. Antikörper und moleküle, die immunspezifisch an btn1a1 binden, und therapeutische verwendungen davon
US11225523B2 (en) 2017-06-01 2022-01-18 Compugen Ltd. Triple combination antibody therapies
HUE063274T2 (hu) 2017-06-01 2024-01-28 Akamis Bio Ltd Onkolitikus vírus és eljárás
EP3630841A1 (de) 2017-06-02 2020-04-08 Pfizer Inc. Für flt3 spezifische antikörper und ihre verwendungen
EP3634995A4 (de) 2017-06-05 2021-06-09 Janssen Biotech, Inc. Spezifisch an pd-1 bindende antikörper und verwendungsverfahren
CN110997724A (zh) 2017-06-06 2020-04-10 斯特库伯株式会社 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
AU2018279728B2 (en) 2017-06-08 2023-07-20 The Brigham And Women's Hospital, Inc. Methods and compositions for identifying epitopes
BR112019024291A2 (pt) 2017-06-09 2020-07-28 Providence Health & Services-Oregon utilização de cd39 e de cd103 para a identificação de células t tumorais humanas reativas para o tratamento do câncer
GB201709379D0 (en) * 2017-06-13 2017-07-26 Univ Leuven Kath Humanised ADAMTS13 binding antibodies
US20210079057A1 (en) 2017-06-13 2021-03-18 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
US11583576B2 (en) 2017-06-15 2023-02-21 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
BR112019024410A2 (pt) 2017-06-20 2020-07-14 Amgen Inc. método de tratamento ou melhoria de disfunções metabólicas usando proteínas de ligação para receptor do peptídeo inibidor gástrico (gipr) em combinação com agonistas de glp 1
EP3642344A4 (de) 2017-06-21 2021-03-31 The University of North Carolina at Chapel Hill Verfahren und zusammensetzungen für auf krebszellen abzielende chimäre antigenrezeptoren
WO2018234843A1 (en) 2017-06-22 2018-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS WITH AGENTS CAPABLE OF INHIBITING THE ACTIVATION OF MOSES-ASSOCIATED INVARIANT T CELLS (MAIT)
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
JP7433910B2 (ja) 2017-06-22 2024-02-20 ノバルティス アーゲー Ｃｄ７３に対する抗体分子及びその使用
JP2020529862A (ja) * 2017-06-25 2020-10-15 システィミューン， インク．Ｓｙｓｔｉｍｍｕｎｅ， Ｉｎｃ． 抗ｐｄ−１抗体とその作製及び使用方法
WO2019006007A1 (en) 2017-06-27 2019-01-03 Novartis Ag POSOLOGICAL REGIMES FOR ANTI-TIM3 ANTIBODIES AND USES THEREOF
CN110785433A (zh) 2017-06-28 2020-02-11 诺华股份有限公司 预防和治疗尿失禁的方法
CA3068672A1 (en) 2017-06-28 2019-01-03 The Rockefeller University Anti-mertk agonistic antibody-drug conjugates and uses thereof
JP2020529832A (ja) 2017-06-30 2020-10-15 ゼンコア インコーポレイテッド ＩＬ−１５／ＩＬ−１５Ｒαおよび抗原結合ドメインを含む標的化ヘテロダイマーＦｃ融合タンパク質
WO2019010131A1 (en) 2017-07-03 2019-01-10 Abbott Laboratories IMPROVED METHODS FOR MEASURING CARBOXY TERMINATION HYDROLASE LEVELS OF UBIQUITIN L1 IN BLOOD
GB201710838D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
AU2018298676A1 (en) * 2017-07-10 2019-12-19 Innate Pharma Siglec-9-neutralizing antibodies
MX2020000342A (es) 2017-07-11 2020-08-17 Compass Therapeutics Llc Anticuerpos agonistas que se unen a cd137 humano y sus usos.
US11892457B2 (en) 2017-07-12 2024-02-06 The Johns Hopkins University Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
EA202090247A1 (ru) 2017-07-14 2020-05-12 Цитомкс Терапьютикс, Инк. Антитела против cd166 и их применения
SG11202000298VA (en) 2017-07-14 2020-02-27 Pfizer Antibodies to madcam
EP3431496A1 (de) 2017-07-19 2019-01-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-isoasp7-amyloid-beta-antikörper und verwendungen davon
US20190048073A1 (en) 2017-07-20 2019-02-14 Pfizer Inc. Anti-gd3 antibodies and antibody-drug conjugates
JP2020527572A (ja) 2017-07-20 2020-09-10 ノバルティス アーゲー 抗ｌａｇ−３抗体の投薬量レジメンおよびその使用
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
US11174322B2 (en) 2017-07-24 2021-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies and peptides to treat HCMV related diseases
WO2019020593A1 (en) 2017-07-25 2019-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATION OF MONOCYTOPOISIS
WO2019023245A1 (en) 2017-07-25 2019-01-31 Cedars-Sinai Medical Center METHODS OF TREATING HEPATIC DISEASES
WO2019023316A1 (en) 2017-07-26 2019-01-31 Sutro Biopharma, Inc. METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN THE TREATMENT OF A T CELL LYMPHOMA
EP3658589B1 (de) 2017-07-26 2023-09-27 Forty Seven, Inc. Anti-sirp-alpha-antikörper und verwandte verfahren
JP6889328B2 (ja) 2017-07-31 2021-06-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 三次元構造に基づくヒト化方法
BR112020001679A2 (pt) * 2017-08-02 2020-07-21 Phanes Therapeutics, Inc. anticorpos anti-cd47 e usos dos mesmos
CN117700548A (zh) 2017-08-03 2024-03-15 艾利妥 抗cd33抗体及其使用方法
MX2020001327A (es) 2017-08-04 2020-03-20 Amgen Inc Metodo de conjugacion de cys-acm.
TW202402809A (zh) 2017-08-15 2024-01-16 美商歐米諾斯公司 用於治療和／或預防與造血幹細胞移植有關的移植物抗宿主病和／或瀰漫性肺泡出血和／或靜脈閉塞性病的方法
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
WO2019035034A1 (en) 2017-08-16 2019-02-21 The Broad Institute, Inc. NEURONAL DOSAGE METHOD INVOLVING CALCINEURIN
EP3444272A1 (de) 2017-08-17 2019-02-20 International-Drug-Development-Biotech Behandlung von ck8-positivem krebs in verbindung mit dem k-ras-genstatus
JP7263320B2 (ja) 2017-08-22 2023-04-24 バイオジェン・エムエイ・インコーポレイテッド 抗ベータアミロイド抗体を含有する医薬組成物
CN111094349A (zh) 2017-08-23 2020-05-01 马克思-德布鲁克-分子医学中心亥姆霍兹联合会 嵌合抗原受体和结合cxcr5的car-t细胞
AU2018323470A1 (en) 2017-08-28 2020-03-19 Angiex, Inc. Anti-TM4SF1 antibodies and methods of using same
EP3679070A1 (de) 2017-09-07 2020-07-15 Augusta University Research Institute, Inc. Antikörper gegen protein 1 des programmierten zelltods
US10849960B2 (en) 2017-09-08 2020-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer
JP2020533022A (ja) * 2017-09-11 2020-11-19 モナシュ ユニバーシティー ヒトトロンビン受容体ｐａｒ４に対する結合タンパク質
SG11202001606XA (en) 2017-09-13 2020-03-30 Five Prime Therapeutics Inc Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
AU2018334213A1 (en) 2017-09-15 2020-03-26 Cedars-Sinai Medical Center Methods for improving organ function in organ transplant patients
US20200353076A1 (en) 2017-09-18 2020-11-12 Sutro Biopharma, Inc. Anti-folate receptor alpha antibody conjugates and their uses
EP3684821A4 (de) * 2017-09-19 2021-06-16 The University Of British Columbia Anti-hla-a2-antikörper und verfahren zur verwendung davon
JP7330174B2 (ja) 2017-09-20 2023-08-21 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル オートファジーをモジュレーションするための方法及び医薬組成物
JP7279026B2 (ja) 2017-09-20 2023-05-22 メルサナ セラピューティクス インコーポレイテッド Ｎａｐｉ２ｂ標的化療法に対する応答を予測するための組成物および方法
JP7317023B2 (ja) 2017-09-20 2023-07-28 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 新規抗ｈｌａ－ａ２抗体、およびその使用
MX2020003219A (es) 2017-09-21 2020-07-20 Imcheck Therapeutics Sas Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
EP3684803A1 (de) * 2017-09-22 2020-07-29 Kite Pharma, Inc. Antigenbindende moleküle und verfahren zur verwendung davon
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
EP3854414A1 (de) 2017-09-25 2021-07-28 AdrenoMed AG Anti-adrenomedullin (adm)-bindemittel zur verwendung in der therapie oder prävention von symptomen einer krankheit
US11919949B2 (en) * 2017-09-27 2024-03-05 Elasmogen Ltd Specific binding molecules
US11547747B2 (en) 2017-09-27 2023-01-10 University Of Georgia Research Foundation, Inc. Treatment and detection of infection and disease associated with different fungal pathogens
US11761963B2 (en) 2017-09-27 2023-09-19 Alexion Pharmaceuticals, Inc. Biomarker signature for predicting tumor response to anti-CD200 therapy
CA3076313A1 (en) 2017-09-28 2019-04-04 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
WO2019067015A1 (en) 2017-09-29 2019-04-04 City Of Hope RECEPTORS OF CHIMERIC ANTIGENS AND BISPECIFIC ANTIBODIES FOR THE TREATMENT OF COAT CELL LYMPHOMA
US20190100587A1 (en) 2017-10-02 2019-04-04 Covagen Ag IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
EP3461841B1 (de) 2017-10-02 2019-09-11 Certest Biotec, S.L. Antikörper gegen dps und testvorrichtungen zum nachweis von bakterien der gattung campylobacter
US20190153096A1 (en) 2017-10-02 2019-05-23 Covagen Ag Cd3/cd33 bispecific binding molecules
WO2019070726A1 (en) 2017-10-02 2019-04-11 Visterra, Inc. CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF
CA3078460A1 (en) 2017-10-04 2019-04-11 Opko Pharmaceuticals, Llc Articles and methods directed to personalized therapy of cancer
EP3693013A4 (de) 2017-10-06 2021-06-30 Ono Pharmaceutical Co., Ltd. Bispezifischer antikörper
SG11202002489YA (en) 2017-10-06 2020-04-29 Prothena Biosciences Ltd Anti-transthyretin antibodies
US20230192897A1 (en) 2017-10-10 2023-06-22 Numab Therapeutics AG Multispecific antibody
EP3470426A1 (de) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispezifischer antikörper
CN111183159A (zh) 2017-10-10 2020-05-19 努玛治疗有限公司 靶向cd137的抗体及其使用方法
EP3470428A1 (de) 2017-10-10 2019-04-17 Numab Innovation AG Anti cd137 antikörper und deren verwendung
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
EP3694879A1 (de) 2017-10-10 2020-08-19 Numab Therapeutics AG Gegen pdl1 gerichtete antikörper und verfahren zur verwendung davon
EP3470429A1 (de) 2017-10-10 2019-04-17 Numab Innovation AG Auf pdl1 gerichtete antikörper und verfahren zur verwendung davon
JP7356727B2 (ja) 2017-10-12 2023-10-05 慶應義塾 アクアポリン３（ａｑｐ３）の細胞外ドメインに特異的に結合する抗ａｑｐ３モノクローナル抗体、及びその使用
KR102569133B1 (ko) 2017-10-13 2023-08-21 하푼 테라퓨틱스, 인크. 삼중특이적 단백질 및 사용 방법
CR20200195A (es) 2017-10-13 2020-08-14 Harpoon Therapeutics Inc Proteínas de unión a antigenos de maduraciòn de celulas b
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2019077082A1 (en) 2017-10-18 2019-04-25 Adrenomed Ag SURVEILLANCE OF THERAPY UNDER TREATMENT WITH ANTI-ADRENOMEDULIN BINDER (ADM)
US11466073B2 (en) 2017-10-18 2022-10-11 Csl Limited Human serum albumin variants and uses thereof
EP3697816A1 (de) 2017-10-19 2020-08-26 Debiopharm International S.A. Kombinationsprodukt zur behandlung von krebs
KR20200074160A (ko) 2017-10-20 2020-06-24 가꼬우호우징 효고 이카다이가쿠 항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물
US11530276B2 (en) 2017-10-25 2022-12-20 4TEEN4 Pharmaceuticals GmbH DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
WO2019089594A1 (en) 2017-10-31 2019-05-09 Immunogen, Inc. Combination treatment with antibody-drug conjugates and cytarabine
CA3080103A1 (en) 2017-10-31 2019-05-09 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
US11673963B2 (en) 2017-11-02 2023-06-13 Oxford Biotherapeutics Ltd CRTAM antibodies and methods of treating cancer
EP3706793A1 (de) 2017-11-08 2020-09-16 Xencor, Inc. Bispezifische und monospezifische antikörper unter verwendung von neuartigen anti-pd-1-sequenzen
US10597462B1 (en) * 2017-11-08 2020-03-24 University Of Puerto Rico Anti-TLT-1 antibody and uses thereof
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2019094595A2 (en) 2017-11-09 2019-05-16 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
WO2019099440A1 (en) 2017-11-14 2019-05-23 Arcellx, Inc. Multifunctional immune cell therapies
JP2021503478A (ja) 2017-11-16 2021-02-12 ノバルティス アーゲー 組み合わせ治療
MX2020004674A (es) 2017-11-17 2020-08-13 Abl Bio Inc Anticuerpos contra alfa-sinucleina y usos de los mismos.
WO2019100052A2 (en) 2017-11-20 2019-05-23 Compass Therapeutics Llc Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
EP3713959A1 (de) 2017-11-21 2020-09-30 Innate Pharma Multispezifische antigenbindende proteine
EP3713575A4 (de) 2017-11-21 2021-08-25 Rgenix, Inc. Polymorphe und ihre verwendung
EP3713965A1 (de) 2017-11-22 2020-09-30 Novartis AG Reverse bindemittel für anti-faktor-xi/xia-antikörper und verwendungen davon
EP3713966A1 (de) * 2017-11-22 2020-09-30 Vacara AB Antikörper gegen citrullinierte proteine
EP3489259A1 (de) 2017-11-23 2019-05-29 Etablissement Français du Sang Anti-il-1rap-car-t-exprimierende zellen and deren verwendung
WO2019102435A1 (en) 2017-11-27 2019-05-31 Euro-Celtique S.A. Humanized antibodies targeting human tissue factor
WO2019101995A1 (en) 2017-11-27 2019-05-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for cardiac regeneration
PL3717011T3 (pl) 2017-11-29 2023-03-27 Csl Limited Sposób leczenia lub zapobiegania uszkodzeniu niedokrwienno- reperfuzyjnemu
CN112040970A (zh) 2017-11-29 2020-12-04 得克萨斯大学体系董事会 用于癌症疗法的组合物和方法
JOP20200132A1 (ar) 2017-11-29 2022-10-30 Prothena Biosciences Ltd [Ie/Ie] صيغة مجففة بالتبريد من جسم مضاد أحادي النسيلة ضد ترانس ثيرتين
EP3717517A1 (de) * 2017-11-30 2020-10-07 H. Hoffnabb-La Roche Ag Anti-pd-l1-antikörper und verfahren zu deren verwendung zum nachweis von pd-l1
WO2019106126A1 (en) 2017-12-01 2019-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Mdm2 modulators for the diagnosis and treatment of liposarcoma
AU2018375375A1 (en) 2017-12-01 2020-05-28 Seagen Inc. CD47 antibodies and uses thereof for treating cancer
CA3084495A1 (en) 2017-12-01 2019-06-06 Seattle Genetics, Inc. Humanized anti-liv1 antibodies for the treatment of breast cancer
US11629198B2 (en) * 2017-12-05 2023-04-18 The Trustees Of The University Of Pennsylvania Fusion proteins and antibodies targeting human red blood cell antigens
PT3720879T (pt) 2017-12-05 2022-07-13 Progastrine Et Cancers S A R L Terapia de combinação entre anticorpo anti-progastrina e imunoterapia para tratar o cancro
WO2019113375A2 (en) 2017-12-06 2019-06-13 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
WO2019113464A1 (en) 2017-12-08 2019-06-13 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
US11022617B2 (en) 2017-12-09 2021-06-01 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1)
BR112020010085A2 (pt) 2017-12-09 2020-10-13 Abbott Laboratories métodos para auxiliar no diagnóstico e avaliar uma lesão cerebral traumática em um indivíduo humano usando uma combinação de gfap e uch-l1
EP3724229A1 (de) 2017-12-11 2020-10-21 Amgen Inc. Kontinuierliches herstellungsverfahren für bispezifische antikörperprodukte
EP3725806A4 (de) 2017-12-14 2022-03-30 ABL Bio Inc. Bispezifischer antikörper gegen a-syn/igf1r und seine verwendung
KR20200117997A (ko) 2017-12-15 2020-10-14 알레타 바이오쎄라퓨틱스, 인크. Cd19 변이체
EP3724225A1 (de) 2017-12-15 2020-10-21 Juno Therapeutics, Inc. Anti-cct5-bindende moleküle und verfahren zur verwendung davon
WO2019125732A1 (en) 2017-12-19 2019-06-27 Xencor, Inc. Engineered il-2 fc fusion proteins
WO2019121872A1 (en) 2017-12-20 2019-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of liver cancer
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
KR20200104364A (ko) 2017-12-27 2020-09-03 테네오바이오, 인코포레이티드 Cd3-델타/엡실론 이형이량체 특이적 항체
US11891439B2 (en) 2017-12-28 2024-02-06 Astute Medical, Inc. Antibodies and assays for CCL14
US11440957B2 (en) 2017-12-29 2022-09-13 Alector Llc Anti-TMEM106B antibodies and methods of use thereof
TW201940518A (zh) 2017-12-29 2019-10-16 美商安進公司 針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
EP3724223A1 (de) 2018-01-02 2020-10-21 The United States of America, as represented by The Secretary, Department of Health and Human Services Neutralisierender antikörper gegen ebola-virus-glycoprotein und deren verwendung
EP3735422A1 (de) 2018-01-05 2020-11-11 AC Immune SA Fehlgefaltete tdp-43-bindende moleküle
MX2020006976A (es) 2018-01-12 2020-10-05 Amgen Inc Anticuerpos del receptor de tipo i del polipeptido activador de la adenilato?ciclasa hipofisaria (pac1) y sus usos.
JP7358361B2 (ja) 2018-01-12 2023-10-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｉｍ３に対する抗体およびその使用
WO2019145413A1 (en) 2018-01-25 2019-08-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonists of il-33 for use in methods for preventing ischemia reperfusion injury in an organ
CN111954541A (zh) 2018-01-25 2020-11-17 Acm生物实验室私人有限公司 包含可溶性包封抗原的聚合物囊泡以及其制备方法和用途
WO2019145537A1 (en) 2018-01-26 2019-08-01 Ecs-Progastrin Sa Combination of progastrin detection with other cancer biomarkers in cancer diagnosis
EA202091563A1 (ru) * 2018-01-26 2020-10-08 Регенерон Фармасьютикалз, Инк. Человеческие антитела к гемагглютинину вируса гриппа
US11472874B2 (en) 2018-01-31 2022-10-18 Alector Llc Anti-MS4A4A antibodies and methods of use thereof
JP7404247B2 (ja) 2018-02-01 2023-12-25 ファイザー・インク Ｃｄ７０を標的とするキメラ抗原受容体
US11377500B2 (en) 2018-02-01 2022-07-05 Pfizer Inc. Antibodies specific for CD70 and their uses
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
CA3089906A1 (en) 2018-02-08 2019-08-15 Amgen Inc. Low ph pharmaceutical antibody formulation
SG11202006686SA (en) 2018-02-08 2020-08-28 Sphingotec Gmbh Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia
TWI804572B (zh) 2018-02-09 2023-06-11 日商小野藥品工業股份有限公司 雙特異性抗體
WO2019155474A1 (en) 2018-02-12 2019-08-15 Hadasit Medical Research Services & Development Ltd. Modulation of slamf6 splice variants for cancer therapy
WO2019157772A1 (zh) 2018-02-13 2019-08-22 和元生物技术（上海）股份有限公司 抗trailr2抗体-毒素-偶联物及其在抗肿瘤治疗中的药物用途
WO2019158512A1 (en) 2018-02-13 2019-08-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prognosis and the treatment of glioblastoma
EP3752195A4 (de) 2018-02-14 2021-11-17 Viela Bio, Inc. Antikörper gegen felinen mcdonough-sarkom(fms)-ähnlichen tyrosinkinase-3-rezeptorliganden (flt3l) und verwendungen davon zur behandlung von autoimmun- und entzündungskrankheiten
CN111757894A (zh) * 2018-02-14 2020-10-09 Abba 疗法股份公司 抗人类pd-l2抗体
EP3755707A1 (de) 2018-02-20 2020-12-30 Seagen Inc. Hydrophobe auristatin-f-verbindungen und deren konjugate
AU2019226034A1 (en) 2018-02-21 2020-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 Env and their use
AU2019225393A1 (en) 2018-02-23 2020-08-20 Cartherics Pty. Ltd. T cell disease treatment targeting TAG-72
US11859250B1 (en) 2018-02-23 2024-01-02 Children's Hospital Medical Center Methods for treating eosinophilic esophagitis
WO2019166499A1 (en) 2018-02-27 2019-09-06 Ecs-Progastrin Sa Progastrin as a biomarker for immunotherapy
PE20211001A1 (es) 2018-02-27 2021-06-01 Incyte Corp Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
US20210002373A1 (en) 2018-03-01 2021-01-07 Nextcure, Inc. KLRG1 Binding Compositions and Methods of Use Thereof
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
JP2021515770A (ja) 2018-03-05 2021-06-24 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ−２３特異的抗体を用いたクローン病の治療方法
WO2019170131A1 (zh) 2018-03-07 2019-09-12 复旦大学 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
CA3093694A1 (en) 2018-03-12 2019-09-19 Memorial Sloan Kettering Cancer Center Bispecific binding agents and uses thereof
WO2019177690A1 (en) 2018-03-12 2019-09-19 Zoetis Services Llc Anti-ngf antibodies and methods thereof
EP3765517A1 (de) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. An calreticulin bindende multifunktionsmoleküle und ihre verwendungen
CN110272490B (zh) 2018-03-14 2021-05-14 上海开拓者生物医药有限公司 靶向ctla-4抗体、其制备方法和用途
US20210009711A1 (en) 2018-03-14 2021-01-14 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
CA3093729A1 (en) * 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
CA3094098A1 (en) * 2018-03-21 2019-09-26 ALX Oncology Inc. Antibodies against signal-regulatory protein alpha and methods of use
GB201804701D0 (en) 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
TW202003565A (zh) 2018-03-23 2020-01-16 美商必治妥美雅史谷比公司 抗mica及/或micb抗體及其用途
WO2019190969A1 (en) 2018-03-26 2019-10-03 Sutro Biopharma, Inc. Anti-bcma receptor antibodies, compositions comprising anti bcma receptor antibodies and methods of making and using anti-bcma antibodies
HRP20230744T1 (hr) 2018-03-26 2023-10-27 Glycanostics S.R.O. Sredstva i metode glikoprofiliranja proteina
EP3775206A1 (de) 2018-03-28 2021-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzungen zur behandlung von krebs
CN112313248A (zh) 2018-03-29 2021-02-02 百时美施贵宝公司 纯化单体单克隆抗体的方法
KR20200138254A (ko) 2018-03-30 2020-12-09 암젠 인크 C-말단 항체 변이체
US11155618B2 (en) 2018-04-02 2021-10-26 Bristol-Myers Squibb Company Anti-TREM-1 antibodies and uses thereof
CN110343178B (zh) 2018-04-03 2022-07-22 上海开拓者生物医药有限公司 抗人lag-3单克隆抗体及其应用
WO2019193375A1 (en) 2018-04-04 2019-10-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fzd7 inhibitors for the treatment of retinal neovascularization
AU2019247415A1 (en) 2018-04-04 2020-10-22 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
WO2019195561A2 (en) 2018-04-06 2019-10-10 BioLegend, Inc. Anti-tetraspanin 33 agents and compositions and methods for making and using the same
EP3774912A1 (de) 2018-04-10 2021-02-17 The United States of America, as represented by the Secretary, Department of Health and Human Services Kombination von nah-infrarot-fotoimmunotherapie gegen krebszellen und wirtsimmunaktivierung
JP2021521273A (ja) 2018-04-12 2021-08-26 メディアファーマ エス．アール．エル． Ｌｇａｌｓ３ｂｐ抗体−薬剤結合体及びがん治療のためのその使用
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
EP3775908A1 (de) 2018-04-13 2021-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur vorhersage des ergebnisses und der behandlung von patienten mit prostatakrebs oder brustkrebs
CA3097593A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
AU2019256529A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains
WO2019201995A1 (en) 2018-04-20 2019-10-24 Medizinische Hochschule Hannover Chimeric antigen receptor and car-t cells that bind a herpes virus antigen
WO2019209952A2 (en) 2018-04-23 2019-10-31 Emory University Vip antagonists and uses in treating cancer
EP3785732A4 (de) 2018-04-24 2022-02-23 Ampsource Biopharma Shanghai Inc. Antikörper gegen tim-3 und anwendung davon
CN112585165A (zh) 2018-04-25 2021-03-30 普罗米修斯生物科学公司 优化的抗tl1a抗体
WO2019207030A1 (en) 2018-04-26 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
WO2019207066A1 (en) 2018-04-26 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of sjögren's syndrome
WO2019207159A1 (en) 2018-04-27 2019-10-31 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
WO2019211369A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
WO2019211370A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
WO2019217450A1 (en) * 2018-05-08 2019-11-14 Rhode Island Hospital Anti-chi3l1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatohepatitis and subsequent complications
US20210130459A1 (en) 2018-05-09 2021-05-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human nectin4
WO2019217913A1 (en) 2018-05-10 2019-11-14 Sensei Biotherapeutics, Inc. Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof
WO2019222130A1 (en) 2018-05-15 2019-11-21 Immunogen, Inc. Combination treatment with antibody-drug conjugates and flt3 inhibitors
CN110483639A (zh) 2018-05-15 2019-11-22 复旦大学 靶向axl的抗体及抗体-药物偶联物及其制备方法和用途
CA3097253A1 (en) * 2018-05-16 2019-11-21 Morphosys Ag Antibodies targeting glycoprotein vi
KR20210013091A (ko) 2018-05-16 2021-02-03 시에스엘 리미티드 가용성 보체 수용체 1형 변이체 및 이의 용도
EP3569614A1 (de) 2018-05-18 2019-11-20 Julius-Maximilians-Universität Würzburg Verbindungen und verfahren zur immobilisierung von myostatin-inhibitoren auf der extrazellulären matrix durch transglutaminase
JP7391046B2 (ja) 2018-05-18 2023-12-04 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
AU2019270181B2 (en) 2018-05-18 2023-06-01 Cz Biohub Sf, Llc Methods of isolating allergen-specific antibodies from humans and uses thereof
TWI793325B (zh) 2018-05-23 2023-02-21 美商輝瑞大藥廠 對cd3具特異性之抗體及其用途
EP3796983A2 (de) 2018-05-23 2021-03-31 Pfizer Inc. Antikörper mit spezifität für gucy2c und verwendungen davon
PE20210634A1 (es) 2018-05-24 2021-03-23 Janssen Biotech Inc Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos
JOP20200302A1 (ar) * 2018-05-24 2020-11-23 Janssen Biotech Inc الأجسام المضادة لـ cd3 واستخداماتها
WO2019225787A1 (ko) 2018-05-24 2019-11-28 에이비엘바이오 주식회사 항-b7-h3 항체 및 그 용도
CA3098710A1 (en) 2018-05-25 2019-11-28 Alector Llc Anti-sirpa antibodies and methods of use thereof
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
TW202015726A (zh) 2018-05-30 2020-05-01 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
MX2020011385A (es) 2018-05-31 2021-04-13 Glyconex Inc Anticuerpos terapeuticos que se unen antigenos de lewis b y lewis y biantenarios.
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019232484A1 (en) 2018-06-01 2019-12-05 Compugen Ltd Anti-pvrig/anti-tigit bispecific antibodies and methods of use
MX2020012888A (es) 2018-06-01 2021-04-28 Rakuten Medical Inc Composiciones de conjugado de tinte de ftalocianina.
AU2019277029C1 (en) 2018-06-01 2024-01-04 Novartis Ag Binding molecules against BCMA and uses thereof
WO2019234099A1 (en) 2018-06-06 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
TW202015740A (zh) 2018-06-07 2020-05-01 美商西雅圖遺傳學公司 喜樹鹼結合物
KR102480493B1 (ko) 2018-06-08 2022-12-21 크리스탈 바이오사이언스 주식회사 동일한 경쇄 i을 갖는 다양한 항체를 생산하기 위한 트랜스제닉 동물
WO2019234221A1 (en) 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
DK3806903T3 (da) 2018-06-14 2024-04-15 2Seventy Bio Inc Cd79a kimæriske antigenreceptorer
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
US11830582B2 (en) 2018-06-14 2023-11-28 University Of Miami Methods of designing novel antibody mimetics for use in detecting antigens and as therapeutic agents
EP3806848A2 (de) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V, Inc. Erhöhung der immunaktivität durch modulation von postzellulären signalisierungsfaktoren
EA202092518A1 (ru) 2018-06-18 2021-08-23 Иннейт Фарма Композиции и способы лечения рака
KR20210035173A (ko) 2018-06-19 2021-03-31 아타르가, 엘엘씨 보체 성분 5에 대한 항체분자 및 이의 용도
MX2020014158A (es) 2018-06-20 2021-04-12 Incyte Corp Anticuerpos anti proteína de muerte programada 1 (pd-1) y usos de estos.
US20210276971A1 (en) 2018-06-20 2021-09-09 The Research Foundation For The State University Of New York Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same
EA202190092A1 (ru) 2018-06-21 2021-05-18 Юманити Терапьютикс, Инк. Композиции и способы лечения и профилактики неврологических расстройств
WO2019244107A1 (en) 2018-06-21 2019-12-26 Daiichi Sankyo Company, Limited Compositions including cd3 antigen binding fragments and uses thereof
EP3586865A1 (de) 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Ergänzende anaphylatoxinbindemittel und deren verwendung in der behandlung einer person mit okularer wunde und/oder fibrose
MX2020014101A (es) 2018-06-22 2021-05-27 Junten Bio Co Ltd Anticuerpo que induce tolerancia inmunitaria, linfocito inducido, y agente de terapia celular/metodo terapeutico que usa linfocitos inducidos.
EP3814369A1 (de) 2018-06-29 2021-05-05 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Tweak-rezeptor-agonisten zur verwendung in kombination mit der immuntherapie einer krebsart
WO2020003210A1 (en) 2018-06-29 2020-01-02 Kangwon National University University-Industry Cooperation Foundation Anti-l1cam antibodies and uses thereof
JP2021529765A (ja) 2018-06-29 2021-11-04 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ａｘｌ／ｍｅｒ阻害剤の製剤
CN112384532A (zh) 2018-06-29 2021-02-19 艾利妥 抗SIRP-β1抗体及其使用方法
JP7376564B2 (ja) 2018-06-29 2023-11-08 シティ・オブ・ホープ 特定の自己免疫疾患を治療するためのｃｄ６標的キメラ抗原受容体
WO2020010079A2 (en) 2018-07-02 2020-01-09 Amgen Inc. Anti-steap1 antigen-binding protein
BR112020025623A2 (pt) 2018-07-03 2021-03-23 Bristol-Myers Squibb Company métodos de produção de proteínas recombinantes
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
WO2020007898A1 (en) 2018-07-04 2020-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating brain injury or neurodegenerative disease
PE20211604A1 (es) 2018-07-09 2021-08-23 Five Prime Therapeutics Inc Anticuerpos de union a ilt4
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
WO2020014353A1 (en) 2018-07-11 2020-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibody for the detection of the antiretroviral drug emtricitabine (ftc, 2',3'-dideoxy-5-fluoro-3'-thiacytidine)
GB201811368D0 (en) 2018-07-11 2018-08-29 Ucb Biopharma Sprl Antibody
CN110713537B (zh) 2018-07-13 2023-04-21 江苏怀瑜药业有限公司 一种sema4d抗体及其制备方法和应用
CA3060547A1 (en) 2018-07-13 2020-01-13 Alector Llc Anti-sortilin antibodies and methods of use thereof
WO2020018556A1 (en) 2018-07-16 2020-01-23 Amgen Inc. Method of treating multiple myeloma
AU2019306543A1 (en) 2018-07-17 2021-01-28 Humabs Biomed Sa Antibodies against campylobacter species
WO2020016838A2 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
BR112021000934A2 (pt) 2018-07-20 2021-04-27 Pierre Fabre Medicament receptor para vista
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
WO2020021061A1 (en) 2018-07-26 2020-01-30 Pieris Pharmaceuticals Gmbh Humanized anti-pd-1 antibodies and uses thereof
JP2021532140A (ja) 2018-07-30 2021-11-25 アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３３及びｃｄ３に結合する二重特異性抗体コンストラクトの長期投与
MA53333A (fr) 2018-07-31 2021-11-03 Amgen Inc Formulations pharmaceutiques d'anticorps masqués
BR112021001776A2 (pt) 2018-08-01 2021-05-04 Imcheck Therapeutics Sas anticorpos anti-btn3a e seu uso no tratamento de câncer ou distúrbios infecciosos
MA53330A (fr) 2018-08-03 2021-06-09 Amgen Inc Constructions d'anticorps pour cldn18.2 et cd3
CN112638946A (zh) 2018-08-16 2021-04-09 坎塔吉亚有限责任公司 抗il1rap抗体组合物
BR112021002747A2 (pt) 2018-08-17 2021-08-10 Mersana Therapeutics, Inc. conjugados de anticorpo-fármaco e polímero direcionados a napi2b e métodos de uso dos mesmos
US11548938B2 (en) 2018-08-21 2023-01-10 Quidel Corporation DbpA antibodies and uses thereof
CA3109999A1 (en) 2018-08-21 2020-02-27 Abl Bio Inc. Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
US20210221864A1 (en) 2018-08-24 2021-07-22 City Of Hope Masked cytokine conjugates
CA3109732A1 (en) 2018-08-27 2020-03-05 Affimed Gmbh Cryopreserved nk cells preloaded with an antibody construct
SG11202101811VA (en) 2018-08-30 2021-03-30 Tcr2 Therapeutics Inc Compositions and methods for tcr reprogramming using fusion proteins
EP3843840A1 (de) 2018-08-30 2021-07-07 Dyax Corp. Plasma-kallikrein-inhibitoren und verwendungen davon zur behandlung von hereditärem angioödem
EP3843851A1 (de) 2018-08-31 2021-07-07 Alector LLC Anti-cd33-antikörper und verfahren zur verwendung davon
US20210340279A1 (en) 2018-08-31 2021-11-04 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
US20220048995A1 (en) 2018-09-10 2022-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of an inhibitor of ntsr1 activation or expression for preventing weight loss, muscle loss, and protein blood level decrease in subjects in need thereof
US20220047701A1 (en) 2018-09-10 2022-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of her2/neu antibody with heme for treating cancer
CN112996539A (zh) 2018-09-12 2021-06-18 Acm生物实验室私人有限公司 包含共价结合的抗原的聚合物囊泡以及其制备方法和用途
EP4268831A2 (de) 2018-09-12 2023-11-01 Fred Hutchinson Cancer Center Verminderung der cd33-expression zum selektiven schutz von therapeutischen zellen
US20220047716A1 (en) 2018-09-17 2022-02-17 Sutro Biopharma, Inc. Combination therapies with anti-folate receptor antibody conjugates
WO2020061210A1 (en) 2018-09-18 2020-03-26 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
WO2020058372A1 (en) 2018-09-19 2020-03-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
WO2020061381A1 (en) 2018-09-19 2020-03-26 La Jolla Institute For Immunology Ptprs and proteoglycans in rheumatoid arthritis
DK3883606T5 (da) 2018-09-24 2024-01-02 Janssen Biotech Inc Sikker og effektiv fremgangsmåde til behandling af colitis ulcerosa med anti-il12/il23-antistof
JP7425049B2 (ja) 2018-09-25 2024-01-30 ハープーン セラピューティクス，インク． Ｄｌｌ３結合タンパク質および使用方法
WO2020064702A1 (en) 2018-09-25 2020-04-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
CN113365697A (zh) 2018-09-25 2021-09-07 百进生物科技公司 抗tlr9药剂和组合物及其制备方法和使用方法
MX2021003382A (es) 2018-09-26 2021-05-27 Jiangsu Hengrui Medicine Co Conjugado de ligando y farmaco analogo de exatecan, metodo de preparacion del mismo y aplicacion del mismo.
AR116526A1 (es) 2018-09-27 2021-05-19 Tizona Therapeutics Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y métodos de uso de anticuerpos anti-hla-g
AU2019346645A1 (en) 2018-09-27 2021-04-29 Marengo Therapeutics, Inc. CSF1R/CCR2 multispecific antibodies
CN113453724A (zh) 2018-09-27 2021-09-28 皮埃尔法布雷医药公司 基于磺酰基马来酰亚胺的连接子和相应的偶联物
WO2020069303A1 (en) 2018-09-28 2020-04-02 Amgen Inc. Antibodies against soluble bcma
US20210347851A1 (en) 2018-09-28 2021-11-11 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
AU2019349958A1 (en) 2018-09-28 2021-05-06 Kyowa Kirin Co., Ltd. IL-36 antibodies and uses thereof
US20220047633A1 (en) 2018-09-28 2022-02-17 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
CA3114179A1 (en) 2018-09-28 2020-04-02 Pierre Fabre Medicament New immunocytokines for the treatment of cancer
WO2020070062A1 (en) 2018-10-01 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
EP3829606A4 (de) * 2018-10-03 2022-07-06 Nepenthe Bioscience, LLC Anti-cd79-antikörper und deren verwendungen
JP2022503959A (ja) 2018-10-03 2022-01-12 ゼンコア インコーポレイテッド Ｉｌ－１２ヘテロ二量体ｆｃ－融合タンパク質
CN112969503A (zh) 2018-10-03 2021-06-15 斯塔滕生物技术有限公司 对人类和食蟹猕猴apoc3具有特异性的抗体和其使用方法
JP2022512626A (ja) 2018-10-04 2022-02-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 粘膜炎症性疾患の処置のための方法及び医薬組成物
JP2022512580A (ja) 2018-10-05 2022-02-07 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 細菌バイオフィルムの酵素的破壊のための組成物および方法
US20210347898A1 (en) 2018-10-09 2021-11-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of alpha-v-integrin (cd51) inhibitors for the treatment of cardiac fibrosis
US20210395379A1 (en) 2018-10-09 2021-12-23 Numab Therapeutics AG Antibodies targeting cd137 and methods of use thereof
EP3636320A1 (de) 2018-10-09 2020-04-15 Numab Therapeutics AG Auf cd137 gerichtete antikörper und verfahren zur verwendung davon
US20210380923A1 (en) 2018-10-10 2021-12-09 Boehringer Ingelheim International Gmbh Method for membrane gas transfer in high density bioreactor culture
JP2022504839A (ja) 2018-10-10 2022-01-13 ティロス・セラピューティクス・インコーポレイテッド 抗ｌａｐ抗体変異体及びその使用
JP2022512636A (ja) 2018-10-11 2022-02-07 アムジエン・インコーポレーテツド 二重特異性抗体コンストラクトの下流プロセシング
US11674961B2 (en) 2018-10-12 2023-06-13 Quidel Corporation Extraction reagent for use in an assay for detection of group A Streptococcus
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
EP3867269A1 (de) 2018-10-18 2021-08-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Kombination aus einem big-h3-antagonisten und einem immun-checkpoint-inhibitor zur behandlung von soliden tumoren
CA3117240A1 (en) 2018-10-22 2020-04-30 Shanghai GenBase Biotechnology Co., Ltd. Anti-cldn18.2 antibody and uses thereof
GB201817311D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
GB201817309D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
CA3117695A1 (en) 2018-10-26 2020-04-30 Keros Therapeutics, Inc. Crystal forms of an alk2 inhibitor
TW202029980A (zh) 2018-10-26 2020-08-16 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
CN112955467A (zh) 2018-10-26 2021-06-11 特尼奥生物股份有限公司 与cd38结合的重链抗体
WO2020092455A2 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Car t cell transcriptional atlas
EP3873488A4 (de) 2018-10-31 2022-08-03 The University of Sydney Zusammensetzungen und verfahren zur behandlung von virusinfektionen
MX2021005151A (es) * 2018-11-01 2021-07-15 Bioinvent Int Ab Novedosas moleculas de anticuerpos anti-tnfr2 agonistas.
EP4219550A1 (de) 2018-11-02 2023-08-02 Oklahoma Medical Research Foundation Monoklonale antikörper gegen etld1 und verwendungen davon
WO2020095104A1 (en) 2018-11-05 2020-05-14 Ludwig Institute For Cancer Research Ltd. HUMANIZED AND VARIANT TGF-β3 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
CN113613725A (zh) 2018-11-05 2021-11-05 路德维格癌症研究所有限公司 人源化和变体TGF-β1特异性抗体及其方法和用途
EP3877413A1 (de) 2018-11-06 2021-09-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzungen zur behandlung von akuter myeloischer leukämie durch vernichtung von leukämischen stammzellen
US20220259306A1 (en) 2018-11-07 2022-08-18 Shanghai Hyamab Biotech Co., Ltd. Nkg2a antibody, preparation method therefor and application thereof
WO2020097566A1 (en) 2018-11-08 2020-05-14 Cedars-Sinai Medical Center Use of clazakizumab to desensitize and improve renal transplantation in hla-sensitized patients
MX2021005594A (es) 2018-11-13 2021-10-22 Compass Therapeutics Llc Constructos multiespecificos de union contra moleculas de puntos de control y usos de los mismos.
PE20211284A1 (es) 2018-11-16 2021-07-19 Bristol Myers Squibb Co Anticuerpos anti-nkg2a y usos de los mismos
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN113348180B (zh) 2018-11-20 2023-05-26 上海开拓者生物医药有限公司 Ox40抗体及其制备方法和应用
WO2020106358A1 (en) 2018-11-20 2020-05-28 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
SG11202105163UA (en) 2018-11-20 2021-06-29 Perseus Proteomics Inc Agent for inhibiting iron uptake into cells
WO2020104943A2 (en) 2018-11-20 2020-05-28 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il-23 specific antibody
CN113194991A (zh) 2018-11-26 2021-07-30 四十七公司 针对c-kit的人源化抗体
EP3886869A4 (de) 2018-11-28 2022-07-06 Forty Seven, Inc. Genetisch modifizierte ablationsresistente hspcs
CN111234018A (zh) 2018-11-29 2020-06-05 上海开拓者生物医药有限公司 全人抗gitr抗体及其制备方法
CN111253485A (zh) 2018-11-30 2020-06-09 上海开拓者生物医药有限公司 抗人tim-3单克隆抗体及其应用
JP7328658B2 (ja) 2018-11-30 2023-08-17 エービーエル バイオ インコーポレイテッド 抗ｐｄ－ｌ１／抗４－１ｂｂ二重特異性抗体およびその使用
JP2022513700A (ja) 2018-12-03 2022-02-09 フュージョン ファーマシューティカルズ インコーポレイテッド 放射性免疫複合体とチェックポイント阻害剤の併用療法
EP3892637A1 (de) 2018-12-03 2021-10-13 Shanghai Pharmaexplorer Co., Ltd. Cd47-antikörper, verfahren zu seiner herstellung und seine verwendungen
WO2020117627A1 (en) 2018-12-03 2020-06-11 Bristol-Myers Squibb Company Anti-ido antibody and uses thereof
US20220026445A1 (en) 2018-12-07 2022-01-27 Georgia Tech Research Corporation Antibodies that bind to natively folded myocilin
WO2020123662A2 (en) 2018-12-11 2020-06-18 AdMIRx Inc. Fusion protein constructs for complement associated disease
CN111303283A (zh) 2018-12-12 2020-06-19 上海君实生物医药科技股份有限公司 抗il-17a抗体及其应用
EP3896085A4 (de) 2018-12-12 2022-11-30 Shanghai Pharmaexplorer Co., Ltd. Monoklonaler antikörper gegen menschliches interleukin 5 (il-5) und dessen verwendung
JP2022516408A (ja) 2018-12-14 2022-02-28 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 単離されたＭＨＣ由来ヒトペプチドおよびＣＤ８＋ＣＤ４５ＲＣｌｏｗＴｒｅｇの抑制機能を刺激し、かつ活性化するためのその使用
EP3898700A1 (de) 2018-12-18 2021-10-27 Novartis AG Reverse bindemittel für anti-faktor-xi/xia-antikörper und verwendungen davon
US20200197517A1 (en) 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
WO2020128863A1 (en) 2018-12-19 2020-06-25 Novartis Ag Anti-tnf-alpha antibodies
US20220089694A1 (en) 2018-12-20 2022-03-24 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
CA3121934A1 (en) 2018-12-20 2020-06-25 Cedars-Sinai Medical Center Clazakizumab in the treatment of chronic antibody-mediated rejection of organ transplant
JP2022514017A (ja) 2018-12-20 2022-02-09 ノバルティス アーゲー 医薬の組み合わせ
WO2020128927A1 (en) 2018-12-20 2020-06-25 Kyowa Kirin Co., Ltd. Fn14 antibodies and uses thereof
US20220025050A1 (en) 2018-12-21 2022-01-27 Ose Immunotherapeutics Bifunctional molecule directed against human pd-1
US20220056135A1 (en) 2018-12-21 2022-02-24 Ose Immunotherapeutics Bifunctional anti-pd-1/sirpa molecule
CN113474048A (zh) 2018-12-21 2021-10-01 Aim免疫科技有限公司 用于癌症治疗的组合物和方法
US20220090125A1 (en) 2018-12-21 2022-03-24 Compass Therapeutics Llc Transgenic mouse expressing common human light chain
CN113614109A (zh) 2018-12-21 2021-11-05 Ose免疫疗法公司 双功能抗pd-1/il-7分子
US20220211798A1 (en) 2018-12-21 2022-07-07 4TEEN4 Pharmaceuticals GmbH Therapy guidance and/or therapy monitoring for a treatment with angiotensin-receptor-agonist and/or a precursor thereof
KR20210109520A (ko) 2018-12-28 2021-09-06 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 항체 및 이의 용도
KR20220008253A (ko) 2019-01-03 2022-01-20 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름) 암을 앓는 대상에서 cd8+ t 세포 의존성 면역 반응을 향상시키기 위한 방법 및 약학적 조성물
US11639380B2 (en) 2019-01-08 2023-05-02 H. Lundbeck A/S Acute treatment and rapid treatment of headache using anti-CGRP antibodies
CN111434688A (zh) 2019-01-11 2020-07-21 上海开拓者生物医药有限公司 Cd73抗体及其制备方法和应用
JP2022519341A (ja) 2019-01-13 2022-03-23 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー． ヒトネクチン－２に特異的な抗体
US20220119532A1 (en) 2019-01-14 2022-04-21 University Of Virginia Patent Foundation Use of integrin inhibitors for treatment or prevention of a neurological immunity disorder and/or nervous system injury
BR112021013903A2 (pt) 2019-01-15 2021-09-21 Janssen Biotech, Inc. Composições e métodos de anticorpos anti-tnf para o tratamento da artrite idiopática juvenil
CN109762067B (zh) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
GB201900724D0 (en) 2019-01-18 2019-03-06 King S College London Antibody
US20200231686A1 (en) 2019-01-18 2020-07-23 Janssen Biotech, Inc. Gprc5d chimeric antigen receptors and cells expressing the same
CA3127236A1 (en) 2019-01-22 2020-07-30 Bristol-Myers Squibb Company Antibodies against il-7r alpha subunit and uses thereof
WO2020152544A1 (en) 2019-01-23 2020-07-30 Janssen Biotech, Inc. Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis
WO2020154475A1 (en) 2019-01-23 2020-07-30 Molecular Templates, Inc. Proteins comprising modified immunoglobulin variable light chains
JP2020117502A (ja) 2019-01-28 2020-08-06 ファイザー・インク 変形性関節症の徴候および症状を処置する方法
CA3126727A1 (en) 2019-01-28 2020-08-06 Maple Biotech Llc Psmp antagonists for use in treatment of fibrotic disease of the lung, kidney or liver
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2020157305A1 (en) 2019-01-31 2020-08-06 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
EP3689907A1 (de) 2019-01-31 2020-08-05 Numab Therapeutics AG Auf il-17a gerichtete antikörper und verfahren zur verwendung davon
WO2020163225A1 (en) 2019-02-05 2020-08-13 Seattle Genetics, Inc. Anti-cd228 antibodies and antibody-drug conjugates
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
JP7232925B2 (ja) 2019-02-15 2023-03-03 ウーシー バイオロジクス アイルランド リミテッド 改善された均一性を有する抗体薬物コンジュゲートの調製するプロセス
EP3927430A1 (de) 2019-02-18 2021-12-29 Pfizer Inc. Verfahren zur behandlung von chronischen schmerzen im unteren rücken
WO2020169472A2 (en) 2019-02-18 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of inducing phenotypic changes in macrophages
SG11202109033XA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
CN114072423A (zh) 2019-02-21 2022-02-18 翠舒拉治疗股份有限公司 涉及抗cd39抗体和抗pd-1或抗pd-l1抗体的组合疗法
CN114127111A (zh) 2019-02-21 2022-03-01 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
AU2020226904A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
SG11202109056TA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to calreticulin and uses thereof
WO2020172571A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
EP3927371A1 (de) 2019-02-22 2021-12-29 Novartis AG Kombinationstherapien von chimären egfrviii-antigenrezeptoren und pd-1-inhibitoren
EP3929212A4 (de) 2019-02-22 2022-11-23 Wuhan Yzy Biopharma Co., Ltd. Modifiziertes fc-fragment, dieses enthaltender antikörper und dessen verwendung
WO2020168555A1 (zh) 2019-02-22 2020-08-27 武汉友芝友生物制药有限公司 Cd3抗原结合片段及其应用
JP2022521428A (ja) 2019-02-25 2022-04-07 ザ・ユニバーシティ・オブ・シカゴ 抗炎症剤に連結されたｅｃｍ親和性ペプチドを用いて炎症性状態および自己免疫状態を処置するための方法および組成物
MA55080A (fr) 2019-02-26 2022-01-05 Inspirna Inc Anticorps anti-mertk à affinité élevée et utilisations associées
TW202045206A (zh) 2019-02-27 2020-12-16 美商健生生物科技公司 抗體調配物
EP3930757A1 (de) 2019-03-01 2022-01-05 President And Fellows Of Harvard College Verfahren und zusammensetzungen zur proteinabgabe
WO2020180726A1 (en) 2019-03-01 2020-09-10 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
CA3131953A1 (en) 2019-03-01 2020-09-10 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
WO2020178193A1 (en) 2019-03-01 2020-09-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treatment of sarcoidosis
WO2020180819A1 (en) 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
EP3938404A1 (de) 2019-03-14 2022-01-19 Takeda Pharmaceutical Company Limited Plasma-kallikrein-inhibitoren und verwendungen davon zur behandlung von hereditärem angioödem
EP3938391A1 (de) 2019-03-14 2022-01-19 Janssen Biotech, Inc. Verfahren zur herstellung von anti-tnf-antikörperzusammensetzungen
EP3938392A1 (de) 2019-03-14 2022-01-19 Janssen Biotech, Inc. Verfahren zur herstellung von anti-tnf-antikörperzusammensetzungen
JP2022525145A (ja) 2019-03-14 2022-05-11 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２／ｉｌ２３抗体組成物を生成するための製造方法
CN113840838A (zh) 2019-03-14 2021-12-24 詹森生物科技公司 用于产生抗tnf抗体组合物的制造方法
KR20210141583A (ko) 2019-03-18 2021-11-23 얀센 바이오테크 인코포레이티드 항-il-12/il-23 항체를 사용한 소아 대상의 건선 치료 방법
CA3133862A1 (en) 2019-03-19 2020-09-24 Albert Einstein College Of Medicine Monoclonal antibodies for prevention and treatment of herpes simplex viral infections
WO2020188086A1 (en) 2019-03-20 2020-09-24 Imcheck Therapeutics Sas Antibodies having specificity for btn2 and uses thereof
EP3942026A1 (de) 2019-03-22 2022-01-26 Université de Paris Neue inhibitoren der lrrk2/pp1-interaktion
EP3946435B1 (de) 2019-03-25 2023-12-27 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Erweiterung der wirkung zytolytischer t-zellen durch hemmung von ebag9
US20220177558A1 (en) 2019-03-25 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of taupathy disorders by targeting new tau species
US20210277131A1 (en) 2019-03-26 2021-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT EMPLOYING ANTI-IL-l3R ANTIBODY OR BINDING FRAGMENT THEREOF
CN113811547A (zh) 2019-03-27 2021-12-17 国家医疗保健研究所 具有cd40激活特性的重组蛋白
WO2020198731A2 (en) 2019-03-28 2020-10-01 Danisco Us Inc Engineered antibodies
TW202102261A (zh) 2019-03-29 2021-01-16 美商艾特加有限責任公司 Fgf23之抗體分子及其用途
TW202102272A (zh) 2019-03-29 2021-01-16 美商樂天醫藥生技股份有限公司 光免疫療法之方法及相關之生物標記
JP2022527493A (ja) 2019-03-29 2022-06-02 ブリストル－マイヤーズ スクイブ カンパニー クロマトグラフィー樹脂の疎水性を測定する方法
KR20210145152A (ko) 2019-04-01 2021-12-01 제넨테크, 인크. 단백질-함유 제제들의 안정화를 위한 조성물들 및 방법들
US11384146B2 (en) 2019-04-01 2022-07-12 Curia Ip Holdings, Llc BTLA-binding antibodies for modulating immune response and treating disease
US20220177978A1 (en) 2019-04-02 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
JP2022527860A (ja) 2019-04-02 2022-06-06 ケンジョッケティ バイオテクノロジー，インク． 排出ポンプ－癌抗原マルチ特異性抗体ならびにそれに関する組成物、試薬、キットおよび方法
US20220175815A1 (en) 2019-04-03 2022-06-09 Orega Biotech Combination therapies based on pd1 and il-17b inhibitors
TW202102544A (zh) 2019-04-04 2021-01-16 日商小野藥品工業股份有限公司 雙特異性抗體
AU2020271123A1 (en) 2019-04-10 2021-11-25 Elevatebio Technologies, Inc. FLT3-specific chimeric antigen receptors and methods of using the same
CN113993885A (zh) 2019-04-12 2022-01-28 格尔托公司 重组弹性蛋白及其生产
WO2020211674A1 (zh) 2019-04-16 2020-10-22 四川科伦博泰生物医药股份有限公司 抗FXI/FXIa抗体及其用途
WO2020213084A1 (en) 2019-04-17 2020-10-22 Keio University Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
EP3955925A4 (de) * 2019-04-18 2023-03-22 QLSF Biotherapeutics Inc. Humanisierte anti-pd-l1-antikörper
MX2021012961A (es) 2019-04-24 2021-11-25 Heidelberg Pharma Res Gmbh Conjugados de anticuerpo y farmaco de amatoxina y usos de los mismos.
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
AU2020270407A1 (en) 2019-05-03 2021-12-02 Celgene Corporation Anti-BCMA antibody conjugate, compositions comprising the same, and methods of making and using the same
EP3962951A1 (de) 2019-05-03 2022-03-09 Sutro Biopharma, Inc. Anti-bcma-antikörper-konjugate
JP2022532192A (ja) 2019-05-10 2022-07-13 武田薬品工業株式会社 抗体薬物複合体
US20220259561A1 (en) 2019-05-14 2022-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof
WO2020230142A1 (en) 2019-05-15 2020-11-19 Neotx Therapeutics Ltd. Cancer treatment
TW202100559A (zh) 2019-05-21 2021-01-01 瑞士商諾華公司 Cd19 結合分子及其用途
US20230071196A1 (en) 2019-05-21 2023-03-09 Novartis Ag Variant cd58 domains and uses thereof
SG11202112453TA (en) 2019-05-23 2021-12-30 Ac Immune Sa Anti-tdp-43 binding molecules and uses thereof
WO2020233715A1 (zh) 2019-05-23 2020-11-26 厦门大学 抗乙肝病毒抗体及其用途
JP2022534020A (ja) 2019-05-23 2022-07-27 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
EP3744400A1 (de) 2019-05-28 2020-12-02 Etablissement Français du Sang Gegen il-1rap gerichtete car-t-zellen und deren verwendung bei akuter myeloischer leukämie (aml)
CN114174344A (zh) 2019-05-30 2022-03-11 美国安进公司 工程改造铰链区以驱动抗体二聚化
EP3976648A1 (de) 2019-06-03 2022-04-06 Janssen Biotech, Inc. Anti-tnf-antikörperzusammensetzungen und verfahren zur behandlung von aktiver psoriasis-arthritis
MX2021014882A (es) 2019-06-03 2022-03-25 Janssen Biotech Inc Anticuerpos anti-tnf, composiciones y métodos para el tratamiento de la espondilitis anquilosante activa.
EP3976061A4 (de) 2019-06-03 2023-07-12 The University of Chicago Verfahren und zusammensetzungen zur behandlung von krebs mit gegen krebs gerichteten adjuvanzien
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
IT201900008376A1 (it) 2019-06-07 2020-12-07 Univ Degli Studi Di Modena E Reggio Emilia Anticorpi ad attività antitumorale
CN114269749A (zh) 2019-06-10 2022-04-01 苏特罗生物制药公司 5H-吡咯并[3,2-d]嘧啶-2,4-二氨基化合物及其抗体偶联物
US20200392229A1 (en) 2019-06-11 2020-12-17 Alector Llc Methods of use of anti-sortilin antibodies
BR112021024938A2 (pt) 2019-06-12 2022-01-25 Novartis Ag Anticorpos de receptor 1 de peptídeo natriurético e métodos de uso
TW202045711A (zh) 2019-06-13 2020-12-16 美商安進公司 生物製品製造中基於生物量之自動灌注控制
JP2022536800A (ja) 2019-06-17 2022-08-18 ストロ バイオファーマ インコーポレーテッド Ｔｏｌｌ様受容体（ｔｌｒ）７／８アゴニストとしての１－（４－（アミノメチル）ベンジル）－２－ブチル－２ｈ－ピラゾロ［３，４－ｃ］キノリン－４－アミン誘導体および関連化合物、ならびにがん療法および診断に使用するためのその抗体薬物コンジュゲート
WO2020257289A2 (en) 2019-06-17 2020-12-24 Visterra, Inc. Humanized antibody molecules to cd138 and uses thereof
EP3753954A1 (de) 2019-06-21 2020-12-23 Université de Franche-Comté Anti-cd123-antikörper, chimäre anti-cd123-antigen-rezeptoren und chimäre anti-cd123-antigen-rezeptoren-t-zellen
JP2022538237A (ja) 2019-06-24 2022-09-01 ノバルティス アーゲー Ｂ細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療
CA3143524A1 (en) 2019-06-28 2020-12-30 Amgen Inc. Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
AU2020300002A1 (en) 2019-07-01 2022-02-24 Tonix Pharma Limited Anti-CD154 antibodies and uses thereof
SG11202111943UA (en) 2019-07-02 2021-11-29 Hutchinson Fred Cancer Res Recombinant ad35 vectors and related gene therapy improvements
MX2022000174A (es) 2019-07-02 2022-05-20 Us Health Anticuerpos monoclonales que se enlazan a egfrviii y sus usos.
US20220372137A1 (en) 2019-07-03 2022-11-24 Oxford Biotherapeutics Ltd Antibodies and methods of use
KR20220030956A (ko) 2019-07-05 2022-03-11 오노 야꾸힝 고교 가부시키가이샤 Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료
JPWO2021006212A1 (de) 2019-07-08 2021-01-14
AU2020311897A1 (en) 2019-07-08 2022-02-03 Research Institute At Nationwide Children's Hospital Antibody compositions for disrupting biofilms
CN113968910A (zh) 2019-07-11 2022-01-25 武汉友芝友生物制药有限公司 四价对称双特异性抗体
JPWO2021010326A1 (de) 2019-07-12 2021-01-21
WO2021008523A1 (zh) 2019-07-15 2021-01-21 上海君实生物医药科技股份有限公司 抗tigit抗体及其应用
CN114828886A (zh) * 2019-07-17 2022-07-29 双子治疗分公司 因子h增强抗体及其用途
US20210030885A1 (en) 2019-07-22 2021-02-04 Seagen Inc. Humanized anti-liv1 antibodies for the treatment of cancer
JP2022542863A (ja) 2019-07-24 2022-10-07 ハー・ルンドベック・アクチエゼルスカベット 抗ｍＧｌｕＲ５抗体及びその使用
WO2021019386A1 (en) 2019-07-26 2021-02-04 Janssen Biotech, Inc. Anti-hk2 chimeric antigen receptor (car)
WO2021021606A1 (en) 2019-07-26 2021-02-04 Visterra, Inc. Interleukin-2 agents and uses thereof
JP6856183B1 (ja) 2019-07-30 2021-04-07 小野薬品工業株式会社 二重特異性抗体
CA3146341A1 (en) 2019-07-30 2021-02-04 Aaron L. Kurtzman Bispecific anti lrrc15 and cd3epsilun antibudies
CA3145885A1 (en) 2019-07-31 2021-02-04 Jeonghoon Sun Anti-ms4a4a antibodies and methods of use thereof
WO2021019706A1 (ja) 2019-07-31 2021-02-04 国立大学法人信州大学 Ｃａｒ発現免疫細胞を含む細胞集団の製造方法
KR20220039777A (ko) 2019-08-01 2022-03-29 브리스톨-마이어스 스큅 컴퍼니 유가식 세포 배양에서 단백질 생산성을 개선시키는 방법
MX2022001133A (es) 2019-08-01 2022-04-25 Incyte Corp Regimen de dosificacion para un inhibidor de indolamina 2,3-dioxigenasa (ido).
AU2020322474A1 (en) 2019-08-01 2022-03-10 Vaccinex,Inc. Combined inhibition of semaphorin-4D and TGFβ and compositions therefor
WO2021023624A1 (en) 2019-08-02 2021-02-11 Orega Biotech Novel il-17b antibodies
CA3146474A1 (en) 2019-08-02 2021-02-11 Denis BURGER Methods for treating or preventing cancers involving the administration of anti-ccr5 receptor agents
CN114401743A (zh) 2019-08-02 2022-04-26 法国国家健康和医学研究院 中和颗粒酶b用于向经历过心肌梗塞的受试者提供心脏保护
US20220288208A1 (en) 2019-08-07 2022-09-15 Rakuten Medical, Inc. Cetuximab-ir700 conjugate compositions
EP4031658A1 (de) 2019-08-07 2022-07-27 DB Biotech, AS Verbesserte meerrettichperoxidase-polypeptide
WO2021025140A1 (ja) 2019-08-08 2021-02-11 小野薬品工業株式会社 二重特異性タンパク質
WO2021028921A1 (en) 2019-08-12 2021-02-18 Biond Biologics Ltd. Antibodies against ilt2 and use thereof
US20220242962A1 (en) 2019-08-12 2022-08-04 Aptevo Research And Development Llc 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
WO2021035170A1 (en) 2019-08-21 2021-02-25 Precision Biosciences, Inc. Compositions and methods for tcr reprogramming using fusion proteins
EP4021571A1 (de) 2019-08-30 2022-07-06 4TEEN4 Pharmaceuticals GmbH Therapieführung und therapieüberwachung zur schockbehandlung
US11680098B2 (en) 2019-08-30 2023-06-20 Agenus Inc. Antibodies that specifically bind human CD96
JP2022547850A (ja) 2019-09-03 2022-11-16 バイオ － テラ ソリューションズ、リミテッド 抗ｔｉｇｉｔ免疫阻害剤及び応用
CA3150807A1 (en) 2019-09-04 2021-03-11 Y-Biologics Inc. Anti-vsig4 antibody or antigen binding fragment and uses thereof
EP4025303A1 (de) 2019-09-04 2022-07-13 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) Herv-inhibitoren zur verwendung bei der behandlung von tauopathien
EP4026560A4 (de) 2019-09-04 2023-10-25 Perseus Proteomics Inc. Therapeutisches mittel für polyzythämie
MX2022002981A (es) 2019-09-10 2022-04-06 Amgen Inc Metodo de purificacion para polipeptidos de union a antigeno biespecificos con capacidad de union dinamica de captura de proteina l mejorada.
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
US20210130492A1 (en) * 2019-09-18 2021-05-06 Genentech, Inc. Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
BR112022004863A2 (pt) 2019-09-19 2022-06-07 Seagen Inc Composição conjugado de ligante fármaco, compostos conjugado de ligante-fármaco e conector de fármaco, e, formulação farmaceuticamente aceitável
CN114423459A (zh) 2019-09-19 2022-04-29 飞跃治疗公司 Dkk-1抑制剂用于治疗癌症的用途
CN114401989B (zh) 2019-09-20 2024-02-09 上海吉倍生物技术有限公司 靶向bcma的抗体及嵌合抗原受体
JP2022549504A (ja) 2019-09-26 2022-11-25 エスティーキューブ アンド カンパニー グリコシル化ｃｔｌａ－４に対して特異的な抗体およびその使用方法
US20220324962A1 (en) 2019-09-27 2022-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance antibodies and uses thereof
WO2021059075A1 (en) 2019-09-27 2021-04-01 Janssen Biotech, Inc. Anti-ceacam antibodies and uses thereof
WO2021058729A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
WO2021058744A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of müllerian inhibiting substance inhibitors for treating cancer
JP2022550243A (ja) 2019-09-30 2022-12-01 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド 抗ｐｄ－１抗体及びその使用
US11851466B2 (en) 2019-10-03 2023-12-26 Xencor, Inc. Targeted IL-12 heterodimeric Fc-fusion proteins
WO2021067820A1 (en) 2019-10-04 2021-04-08 Seagen Inc. Formulation of antibody-drug conjugate
CN115151564A (zh) 2019-10-04 2022-10-04 思进股份有限公司 抗pd-l1抗体和抗体-药物缀合物
EP4037710A1 (de) 2019-10-04 2022-08-10 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren und pharmazeutische zusammensetzung zur behandlung von eierstockkrebs, brustkrebs oder bauchspeicheldrüsenkrebs
CN114929284A (zh) 2019-10-04 2022-08-19 西根公司 喜树碱肽缀合物
WO2021071830A1 (en) 2019-10-07 2021-04-15 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
WO2021072277A1 (en) 2019-10-09 2021-04-15 Stcube & Co. Antibodies specific to glycosylated lag3 and methods of use thereof
EP3804754A1 (de) 2019-10-09 2021-04-14 OSE Immunotherapeutics Cmklr1-agonisten mit resolvin-e1-ähnlicher fähigkeit und ihre therapeutischen anwendungen
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
US20210147525A1 (en) 2019-10-18 2021-05-20 The Regents Of The University Of California Methods and compositions for treating pathogenic blood vessel disorders
CN114786679A (zh) 2019-10-21 2022-07-22 诺华股份有限公司 具有维奈托克和tim-3抑制剂的组合疗法
MX2022004769A (es) 2019-10-21 2022-05-16 Novartis Ag Inhibidores de tim-3 y sus usos.
EP3812008A1 (de) 2019-10-23 2021-04-28 Gamamabs Pharma Amh-kompetitiver antagonistischer antikörper
CN114901311A (zh) 2019-10-24 2022-08-12 普罗米修斯生物科学公司 Tnf样配体1a（tl1a）的人源化抗体及其用途
EP4051298A1 (de) 2019-11-01 2022-09-07 Magenta Therapeutics, Inc. Dosierschema zur mobilisierung von hämatopoetischen stammzellen und vorläuferzellen
WO2021092355A1 (en) 2019-11-08 2021-05-14 Amgen Inc. Engineering charge pair mutations for pairing of hetero-igg molecules
CA3156683A1 (en) 2019-11-13 2021-05-20 Amgen Inc. METHOD FOR REDUCING AGGREGATE FORMATION IN DOWNSTREAM PROCESSING OF BI-SPECIFIC ANTIGEN-BINDING MOLECULES
KR20220113386A (ko) 2019-11-15 2022-08-12 플라이언트 테라퓨틱스, 인크. 인테그린의 활성화를 위한 조성물 및 방법
BR112022009273A2 (pt) * 2019-11-15 2022-10-04 Univ Tennessee Res Found Imunoglobulinas modificadas para direcionar depósitos amiloides
WO2021099944A1 (en) 2019-11-18 2021-05-27 Janssen Biotech, Inc. Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof
EP3825330A1 (de) 2019-11-19 2021-05-26 International-Drug-Development-Biotech Anti-cd117-antikörper und verfahren zur verwendung davon
US20230047631A1 (en) 2019-11-19 2023-02-16 Amgen Inc. Novel multispecific antibody format
WO2021100034A1 (en) 2019-11-19 2021-05-27 Protalix Ltd. Removal of constructs from transformed cells
CN114787181A (zh) 2019-11-21 2022-07-22 Inserm(法国国家健康医学研究院) 用抗pd-1/il-15免疫细胞因子靶向pd-1的新型免疫疗法
CN114929275A (zh) 2019-11-22 2022-08-19 飞跃治疗公司 使用dkk-1抑制剂治疗癌症的方法
EP4247957A1 (de) 2019-11-22 2023-09-27 MedImmune Limited Fusionsproteine mit einer e2 ubiquitin- oder ubiquitin-ähnlichen konjugationsdomäne und einer zieldomäne für spezifischen proteinabbau
EP4061944A1 (de) 2019-11-22 2022-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibitoren von adrenomedullin zur behandlung von akuter myeloischer leukämie durch vernichtung von leukämischen stammzellen
WO2021107082A1 (ja) 2019-11-27 2021-06-03 株式会社ペルセウスプロテオミクス 癌性腹膜炎の治療薬
JP2023505169A (ja) 2019-12-03 2023-02-08 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｂ型肝炎感染の治療における使用のためのインターフェロン会合抗原結合タンパク質
US20230242655A1 (en) 2019-12-03 2023-08-03 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
JP2023504543A (ja) 2019-12-04 2023-02-03 オメロス コーポレーション Ｍａｓｐ－２阻害剤および使用方法
WO2021113831A1 (en) 2019-12-05 2021-06-10 Compugen Ltd. Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing
WO2021113780A1 (en) 2019-12-06 2021-06-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
US11897950B2 (en) 2019-12-06 2024-02-13 Augusta University Research Institute, Inc. Osteopontin monoclonal antibodies
WO2021111636A1 (ja) 2019-12-06 2021-06-10 大塚製薬株式会社 抗ｇｄｆ１５抗体
JP2023504740A (ja) 2019-12-06 2023-02-06 ジュノー セラピューティクス インコーポレイテッド Ｂｃｍａ標的結合ドメインに対する抗イディオタイプ抗体ならびに関連する組成物および方法
WO2021119012A1 (en) 2019-12-09 2021-06-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF
WO2021116119A1 (en) 2019-12-09 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to her4 and uses thereof
WO2021116277A1 (en) 2019-12-10 2021-06-17 Institut Pasteur New antibody blocking human fcgriiia and fcgriiib
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
JP2023505408A (ja) 2019-12-13 2023-02-09 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド 抗ｔｓｌｐ抗体及びその使用
BR112022011570A2 (pt) 2019-12-13 2022-12-13 Alector Llc Anticorpos anti-mertk e métodos de uso dos mesmos
CA3161274A1 (en) 2019-12-13 2021-06-17 Stephen Wald Metal salts and uses thereof
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
AU2020405183A1 (en) 2019-12-18 2022-06-09 TeneoFour, Inc. Heavy chain antibodies binding to CD38
JP2023507083A (ja) 2019-12-19 2023-02-21 クイデル コーポレーション モノクローナル抗体融合物
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
GB201919058D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
WO2021123996A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
UY38995A (es) 2019-12-20 2021-06-30 Amgen Inc Constructos de anticuerpo multiespecíficos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores sólidos
EP4077378A1 (de) 2019-12-20 2022-10-26 NovaRock Biotherapeutics, Ltd. Anti-interleukin-23-p19-antikörper und verfahren zur verwendung davon
MX2022007833A (es) 2019-12-23 2022-09-23 Cellectis Nuevos receptores de antigenos quimericos (car) especificos de mesotelina para inmunoterapia de cancer de tumores solidos.
KR20220119467A (ko) 2019-12-27 2022-08-29 아피메트 게엠베하 이중특이적 fcyriii x cd30 항체 작제물의 제조 방법
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
WO2021138454A1 (en) 2019-12-30 2021-07-08 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
EP4085060A1 (de) 2020-01-03 2022-11-09 Incyte Corporation Kombinationstherapie mit a2a/a2b- und pd-1/pd-l1-inhibitoren
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
CN115996950A (zh) 2020-01-06 2023-04-21 高诚生物医药(香港)有限公司 抗tnfr2抗体和其用途
CA3163988A1 (en) 2020-01-07 2021-07-15 Germain MARGALL DUCOS Anti-galectin-9 antibody and uses thereof
US20230090552A1 (en) 2020-01-08 2023-03-23 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
KR20220139886A (ko) 2020-01-08 2022-10-17 리제너론 파아마슈티컬스, 인크. 진행성 골화성 섬유이형성증의 치료
CA3167336A1 (en) 2020-01-13 2021-07-22 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
TW202140553A (zh) 2020-01-13 2021-11-01 美商威特拉公司 C5ar1抗體分子及其用途
EP4090681A1 (de) 2020-01-17 2022-11-23 Biolegend, Inc. Anti-tlr7-mittel und zusammensetzungen sowie verfahren zu ihrer herstellung und verwendung
CN114980902A (zh) 2020-01-17 2022-08-30 诺华股份有限公司 用于治疗骨髓增生异常综合征或慢性粒单核细胞白血病的包含tim-3抑制剂和低甲基化药物的组合
CN113138276B (zh) 2020-01-19 2022-09-16 厦门万泰凯瑞生物技术有限公司 用于检测HBcAg的方法及抗体
TWI793503B (zh) 2020-01-20 2023-02-21 美商美國禮來大藥廠 抗IL-1β抗體
WO2021148524A1 (en) 2020-01-21 2021-07-29 Celex Oncology Innovations Limited Monoclonal antibodies against neonatal nav1.5
JP2023511163A (ja) 2020-01-22 2023-03-16 上海森輝医薬有限公司 エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用
WO2021150824A1 (en) 2020-01-22 2021-07-29 Amgen Research (Munich) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
WO2021151079A1 (en) 2020-01-24 2021-07-29 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
CN115768800A (zh) 2020-01-31 2023-03-07 克利夫兰诊所基金会 抗苗勒管激素受体2抗体和使用方法
CN115087668A (zh) 2020-01-31 2022-09-20 奥斯瓦道·克鲁兹基金会 抗体、其用途、药物组合物，包括真菌感染诊断方法、真菌感染诊断试剂盒和真菌感染治疗方法
BR112022015374A2 (pt) 2020-02-03 2022-10-11 Vir Biotechnology Inc Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
US20230070181A1 (en) 2020-02-05 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of treatment of cancer disease by targeting an epigenetic factor
CA3167027A1 (en) 2020-02-05 2021-08-12 Larimar Therapeutics, Inc. Tat peptide binding proteins and uses thereof
CN113248611A (zh) 2020-02-13 2021-08-13 湖南华康恒健生物技术有限公司 抗bcma抗体、其药物组合物及应用
US20230151109A1 (en) 2020-02-13 2023-05-18 UCB Biopharma SRL Bispecific antibodies against cd9
EP4103611B1 (de) 2020-02-13 2024-03-27 UCB Biopharma SRL Bispezifische, an hvem und cd9 bindende antikörper
WO2021163588A1 (en) 2020-02-13 2021-08-19 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
US20230125234A1 (en) 2020-02-13 2023-04-27 UCB Biopharma SRL Anti cd44-ctla4 bispecific antibodies
JP2023513312A (ja) 2020-02-13 2023-03-30 アムジェン インコーポレイテッド ヒト抗ｔｓｌｐ抗体の製剤及び炎症性疾患を治療する方法
US20230096030A1 (en) 2020-02-13 2023-03-30 UCB Biopharma SRL Bispecific antibodies against cd9 and cd7
EP4103608A1 (de) 2020-02-13 2022-12-21 UCB Biopharma SRL Bispezifische antikörper gegen cd9 und cd137
MX2022010120A (es) 2020-02-18 2022-09-05 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y metodos de uso de los mismos.
WO2021168292A1 (en) 2020-02-20 2021-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epstein-barr virus monoclonal antibodies and uses thereof
AU2021224851A1 (en) 2020-02-21 2022-09-15 Harpoon Therapeutics, Inc. FLT3 binding proteins and methods of use
KR20230012465A (ko) 2020-02-24 2023-01-26 이매틱스 유에스 인코포레이티드 암 및 관련 악성 종양을 치료하기 위해 t 세포를 확장하는 방법
CN115551552A (zh) 2020-02-25 2022-12-30 祐方有限公司 喜树碱衍生物及其缀合物
EP3871689A1 (de) 2020-02-26 2021-09-01 sphingotec GmbH Anti-adm-antikörper, die an den freien n-terminus binden, für einen beschleunigten übergang von adm-gly zu bio-adm bei patienten mit einem adm-gly/bio-adm-verhältnis über einem schwellenwert und kombination mit vitamin c
HUE062777T2 (hu) 2020-02-26 2023-12-28 Vir Biotechnology Inc SARS-CoV-2 elleni antitestek
US20230105029A1 (en) 2020-02-27 2023-04-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Antibodies binding il4r and uses thereof
MX2022010207A (es) 2020-02-27 2022-11-16 Adrenomed Ag Anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm o andamiaje no ig anti-adm para usarse en terapia o prevencion de choque.
JP2023515985A (ja) 2020-02-27 2023-04-17 アドレノメト アクチェンゲゼルシャフト ショック状態の患者の治療において使用するための抗アドレノメデュリン（ａｄｍ）結合剤
US20230193348A1 (en) 2020-02-27 2023-06-22 4TEEN4 Pharmaceuticals GmbH Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock
WO2021170750A1 (en) 2020-02-28 2021-09-02 Orega Biotech Combination therapies based on ctla4 and il-17b inhibitors
IL295590A (en) 2020-02-28 2022-10-01 Genzyme Corp Optimized binding polypeptides to optimize drug conjugation
EP4114368A1 (de) 2020-03-03 2023-01-11 Active Biotech AB Tasquinimod oder pharmazeutisch unbedenkliches salz davon zur verwendung in der kombinationstherapie
WO2021175954A1 (en) 2020-03-04 2021-09-10 Imcheck Therapeutics Sas Antibodies having specificity for btnl8 and uses thereof
IL296065A (en) 2020-03-06 2022-10-01 Incyte Corp Combined treatment including axl/mer and pd-1/pd-l1 inhibitors
CN115315446A (zh) 2020-03-06 2022-11-08 Go医疗股份有限公司 抗糖-cd44抗体及其用途
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20230146593A1 (en) 2020-03-12 2023-05-11 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecific antibodies binding to cds x cancer cell and tnf alpha or il-6 inhibitor
EP3922993A1 (de) 2020-06-12 2021-12-15 4TEEN4 Pharmaceuticals GmbH Dpp3 bei patienten, die mit coronavirus infiziert sind
US20230213519A1 (en) 2020-03-16 2023-07-06 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
BR112022017890A2 (pt) 2020-03-16 2022-11-01 Sphingotec Gmbh Proadrenomedulina ou fragmento da mesma em pacientes infectados com coronavírus e tratamentos com ligante contra adrenomedulina
KR20220155338A (ko) 2020-03-19 2022-11-22 암젠 인크 뮤신 17에 대한 항체 및 이의 용도
BR112022019073A2 (pt) 2020-03-25 2022-11-08 Jiangsu Hengrui Pharmaceuticals Co Ltd Composição farmacêutica que compreende conjugado anticorpo-fármaco e uso da mesma
CN115103858A (zh) 2020-03-25 2022-09-23 江苏恒瑞医药股份有限公司 一种抗体药物偶联物的制备方法
BR112022018987A2 (pt) 2020-03-26 2022-11-01 Seagen Inc Métodos de tratamento de mieloma múltiplo
US20230203191A1 (en) 2020-03-30 2023-06-29 Danisco Us Inc Engineered antibodies
US11045546B1 (en) 2020-03-30 2021-06-29 Cytodyn Inc. Methods of treating coronavirus infection
WO2021197340A1 (zh) 2020-03-31 2021-10-07 百奥泰生物制药股份有限公司 用于治疗冠状病毒的抗体、融合蛋白及其应用
EP4126937A1 (de) 2020-03-31 2023-02-08 Alector LLC Anti-mertk-antikörper und verfahren zur verwendung davon
EP3889183A1 (de) 2020-04-01 2021-10-06 Pierre Fabre Medicament Proteinkomplex mit einem immunzytokin
EP4126064A1 (de) 2020-04-03 2023-02-08 Visterra, Inc. Antikörpermolekül-wirkstoff-konjugate und verwendungen davon
WO2021203053A1 (en) 2020-04-03 2021-10-07 Vir Biotechnology, Inc. Immunotherapy targeting a conserved region in sars coronaviruses
EP4126219A2 (de) 2020-04-04 2023-02-08 Takeda Pharmaceutical Company Limited Plasmakallikreinhemmer und verwendungen davon zur behandlung von akutem atemnotsyndrom
JP2023520587A (ja) 2020-04-06 2023-05-17 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー． 癌及び感染症の治療のためのＮＫｐ４６に対する抗体及びそのコンストラクト
AU2020202454A1 (en) 2020-04-06 2021-10-21 H. Lundbeck A/S Treatment of most bothersome symptom (MBS) associated with migraine using anti-CGRP antibodies
WO2021207348A1 (en) 2020-04-07 2021-10-14 Albert Einstein College Of Medicine Method of treating and preventing ocular disease with hsv-2 delta gd
US20230132275A1 (en) 2020-04-08 2023-04-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cdon inhibitors for the treatment of endothelial dysfunction
US20230272056A1 (en) 2020-04-09 2023-08-31 Merck Sharp & Dohme Llc Affinity matured anti-lap antibodies and uses thereof
US20230295281A1 (en) 2020-04-10 2023-09-21 Vanudis GmbH Natural antibodies in prophylaxis and therapy
IL297167A (en) 2020-04-10 2022-12-01 Seagen Inc Charging variant connectors
KR20230009890A (ko) 2020-04-10 2023-01-17 라쿠텐 메디칼, 인크. 프탈로시아닌 염료 화합물, 콘쥬게이트 및 이의 사용 방법
WO2021211331A1 (en) 2020-04-13 2021-10-21 Abbott Point Of Care Inc. METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß-CORONAVIRUS ANTIBODY IN A SAMPLE
BR112022020706A2 (pt) 2020-04-14 2022-11-29 Vir Biotechnology Inc Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
WO2021211924A1 (en) 2020-04-16 2021-10-21 Janssen Biotech, Inc. Treatment of atopic dermatitis
CN115843268A (zh) 2020-04-17 2023-03-24 纽约大学 治疗性MuSK抗体
US20230242635A1 (en) 2020-04-17 2023-08-03 Zoetis Services Llc Canine antibody variants
IL297290A (en) 2020-04-17 2022-12-01 Zoetis Services Llc Feline antibody variants
JP2023523919A (ja) 2020-04-21 2023-06-08 ジェイジェイピー バイオロジクス エスピー．ゼット オー．オー． ヒト化抗ヒトｃｄ８９抗体及びその使用
EP4139362A2 (de) 2020-04-22 2023-03-01 IGM Biosciences Inc. Multimere pd-1-agonist-bindungsmoleküle
JP2023523011A (ja) 2020-04-24 2023-06-01 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
WO2021214222A1 (en) 2020-04-24 2021-10-28 Sanofi Antitumor combinations containing anti-ceacam5 antibody conjugates, trifluridine and tipiracil
EP4138926A1 (de) 2020-04-24 2023-03-01 Sanofi Antitumor-kombinationen mit anti-ceacam5-antikörperkonjugaten und folfox
GB202006093D0 (en) 2020-04-24 2020-06-10 King S College London Composition
CN115427083A (zh) 2020-04-24 2022-12-02 赛诺菲 含有抗ceacam5抗体缀合物和西妥昔单抗的抗肿瘤组合
AU2021261553A1 (en) 2020-04-24 2023-01-05 Sanofi Antitumor combinations containing anti-CEACAM5 antibody conjugates and FOLFIFI
WO2021217024A1 (en) 2020-04-24 2021-10-28 Millennium Pharmaceuticals, Inc. Anti-cd19 antibodies and uses thereof
CN113637082A (zh) 2020-04-27 2021-11-12 启愈生物技术(上海)有限公司 一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用
EP4143302A1 (de) 2020-04-27 2023-03-08 Magenta Therapeutics, Inc. Verfahren und zusammensetzungen zur transduktion hämatopoetischer stamm- und vorläuferzellen in vivo
BR112022022045A2 (pt) 2020-04-30 2023-01-10 Sairopa B V Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao cd103 humano, um ou mais ácidos nucleicos, sistema de expressão, célula hospedeira, composição, métodos de produção de um anticorpo ou fragmento de ligação ao antígeno, para detectar a presença de cd103 em uma amostra biológica, para tratar ou prevenir uma condição mediada por sinalização de cd103 em um indivíduo em necessidade, para inibir a sinalização de cd103 em uma célula, para inibir a ligação de cd103 à e-caderina presente em uma célula, para retirar as células que expressam cd103 em um indivíduo, para tratar ou prevenir uma doença e agente de imageamento
EP4143236A1 (de) 2020-05-01 2023-03-08 Novartis AG Manipulierte immunglobuline
CN115461363A (zh) 2020-05-01 2022-12-09 诺华股份有限公司 免疫球蛋白变体
WO2021225781A2 (en) 2020-05-07 2021-11-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
JP2023525039A (ja) 2020-05-08 2023-06-14 ヴィア・バイオテクノロジー・インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２に対する抗体
EP3909601A1 (de) 2020-05-11 2021-11-17 LeukoCom GmbH Neuer antikörper, der spezifisch an menschliches ceacam1/3/5 bindet, und dessen verwendung
EP4149558A1 (de) 2020-05-12 2023-03-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Neues verfahren zur behandlung von kutanen t-zell-lymphomen und tfh-abgeleiteten lymphomen
WO2021227307A1 (zh) 2020-05-12 2021-11-18 普米斯生物技术(珠海)有限公司 抗cd73抗体及其用途
US20230272086A1 (en) 2020-05-12 2023-08-31 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. St2 antigen binding protein
US20230183366A1 (en) 2020-05-13 2023-06-15 Inserm (Institut National De La Santé Et De La Recherch Médicale) Recombinant proteins with ox40 activating properties
WO2021228218A1 (zh) 2020-05-14 2021-11-18 江苏恒瑞医药股份有限公司 抗cd25抗体、其抗原结合片段及其医药用途
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
CA3178406A1 (en) 2020-05-15 2021-11-18 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody drug conjugate, preparation method therefor and use thereof
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
JP2023526529A (ja) 2020-05-19 2023-06-21 アンスティテュ・クリー サイトカイン放出症候群の診断及び処置の方法
MX2022014636A (es) 2020-05-19 2023-02-23 Amgen Inc Construcciones de unión a mageb2.
JP2023528017A (ja) 2020-05-26 2023-07-03 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） 重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）ポリペプチドおよびワクチン目的でのその使用
IL298537A (en) 2020-05-27 2023-01-01 Arialys Therapeutics Inc Derivation of human anti-nr1 antibody
EP3915641A1 (de) 2020-05-27 2021-12-01 International-Drug-Development-Biotech Anti-cd5-antikörper und verfahren zu ihrer verwendung
JP2023527972A (ja) 2020-05-29 2023-07-03 アムジエン・インコーポレーテツド Ｃｄ３３及びｃｄ３に結合する二重特異性コンストラクトの有害作用軽減投与
CN113754766A (zh) 2020-06-02 2021-12-07 明慧医药（上海）有限公司 抗b7-h3抗体及其制备和应用
MX2022015157A (es) 2020-06-02 2023-01-16 Arcus Biosciences Inc Anticuerpos para tigit.
WO2021247908A1 (en) 2020-06-03 2021-12-09 Bionecure Therapeutics, Inc. Trophoblast cell-surface antigen-2 (trop-2) antibodies
WO2021247925A1 (en) 2020-06-03 2021-12-09 Vir Biotechnology, Inc. Structure-guided immunotherapy against sars-cov-2
JP2023528417A (ja) 2020-06-04 2023-07-04 ケンジョッケティ バイオテクノロジー，インク． Ａｂｃｇ２排出ポンプ－がん抗原多重特異性抗体並びにそれらに関連する組成物、試薬、キット、及び方法
AU2021288751A1 (en) 2020-06-08 2023-02-09 Janssen Biotech, Inc. Cell-based assay for determining the in vitro tumor killing activity of chimeric antigen expressing immune cells
US11702470B2 (en) 2020-06-11 2023-07-18 Imperial College Innovations Limited Use of CXCL13 binding molecules to promote peripheral nerve regeneration
EP4165169A1 (de) 2020-06-11 2023-04-19 Novartis AG Zbtb32 inhibitoren und deren verwendungen
EP4165077A1 (de) 2020-06-12 2023-04-19 VIR Biotechnology, Inc. Antikörpertherapien für sars-cov-2-infektion
WO2021257497A1 (en) 2020-06-15 2021-12-23 Sarepta Therapeutis, Inc. Adeno-associated virus antibodies and fragments thereof
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
JP2023532266A (ja) 2020-06-23 2023-07-27 ジアンスー カニョン ファーマシューティカル カンパニー リミテッド 抗ｃｄ３８抗体及びその使用
EP4172206A1 (de) 2020-06-24 2023-05-03 Visterra, Inc. Antikörpermoleküle gegen april und verwendungen davon
US20230305023A1 (en) 2020-06-25 2023-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of treatment and diagnostic of pathological conditions associated with intense stress
KR20230135556A (ko) 2020-06-25 2023-09-25 백시넥스 인코포레이티드 레트 증후군의 치료를 위한 세마포린-4d 결합 분자의 용도
TW202216771A (zh) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
EP4172193A1 (de) 2020-06-29 2023-05-03 Zoetis Services LLC Katzenantikörpervarianten zur verbesserung der stabilität
JP2023532339A (ja) 2020-06-29 2023-07-27 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用
WO2022010797A2 (en) 2020-07-07 2022-01-13 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
TW202214683A (zh) 2020-07-09 2022-04-16 大陸商北京凱因科技股份有限公司 結合ｂ型肝炎病毒表面抗原的抗體及其應用
EP4180457A1 (de) 2020-07-13 2023-05-17 Shanghai Junshi Biosciences Co., Ltd. Anti-cldn-18.2-antikörper und verwendung davon
TW202216761A (zh) 2020-07-16 2022-05-01 瑞士商諾華公司 抗β細胞素抗體、其片段及多特異性結合分子
WO2022013613A2 (en) 2020-07-17 2022-01-20 Onena Medicines S.L. Antibodies against lefty proteins
AU2021311701A1 (en) 2020-07-21 2023-02-16 Shanghai Junshi Biosciences Co., Ltd. Anti-CTLA-4 antibody and use thereof
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
WO2022022662A1 (zh) 2020-07-31 2022-02-03 百奥泰生物制药股份有限公司 Cd47抗体及其应用
US20220043003A1 (en) 2020-08-04 2022-02-10 Abbott Rapid Diagnostics International Unlimited Company Assays for detecting sars-cov-2
US20220043000A1 (en) 2020-08-04 2022-02-10 Abbott Laboratories Methods and kits for detecting sars-cov-2 protein in a sample
EP4192868A1 (de) 2020-08-05 2023-06-14 Juno Therapeutics, Inc. Antiidiotypische antikörper gegen ror1-gerichtete bindungsdomänen und zugehörige zusammensetzungen und verfahren
WO2022028608A1 (zh) 2020-08-07 2022-02-10 百奥泰生物制药股份有限公司 抗pd-l1抗体及其应用
US20230303695A1 (en) 2020-08-10 2023-09-28 Tengfei XIAO Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
WO2022035998A1 (en) 2020-08-11 2022-02-17 City Of Hope Compositions and uses of sars-cov-2 targeted chimeric antigen receptor modified nk cells
EP4196227A2 (de) 2020-08-12 2023-06-21 Biond Biologics Ltd. Antikörper gegen ilt2 und verwendung davon
TW202221026A (zh) 2020-08-14 2022-06-01 瑞士商Ａｃ 免疫有限公司 人源化抗ｔｄｐ－４３結合分子及其用途
US20230303658A1 (en) 2020-08-19 2023-09-28 Astellas Pharma Inc. Human non-naturally occurring modified fc region of igg specifically binding to non-naturally occurring modified fc receptor
AU2021329378A1 (en) 2020-08-19 2023-03-23 Xencor, Inc. Anti-CD28 compositions
EP4200338A1 (de) 2020-08-20 2023-06-28 Amgen Inc. Antigenbindende proteine mit nichtkanonischem disulfid in der fab-region
TW202227616A (zh) 2020-08-21 2022-07-16 美商英麥提克斯股份有限公司 分離ｃｄ８＋選擇ｔ細胞的方法
KR20230048150A (ko) 2020-08-21 2023-04-10 상하이 젠베이스 바이오테크놀로지 씨오., 엘티디. 글리코실화된 ceacam5에 특이적으로 결합하는 항체
WO2022043312A1 (en) 2020-08-24 2022-03-03 Charité - Universitätsmedizin Berlin Chimeric antigen receptor (car)-expressing cells recognizing cea
US20240009310A1 (en) 2020-08-24 2024-01-11 Charité - Universitätsmedizin Berlin A CHIMERIC ANTIGEN RECEPTOR CONSTRUCT ENCODING A CHECKPOINT INHIBITORY MOLECULE AND AN IMMUNE STIMULATORY CYTOKINE AND CAR-EXPRESSING CELLS RECOGNIZING CD44v6
BR112023002803A2 (pt) 2020-08-25 2023-03-14 Bristol Myers Squibb Co Método de tratamento de uma doença autoimune com anticorpos monoclonais cd40 antagonísticos
CN116761818A (zh) 2020-08-26 2023-09-15 马伦戈治疗公司 检测trbc1或trbc2的方法
WO2022044010A1 (en) 2020-08-26 2022-03-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections
CN116249718A (zh) 2020-08-26 2023-06-09 马伦戈治疗公司 结合至钙网蛋白的多功能性分子及其用途
CN114106173A (zh) 2020-08-26 2022-03-01 上海泰槿生物技术有限公司 抗ox40抗体、其药物组合物及应用
GB2616128A (en) 2020-08-26 2023-08-30 Marengo Therapeutics Inc Antibody molecules that bind to NKp30 and uses thereof
EP4204448A2 (de) 2020-08-27 2023-07-05 cureab GmbH Anti-golph2-antikörper zur makrophagen- und dendritischen zelldifferenzierung
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043558A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
BR112023001733A2 (pt) 2020-09-04 2023-03-28 Merck Patent Gmbh Anticorpos anti-ceacam5 e conjugados e usos dos mesmos
US20230331867A1 (en) 2020-09-04 2023-10-19 Novarock Biotherapeutics, Ltd. Nectin-4 antibodies and uses thereof
US20230340149A1 (en) 2020-09-07 2023-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of treatment of inflammatory bowel diseases
BR112023004415A2 (pt) 2020-09-11 2023-05-09 Medimmune Ltd Moléculas terapêuticas de ligação a b7-h4
EP4211663A2 (de) 2020-09-12 2023-07-19 MedImmune Limited Bewertungsverfahren für eine anti-b7h4-antikörper-wirkstoff-konjugattherapie
CA3194792A1 (en) 2020-09-15 2022-03-24 Bayer Aktiengesellschaft Novel anti-a2ap antibodies and uses thereof
WO2022060806A1 (en) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
KR20230073270A (ko) 2020-09-22 2023-05-25 브리스톨-마이어스 스큅 컴퍼니 치료 단백질의 생산 방법
GB202015235D0 (en) 2020-09-25 2020-11-11 Ucl Business Plc Anti-CD45 antibodies and related therapeutics
TW202229337A (zh) 2020-09-28 2022-08-01 美商碩騰服務公司 犬抗體變異體
EP4217395A1 (de) 2020-09-28 2023-08-02 Seagen Inc. Humanisierte anti-liv1-antikörper zur behandlung von krebs
EP4217385A2 (de) 2020-09-28 2023-08-02 VIR Biotechnology, Inc. Antikörper gegen sars-cov-2
PE20240110A1 (es) 2020-09-29 2024-01-22 Zoetis Services Llc Variantes de anticuerpos felinos
US20230374447A1 (en) 2020-10-05 2023-11-23 Protalix Ltd. Dicer-like knock-out plant cells
US20230375571A1 (en) 2020-10-05 2023-11-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Gdf3 as biomarker and biotarget in post-ischemic cardiac remodeling
US20230374162A1 (en) 2020-10-07 2023-11-23 Amgen Inc. Rational selection of building blocks for the assembly of multispecific antibodies
EP4227686A1 (de) 2020-10-08 2023-08-16 National University Corporation Tokai National Higher Education and Research System Verfahren zur bestimmung der empfindlichkeit oder der medizinischen wirkung eines anti-transferrin-rezeptorantikörpers
IL300314A (en) 2020-10-08 2023-04-01 Affimed Gmbh Coupling materials with triple specificity
EP3981789A1 (de) 2020-10-12 2022-04-13 Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives Anti-lilrb-antikörper und verwendungen davon
WO2022081718A1 (en) 2020-10-14 2022-04-21 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
EP4229086A1 (de) 2020-10-15 2023-08-23 UCB Biopharma SRL Bindungsmoleküle, die cd45 multimerisieren
EP4229081A1 (de) 2020-10-15 2023-08-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Für sars-cov-2-rezeptor-bindungsdomäne spezifischer antikörper und therapeutische verfahren
US20230414700A1 (en) 2020-10-15 2023-12-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Tg2 inhibitors for improving mucociliary clearance in respiratory diseases
CA3191224A1 (en) 2020-10-16 2022-04-21 Shenda GU Multispecific binding compounds that bind to pd-l1
EP4232475A1 (de) 2020-10-20 2023-08-30 Kantonsspital St. Gallen Antikörper oder antigenbindende fragmente mit spezifischer bindung an gremlin-1 und verwendungen davon
EP4232064A1 (de) 2020-10-21 2023-08-30 Institut National de la Santé et de la Recherche Médicale (INSERM) C-terminale sparc-fragmente zur behandlung von krebs
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
WO2022090801A2 (en) 2020-10-26 2022-05-05 Compugen Ltd. Pvrl2 and/or pvrig as biomarkers for treatment
WO2022093640A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2c agents and compositions and methods for making and using the same
WO2022093641A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2a agents and compositions and methods for making and using the same
JP2023550596A (ja) 2020-11-02 2023-12-04 ユーシービー バイオファルマ エスアールエル 運動ニューロン神経変性障害の治療のための抗ｔｒｅｍ１中和抗体の使用
CA3197423A1 (en) 2020-11-04 2022-05-12 Daniel Getts Engineered chimeric fusion protein compositions and methods of use thereof
WO2022097090A1 (en) 2020-11-05 2022-05-12 Novartis Ag Dosing regimen for combination therapies with multispecific antibodies targeting b-cell maturation antigen and gamma secretase inhibitors
WO2022096547A1 (en) 2020-11-05 2022-05-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-6 inhibitors for the treatment of acute chest syndrome in patients suffering from sickle cell disease
US20240067728A1 (en) 2020-11-06 2024-02-29 Bio-Thera Solutions, Ltd. Bispecific antibody and use thereof
EP4240765A2 (de) 2020-11-06 2023-09-13 Novartis AG Antikörper-fc-varianten
WO2022096704A1 (en) 2020-11-06 2022-05-12 Amgen Inc. Antigen binding domain with reduced clipping rate
AU2021374839A1 (en) 2020-11-06 2023-06-08 Amgen Inc. Multitargeting bispecific antigen-binding molecules of increased selectivity
JP2023547662A (ja) 2020-11-06 2023-11-13 アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物
BR112023008670A2 (pt) 2020-11-06 2024-02-06 Amgen Inc Construtos polipeptídicos ligados à cd3
EP4240494A1 (de) 2020-11-06 2023-09-13 Novartis AG Anti-cd19-mittel und auf b-zellen abzielende kombinationstherapie zur behandlung von b-zell-malignomen
WO2022097060A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
US20240011094A1 (en) 2020-11-06 2024-01-11 Institut National de la Santé et de la Recherche Médicale Methods for diagnosis and treating polycystic ovary syndrome (pcos)
WO2022097117A1 (en) 2020-11-09 2022-05-12 Takeda Pharmaceutical Company Ltd. Antibody drug conjugates
EP4244246A1 (de) 2020-11-10 2023-09-20 Amgen Inc. Neue linker von multispezifischen antigenbindenden domänen
US20220143026A1 (en) 2020-11-12 2022-05-12 Tg Therapeutics, Inc. Triple combination to treat b-cell malignancies
EP4244253A1 (de) 2020-11-12 2023-09-20 Inserm (Institut National De La Sante Et De La Recherche Medicale) An die rezeptorbindungsdomäne des sars-cov-2-spikeproteins konjugierte oder fusionierte antikörper und verwendungen davon für impfstoffzwecke
MX2023005609A (es) 2020-11-13 2023-05-29 Novartis Ag Terapias de combinacion con celulas que expresan receptores quimericos para el antigeno (car).
CR20230244A (es) 2020-11-16 2023-07-12 Astellas Pharma Inc Anticuerpo biespecífico anti-tspan8/anti-cd3 y anticuerpo anti-tspan8
WO2022109313A1 (en) 2020-11-20 2022-05-27 Zoetis Services Llc Bovine antibody variants
WO2022109291A1 (en) 2020-11-23 2022-05-27 Vir Biotechnology, Inc. Antibodies against influenza a viruses
WO2022109317A1 (en) 2020-11-23 2022-05-27 Vir Biotechnology, Inc. Anti-influenza antibodies and combinations thereof
JP2023551668A (ja) 2020-11-23 2023-12-12 ヴィア・バイオテクノロジー・インコーポレイテッド インフルエンザのノイラミニダーゼに対する広域中和抗体
WO2022115486A1 (en) 2020-11-25 2022-06-02 Vir Biotechnology, Inc. Antibodies that bind to multiple betacoronaviruses
EP4251282A1 (de) 2020-11-27 2023-10-04 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren zur diagnose und überwachung von toxischer epidermaler nekrolyse
WO2022115120A1 (en) 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
TW202241436A (zh) 2020-11-30 2022-11-01 美商英塞特公司 抗ｃｄ１９抗體及帕薩昔布（ｐａｒｓａｃｌｉｓｉｂ）之組合療法
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
MX2023006426A (es) 2020-12-01 2023-07-17 Aptevo Res And Development Llc Antígenos asociados a tumores y proteínas de unión a cd3 y composiciones y métodos relacionados.
CA3198161A1 (en) 2020-12-01 2022-06-09 Beth MCQUISTON Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
AU2021392039A1 (en) 2020-12-02 2023-06-29 Alector Llc Methods of use of anti-sortilin antibodies
EP4023218A1 (de) 2020-12-02 2022-07-06 S-Form Pharma Kombinationstherapie für patienten mit akuter und/oder anhaltender dyspnoe
WO2022120224A1 (en) 2020-12-04 2022-06-09 Visterra, Inc. Methods of using interleukin-2 agents
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
WO2022125755A1 (en) 2020-12-10 2022-06-16 Thermo Fisher Scientific Inc. Method and composition for multiplexed and multimodal single cell analysis
US20240002911A1 (en) 2020-12-10 2024-01-04 Phitonex, Inc. Methods Of Signal Amplification
WO2022130182A1 (en) 2020-12-14 2022-06-23 Novartis Ag Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
CN116547298A (zh) 2020-12-18 2023-08-04 硕腾服务有限责任公司 猫抗体恒定区中的突变
US20220281914A1 (en) 2020-12-18 2022-09-08 Kiniksa Pharmaceuticals, Ltd. Protein compositions and methods for producing and using the same
CN117015386A (zh) 2020-12-21 2023-11-07 旗舰创业创新五公司 细胞周转因子用于增加组织再生的用途
MX2023007610A (es) 2020-12-23 2023-07-12 Inserm Institut National De La Sante Et De La Rech Medicale Vacuna contra clamidia basada en el direccionamiento del antigeno momp vs4 a las celulas presentadoras de antigeno.
CA3207066A1 (en) 2020-12-29 2022-07-07 Incyte Corporation Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
AU2021412369A1 (en) 2020-12-29 2023-07-13 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Anti-april antibodies and uses thereof
CN114685669A (zh) 2020-12-30 2022-07-01 和铂医药(苏州)有限公司 结合trop2的抗体及其用途
WO2022147147A1 (en) 2020-12-30 2022-07-07 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
US20240092892A1 (en) 2020-12-30 2024-03-21 Bio-Thera Solutions, Ltd. Anti-cldn18.2 antibody, and preparation method therefor and use thereof
JP2024501739A (ja) 2020-12-31 2024-01-15 諾納生物（蘇州）有限公司 ヒトｌｉｆｒ抗原結合タンパク質、その製造方法及び応用
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
JP2024503625A (ja) 2021-01-06 2024-01-26 トニックス ファーマ リミテッド 改変された抗ｃｄ１５４抗体により免疫寛容を誘導する方法
CN114763381A (zh) 2021-01-13 2022-07-19 博生吉医药科技(苏州)有限公司 B7-h3嵌合抗原受体修饰的t细胞及其应用
KR20230146521A (ko) 2021-01-13 2023-10-19 메모리얼 슬로안 케터링 캔서 센터 항체-피롤로벤조디아제핀 유도체 접합체
EP4279594A1 (de) 2021-01-13 2023-11-22 Astellas Pharma Inc. Multispezifischer antikörper mit bindung an actriia, actriib und fn14
US20240115721A1 (en) 2021-01-13 2024-04-11 Memorial Sloan Kettering Cancer Center Anti-dll3 antibody-drug conjugate
WO2022155410A1 (en) 2021-01-15 2022-07-21 President And Fellows Of Harvard College Methods and compositions relating to anti-mfsd2a antibodies
BR112023014128A2 (pt) 2021-01-15 2023-10-31 Seagen Inc Conjugados de anticorpo-fármaco imunomodulatórios
WO2022159575A1 (en) 2021-01-20 2022-07-28 Bioentre Llc Ctla4-binding proteins and methods of treating cancer
KR20230147072A (ko) 2021-01-20 2023-10-20 비스테라, 인크. 인터류킨-2 돌연변이체 및 이의 용도
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
KR20230147092A (ko) 2021-01-22 2023-10-20 바이원큐어 테라퓨틱스, 인크. 항-her-2/trop-2 작제물 및 이의 용도
JP2024503908A (ja) 2021-01-22 2024-01-29 バイエル アクチェンゲゼルシャフト Ｌｒｒｃ１５抗体およびそのコンジュゲート
BR112023015097A2 (pt) 2021-01-28 2023-10-03 Janssen Biotech Inc Proteínas de ligação a psma e usos das mesmas
CN117440966A (zh) * 2021-01-28 2024-01-23 塔勒姆治疗有限责任公司 抗SARS-CoV-2刺突糖蛋白抗体及其治疗用途
CN116802205A (zh) 2021-01-28 2023-09-22 硕腾服务有限责任公司 犬抗体恒定区中的突变
JP2024504195A (ja) 2021-01-29 2024-01-30 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） クラミジア・トラコマチス抗原性ポリペプチドおよびワクチン目的のためのその使用
AU2022213415A1 (en) 2021-01-29 2023-08-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Near infrared photoimmunotherapy (nir-pit) combination therapy to treat cancer
JP2024505049A (ja) 2021-01-29 2024-02-02 ノバルティス アーゲー 抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用
WO2022170002A1 (en) 2021-02-03 2022-08-11 Seagen Inc. Immunostimulatory compounds and conjugates
CN114907479A (zh) 2021-02-09 2022-08-16 上海君实生物医药科技股份有限公司 抗cd112r抗体及其用途
CN114907473A (zh) 2021-02-10 2022-08-16 厦门大学 用于预防和治疗eb病毒感染及相关疾病的表位肽及抗体
AU2022219681A1 (en) 2021-02-11 2023-09-21 Nectin Therapeutics Ltd. Antibodies against cd112r and uses thereof
JP2024506200A (ja) 2021-02-15 2024-02-09 武田薬品工業株式会社 細胞治療用組成物及びｔｇｆ－ｂシグナル伝達を調節する方法
US11639396B2 (en) 2021-02-16 2023-05-02 Janssen Biotech, Inc. Antibody binding to a linker peptide
CA3206901A1 (en) 2021-02-19 2022-08-25 Theripion, Inc. Paraoxonase fusion polypeptides and related compositions and methods
CN117321076A (zh) 2021-02-19 2023-12-29 美国卫生及公众服务部代表 中和SARS-CoV-2的单结构域抗体
JP2022128212A (ja) * 2021-02-22 2022-09-01 シスメックス株式会社 モノクローナル抗体、サイトケラチン１８フラグメントの測定試薬、試薬キットおよび測定方法
CA3211686A1 (en) 2021-02-26 2022-09-01 Bayer Aktiengesellschaft Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding
WO2022186772A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
WO2022186773A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION
US20240041978A1 (en) 2021-03-03 2024-02-08 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services La protein as a novel regulator of osteoclastogenesis
WO2022184853A1 (en) 2021-03-03 2022-09-09 Pierre Fabre Medicament Anti-vsig4 antibody or antigen binding fragment and uses thereof
JP2024508157A (ja) 2021-03-04 2024-02-22 センター ナショナル デ ラ レシェルシェ サイエンティフィーク 炎症、線維症及び肺疾患を治療するためのペリオスチン抗体の使用
CN116940377A (zh) 2021-03-05 2023-10-24 上海吉倍生物技术有限公司 抗cldn6抗体及其用途
EP4301782A1 (de) 2021-03-05 2024-01-10 Go Therapeutics, Inc. Anti-glyco-cd44-antikörper und deren verwendungen
EP4305067A1 (de) 2021-03-09 2024-01-17 Xencor, Inc. Cd3 und cldn6 bindende heterodimere antikörper
MX2023008176A (es) 2021-03-09 2023-07-18 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Proteina de union a ror1 y uso de la misma.
WO2022192586A1 (en) 2021-03-10 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
EP4305062A1 (de) 2021-03-12 2024-01-17 Janssen Biotech, Inc. Verfahren zur behandlung von patienten mit psoriasisarthritis mit unzureichender reaktion auf eine tnf-therapie mit anti-il23-spezifischem antikörper
IL305802A (en) 2021-03-12 2023-11-01 Janssen Biotech Inc A safe and effective method for the treatment of rheumatoid arthritis with a specific anti-IL23 antibody
EP4308694A1 (de) 2021-03-16 2024-01-24 Magenta Therapeutics, Inc. Dosierschemata zur mobilisierung hämatopoetischer stammzellen für stammzelltransplantationen bei patienten mit multiplem myelom
CA3208011A1 (en) 2021-03-17 2022-09-22 Sarah Harris Methods of treating atopic dermatitis with anti il-13 antibodies
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
WO2022197947A1 (en) 2021-03-18 2022-09-22 Alector Llc Anti-tmem106b antibodies and methods of use thereof
CN117321418A (zh) 2021-03-18 2023-12-29 诺华股份有限公司 癌症生物标志物及其使用方法
BR112023018331A2 (pt) 2021-03-18 2023-12-12 Medimmune Ltd Molécula terapêutica de ligação que se liga a ccr9
TW202300179A (zh) 2021-03-18 2023-01-01 美商西根公司 內化的生物活性化合物偶聯物選擇性釋放藥物
WO2022195504A1 (en) 2021-03-19 2022-09-22 Pfizer Inc. Method of treating osteoarthritis pain with an anti ngf antibody
KR20230159851A (ko) 2021-03-22 2023-11-22 주노 쎄러퓨티크스 인코퍼레이티드 치료 세포 조성물의 효력을 결정하는 방법
KR20230158573A (ko) 2021-03-22 2023-11-20 주노 쎄러퓨티크스 인코퍼레이티드 바이러스 벡터 입자의 효력을 평가하는 방법
WO2022204202A1 (en) 2021-03-23 2022-09-29 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
EP4314063A1 (de) 2021-03-23 2024-02-07 Alector LLC Anti-tmem106b-antikörper zur behandlung und prävention von coronavirusinfektionen
AU2022246275A1 (en) 2021-03-26 2023-11-09 Janssen Biotech, Inc. Humanized antibodies against paired helical filament tau and uses thereof
WO2022200525A1 (en) 2021-03-26 2022-09-29 Innate Pharma Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
IL307233A (en) 2021-03-30 2023-11-01 Bayer Ag Anti-SEMA3A antibodies and uses thereof
JP2024512669A (ja) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
EP4067381A1 (de) 2021-04-01 2022-10-05 Julius-Maximilians-Universität Würzburg Neue tnfr2-bindende moleküle
EP4314068A1 (de) 2021-04-02 2024-02-07 The Regents Of The University Of California Antikörper gegen gespaltenes cdcp1 und verwendungen davon
AR125290A1 (es) 2021-04-02 2023-07-05 Amgen Inc Construcciones de unión a mageb2
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
BR112023020832A2 (pt) 2021-04-08 2023-12-19 Marengo Therapeutics Inc Moléculas multifuncionais ligadas a tcr e seus usos
CN117425673A (zh) 2021-04-09 2024-01-19 武田药品工业株式会社 靶向补体因子d的抗体和其用途
CN117440798A (zh) 2021-04-12 2024-01-23 Acm 生物实验室私人有限公司 包含可溶性被包封多核苷酸和可电离的脂质的聚合物囊泡及其制备方法和用途
WO2022218998A1 (en) 2021-04-13 2022-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating hepatitis b and d virus infection
WO2022221409A1 (en) 2021-04-14 2022-10-20 Villaris Therapeutics, Inc. Anti-cd122 antibodies and uses thereof
KR20230171980A (ko) 2021-04-20 2023-12-21 씨젠 인크. 항체 의존성 세포 독성의 조절
EP4326761A1 (de) 2021-04-20 2024-02-28 Amgen Inc. Ausgeglichene ladungsverteilung bei der elektrostatischen lenkung von kettenpaarung in einer multispezifischen und monovalenten igg-molekülanordnung
AR125398A1 (es) 2021-04-22 2023-07-12 Astellas Pharma Inc Anticuerpo biespecífico anti-cldn4 / anti-cd137
AR125404A1 (es) 2021-04-23 2023-07-12 Amgen Inc Anticuerpos anti-tslp modificados
EP4326766A1 (de) 2021-04-23 2024-02-28 Amgen Inc. Anti-tslp-antikörperzusammensetzungen und verwendungen davon
WO2022223784A1 (en) 2021-04-23 2022-10-27 King's College London Composition comprising an ige antibody
EP4330283A1 (de) 2021-04-26 2024-03-06 Millennium Pharmaceuticals, Inc. Anti-adgre2-antikörper und verwendungen davon
KR20240004286A (ko) 2021-04-26 2024-01-11 밀레니엄 파머슈티컬스 인코퍼레이티드 항 Clec12A 항체 및 이의 용도
EP4330281A1 (de) 2021-04-29 2024-03-06 Amgen Inc. Verfahren zur reduzierung von spezies mit niedrigem molekulargewicht von rekombinant hergestellten proteinen
US11931420B2 (en) 2021-04-30 2024-03-19 Celgene Corporation Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI)
EP4172212A1 (de) 2021-04-30 2023-05-03 Pierre Fabre Medicament Neuer stabiler anti-vista-antikörper
IL308012A (en) 2021-04-30 2023-12-01 Cellectis Sa Anti-MUC1 for novel chimeric antigen receptors and genetically engineered immune cells for solid tumor immunotherapy
US20220372168A1 (en) 2021-05-04 2022-11-24 Regeneron Pharmaceuticals, Inc. Multispecific fgf21 receptor agonists and their uses
EP4334358A1 (de) 2021-05-06 2024-03-13 Amgen Research (Munich) GmbH Cd20 und cd22 zielende antigenbindende moleküle zur verwendung bei proliferativen erkrankungen
EP4334354A1 (de) 2021-05-06 2024-03-13 Dana-Farber Cancer Institute, Inc. Antikörper gegen alk und verfahren zur verwendung davon
WO2022241057A1 (en) 2021-05-12 2022-11-17 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
AU2022279156A1 (en) 2021-05-18 2023-11-02 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
EP4340876A1 (de) 2021-05-19 2024-03-27 Sutro Biopharma, Inc. Kombinationstherapie mit anti-folat-rezeptorkonjugaten mit bevacizumab
US20220372129A1 (en) 2021-05-20 2022-11-24 Janssen Biotech, Inc. Method of Treating Inflammatory Bowel Disease with a Combination Therapy of Antibodies to IL-23 and TNF Alpha
BR112023024494A2 (pt) 2021-05-24 2024-02-06 Humabs Biomed Sa Polipeptídeos engenheirados
TW202314247A (zh) 2021-05-25 2023-04-01 美商思進公司 量化抗cd40抗體之方法
CA3221398A1 (en) 2021-05-28 2022-12-01 Seagen Inc. Anthracycline antibody conjugates
EP4348263A1 (de) 2021-05-28 2024-04-10 Alexion Pharmaceuticals, Inc. Verfahren zum nachweis von cm-tma-biomarkern
WO2022253756A1 (en) 2021-06-01 2022-12-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of b cell depleting agents for the treatment of rheumatic heart disease
US11345742B1 (en) * 2021-06-07 2022-05-31 Ossianix, Inc. Shark VNARs for treating COVID-19
BR112023022097A2 (pt) 2021-06-07 2023-12-19 Agonox Inc Cxcr5, pd-1 e icos expressando células t cd4 reativas de tumor e seu uso
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
EP4351732A1 (de) 2021-06-09 2024-04-17 Evotec International GmbH Interferon-assoziierte antigenbindende proteine zur verwendung zur behandlung oder prävention von coronavirus-infektionen
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
CN117616050A (zh) 2021-06-09 2024-02-27 先天制药公司 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质
CA3222291A1 (en) 2021-06-14 2022-12-22 Jaime MARINO Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
IL309349A (en) 2021-06-14 2024-02-01 argenx BV Antibodies against interleukin 9 and methods of using them
EP4355783A1 (de) 2021-06-16 2024-04-24 Alector LLC Monovalente anti-mertk-antikörper und verfahren zur verwendung davon
WO2022266223A1 (en) 2021-06-16 2022-12-22 Alector Llc Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
EP4355780A1 (de) 2021-06-18 2024-04-24 Alligator Bioscience AB Neuartige kombinationstherapien und verwendungen davon
EP4357361A1 (de) 2021-06-18 2024-04-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Anti-il-36r-antikörper und verwendung davon
US20230174651A1 (en) 2021-06-23 2023-06-08 Janssen Biotech, Inc. Materials and methods for hinge regions in functional exogenous receptors
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
IL309405A (en) 2021-06-29 2024-02-01 Seagen Inc Methods for treating cancer with a combination of non-fucosylated anti-CD70 antibody and CD47 antagonist
WO2023278641A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
IL309346A (en) 2021-07-01 2024-02-01 Denali Therapeutics Inc Transferrin receptor-targeted oligonucleotide conjugates
WO2023275621A1 (en) 2021-07-01 2023-01-05 Compugen Ltd. Anti-tigit and anti-pvrig in monotherapy and combination treatments
AU2022306144A1 (en) 2021-07-09 2024-02-22 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
US20230042465A1 (en) 2021-07-09 2023-02-09 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-TNF Antibody Compositions
AU2022306973A1 (en) 2021-07-09 2024-02-22 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
WO2023285362A1 (en) 2021-07-12 2023-01-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-36 inhibitors for the treatment of netherton syndrome
WO2023005805A1 (zh) 2021-07-26 2023-02-02 北京万泰生物药业股份有限公司 人鼻病毒的通用亲和表位多肽、抗体及其用途
WO2023007374A1 (en) 2021-07-27 2023-02-02 Pfizer Inc. Method of treatment of cancer pain with tanezumab
CN117642421A (zh) 2021-07-29 2024-03-01 武田药品工业株式会社 特异性靶向间皮素的工程化免疫细胞以及其用途
IL310437A (en) 2021-07-29 2024-03-01 Inst Nat Sante Rech Med Humanized anti-human βig-h3 protein and uses thereof
WO2023006391A1 (en) 2021-07-30 2023-02-02 Ludwig-Maximilians-Universität München Anti-cd47 antibodies and use thereof
WO2023006390A1 (en) 2021-07-30 2023-02-02 Ludwig-Maximilians-Universität München Mesothelin antibodies and use thereof
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
WO2023014863A1 (en) 2021-08-05 2023-02-09 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
WO2023015234A1 (en) 2021-08-05 2023-02-09 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
CA3227511A1 (en) 2021-08-06 2023-02-09 Lætitia LINARES Methods for the treatment of cancer
CA3228576A1 (en) 2021-08-10 2023-02-16 Byomass Inc. Anti-gdf15 antibodies, compositions and uses thereof
WO2023019200A1 (en) 2021-08-11 2023-02-16 Viela Bio, Inc. Inebilizumab and methods of using the same in the treatment or prevention of igg4-related disease
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
AU2022332285A1 (en) 2021-08-23 2024-02-15 Immunitas Therapeutics, Inc. Anti-cd161 antibodies and uses thereof
CN117836003A (zh) 2021-08-26 2024-04-05 株式会社英仙蛋白质科学 Ros（活性氧类）产生增强剂
WO2023025303A1 (zh) 2021-08-26 2023-03-02 上海君实生物医药科技股份有限公司 抗cldn-18.2抗体药物偶联物及其用途
AU2022335718A1 (en) 2021-08-26 2024-03-28 Glycanostics S.R.O Glycoprotein biomarkers for diagnosing cancer
WO2023025932A1 (en) 2021-08-27 2023-03-02 Medimmune Limited Treatment of chronic obstructive pulmonary disease with an anti-interleukin-33 antibody
WO2023026245A1 (en) 2021-08-27 2023-03-02 H. Lundbeck A/S Treatment of cluster headache using anti-cgrp antibodies
WO2023034777A1 (en) 2021-08-31 2023-03-09 Abbott Laboratories Methods and systems of diagnosing brain injury
CN117881784A (zh) 2021-08-31 2024-04-12 大正制药株式会社 抗生长激素抗体
CA3230613A1 (en) 2021-09-01 2023-03-09 Daren J. AUSTIN Antibody therapies for sars-cov-2 infection in pediatric subjects
WO2023034871A1 (en) 2021-09-01 2023-03-09 Vir Biotechnology, Inc. High concentration antibody therapies for sars-cov-2 infection
AU2022340907A1 (en) 2021-09-02 2024-03-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Anti-cecam6 antibodies with reduced side-effects
CA3230934A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
TW202325733A (zh) 2021-09-03 2023-07-01 美商Ｇｏ治療公司 抗醣化-lamp1抗體及其用途
WO2023039249A1 (en) 2021-09-10 2023-03-16 Leap Therapeutics, Inc. Combination therapy
AU2022346688A1 (en) 2021-09-14 2024-04-04 Glycanostics S.R.O Use of lectins to determine mammaglobin-a glycoforms in breast cancer
WO2023041744A1 (en) 2021-09-17 2023-03-23 Institut Curie Bet inhibitors for treating pab1 deficient cancer
WO2023044280A1 (en) 2021-09-20 2023-03-23 Eli Lilly And Company Anti-il-1-beta antibodies
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023049687A1 (en) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
TW202327650A (zh) 2021-09-23 2023-07-16 美商思進公司 治療多發性骨髓瘤之方法
WO2023046037A1 (zh) 2021-09-24 2023-03-30 正大天晴药业集团股份有限公司 抗cd40抗体及其用途
WO2023048650A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
WO2023048726A1 (en) 2021-09-27 2023-03-30 Vaccinex, Inc. Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders
WO2023048651A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd Method for treatment of moderate to severe atoptic dematitis
AU2022354059A1 (en) 2021-09-30 2024-03-28 Abbott Laboratories Methods and systems of diagnosing brain injury
CA3232806A1 (en) 2021-09-30 2023-04-06 Seagen Inc. B7-h4 antibody-drug conjugates for the treatment of cancer
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2023052541A1 (en) 2021-09-30 2023-04-06 Imcheck Therapeutics Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
CA3234162A1 (en) 2021-10-15 2023-04-20 Michele Fiscella Antibodies and methods of using thereof
WO2023069421A1 (en) 2021-10-18 2023-04-27 Byomass Inc. Anti-activin a antibodies, compositions and uses thereof
WO2023069919A1 (en) 2021-10-19 2023-04-27 Alector Llc Anti-cd300lb antibodies and methods of use thereof
AU2022372894A1 (en) 2021-10-20 2024-04-18 Takeda Pharmaceutical Company Limited Compositions targeting bcma and methods of use thereof
GB202115122D0 (en) 2021-10-21 2021-12-08 Dualyx Nv Binding molecules targeting IL-2 receptor
WO2023073084A1 (en) 2021-10-27 2023-05-04 Imcheck Therapeutics Butyrophilin (btn) 3a activating antibodies for use in methods for treating infectious disorders
WO2023073599A1 (en) 2021-10-28 2023-05-04 Novartis Ag Engineered fc variants
TW202333784A (zh) 2021-10-29 2023-09-01 新加坡商亞獅康私人有限公司 抗ｉｌ１３ｒ抗體調配物
WO2023073615A1 (en) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
US11542340B1 (en) 2021-10-29 2023-01-03 Biodesix, Inc. Antibodies targeting pulmonary nodule specific biomarkers and uses thereof
WO2023081160A1 (en) 2021-11-02 2023-05-11 Visterra, Inc. Fc variants with abolished binding to fcgammar and c1q
WO2023079493A1 (en) 2021-11-03 2023-05-11 Affimed Gmbh Bispecific cd16a binders
CA3233696A1 (en) 2021-11-03 2023-05-11 Joachim Koch Bispecific cd16a binders
TW202333797A (zh) 2021-11-05 2023-09-01 法商賽諾菲公司 含有抗ceacam5抗體-藥物接合物及抗vegfr-2抗體之抗腫瘤組合
EP4180518A1 (de) 2021-11-12 2023-05-17 Istituto Europeo di Oncologia S.r.l. T-zellen und deren verwendungen
WO2023084488A1 (en) 2021-11-15 2023-05-19 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
AR127692A1 (es) 2021-11-16 2024-02-21 Ac Immune Sa Anticuerpos anti-asc para uso en tratamientos antiinflamatorios
WO2023088968A1 (en) 2021-11-17 2023-05-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Universal sarbecovirus vaccines
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023089314A1 (en) 2021-11-18 2023-05-25 Oxford Biotherapeutics Limited Pharmaceutical combinations
WO2023089032A1 (en) 2021-11-19 2023-05-25 Institut Curie Methods for the treatment of hrd cancer and brca-associated cancer
US20230159633A1 (en) 2021-11-23 2023-05-25 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
WO2023097024A1 (en) 2021-11-24 2023-06-01 Dana-Farber Cancer Institute, Inc. Antibodies against ctla-4 and methods of use thereof
US20230348614A1 (en) 2021-11-24 2023-11-02 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof
US20240041981A1 (en) 2021-12-01 2024-02-08 Visterra, Inc. Methods of using interleukin-2 agents
WO2023102077A1 (en) 2021-12-01 2023-06-08 Sutro Biopharma, Inc. Anti-folate receptor conjugate cancer therapy
WO2023099763A1 (en) 2021-12-03 2023-06-08 Institut Curie Sirt6 inhibitors for use in treating resistant hrd cancer
WO2023104904A2 (en) 2021-12-08 2023-06-15 Genclis The sars-cov-2 and variants use two independent cell receptors to replicate
WO2023105528A1 (en) 2021-12-12 2023-06-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to ceacam1
WO2023114543A2 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Platform for antibody discovery
WO2023114544A1 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Antibodies and uses thereof
WO2023114978A1 (en) 2021-12-17 2023-06-22 Abbott Laboratories Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
US20230357392A1 (en) 2021-12-22 2023-11-09 Morphosys Ag Treatment Paradigm for an Anti-CD19 Antibody Therapy
WO2023129942A1 (en) 2021-12-28 2023-07-06 Abbott Laboratories Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
WO2023131901A1 (en) 2022-01-07 2023-07-13 Johnson & Johnson Enterprise Innovation Inc. Materials and methods of il-1beta binding proteins
WO2023140780A1 (en) 2022-01-24 2023-07-27 Aslan Pharmaceuticals Pte Ltd. Method of treating inflammatory disease
WO2023147107A1 (en) 2022-01-31 2023-08-03 Byomass Inc. Myeloproliferative conditions
WO2023150181A1 (en) 2022-02-01 2023-08-10 President And Fellows Of Harvard College Methods and compositions for treating cancer
WO2023150652A1 (en) 2022-02-04 2023-08-10 Abbott Laboratories Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
WO2023150778A1 (en) 2022-02-07 2023-08-10 Visterra, Inc. Anti-idiotype antibody molecules and uses thereof
WO2023154906A1 (en) 2022-02-13 2023-08-17 Vaccinex, Inc. Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease
TW202348252A (zh) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 用治療性結合分子治療癌症的組合療法
TW202342519A (zh) 2022-02-16 2023-11-01 瑞士商Ａｃ 免疫有限公司 人源化抗ｔｄｐ－４３結合分子及其用途
TW202337905A (zh) 2022-02-23 2023-10-01 新加坡商亞獅康私人有限公司 抗il13r抗體之糖基化形式
WO2023166081A1 (en) 2022-03-02 2023-09-07 Heidelberg Immunotherapeutics Gmbh Vaccine comprising an antibody or an fc-containing fusion protein comprising an fc part of an antibody
WO2023169896A1 (en) 2022-03-09 2023-09-14 Astrazeneca Ab BINDING MOLECULES AGAINST FRα
WO2023172968A1 (en) 2022-03-09 2023-09-14 Merck Patent Gmbh Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof
WO2023170240A1 (en) 2022-03-09 2023-09-14 Merck Patent Gmbh Anti-ceacam5 antibodies and conjugates and uses thereof
WO2023170290A1 (en) 2022-03-11 2023-09-14 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof
WO2023170291A1 (en) 2022-03-11 2023-09-14 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof
TW202345899A (zh) 2022-03-11 2023-12-01 比利時商健生藥品公司 多特異性抗體及其用途(三)
WO2023170216A1 (en) 2022-03-11 2023-09-14 Astrazeneca Ab A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
WO2023175035A1 (en) 2022-03-15 2023-09-21 Adrenomed Ag Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment
WO2023175614A1 (en) 2022-03-15 2023-09-21 Yeda Research And Development Co. Ltd. Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof
WO2023178289A2 (en) 2022-03-17 2023-09-21 Seagen Inc. Camptothecin conjugates
EP4245772A1 (de) 2022-03-18 2023-09-20 Netris Pharma Anti-netrin-1-antikörper zur behandlung von leberentzündung
US20240103010A1 (en) 2022-03-18 2024-03-28 Compugen Ltd. Pvrl2 and/or pvrig as biomarkers for treatment
EP4249509A1 (de) 2022-03-22 2023-09-27 Netris Pharma Anti-netrin-1-antikörper gegen arthritis-assoziierte schmerzen
TW202402790A (zh) 2022-03-25 2024-01-16 英商梅迪繆思有限公司 減少呼吸系統感染之方法
WO2023186968A1 (en) 2022-03-29 2023-10-05 Netris Pharma Novel mcl-1 inhibitor and combination of mcl-1 and a bh3 mimetic, such as a bcl-2 inhibitor
WO2023187707A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of treating mild to moderate psoriasis with il-23 specific antibody
WO2023187657A1 (en) 2022-03-30 2023-10-05 Novartis Ag Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies
WO2023194539A1 (en) 2022-04-07 2023-10-12 Heidelberg Pharma Research Gmbh Methods of improving the therapeutic index of amatoxin-antibody conjugates
EP4257609A1 (de) 2022-04-08 2023-10-11 iOmx Therapeutics AG Kombinationstherapien basierend auf pd-1-inhibitoren und sik3-inhibitoren
WO2023194565A1 (en) 2022-04-08 2023-10-12 Ac Immune Sa Anti-tdp-43 binding molecules
WO2023201256A1 (en) 2022-04-12 2023-10-19 Vir Biotechnology, Inc. High dose antibody therapies for sars-cov-2 infection
WO2023203177A1 (en) 2022-04-20 2023-10-26 Kantonsspital St. Gallen Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
TW202400637A (zh) 2022-04-25 2024-01-01 美商威特拉公司 April之抗體分子及其用途
WO2023209568A1 (en) 2022-04-26 2023-11-02 Novartis Ag Multispecific antibodies targeting il-13 and il-18
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2023215740A1 (en) 2022-05-06 2023-11-09 Seagen Inc. Immunomodulatory antibody-drug conjugates
WO2023218027A1 (en) 2022-05-12 2023-11-16 Amgen Research (Munich) Gmbh Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023218099A1 (en) 2022-05-13 2023-11-16 argenx BV In utero treatment of a fetus having genetic disease/neuromuscular disease
WO2023223265A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody
WO2023230445A2 (en) 2022-05-23 2023-11-30 Humabs Biomed Sa Broadly neutralizing antibodies against influenza neuraminidase
WO2023230448A1 (en) 2022-05-23 2023-11-30 Vir Biotechnology, Inc. Combination immunotherapy for influenza
WO2023230532A1 (en) 2022-05-26 2023-11-30 Compugen Ltd. Anti-tigit antibody formulation
WO2023239803A1 (en) 2022-06-08 2023-12-14 Angiex, Inc. Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
WO2023240287A1 (en) 2022-06-10 2023-12-14 Bioentre Llc Combinations of ctla4 binding proteins and methods of treating cancer
WO2023245078A1 (en) 2022-06-15 2023-12-21 Humabs Biomed Sa Anti-parvovirus antibodies and uses thereof
EP4296279A1 (de) 2022-06-23 2023-12-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-transthyretin(ttr)-bindende proteine und ihre verwendungen
WO2023247050A1 (en) 2022-06-23 2023-12-28 Alligator Bioscience Ab Combination therapies
WO2024006876A1 (en) 2022-06-29 2024-01-04 Abbott Laboratories Magnetic point-of-care systems and assays for determining gfap in biological samples
WO2024003103A1 (en) 2022-06-29 2024-01-04 Astrazeneca Ab Anti-pcrv and psl bispecific antibodies for treatment of bronchiectasis
WO2024006472A1 (en) 2022-06-30 2024-01-04 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
GB202209786D0 (en) 2022-07-04 2022-08-17 Ucl Business Ltd B7H3 Binders
WO2024015463A1 (en) 2022-07-12 2024-01-18 Leap Therapeutics, Inc. Combination therapy
WO2024015830A1 (en) 2022-07-12 2024-01-18 Cytomx Therapeutics, Inc. Epcam immunoconjugates and uses thereof
WO2024015953A1 (en) 2022-07-15 2024-01-18 Danisco Us Inc. Methods for producing monoclonal antibodies
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
WO2024013723A1 (en) 2022-07-15 2024-01-18 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof
WO2024020051A1 (en) 2022-07-19 2024-01-25 BioLegend, Inc. Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
GB202210680D0 (en) 2022-07-21 2022-09-07 Dualyx Nv Binding molecules targeting il-35r
GB202210679D0 (en) 2022-07-21 2022-09-07 Dualyx Nv Binding molecules targeting il-12rb2
WO2024018426A1 (en) 2022-07-22 2024-01-25 Janssen Biotech, Inc. Enhanced transfer of genetic instructions to effector immune cells
GB202210957D0 (en) 2022-07-27 2022-09-07 Alligator Bioscience Ab Novel dosages
WO2024026411A1 (en) 2022-07-27 2024-02-01 Humabs Biomed Sa Broadly neutralizing antibodies against rsv and mpv paramyxoviruses
GB202210965D0 (en) 2022-07-27 2022-09-07 Alligator Bioscience Ab Novel dosages
US20240108744A1 (en) 2022-07-27 2024-04-04 Mediboston Limited Auristatin derivatives and conjugates thereof
WO2024026472A2 (en) 2022-07-29 2024-02-01 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
WO2024026471A1 (en) 2022-07-29 2024-02-01 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2024023368A1 (en) 2022-07-29 2024-02-01 4TEEN4 Pharmaceuticals GmbH Prediction of an increase of dpp3 in a patient with septic shock
WO2024026447A1 (en) 2022-07-29 2024-02-01 Alector Llc Anti-gpnmb antibodies and methods of use thereof
WO2024023369A1 (en) 2022-07-29 2024-02-01 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
WO2024028794A1 (en) 2022-08-02 2024-02-08 Temple Therapeutics BV Methods for treating endometrial and ovarian hyperproliferative disorders
WO2024030577A1 (en) 2022-08-03 2024-02-08 Seagen Inc. Immunostimulatory anti-pd-l1-drug conjugates
WO2024030976A2 (en) 2022-08-03 2024-02-08 Voyager Therapeutics, Inc. Compositions and methods for crossing the blood brain barrier
EP4321522A1 (de) 2022-08-12 2024-02-14 Seagen Inc. Zytotoxische verbindungen und konjugate davon
WO2024039670A1 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against cldn4 and methods of use thereof
WO2024039672A2 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof
WO2024038183A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
WO2024040114A2 (en) 2022-08-18 2024-02-22 BioLegend, Inc. Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
WO2024038193A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
WO2024038198A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
WO2024042212A1 (en) 2022-08-26 2024-02-29 Medimmune Limited Treatment of asthma with an anti-interleukin-33 antibody
WO2024043837A1 (en) 2022-08-26 2024-02-29 Aslan Pharmaceuticals Pte Ltd High concentration anti-il13r antibody formulation
WO2024050354A1 (en) 2022-08-31 2024-03-07 Washington University Alphavirus antigen binding antibodies and uses thereof
WO2024050524A1 (en) 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
WO2024050526A1 (en) 2022-09-02 2024-03-07 Biomarin Pharmaceutical Inc. Compositions and methods for treating long qt syndrome
WO2024054157A1 (en) 2022-09-06 2024-03-14 Aslan Pharmaceuticals Pte Ltd Treatment for sleep loss or sleep disturbance in patients with dermatitis
WO2024052503A1 (en) 2022-09-08 2024-03-14 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to ltbp2 and uses thereof
WO2024052517A2 (en) 2022-09-09 2024-03-14 Bayer Aktiengesellschaft Medical use of ccr8 antibodies and dosing schedule
WO2024056668A1 (en) 2022-09-12 2024-03-21 Institut National de la Santé et de la Recherche Médicale New anti-itgb8 antibodies and its uses thereof
WO2024059675A2 (en) 2022-09-14 2024-03-21 Amgen Inc. Bispecific molecule stabilizing composition
WO2024059708A1 (en) 2022-09-15 2024-03-21 Abbott Laboratories Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
WO2024056861A1 (en) 2022-09-15 2024-03-21 Avidicure Ip B.V. Multispecific antigen binding proteins for stimulating nk cells and use thereof
WO2024062082A1 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062072A2 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062076A1 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024072893A1 (en) 2022-09-28 2024-04-04 Incyte Corporation Anti-pd-1/lag-3 bispecific antibodies and uses thereof
EP4345109A1 (de) 2022-09-30 2024-04-03 AdrenoMed AG Anti-adrenomedullin (adm)-bindemittel zur verwendung bei der behandlung von pädiatrischen patienten mit angeborener herzerkrankung
WO2024068996A1 (en) 2022-09-30 2024-04-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
WO2024074498A1 (en) 2022-10-04 2024-04-11 Imcheck Therapeutics Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer
WO2024074571A1 (en) 2022-10-05 2024-04-11 Institut National de la Santé et de la Recherche Médicale Dc-targeting vaccine against nipah virus infection
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
GB202215115D0 (en) 2022-10-13 2022-11-30 Univ Nottingham VEGF antibodies

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4578335A (en) 1984-05-21 1986-03-25 Immunex Corporation Interleukin 2 receptor
US4845198A (en) * 1984-05-21 1989-07-04 Immunex Corporation Hybridoma antibody which binds IL-2 receptor
JPS6147500A (ja) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) * 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
JPS61134325A (ja) * 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
WO1986005513A1 (en) * 1985-03-18 1986-09-25 Gene Labs, Inc. Hybrid-gene cassette vector
US4816565A (en) * 1985-08-13 1989-03-28 Tasuku Honjo Interleukin 2 receptor and a method for production thereof
US5336489A (en) 1985-09-05 1994-08-09 The Beth Israel Hospital Association Treatment of allograft rejection with IL-2 receptor-specific cytotoxins
AU606320B2 (en) * 1985-11-01 1991-02-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US5552304A (en) 1985-11-19 1996-09-03 Schering Corporation CDNA Clones coding for human protein exhibiting a broad cellular activity spectrum (human interleukin-4)
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB2188941B (en) * 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
CA1340456C (en) * 1986-07-07 1999-03-23 Hubert J.P. Schoemaker Chimeric rodent/human immunoglobulins specific for tumor-associated antigens
US5362490A (en) 1986-07-25 1994-11-08 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Human myelomonocyte interferon-gamma, and process for preparation and use thereof
IL84285A (en) * 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
US4975467A (en) 1987-03-17 1990-12-04 Merrell Dow Pharmaceuticals Inc. Method of inhibiting interleukin-1 release and alleviating interleukin-1 mediated conditions
NL8700927A (nl) * 1987-04-16 1988-11-16 Stichting Rega V Z W Anti-interferon-gamma-antilichamen; en hun therapeutische toepassing.
ATE120761T1 (de) * 1987-05-21 1995-04-15 Creative Biomolecules Inc Multifunktionelle proteine mit vorbestimmter zielsetzung.
CA1335792C (en) 1987-08-18 1995-06-06 Chaim O. Jacob Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
AU625613B2 (en) * 1988-01-05 1992-07-16 Novartis Ag Novel chimeric antibodies
DE10199051I2 (de) * 1988-02-12 2005-05-04 Btg Int Ltd Modifizierte Antik¦rper.
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
EP0365209A3 (de) * 1988-10-17 1990-07-25 Becton, Dickinson and Company Aminosäuresequenz des Anti-leu 3a
WO1990004410A1 (en) * 1988-10-19 1990-05-03 The Dow Chemical Company A novel family of high affinity, modified antibodies for cancer treatment
KR0184860B1 (ko) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5198359A (en) * 1989-03-07 1993-03-30 Boehringer Ingelheim International Gmbh Recombinant protein receptor for il-2
GB8905400D0 (en) 1989-03-09 1989-04-19 Jonker Margreet Medicaments
IT1231727B (it) 1989-08-11 1991-12-21 Enrico Savoldi Peptidi utili per la determinazione e la purificazione di anticorpi anti gamma interferone.
IL91562A0 (en) 1989-09-07 1990-04-29 Yeda Res & Dev Interferon-gamma receptor fragment and its production
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB2268745B (en) 1989-12-21 1994-05-11 Celltech Ltd Heavy and light chains having a variable domain comprising acceptor framework residues and donor antigen binding residues
DE4014753A1 (de) 1990-05-08 1991-11-14 Elpag Ag Chur Rohrheizkoerper mit sicherung
US5192773A (en) 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
EP0519596B1 (de) 1991-05-17 2005-02-23 Merck & Co. Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1994011509A2 (en) 1992-11-16 1994-05-26 Cancer Research Fund Of Contra Costa Peptides and anti-sense peptides with broad neoplastic specificity
ATE173630T1 (de) 1992-12-29 1998-12-15 Genentech Inc Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
EP0659766A1 (de) 1993-11-23 1995-06-28 Schering-Plough Menschliche Monoklonalantikörper gegen menschliche Cytokine und Verfahren zur Herstellung dieser Antikörper
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
EP0823941A4 (de) 1995-04-28 2001-09-19 Abgenix Inc Menschliche antikörper aus xenomäusen
US5780027A (en) 1995-07-14 1998-07-14 Meiogen Biotechnology Corporation Methods of treatment of down syndrome by interferon antagonists
GB2304342A (en) 1995-08-18 1997-03-19 Univ Manchester Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma
US20020025316A1 (en) 1995-08-18 2002-02-28 Ferguson Mark Williams James Pharmaceutical composition containing inhibitors of interferon-gamma
AU2452797A (en) 1996-04-10 1997-10-29 Board Of Trustees Of The University Of Illinois, The Interferon-gamma anti-inflammatory methods, compounds, and pharmaceutical compositions
US5830454A (en) 1996-08-30 1998-11-03 Ludwig Institute For Cancer Research Method for treating cell mediated autoimmune disorders using interleukin-9
PL336464A1 (en) 1997-03-18 2000-06-19 Basf Ag Method of and compositions for modulating reactivity in respect to corticosteroids i
EP1015480A2 (de) 1997-08-18 2000-07-05 Innogenetics N.V. Interferon gamma bindende moleküle zur behandlung von septischem schock, cachexia, immunkrankheiten und hautkrankheiten
MXPA01005515A (es) 1998-12-01 2003-07-14 Protein Design Labs Inc Anticuerpos humanizados para gamma-interferon.
US6544504B1 (en) 1999-07-28 2003-04-08 Schering Corporation Combined use of interleukin 10 and methotrexate for immuno-modulatory therapy
US6346247B1 (en) 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
WO2001051046A1 (en) 2000-01-14 2001-07-19 University Of Virginia Patent Foundation Airway alkalinization as therapy for airway diseases
US6534059B2 (en) 2001-06-05 2003-03-18 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye

Also Published As

Publication number Publication date
US6180370B1 (en) 2001-01-30
EP0566647B1 (de) 2003-10-08
KR100231090B1 (ko) 1999-11-15
AU7548196A (en) 1997-02-20
US5693762A (en) 1997-12-02
EP0566647A1 (de) 1993-10-27
DE69133326T2 (de) 2004-08-05
US7022500B1 (en) 2006-04-04
US5693761A (en) 1997-12-02
JPH06503963A (ja) 1994-05-12
US5530101A (en) 1996-06-25
AU9172691A (en) 1992-07-22
AU671949B2 (en) 1996-09-19
JP3276369B2 (ja) 2002-04-22
EP1386932A1 (de) 2004-02-04
US5585089A (en) 1996-12-17
WO1992011018A1 (en) 1992-07-09
EP0566647A4 (de) 1995-06-14
CA2098404C (en) 2002-08-20
ATE251639T1 (de) 2003-10-15
CA2098404A1 (en) 1992-06-20

Similar Documents

Publication Publication Date Title
DE69133326D1 (de) Verbesserte humanähnlich gemachte immunglobuline
DE69334258D1 (de) Immunoglobuline ohne Leichtkette
DE69532889D1 (de) Interleukin-5-spezifische rekombinante antikörper
ATE176926T1 (de) Antikörperherstellung
NZ314793A (en) Humanised immunoglobulins; production and use to manufacture a medicament, polynucleotides and cell lines
NO2006008I1 (no) Natalizumab, anti alfa-4 integrin humanized monoclonal antibody
NO20001671L (no) Naturlige humaniserte antistoff
NO980030L (no) Monoklonale antistoffer som binder CD40-L
GB2144147B (en) Monoclonal antibody having only one light chain which will bind a specific antigen
DE69231058T2 (de) Hochaffine humanisierte monoklonale antikoerper
ATE136929T1 (de) Monoklonaler antikörper, der spezifisch mit dem humanen perforin reagiert
DE69118827D1 (de) Antikörper gegen Hamsterimmunglobulinen
AU6159090A (en) Hybridomas and monoclonal antibodies therefrom having specific reactivity toward heavy chain immunoglobulin from catfish

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: PDL BIOPHARMA, INC. (N.D.GES.D. STAATES DELAWARE),

8327 Change in the person/name/address of the patent owner

Owner name: PDL BIOPHARMA, INC., REDWOOD CITY, CALIF., US

8327 Change in the person/name/address of the patent owner

Owner name: FACET BIOTECH CORP., REDWOOD CITY, CALIF., US

8327 Change in the person/name/address of the patent owner

Owner name: ABBOTT BIOTHERAPEUTICS CORP. ( N. D. GES D. ST, US